0001193125-14-387033.txt : 20141029 0001193125-14-387033.hdr.sgml : 20141029 20141029152557 ACCESSION NUMBER: 0001193125-14-387033 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141029 DATE AS OF CHANGE: 20141029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL BIOSENSORS INC CENTRAL INDEX KEY: 0001279695 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980424072 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52607 FILM NUMBER: 141179925 BUSINESS ADDRESS: STREET 1: 1 CORPORATE AVENUE STREET 2: ROWVILLE CITY: VICTORIA STATE: C3 ZIP: 3178 BUSINESS PHONE: 613-9213-9000 MAIL ADDRESS: STREET 1: 1 CORPORATE AVENUE STREET 2: ROWVILLE CITY: VICTORIA STATE: C3 ZIP: 3178 10-Q 1 d798417d10q.htm 10-Q 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

Commission File Number: 000-52607

 

 

Universal Biosensors, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware    98-0424072

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification Number)

Universal Biosensors, Inc.

1 Corporate Avenue,

Rowville, 3178, Victoria

Australia

   Not Applicable
(Address of principal executive offices)    (Zip Code)

Telephone: +61 3 9213 9000

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “accelerated filer”, “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer   ¨    Accelerated Filer   ¨
Non-Accelerated Filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 175,610,978 shares of Common Stock, U.S.$0.0001 par value, outstanding as of October 29, 2014.

 

 

 


Table of Contents

UNIVERSAL BIOSENSORS, INC.

TABLE OF CONTENTS

 

     Page  
PART I   FINANCIAL INFORMATION   
Item 1   Financial Statements   
  1)   

Consolidated condensed balance sheets at September 30, 2014 and December 31, 2013 (unaudited)

     1   
  2)   

Consolidated condensed statements of comprehensive income for the three months and nine months ended September 30, 2014 and 2013 (unaudited)

     2   
  3)   

Consolidated condensed statements of changes in stockholder’s equity and comprehensive income for the period ended September 30, 2014 and 2013 (unaudited)

     3   
  4)   

Consolidated condensed statements of cash flows for the nine months ended September  30, 2014 and 2013 (unaudited)

     4   
  5)   

Notes to consolidated condensed financial statements (unaudited)

     5   
Item 2  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     21   
Item 3  

Quantitative and Qualitative Disclosures About Market Risk

     34   
Item 4  

Controls and Procedures

     35   
PART II   OTHER INFORMATION   
Item 1   Legal Proceedings      36   
Item 1A   Risk Factors      36   
Item 2   Unregistered Sales of Equity Securities and Use of Proceeds      36   
Item 3   Defaults Upon Senior Securities      36   
Item 4   Mine Safety Disclosures      36   
Item 5   Other Information      36   
Item 6   Exhibits      36   
  Exhibit 31.1   
  Exhibit 31.2   
  Exhibit 32   
  Exhibit 101   
SIGNATURES      37   

Unless otherwise noted, references on this Form 10-Q to “Universal Biosensors”, the “Company,” “Group,” “we,” “our” or “us” means Universal Biosensors, Inc. (“UBI”) a Delaware corporation and, when applicable, its wholly owned Australian operating subsidiary, Universal Biosensors Pty Ltd (“UBS”).


Table of Contents

Universal Biosensors, Inc.

 

Item 1 Financial Statements

Consolidated Condensed Balance Sheets (Unaudited)

 

     September 30,
2014
    December 31,
2013
 
     A$     A$  

ASSETS

    

Current assets:

    

Cash and cash equivalents

     19,830,109        23,742,422   

Inventories, net

     393,745        4,207   

Accounts receivable

     2,012,682        2,167,867   

Prepayments

     870,573        825,800   

Other current assets

     5,850,695        9,049,283   
  

 

 

   

 

 

 

Total current assets

     28,957,804        35,789,579   

Non-current assets:

    

Property, plant and equipment

     34,470,592        33,816,691   

Less accumulated depreciation

     (19,701,816     (17,906,571
  

 

 

   

 

 

 

Property, plant and equipment - net

     14,768,776        15,910,120   
  

 

 

   

 

 

 

Other non-current assets

     2,920,000        2,920,000   
  

 

 

   

 

 

 

Total non-current assets

     17,688,776        18,830,120   
  

 

 

   

 

 

 

Total assets

     46,646,580        54,619,699   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable

     957,140        974,754   

Accrued expenses

     2,615,730        2,329,440   

Deferred revenue

     979,368        957,916   

Employee entitlements provision

     1,412,121        1,160,177   
  

 

 

   

 

 

 

Total current liabilities

     5,964,359        5,422,287   

Non-current liabilities:

    

Asset retirement obligations

     2,600,000        2,549,928   

Employee entitlements provision

     131,165        147,662   

Long term secured loan

     16,352,515        15,857,966   

Deferred revenue

     979,368        957,916   
  

 

 

   

 

 

 

Total non-current liabilities

     20,063,048        19,513,472   
  

 

 

   

 

 

 

Total liabilities

     26,027,407        24,935,759   
  

 

 

   

 

 

 

Commitments and contingencies

     0        0   
  

 

 

   

 

 

 

Stockholders’ equity:

    

Preferred stock, US$0.01 par value. Authorized 1,000,000 shares; issued and outstanding nil in 2014 (2013: nil)

    

Common stock, US$0.0001 par value. Authorized 300,000,000 shares; issued and outstanding 175,610,978 shares in 2014 (2013: 175,600,605)

     17,561        17,560   

Additional paid-in capital

     94,736,989        94,955,051   

Accumulated deficit

     (64,990,359     (53,356,552

Current year loss

     (8,846,706     (11,633,807

Accumulated other comprehensive income

     (298,312     (298,312
  

 

 

   

 

 

 

Total stockholders’ equity

     20,619,173        29,683,940   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

     46,646,580        54,619,699   
  

 

 

   

 

 

 

See accompanying notes to the financial statements

 

1


Table of Contents

Universal Biosensors, Inc.

Consolidated Condensed Statements of Comprehensive Income (Unaudited)

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2014     2013     2014     2013  
     A$     A$     A$     A$  

Revenue

        

Revenue from products

     137,294        1,396,357        137,294        8,597,428   

Revenue from services

     1,949,297        1,117,229        4,815,229        3,495,585   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     2,086,591        2,513,586        4,952,523        12,093,013   

Cost of goods sold & services

        

Cost of goods sold

     218,298        1,756,957        218,298        8,677,388   

Cost of services

     127,084        236,334        150,006        868,347   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of goods sold & services

     345,382        1,993,291        368,304        9,545,735   
  

 

 

   

 

 

   

 

 

   

 

 

 

Contribution from products & services

     1,741,209        520,295        4,584,219        2,547,278   

Other operating costs & expenses

        

Research and development

     4,715,444        3,901,823        13,900,999        11,807,954   

General and administrative

     1,522,175        1,684,703        4,588,686        4,480,101   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating costs & expenses

     6,237,619        5,586,526        18,489,685        16,288,055   
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (4,496,410     (5,066,231     (13,905,466     (13,740,777

Other income/(expense)

        

Interest income

     103,398        123,663        187,247        417,022   

Interest expense

     (4,772     (7,547     (15,905     (18,867

Financing costs

     (654,095     0        (1,944,995     0   

Other

     3,157,820        4,266,790        6,832,413        4,975,853   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income

     2,602,351        4,382,906        5,058,760        5,374,008   

Net loss before tax

     (1,894,059     (683,325     (8,846,706     (8,366,769

Income tax benefit/(expense)

     0        0        0        0   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

     (1,894,059     (683,325     (8,846,706     (8,366,769
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per share

        

Basic and diluted net loss per share

     (0.01     0.00        (0.05     (0.05

Other comprehensive loss, net of tax:

        

Reclassification for gain/(loss) realized in net income

     0        0        0        0   
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive gain/(loss)

     0        0        0        0   
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss

     (1,894,059     (683,325     (8,846,706     (8,366,769
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to the financial statements.

 

2


Table of Contents

Universal Biosensors, Inc.

Consolidated Condensed Statements of Changes in Stockholders’ Equity and Comprehensive Income (Unaudited)

 

     Ordinary shares      Additional Paid-     Accumulated     Accumulated
Other
Comprehensive
    Total
Stockholders’
 
     Shares      Amount      in Capital     Deficit     Income     Equity  
            A$      A$     A$     A$     A$  

Balances at January 1, 2013

     173,959,863         17,396         93,009,607        (53,356,552     (298,312     39,372,139   

Net loss

     0         0         0        (8,366,769     0        (8,366,769

Exercise of stock options issued to employees

     824,663         82         194,679        0        0        194,761   

Shares issued to employees

     917         1         999        0        0        1,000   

Stock option expense

     0         0         469,125        0        0        469,125   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Balances at September 30, 2013

     174,785,443         17,479         93,674,410        (61,723,321     (298,312     31,670,256   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Balances at January 1, 2014

     175,600,605         17,560         94,955,051        (64,990,359     (298,312     29,683,940   

Net loss

     0         0         0        (8,846,706     0        (8,846,706

Exercise of stock options issued to employees

     8,333         0         0        0        0        0   

Shares issued to employees

     2,040         1         999        0        0        1,000   

Stock option expense

     0         0         (219,061     0        0        (219,061
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Balances at September 30, 2014

     175,610,978         17,561         94,736,989        (73,837,065     (298,312     20,619,173   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to the financial statements.

 

3


Table of Contents

Universal Biosensors, Inc.

Consolidated Condensed Statements of Cash Flows (Unaudited)

 

     Nine Months Ended
September 30,
 
     2014     2013  
     A$     A$  

Cash flows from operating activities:

    

Net loss

     (8,846,706     (8,366,769

Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:

    

Depreciation and amortization

     1,847,314        1,890,162   

Share based payments expense

     (219,061     469,125   

Loss on fixed assets disposal

     8,098        907   

Net exchange difference

     390,708        23,549   

Financing costs - amortization of warrants

     133,361        0   

Change in assets and liabilities:

    

Inventory

     (389,538     1,218,518   

Accounts receivable

     155,185        577,192   

Prepaid expenses and other assets

     3,153,816        (4,361,105

Deferred revenue

     42,904        0   

Employee entitlements

     236,446        284,844   

Accounts payable and accrued expenses

     1,934,897        (1,915,731
  

 

 

   

 

 

 

Net cash used in operating activities

     (1,552,576     (10,179,308
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property, plant and equipment

     (691,465     (135,252
  

 

 

   

 

 

 

Net cash used in investing activities

     (691,465     (135,252
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from borrowings

     552,772        767,471   

Repayment of borrowings

     (552,772     (639,559

Proceeds from stock options exercised

     0        194,761   

Financing costs

     (1,638,752     0   
  

 

 

   

 

 

 

Net cash provided by/(used in) financing activities

     (1,638,752     322,673   
  

 

 

   

 

 

 

Net decrease in cash and cash equivalents

     (3,882,793     (9,991,887

Cash and cash equivalent at beginning of period

     23,742,422        23,649,417   

Effect of exchange rate fluctuations on the balances of cash held in foreign currencies

     (29,520     1,013,372   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

     19,830,109        14,670,902   
  

 

 

   

 

 

 

See accompanying notes to the financial statement

 

4


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

Organization of the Company

We are a specialist medical diagnostics company focused on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use.

We were incorporated in the State of Delaware on September 14, 2001 and our shares of common stock in the form of CHESS Depositary Interests (“CDIs”) have been quoted on the Australian Securities Exchange (“ASX”) since December 13, 2006. Our securities are not currently traded on any other public market. Our wholly owned subsidiary and primary operating vehicle, UBS, was incorporated as a proprietary limited company in Australia on September 21, 2001. UBS conducts our research, development and manufacturing activities in Melbourne, Australia.

We have rights to an extensive patent portfolio, with certain patents owned by UBS and a number licensed to UBS by LifeScan, Inc. (“LifeScan”) and other third party licensees. Unless otherwise noted, references to “LifeScan” in this document are references collectively or individually to LifeScan, Inc., and/or LifeScan Europe, a division of Cilag GmbH International, both affiliates of Johnson and Johnson.

We are using our electrochemical cell technology platform to develop tests for a number of different markets. Our current focus is as set out below:

 

    Coagulation testing market – we are working with Siemens Healthcare Diagnostics, Inc. (“Siemens”) to develop a range of products for the point-of-care coagulation market pursuant to a collaboration agreement with Siemens (“Collaboration Agreement”) and, subject to being approved for sale, plan to manufacture test strips for these products under a supply agreement with Siemens (“Supply Agreement”). We are also developing our own Prothrombin Time International Normalized Ratio (“PT-INR”) test targeted at the patient self-test market and intend to enter into distribution agreements with respect to that test.

 

    Blood glucose – we provide services to LifeScan as required from time to time, pursuant to a Master Services and Supply Agreement (“Master Services and Supply Agreement”) and a development and research agreement (“Development and Research Agreement”) with LifeScan.

 

    Other electrochemical-cell based tests – we are working on proving the broader applicability of our technology platform, including tests based on enzymatic, immunoassay and molecular diagnostic methods. We may seek to enter into collaborative arrangements, strategic alliances or distribution agreements with respect to any tests arising from this work.

Interim Financial Statements

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the financial statements and footnotes thereto as of and for the year ended December 31, 2013, included in the Form 10-K of Universal Biosensors, Inc.

The year-end consolidated condensed balance sheets data as at December 31, 2013 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain prior year amounts in the consolidated condensed financial statements have been reclassified to conform to the current presentation.

Basis of Presentation

All amounts within these consolidated financial statements are expressed in Australian dollars (“AUD” or “A$”) unless otherwise stated.

 

5


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. We rely largely on our existing cash and cash equivalents balance and operating cash flow to provide for the working capital needs of our operations. We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. However, in the event, our financing needs for the foreseeable future are not able to be met by our existing cash and cash equivalents balance and operating cash flow, we would seek to raise funds through public or private equity offerings, debt financings, and through other means to meet the financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.

Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, UBS. All intercompany balances and transactions have been eliminated on consolidation.

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations and obligations related to employee benefits. Actual results could differ from those estimates.

Cash & Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments.

Short-Term Investments (Held-to-maturity)

Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.

Concentration of Credit Risk and Other Risks and Uncertainties

Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated balance sheets. The Company’s cash and cash equivalents are invested with one of Australia’s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.

Derivative Instruments and Hedging Activities

Derivative financial instruments

The Company uses derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.

Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.

 

6


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Cash flow hedges

Exposure to foreign exchange risks arises in the normal course of the Company’s business and it is the Company’s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.

Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the non-financial asset or liability.

For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated statements of comprehensive income.

When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated statements of comprehensive income.

Derivative Instruments and Hedging Activities

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. At September 30, 2014 and year ended December 31, 2013, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2. The fair value methodologies described as Level 2 and 3 inputs are defined elsewhere in these notes to the financial statements.

Inventory

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.

 

7


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Raw materials

     315,036         4,169   

Work in progress

     78,709         38   

Finished goods

     0         0   
  

 

 

    

 

 

 
     393,745         4,207   
  

 

 

    

 

 

 

Receivables

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Accounts receivable

     2,012,682         2,167,867   

Allowance for doubtful debts

     0         0   
  

 

 

    

 

 

 
     2,012,682         2,167,867   
  

 

 

    

 

 

 

Property, Plant, and Equipment

Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.

Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.

The Company receives Victorian government grant monies under grant agreements to support our development activities, including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.

Research and Development

Research and development expenses consist of costs incurred to further the Group’s research and development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.

 

8


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Research and development expenses for the three and nine months ended September 30, 2014 and 2013 are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

Research and development expenses

     4,715,444         3,901,823         13,900,999         11,807,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income Taxes

The Company applies ASC 740 - Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.

We are subject to income taxes in the United States and Australia. U.S. federal income tax returns up to and including the 2013 financial year has been filed. Internationally, consolidated income tax returns up to and including the 2013 financial year have been filed.

Asset Retirement Obligations

Asset retirement obligations (“ARO”) are legal obligations associated with the retirement and removal of long-lived assets. ASC 410 – Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.

The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.

Our overall ARO changed as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Opening balance

     2,549,928         2,351,464   

Accretion expense

     50,072         198,464   
  

 

 

    

 

 

 

Ending balance

     2,600,000         2,549,928   
  

 

 

    

 

 

 

 

9


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Fair Value of Financial Instruments

The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:

 

    Market approach – based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

 

    Cost approach – based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.

 

    Income approach – based on the present value of a future stream of net cash flows

These fair value methodologies depend on the following types of inputs:

 

    Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)

 

    Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs)

 

    Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)

Impairment of Long-Lived Assets

The Company reviews its capital assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows.

Australian Goods and Services Tax (GST)

Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheets.

Revenue Recognition

We recognize revenue from all sources based on the provisions of the U.S. SEC’s Staff Accounting Bulletin No. 104 and ASC 605 Revenue Recognition.

The Company’s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.

Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.

 

10


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company’s best estimate of selling price when fair value is not available for a given unit of accounting.

Under ASC 605-25, the delivered item(s) are separate units of accounting, provided (i) the delivered item(s) have value to a customer on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following: non-refundable, upfront payments; funding of research and/or development efforts; and milestone payments.

We typically generate milestone payments from our customers pursuant to the various agreements we have with them. Non-refundable milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the non-refundable milestone payment is not substantive or stand-alone value, the non-refundable milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.

Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company’s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as “revenues”.

Master Services and Supply Agreement

In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a non-exclusive manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).

All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.

 

11


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Collaboration Agreement

On September 9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. In addition to an up-front, non-refundable payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement contained a further six payments from Siemens upon the achievement of certain defined milestones. These six milestones relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the up-front payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company’s best estimate of selling price. The deliverables related to each milestone are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.

Of the six milestones, the Company has delivered on two as of September 30, 2014:

 

    In June 2012, the Company delivered on its first milestone by achieving proof of technical feasibility of a new test strip and received a payment of A$1,522,534 (equivalent to US$1.5 million) as consideration. A sum of A$2,175,048 (equivalent to US$2,142,857) has been recognized as revenue from services in June 2012 in this regards.

 

    In July 2012, the Company delivered on its second milestone by achieving proof of technical feasibility of another new test strip and received a payment of A$1,438,711 (equivalent to US$1.5 million) as consideration. A sum of A$2,055,301 (equivalent to US$2,142,857) has been recognized as revenue from services in July 2012 in this regards.

There were no revenues recognized for the three and nine months ended September 30, 2014 and September 30, 2013 relating to the delivery of the milestones pursuant to the Collaboration Agreement. Of the total amount of A$4,230,349 (equivalent to US$4,285,714) recognized as revenue for the 2012 financial year, A$2,961,245 (equivalent to US$3.0 million) relates to the achievement of the two milestones whilst the balance relates to a portion of the deferred US$3 million up-front payment allocated to these milestones based upon their relative estimate of selling price.

Interest income

Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.

Research and development tax incentive income

Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.

The Company has recorded research and development tax incentive income of A$3,561,209 and A$4,250,864 for the three month period ended September 30, 2014 and 2013, respectively and A$7,281,358 and A$4,250,864 for the nine month period ended September 30, 2014 and 2013, respectively. The research and development tax incentive income is recorded under the caption “Other” in the consolidated statements of comprehensive income. There was no research and development tax incentive income recognized for the six months ended June 30, 2013 as the criteria was not met. The Company determined that it qualified and became eligible for this incentive income during the third quarter of the 2013 financial year.

Foreign Currency

Functional and reporting currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of the Company and UBS is AUD or A$ for all years presented.

 

12


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

The consolidated financial statements are presented using a reporting currency of Australian dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of comprehensive income.

The Company has recorded foreign currency transaction (losses)/gains of (A$399,417) and A$15,926 for the three month period ended September 30, 2014 and 2013, respectively and (A$444,973) and A$724,989 for the nine month period ended September 30, 2014 and 2013, respectively.

The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:

 

  assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;

 

  income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and

 

  all resulting exchange differences are recognized as a separate component of equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.

Commitments and Contingencies

Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Our contingent liabilities as at September 30, 2014 are as follows:

 

  we have a potential obligation to pay 50% of the patent fees paid by LifeScan in respect of the patents we license from LifeScan prior to the date of the first commercial sale of a non-glucose product that utilizes the technology licensed from LifeScan and 50% of the patent fees incurred by LifeScan in respect of such patents thereafter. In the event of the first commercial sale of a non-glucose product, the initial amount that could be paid by us to LifeScan is projected to be between US$1.6 million to US$1.8 million. We would have the right to make this payment either as a lump sum within 45 days of receipt of the supporting documentation from LifeScan or in equal monthly installment payments during the 24 months subsequent to the date of receipt of the supporting documentation. Currently the non-glucose products continue to be in the research and development phase.

 

  during 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch® Verio®, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by us in 2010 and 2011 up to a specified volume limit (“manufacturing initiation payments”). At the same time, we agreed to pay LifeScan a marketing support payment in each of the two years following the first year in which 1 billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The total amount of marketing support payments expected to be paid to LifeScan is approximately US$2 million. Based on the current volume of strips sold by LifeScan and that we have no visibility of future sales by LifeScan, it is uncertain whether we would be required to make this marketing support payment.

 

  we have engaged Planet Innovation Pty Ltd (“Planet Innovation”) to assist us with design and engineering for future analyzers. As part of the agreement, Planet Innovation will be paid a success payment upon the formal acceptance of the analyzer for commercial manufacture and a further success payment on launch sign-off for the first commercial sale of the analyzer. All of the analyzers Planet Innovation is currently working on are in the research and development phases, and therefore at this stage their commercial manufacture and sale and the amount of any future success payment cannot be reliably estimated.

 

13


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Patent and License Costs

Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in research and development expense. Legal and maintenance fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents.

Clinical Trial Expenses

Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.

These prepaid or accrued expenses are based on estimates of the work performed under service agreements.

Leased Assets

All of the Company’s leases for the periods ending September 30, 2014 and December 31, 2013 are considered operating leases. The costs of operating leases are charged to the statement of comprehensive income on a straight-line basis over the lease term.

Stock-based Compensation

We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (“RSUs”) and Zero Priced Employee Options (“ZEPOs”). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company’s stock price. The exercise price of ZEPOs is nil.

We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to paid-in-capital are still available if the tax deduction is less than the deferred tax asset.

 

(a) Stock Option Plan

In 2004, the Company adopted an employee option plan (“Plan”). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options.

 

14


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.

An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.

In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:

 

     Grant Date  
     Aug-14     Dec-13     Dec-13     Aug-13     Mar-13  

Exercise Price (A$)

     0.17        Nil        0.49        0.71        0.79   

Share Price at Grant Date (A$)

     0.17        0.49        0.49        0.71        0.79   

Volatility

     71     63     63     64     65

Expected Life (years)

     7        7        7        7        7   

Risk Free Interest Rate

     3.13     3.82     3.82     3.54     3.37

Fair Value of Option (A$)

     0.10        0.49        0.28        0.41        0.45   

Stock option activity during the current period is as follows:

 

     Number of shares     Weighted average
exercise price
A$
 

Balance at December 31, 2013

     10,606,099        1.07   

Granted

     152,000        0.10   

Exercised

     (8,333     0.00   

Lapsed

     (834,994     1.02   
  

 

 

   

 

 

 

Balance at September 30, 2014

     9,914,772        1.06   
  

 

 

   

 

 

 

The number of options exercisable as at September 30, 2014 and September 30, 2013 was 8,219,892 and 8,344,277, respectively. The total stock compensation expense recognized in income statement was A$61,703 and A$175,623 for the three month period ended September 30, 2014 and 2013, respectively and (A$219,061) and A$469,125 for the nine month period ended September 30, 2014 and 2013, respectively.

As of September 30, 2014, there was A$201,189 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized as follows:

 

Fiscal Year    A$  

2014

     69,817   

2015

     104,597   

2016

     25,869   

2017

     906   
  

 

 

 
     201,189   
  

 

 

 

The aggregate intrinsic value for all options outstanding as at September 30, 2014 and September 30, 2013 was zero.

 

15


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

(b) Restricted Share Plan

Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to non-executive directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company currently proposes to continue to issue A$1,000 worth of RSUs to employees of the Company on a recurring basis, but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.

The table below sets forth the RSUs issued by the Company since January 1, 2013:

 

     Number of
Restricted Shares
Issued
     Market Value of
Restricted Shares
Issued (A$)
 

May, 2013

     917        1,000   

December, 2013

     142,800        69,972   

June, 2014

     2,040        1,000   

Restricted stock awards activity during the current period is as follows:

 

     Number of shares     Weighted average
issue price
A$
 

Balance at December 31, 2013

     260,801        0.72   

Release of restricted shares

     (9,077     0.77   

Granted

     2,040        0.49   
  

 

 

   

 

 

 

Balance at September 30, 2014

     253,764        0.71   
  

 

 

   

 

 

 

Employee Benefit Costs

The Company contributes to standard defined contribution superannuation funds on behalf of all employees. This contribution amount, formerly equal to 9% of each employee’s salary, was increased by law to 9.25% from July 1, 2013 and 9.5% from July 1, 2014 of each such employee’s salary. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee’s remuneration to an approved superannuation fund that the employee is typically not able to access until they are retired. The Company permits employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.

Net Loss per Share and Anti-dilutive Securities

Basic and diluted net loss per share is presented in conformity with ASC 260 – Earnings per Share. Basic and diluted net loss per share has been computed using the weighted-average number of common shares outstanding during the period. Other than in a profit making year, the potentially dilutive options issued under the Universal Biosensors Employee Option Plan were not considered in the computation of diluted net loss per share because they would be anti-dilutive given the Company’s loss making position.

Total Comprehensive Income

The Company follows ASC 220 – Comprehensive Income. Comprehensive income is defined as the total change in shareholders’ equity during the period other than from transactions with shareholders, and for the Company, includes net income and cumulative translation adjustments.

 

16


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Recent Accounting Pronouncements

On May 28, 2014, the FASB issued ASU 2014-09 which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance.

The core principle of the revenue model is that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” In applying the revenue model to contracts within its scope, an entity will:

 

    Identify the contract(s) with a customer (step 1).

 

    Identify the performance obligations in the contract (step 2).

 

    Determine the transaction price (step 3).

 

    Allocate the transaction price to the performance obligations in the contract (step 4).

 

    Recognize revenue when (or as) the entity satisfies a performance obligation (step 5).

The ASU applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. Certain of the ASU’s provisions also apply to transfers of nonfinancial assets, including in-substance nonfinancial assets that are not an output of an entity’s ordinary activities (e.g., sales of (1) property, plant, and equipment; (2) real estate; or (3) intangible assets). Existing accounting guidance applicable to these transfers (e.g., ASC 360-20) has been amended or superseded.

Compared with current U.S. GAAP, the ASU also requires significantly expanded disclosures about revenue recognition.

The ASU is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, for public entities. Early application is not permitted (however, early adoption is optional for entities reporting under IFRSs).

Entities have the option of using either a full retrospective or a modified approach to adopt the guidance in the ASU:

 

    Full retrospective application — Retrospective application would take into account the requirements in ASC 250 (with certain practical expedients).

 

    Modified retrospective application — Under the modified approach, an entity recognizes “the cumulative effect of initially applying the ASU as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application” (revenue in periods presented in the financial statements before that date is reported under guidance in effect before the change). Using this approach, an entity applies the guidance in the ASU to existing contracts (those for which the entity has remaining performance obligations) as of, and new contracts after, the date of initial application. The ASU is not applied to contracts that were completed before the effective date (i.e., an entity has no remaining performance obligations to fulfill). Entities that elect the modified approach must disclose an explanation of the impact of adopting the ASU, including the financial statement line items and respective amounts directly affected by the standard’s application.

The Company is currently evaluating the method and impact the adoption of ASU 2014-09 will have on the Company’s condensed consolidated financial statements.

Related Party Transactions

Details of related party transactions material to the operations of the Group other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, are set out below.

In September 2011, we entered into a non-exclusive license agreement with SpeeDx Pty Ltd (“SpeeDx”) pursuant to which SpeeDx granted us a license to use its proprietary MNAzyme technology in the field of molecular diagnostics. Under the agreement we make milestone payments totaling A$500,000 to SpeeDx if certain specified targets are achieved, and royalty payments ranging from 5% to 15% of that portion of our sales and licensing revenues arising from SpeeDx technology or products incorporating SpeeDx technology.

 

17


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

In August 2013, we entered into a consulting agreement with SpeeDx pursuant to which we provided certain services relating to the establishment and maintenance of a quality management system at SpeeDx. Consulting fees received under this agreement were A$77,758. In addition, a success fee of A$50,000 is payable by SpeeDx during the fourth quarter of 2014 as the criteria for successful completion of the engagement has been met.

Messrs Denver and Jane are directors of the Company and SpeeDx. Talu Ventures Pty Ltd, of which Mr. Jane is a director, is a fund manager for a fund which holds approximately 33% of the issued shares in SpeeDx. Until September 27, 2013, PFM Cornerstone Limited held approximately 6% of our shares (this holding has since decreased to less than 1.0% of our shares) and PFM Cornerstone Limited also holds approximately 33% of the issued shares in SpeeDx. Messrs Denver and Hanley are directors of the Company and PFM Cornerstone Limited.

Borrowings

Future maturities, interest and other payments under the Company’s long term secured loan pursuant to the credit agreement (described below) as of September 30, 2014 and December 31, 2013 are as follows:

 

     September 30, 2014      December 31, 2013  
     US$     A$      US$     A$  

2014

     1,083,125           2,532,500     

2015

     1,749,167           1,749,167     

2016

     1,732,500           1,732,500     

2017

     1,732,500           1,732,500     

2018

     16,732,500           16,732,500     

Thereafter

     0           0     
  

 

 

      

 

 

   

Total minimum payments

     23,029,792           24,479,167     

Less amount representing interest and other fees

     (8,029,792        (9,479,167  
  

 

 

      

 

 

   

Gross balance of long term debt

     15,000,000           15,000,000     

Less fair value of warrants recorded within loan (a)

     (815,655        (815,655  

Plus amortization of warrants

     127,376           5,363     
  

 

 

      

 

 

   

Total carrying value

     14,311,721        16,352,515         14,189,708        15,857,966   
  

 

 

   

 

 

    

 

 

   

 

 

 

Less current portion

     0        0         0        0   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total carrying value, non-current portion

     14,311,721        16,352,515         14,189,708        15,857,966   
  

 

 

   

 

 

    

 

 

   

 

 

 

 

(a) The warrants issued in December 2013 had a fair value of US$815,655 as of September 30, 2014 and December 31, 2013, and are included in long term debt carrying value.

Athyrium Credit Agreement

On December 19, 2013 (“Closing Date”), UBI and its wholly owned subsidiary, UBS (together UBI and UBS, the “Transaction Parties”) entered into a credit agreement with Athyrium Opportunities Fund (A) LP (“Athyrium A”), as administrative agent (the “Administrative Agent”) and as a lender, and Athyrium Opportunities Fund (B) LP (“Athyrium B”) as a lender (Athyrium A and Athyrium B together with any other lenders party thereto from time to time, the “Lenders”) for a secured term loan of up to US$25 million (“Credit Agreement”). Of this amount, US$15 million had been drawn at December 31, 2013, with a further US$10 million available to be drawn down as follows:

 

    US$5 million available within 30 days after the end of any quarter until January 30, 2015, conditional upon UBS satisfying certain conditions precedent including that in the immediately preceding quarter, UBS achieves quarterly service fee revenues from the sale of the OneTouch® Verio® blood glucose strips (“Verio QSFs”) plus coagulation manufacturing revenues of not less than US$1,800,000 in the aggregate; and

 

    US$5 million available within 30 days after the end of any quarter until January 30, 2015, conditional upon UBS satisfying certain conditions precedent including that in the immediately preceding quarter, UBS achieves Verio QSFs plus coagulation manufacturing revenues of not less than US$2,500,000 in the aggregate.

 

18


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

The term loan has a maturity date of December 19, 2018 (“Maturity Date”) and bears interest at 10.5% per annum payable in cash quarterly in arrears over the five year term, and as otherwise described in the Credit Agreement. A default interest rate of 13% per annum shall apply during the existence of a default under the Credit Agreement. Other than as summarized below, UBS is not required to make payments of principal for amounts outstanding under the term loan until maturity, December 19, 2018. The term loan under the Credit Agreement is secured by substantially all of UBI and UBS’ assets. UBI (together with any future subsidiaries) guarantees all of UBS’s obligations under the term loan.

Voluntary prepayments of the term loans are not permitted prior to the second anniversary of the Closing Date, except in the event of a change of control of a Transaction Party. After the second anniversary, UBS can make voluntary repayments in minimum principal amounts of US$2,500,000 together with interest, plus the premium described below. UBS must make mandatory prepayments in certain prescribed circumstances, including in the event of raising additional debt financing, a sale or transfer of assets other than in certain circumstances and in the event of other specified extraordinary receipts. Extraordinary receipts include cash received or paid other than in the ordinary course of business, such as tax refunds (other than GST and R&D tax rebates), LifeScan lump sum fee payments and Siemens termination fees. In such events, UBS must prepay to the Lenders 100% of the net cash proceeds received. In the event of a prepayment on or prior to the second anniversary of the Closing Date, UBS must also pay a prepayment premium of 20% of the loans due and payable on that date. If there is a prepayment after the second anniversary of the Closing Date, UBS must pay a prepayment premium commencing at 15% of the loans due and payable on the applicable date and reducing pro-rata on a monthly basis until the Maturity Date.

UBS paid a non-refundable fee of US$625,000 to the Lenders on the Closing Date (being 2.5% of the aggregate credit facility) and a 2% commitment fee based on any available unused borrowing commitment under the Credit Agreement until January 30, 2015. The Lenders will also be entitled to receive 30% of the net proceeds of milestone payments paid under the Collaboration Agreement by and among UBS, UBI and Siemens Healthcare Diagnostics, Inc., up to a maximum of US$600,000 in the aggregate. UBS has also agreed to pay certain taxes arising in connection with the Credit Agreement and other Loan Documents, including withholding taxes. UBS has also agreed to pay certain reasonable out-of-pocket expenses incurred by the Lenders in connection with the loan documents, or as may be incurred in connection with the enforcement or protection of their rights.

The Credit Agreement also contains certain covenants, including among other things, covenants: (i) relating to the delivery of financial and other information and certificates, notices of defaults, litigation and other material events; payment of taxes and other obligations; maintenance of insurance; (ii) which limit or restrict the incurrence of liens; the making of investments; the incurrence of certain indebtedness; mergers, dispositions, liquidations, or consolidations and significant asset sales; restricted payments; transactions with affiliates other than on normal and arms-length terms; burdensome agreements; prepayment of other indebtedness; ownership of subsidiaries; and (iii) which require UBS to maintain unrestricted cash of not less than US$2,000,000 in a specified bank account at any time.

As further described below, pursuant to the Credit Agreement, UBI issued to the lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at a price of A$1.00 per share (the “Exercise Price”), which represents a 117% premium over the closing price of UBI’s common stock on December 19, 2013. The warrants are immediately exercisable and have a term of seven years.

 

19


Table of Contents

Universal Biosensors, Inc.

Notes to Consolidated Condensed Financial Statements (Unaudited)

 

Other

In January 2014, UBS entered into an arrangement with Pacific Premium Funding to fund the Group’s insurance premium. The total amount financed was A$568,677 at inception. Interest is charged at a fixed rate of 2.88% per annum and the short-term borrowing has been fully repaid. The short-term borrowing was secured by the insurance premium refund. In February 2013, UBS entered into an arrangement with Lumley Finance Ltd to fund the Group’s insurance premium. The total amount financed was A$767,471 at inception. Interest was charged at a fixed rate of 2.95% per annum and the short-term borrowing was fully repaid by December 2013. The short-term borrowing was secured by the insurance premium refund.

Warrants

Pursuant to the Credit Agreement, UBS issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at the Exercise Price.

The warrants may be exercised at any time until December 19, 2020, in whole or in part in minimum multiples of 500,000 shares of common stock. The holder of the warrants can pay the Exercise Price in cash or it has the right to pay all or a portion of the Exercise Price by making a cashless exercise, therefore reducing the number of shares of common stock the holder would otherwise be issued.

The warrant is subject to adjustments in the event of certain issuances by UBS, such as bonus issues, pro rata (rights) issues and reorganizations (e.g., consolidation, subdivision).

The Company assessed that the warrants are not liabilities within scope of ASC 480-10-25. The warrants are legally detachable from the loan and separately exercisable and as such meet the definition of a freestanding derivative instrument pursuant to ASC 815.

However, the scope exception in accordance with ASC 815-10-15-74 applies to warrants and it meets the requirements of ASC 815 that would be classified in stockholders’ equity. Therefore, the warrants were initially accounted for within stockholders’ equity, and subsequent changes in fair value will not be recorded. The fair value of the warrant was estimated using the Trinomial Lattice model.

The debt issuance costs were recorded as deferred issuance costs and are amortized as interest expense, using the effective interest method, over the term of the loan pursuant to ASC 835-30-35-2.

Restricted Cash

Restricted cash maintained by the Company in the form of term deposits is as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Financial covenant pursuant to the Credit Agreement

     2,600,000         2,600,000   

Letter of credit issued in favour of a supplier

     0         575,000   

Collateral for facilities

     320,000         320,000   
  

 

 

    

 

 

 
     2,920,000         3,495,000   
  

 

 

    

 

 

 

 

20


Table of Contents

Universal Biosensors, Inc.

 

Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information that we believe is relevant to an assessment and understanding of our results of operations and financial condition. You should read this analysis in conjunction with our audited consolidated financial statements and related footnotes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Form 10-K filed with the United States Securities and Exchange Commission (“SEC”). This Form 10-Q contains, including this discussion and analysis, certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by such acts. For this purpose, any statements that are not statements of historical fact may be deemed to be forward looking statements, including statements relating to future events and our future financial performance. Those statements in this Form 10-Q containing the words “believes”, “anticipates”, “plans”, “expects”, and similar expressions constitute forward looking statements, although not all forward looking statements contain such identifying words.

The forward looking statements contained in this Form 10-Q are based on our current expectations, assumptions, estimates and projections about the Company and its businesses. All such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those results expressed or implied by these forward-looking statements, including those set forth in this Quarterly Report on Form 10-Q.

Our Business

We are a specialist medical diagnostics company focused on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use.

We were incorporated in the State of Delaware on September 14, 2001 and our shares of common stock in the form of CHESS Depositary Interests have been quoted on the ASX since December 13, 2006. Our securities are not currently traded on any other public market. Our wholly owned subsidiary and primary operating vehicle, UBS, was incorporated as a proprietary limited company in Australia on September 21, 2001. UBS conducts our research, development and manufacturing activities in Melbourne, Australia.

We have rights to an extensive patent portfolio, with certain patents owned by UBS and a number licensed to UBS by LifeScan, Inc. and other third party licensors.

We are using our electrochemical cell technology platform to develop tests for a number of different markets. Our current focus is as set out below:

 

    Coagulation testing market – we are working with Siemens to develop a range of products for the point-of-care coagulation market pursuant to a Collaboration Agreement and, subject to being approved for sale, plan to manufacture test strips for these products under a Supply Agreement with Siemens. We are also developing our own PT-INR test targeted at the patient self-test market and intend to enter into distribution agreements with respect to that test.

 

    Blood glucose – we provide services to LifeScan as required from time to time, pursuant to a Master Services and Supply Agreement and a Development and Research Agreement with LifeScan.

 

    Other electrochemical-cell based tests – we are working on proving the broader the applicability of our technology platform, including tests based on enzymatic, immunoassay and molecular diagnostic methods. We may seek to enter into collaborative arrangements, strategic alliances or distribution agreements with respect to any tests arising from this work.

Results of Operations

Analysis of Consolidated Revenue

Our total revenue decreased by 17% and 59% to A$2,086,591 and A$4,952,523, respectively during the three and nine months ended September 30, 2014 compared to the same periods in the previous financial year.

 

21


Table of Contents

Universal Biosensors, Inc.

 

The movement in total revenue during these periods was primarily due to the following factors:

 

    Revenue from products – we manufactured OneTouch® Verio® strips for LifeScan and generated product revenue up until the end of the 2013 financial year. With effect from December 31, 2013, we ceased the manufacture of the OneTouch® Verio® blood glucose testing product.

 

    Revenue from services – the decline in revenue from products (above) was partly offset by an increase in quarterly service fees.

Revenue from Products

We currently only commercially manufacture PT-INR test strips for Siemens.

The manufacturing results of the test strips we manufactured during the respective periods are as follows:

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2014     2013     2014     2013  
     A$     A$     A$     A$  

Revenue from products

     137,294        1,396,357        137,294        8,597,428   

Cost of goods sold

     (218,298     (1,756,957     (218,298     (8,677,388
  

 

 

   

 

 

   

 

 

   

 

 

 
     (81,004     (360,600     (81,004     (79,960
  

 

 

   

 

 

   

 

 

   

 

 

 

Production margin

     (59 %)      (26 %)      (59 %)      (1 %) 

 

    PT-INR test strips – we commenced manufacture of the PT-INR test strips on behalf of Siemens during the third quarter of 2014. The initial production order submitted by Siemens has been fulfilled and the shipment was made in the third quarter of 2014. Whilst we made a margin from the sale of our PT-INR strips before overheads, the initial low volumes are not sufficient to cover all indirect expenditures. Based on forecast volumes, we expect to generate positive production margins from the supply of the PT-INR strips in 2015.

 

    Between 2009 and 2013, UBS acted as a non-exclusive manufacturer of blood glucose test strips for LifeScan’s OneTouch® Verio® blood glucose testing product. With effect from December 31, 2013, UBS ceased the manufacture of the OneTouch® Verio® blood glucose test strips for LifeScan. Manufacture of the OneTouch® Verio® strips has been transitioned to LifeScan’s existing facility in Inverness, Scotland.

Revenue from Services

We provide various services to our customers and partners. The revenue from services is grouped into the following categories:

 

    Product enhancement – a quarterly service fee based on the number of strips sold by our customers and partners is payable to us as an ongoing reward for our services and efforts to enhance the product;

 

    Contract research and development – we undertake contract research and development on behalf of our customers and partners;

 

    Other services – ad-hoc services provided on an agreed basis based on our customers’ and partners’ requirements.

 

22


Table of Contents

Universal Biosensors, Inc.

 

There are different arrangements for each service being provided. The net margin during the respective periods in relation to the provision of services is as follows:

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2014     2013     2014     2013  
     A$     A$     A$     A$  

Revenue from services:

        

Quarterly services fee

     1,579,765        832,691        4,162,353        2,433,424   

Contract research and development

     0        0        0        479,893   

Other services

     369,532        284,538        652,876        582,268   
  

 

 

   

 

 

   

 

 

   

 

 

 
     1,949,297        1,117,229        4,815,229        3,495,585   

Cost of services

     (127,084     (236,334     (150,006     (868,347
  

 

 

   

 

 

   

 

 

   

 

 

 
     1,822,213        880,895        4,665,223        2,627,238   
  

 

 

   

 

 

   

 

 

   

 

 

 
     93     79     97     75

Quarterly service fee - The quarterly service fee increased by 90% and 71%, respectively during the three and nine months ended September 30, 2014 compared to the same periods in the previous financial year, reflecting ongoing market penetration and growth.

The OneTouch® Verio® is now sold in over 90% of the world self-monitored blood glucose market. LifeScan launched the product initially in the Netherlands in January 2010 before making it available for sale in Australia in September 2010. During 2011, there were further launches of the product in Europe including France, Italy, Germany, the United Kingdom, Ireland and Spain. LifeScan first launched the OneTouch® Verio® system in the United States in January 2012.

LifeScan has the ability to terminate the obligation to pay quarterly service fees to us in certain situations set out in the Master Services and Supply Agreement or with the agreement of Universal Biosensors. LifeScan has the option to give notice to convert the quarterly service fees, which it may only do so once it has paid cumulative quarterly service fees of US$45 million. To date, LifeScan has paid cumulative quarterly service fees of US$9.9 million. Where it gives such notice, LifeScan is required to the pay the quarterly service fees for the remainder of the year in which notice is given and at the end of that year, LifeScan must pay a one-time lump sum fee. This fee is calculated by multiplying the sum of all quarterly service fees for the relevant year in which notice is given by a multiplier (on a sliding scale from 2.8x if notice is given in 2014 to 2x if notice is given in 2018 and beyond). LifeScan may also terminate the obligation to pay quarterly service fees if certain other factors detailed in the Master Services and Supply Agreement arise, including LifeScan ceasing to sell the product, termination for breach, insolvency and bankruptcy, change of control and regulatory termination.

Contract research and development - The nature and scope of contract research and development are determined by our customers and partners based upon their requirements and therefore our revenues and margins tend to fluctuate. We generated revenue of A$479,893 as reimbursement of costs for additional analyzer development work we undertook on behalf of Siemens during the second quarter of 2013. We did not perform or generate any revenue from contract research and development during any other periods mentioned above.

Other services - We generated these revenues principally from Siemens based on work undertaken for them.

Contribution from Products & Services

The contribution from products and services has increased by 235% and 80%, respectively during the three and nine months ended September 30, 2014 compared to the same periods in the previous financial year. The increase is primarily represented by the growth in the quarterly service fee which has a 100% margin.

 

23


Table of Contents

Universal Biosensors, Inc.

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2014     2013     2014     2013  
     A$     A$     A$     A$  

Revenue from products & services

     2,086,591        2,513,586        4,952,523        12,093,013   

Cost of goods sold & services

     (345,382     (1,993,291     (368,304     (9,545,735
  

 

 

   

 

 

   

 

 

   

 

 

 

Contribution from products & services

     1,741,209        520,295        4,584,219        2,547,278   
  

 

 

   

 

 

   

 

 

   

 

 

 

Contribution margin

     83     21     93     21

Research and Development Expenses

Research and development expenses are related to developing electrochemical cell platform technologies. Research and development expenses consist of costs associated with research activities, as well as costs associated with our product development efforts, including pilot manufacturing costs. Research and development expenses include:

 

  consultant and employee related expenses, which include consulting fees, salary and benefits;

 

  materials and consumables acquired for the research and development activities;

 

  external research and development expenses incurred under agreements with third party organizations and universities; and

 

  facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment and laboratory and other supplies.

Our principal research and development activities can be described as follows:

(a) Blood coagulation

We are developing Prothrombin Time tests for monitoring the therapeutic range of the anticoagulant warfarin based on measuring activity of the enzyme thrombin. In September 2011 we entered into a Collaboration Agreement with Siemens which was amended in September 2012, pursuant to which we will develop a range of test strips and reader products for the point-of-care coagulation market. The first test currently being developed is a modified version of our PT-INR test. In 2012, we entered into a Supply Agreement with Siemens under which we will manufacture and supply the test strips for these systems. We are also developing our own PT-INR test targeted at the patient self-test market. All the systems we are currently developing in the blood coagulation platform are in the advanced development phase.

(b) Immunoassay

We are continuing to develop our immunoassay platform targeting a broad range of potential assays. Our vision is to target a single analyzer and consumable design that can detect analytes across a wide range of sensitivities creating a broad-based multi-test solution while minimizing the incremental research and development effort required for each new test. This platform incorporates the ability to perform D-Dimer and C Reactive Protein tests and leverages past research work on these tests.

This work is currently in the feasibility phase.

(c) DNA/RNA

We have undertaken some early stage feasibility work assessing the possibility of using DNA binding chemistries to build a low-cost test for DNA, RNA and as a possible alternative method for improving the sensitivity of protein assays. This concept work is at an early stage and may not yield any positive results. To enable us to access certain molecular diagnostic technology, we entered into a license with SpeeDx. SpeeDx is an Australian technology company focused on the development of catalytic nucleic acid enzymes for medical diagnostics and other applications.

 

24


Table of Contents

Universal Biosensors, Inc.

 

Research and development expenses for the respective periods are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

Research

     263,327         470,363         1,007,863         1,449,042   

Development

     4,452,117         3,431,460         12,893,136         10,358,912   
  

 

 

    

 

 

    

 

 

    

 

 

 

Research and development expenses

     4,715,444         3,901,823         13,900,999         11,807,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Depending on the scope of research and development activities we undertake and the stages of development of each of these activities, our research and development expenditure will fluctuate.

In converting an idea or a concept into a commercial product, a number of development stages are required. The closer the idea or the concept to a product, the lower the technical risk but the greater the effort and cost expended. In our research and development program, the first phase is conducting exploratory research and feasibility studies. In this phase the idea is investigated by a small focused team to establish the viability of the concept as the base for a product. Once this hurdle has been passed, the project enters the development phases, which include building prototype strips and instruments, finalizing the product design, carrying out extensive testing, creating the required documentation and developing or validating the product manufacturing processes. This requires a larger group of people and a higher use of materials compared to the research phase, so is typically more expensive, but necessary to be able to commercialize a product.

Research and development expenditure increased by 21% and 18%, respectively, during the three and nine months ended September 30, 2014 compared to the same periods in the previous financial year. The increase principally reflects the effort required to complete the final stages of the development phase prior to launch of the four tests we are undertaking. The first of these tests, the Prothrombin Time test, for which we have already received a first commercial order from Siemens, had its launch delayed from September 2014. The launch was delayed to allow for additional work to improve the manufacturing reliability of a sub-component of the hand-held analyzer.

Research and development expenses, net of the research and development tax incentive income for the respective periods are as follows:

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2014     2013     2014     2013  
     A$     A$     A$     A$  

Research and development expenses

     4,715,444        3,901,823        13,900,999        11,807,954   

Research and development tax incentive income

     (3,561,209     (4,250,864     (7,281,358     (4,250,864
  

 

 

   

 

 

   

 

 

   

 

 

 
     1,154,235        (349,041     6,619,641        7,557,090   
  

 

 

   

 

 

   

 

 

   

 

 

 

As described elsewhere herein, the Company determined that it qualified and became eligible for the research and development tax incentive income during the third quarter of the 2013 financial year after which all the incentive income for the nine months ended September 30, 2013 was recognized in the third quarter of 2013.

The non-cash components of depreciation and share based payments expense included in the research and development expenditure are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014     2013  
     A$      A$      A$     A$  

Depreciation

     582,663         152,194         1,708,168        456,952   

Share based payments

     44,584         75,537         (166,434     203,188   
  

 

 

    

 

 

    

 

 

   

 

 

 
     627,247         227,731         1,541,734        660,140   
  

 

 

    

 

 

    

 

 

   

 

 

 

While we have a degree of control as to how much we spend on research and development activities in the future, we cannot predict what it will cost to complete our individual research and development programs successfully or when or if they will be commercialized. The timing and cost of any program is dependent upon achieving technical objectives, which are inherently uncertain.

 

25


Table of Contents

Universal Biosensors, Inc.

 

In addition, our business strategy contemplates that we may enter into collaborative arrangements with third parties for one or more of our non-blood glucose programs. In the event that we are successful in securing such third party collaborative arrangements, the third party may direct the research and development activities and may contribute towards all or part of the cost of these activities, both of which will influence our research and development expenditure. Research and development activities undertaken on behalf of our customers and partners for the three months ended September 30, 2014 and September 30, 2013 were A$2,822,374 and A$2,480,533, respectively and A$8,107,127 and A$8,254,523 for the nine months ended September 30, 2014 and September 30, 2013, respectively.

General and Administrative Expenses

General and administrative expenses currently consist principally of salaries and related costs, including stock option expense, for personnel in executive, business development, finance, accounting, information technology and human resources functions. Other general and administrative expenses include depreciation, repairs and maintenance, insurance, facility costs not otherwise included in research and development expenses, consultancy fees and professional fees for legal, audit and accounting services. General and administrative expenses are generally fixed in nature.

General and administrative expenses decreased by 10% during the three months ended September 30, 2014 compared to the same period in the previous financial year, reflecting management’s ongoing efforts to restrict spending on non-core activities. However, due to non-recurring consultancy services commissioned by the Company during the second quarter of 2014, the expenditure increased by 2% during the nine months ended September 30, 2014 compared to the same period in the previous financial year.

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

General and administrative expenses

     1,522,175         1,684,703         4,588,686         4,480,101   
  

 

 

    

 

 

    

 

 

    

 

 

 

The non-cash components of depreciation and share based payments expense included in the general and administrative expenditure are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014     2013  
     A$      A$      A$     A$  

Depreciation

     26,889         17,915         92,472        54,252   

Share based payments

     17,119         84,528         (52,627     224,089   
  

 

 

    

 

 

    

 

 

   

 

 

 
     44,008         102,443         39,845        278,341   
  

 

 

    

 

 

    

 

 

   

 

 

 

Interest Income

Interest income decreased during the three and nine months ended September 30, 2014 compared to the same periods in the previous financial year. The decrease in interest income is generally attributable to the lower amount of funds available for investment in Australian currency. A large portion of our funds is held in US denominated currency which currently does not produce any investment interest.

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

Interest income

     103,398         123,633         187,247         417,022   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

26


Table of Contents

Universal Biosensors, Inc.

 

Interest Expense

Interest expense for the 2014 financial year relates to a 2.88% interest being charged on a short-term borrowing initiated in January 2014. This short-term borrowing has now been fully repaid. In comparison, interest expense for the 2013 financial year relates to a 2.95% interest being charged on a short-term borrowing initiated in February 2013.

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

Interest expense

     4,772         7,547         15,905         18,867   
  

 

 

    

 

 

    

 

 

    

 

 

 

Financing Costs

In December 2013, UBS accessed new capital via a US$25,000,000 term loan facility of which US$15,000,000 was drawn in December 2013. The breakdown of the financing costs is as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

Interest expense

     440,493         0         1,310,346         0   

Warrants expense

     44,999         0         133,361         0   

Other debt issuance costs

     168,603         0         501,288         0   
  

 

 

    

 

 

    

 

 

    

 

 

 
     654,095         0         1,944,995         0   
  

 

 

    

 

 

    

 

 

    

 

 

 

Interest expense relates to applicable interest of 10.5% levied on the loan. The fair value of the warrant issued to the Lenders was estimated using the Trinomial Lattice model. The debt issuance costs were recorded as deferred issuance costs and are amortized as interest expense, using the effective interest method, over the term of the loan.

Other

The Company has recorded research and development tax incentive income of A$3,561,209 and A$4,250,864 for the three months ended September 30, 2014 and 2013, respectively and A$7,281,358 and A$4,250,864 for the nine months ended September 30, 2014 and 2013, respectively under this caption. The Company determined that it qualified and became eligible for this rebate during the third quarter of the 2013 financial year after which all the rebate for the nine months ended September 30, 2013 was recognized in the third quarter of 2013. The balance is primarily represented by foreign exchange movements arising from the settlement of foreign denominated transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies.

The research and development tax incentive receivable has been recorded as “Other current assets” in the consolidated balance sheets.

The research and development tax incentive is one of the key elements of the Australian Government’s support for Australia’s innovation system. It was developed to assist businesses recover some of the costs of undertaking research and development. The research and development tax incentive provides a tax offset to eligible companies that engage in research and development activities.

Companies engaged in research and development may be eligible for either:

 

    a 43.5% refundable tax offset with effect from July 1, 2014 (45% prior to June 30, 2014) for entities with an aggregated turnover of less than A$20 million per annum, or

 

    a 38.5% non-refundable tax offset with effect from July 1, 2014 (40% prior to June 30, 2014) for all other entities.

Critical Accounting Estimates and Judgments

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, costs and expenses, and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates.

 

27


Table of Contents

Universal Biosensors, Inc.

 

We believe that of our significant accounting policies, which are described in the notes to our consolidated financial statements, the following accounting policies involve a greater degree of judgment and complexity. Accordingly, we believe that the following accounting policies are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations.

(a) Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and collection is probable. Product is considered delivered to the customer once it has been shipped and title and risk of loss have been transferred.

In addition, the Company enters into arrangements, which contain multiple revenue generating activities. The revenue for these arrangements is recognized as each activity is performed or delivered, based on the relative fair value and the allocation of revenue to all deliverables based on their relative selling price. In such circumstances, the Company uses a hierarchy to determine the selling price to be used for allocation of revenue to deliverables, vendor-specific objective evidence, third-party evidence of selling price and the Company’s best estimate of selling price. The Company’s process for determining its best estimate of selling price for deliverables without vendor-specific objective evidence or third-party evidence of selling price involves management’s judgment. The Company’s process considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable.

(b) Stock-Based Compensation

We account for stock-based employee compensation arrangements using the modified prospective method as prescribed in accordance with the provisions of ASC 718 – Compensation – Stock Compensation.

Each of the inputs to the Trinomial Lattice model is discussed below.

Share Price and Exercise Price at Valuation Date

With the exception of ZEPOs, the exercise price of the options granted has been determined using the closing price of our common stock trading in the form of CDIs on ASX at the time of grant of the options. The exercise price of ZEPOs is nil. The ASX is the only exchange upon which our securities are quoted.

Volatility

We applied volatility having regard to the historical price change of our shares in the form of CDIs available from the ASX.

Time to Expiry

All options granted under our share option plan have a maximum 10 year term and are non-transferable.

Risk Free Rate

The risk free rate which we applied is equivalent to the yield on an Australian government bond with a time to expiry approximately equal to the expected time to expiry on the options being valued.

(c) Income Taxes

We apply ASC 740 – Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement

 

28


Table of Contents

Universal Biosensors, Inc.

 

carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.

(d) Impairment of Long-Lived Assets

We review our capital assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, we estimate undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows.

(e) Warrants

In connection with our US$25 million loan facility, we issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at a price of A$1.00 per share. The fair value of the warrants to purchase common stock is estimated using the Trinomial Lattice model. Each of the inputs to the Trinomial Lattice model is discussed below.

Share Price and Exercise Price at Valuation Date

The share price of the warrants granted has been determined using the closing price of our common stock trading in the form of CDIs on ASX at the time of entering in to the loan facility. The ASX is the only exchange upon which our securities are quoted. The exercise price has been determined as stated in the Credit Agreement.

Volatility

We applied volatility having regard to the historical price change of our shares in the form of CDIs available from the ASX.

Time to Expiry

The warrants have a term of seven years.

Risk Free Rate

The risk free rate which we applied is equivalent to the yield on an Australian government bond with a time to expiry approximately equal to the expected time to expiry on the warrants to purchase common stock being valued.

 

29


Table of Contents

Universal Biosensors, Inc.

 

Financial Condition, Liquidity and Capital Resources

Net Financial Assets

Our net financial assets position is shown below:

 

     September 30,      December 31,  
     2014      2013  
     A$      A$  

Financial assets:

     

Cash and cash equivalents

     19,830,109         23,742,422   

Accounts receivable

     2,012,682         2,167,867   
  

 

 

    

 

 

 

Total financial assets

     21,842,791         25,910,289   
  

 

 

    

 

 

 

Debt:

     

Short term borrowings

     0         0   

Long term secured loan

     16,352,515         15,857,966   
  

 

 

    

 

 

 

Total debt

     16,352,515         15,857,966   
  

 

 

    

 

 

 

Net financial assets

     5,490,276         10,052,323   
  

 

 

    

 

 

 

Since inception, we have financed our business primarily through the issuance of equity securities, funding from strategic partners, government grants and rebates (including the tax incentive income), revenue from services and product sales.

On December 19, 2013 we entered into the Credit Agreement with the Lenders for a US$25 million secured term loan. The term loan has a maturity date of December 19, 2018 and bears interest at 10.5% per annum. Interest payments are due quarterly over the five-year term of the term loan and, other than as described elsewhere herein, we are not required to make payments of principal for amounts outstanding under the term loan until the Maturity Date. Subject to certain exceptions, the term loan is secured by substantially all of our assets, including our intellectual property. For further details, see Notes to Consolidated Financial Statements - Summary of Significant Accounting Policies – Borrowings – Athyrium Credit Agreement.

We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months.

The carrying value of the cash and cash equivalents and the accounts receivable approximates fair value because of their short-term nature.

We regularly review all our financial assets for impairment. There were no impairments recognized for the nine months ended September 30, 2014 or for the year ended December 31, 2013.

Derivative Instruments and Hedging Activities

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. At September 30, 2014 and December 31, 2013, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives is based on the market approach using observable market inputs, such as forward rates, and incorporates non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2.

We had no outstanding contracts as at September 30, 2014 and December 31, 2013. We recognized gains of nil for the periods ended September 30, 2014 and December 31, 2013. No amount of ineffectiveness was recorded in earnings for these designated cash flow hedges for the periods ended September 30, 2014 and December 31, 2013. For further details, see Notes to Consolidated Financial Statements – Summary of Significant Accounting Policies.

 

30


Table of Contents

Universal Biosensors, Inc.

 

Measures of Liquidity and Capital Resources

The following table provides certain relevant measures of liquidity and capital resources:

 

     September 30,      December 31,  
     2014      2013  
     A$      A$  

Cash and cash equivalents

     19,830,109         23,742,422   

Working capital

     22,993,445         30,367,292   

Ratio of current assets to current liabilities

     4.86 : 1         6.60 : 1   

Shareholders’ equity per common share

     0.12         0.17   

The movement in cash and cash equivalents and working capital during the above periods was primarily due to reductions resulting from outflows of cash (reflects the effort required to complete the final stages of the development phase prior to launch of the four tests we are undertaking) and to the timing of cash receipts, payments, sales and accruals in the ordinary course of business. In addition to the reductions resulting from operating outflows of cash, a first tranche loan of US$15,000,000 (equivalent to A$16,909,029) was drawn in December 2013 by UBS pursuant to the Credit Agreement. The Company was also in receipt of A$8,015,037 as research and development tax incentive income in September 2014 as a tax offset for its 2013 research and development expenses.

We have not identified any collection issues with respect to receivables.

Summary of Cash Flows

 

     Nine Months Ended
September 30,
 
     2014     2013  
     A$     A$  

Cash provided by/(used in):

    

Operating activities

     (1,552,576     (10,179,308

Investing activities

     (691,465     (135,252

Financing activities

     (1,638,752     322,673   
  

 

 

   

 

 

 

Net increase/(decrease) in cash and cash equivalents

     (3,882,793     (9,991,887
  

 

 

   

 

 

 

Our net cash used in operating activities for all periods is for our research and development projects, efforts involved in establishing and maintaining our manufacturing operations, and general and administrative expenditure. Our net cash used in operating activities for the period ended September 30, 2013 was also consumed in the manufacture of OneTouch® Verio® strips. The outflows during these periods have been partially offset by receipts from our customers and partners. The 2014 outflow has also been offset by the receipt of A$8,015,037 as research and development tax incentive income in September 2014 as a tax offset for its 2013 research and development expenses.

Our net cash used in investing activities for all periods is primarily for the purchase of various plant and equipment and fit out of our facilities based on our needs.

An outflow of A$1,638,752 included within our financing activities relates to the payment of interest and other debt issuance costs pursuant to the Credit Agreement for the period ended September 30, 2014. We also took advantage of a favorable borrowing opportunity to prepay our annual insurances. The net proceeds (proceeds less repayments) of A$0 and A$127,912 are reflected as a financing activity for the periods ended September 30, 2014 and 2013, respectively.

 

31


Table of Contents

Universal Biosensors, Inc.

 

Off-Balance Sheet Arrangement

The future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) as of September 30, 2014 are:

 

     A$  

Less than 1 year

     544,555   

1 – 3 years

     1,146,394   

3 – 5 years

     902,877   

More than 5 years

     0   
  

 

 

 

Total minimum lease payments

     2,593,826   
  

 

 

 

The above relates to our operating lease obligations in relation to the lease of our premises and certain office equipment.

Contractual Obligations

Our future contractual obligations at September 30, 2014 were as follows:

 

     Payments Due By Period  
     Total      Less than 1
year
     1 – 3 years      3 – 5 years      More than 5
years
 
     A$      A$      A$      A$      A$  

Asset Retirement Obligations (1)

     2,600,000         0         0         2,600,000         0   

Operating Lease Obligations (2)

     2,593,826         544,555         1,146,394         902,877         0   

Purchase Obligations (3)

     1,105,799         1,105,799         0         0         0   

Long term secured loan (4)

     16,352,515         0         0         16,352,515         0   

Financing costs (5)

     9,174,808         2,741,278         5,938,643         494,887         0   

Other Long-Term Liabilities on Balance Sheet (6)

     131,165         0         67,888         61,950         1,327   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     31,958,113         4,391,632         7,152,925         20,412,229         1,327   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) Represents legal obligations associated with the retirement and removal of long-lived assets.
(2) Our operating lease obligations relate primarily to the lease of our premises.
(3) Represents outstanding purchase orders
(4) US$15 million payable to the lenders on Maturity Date pursuant to the Credit Agreement
(5) Interest and other debt issuance costs payable to the lenders pursuant to the Credit Agreement
(6) Represents long service leave owing to the employees.

Segments

We operate in one segment. Our principal activities are research and development, commercial manufacture of approved medical or testing devices and the provision of services including contract research work.

We operate predominantly in one geographical area, being Australia.

 

32


Table of Contents

Universal Biosensors, Inc.

 

The Company’s total income has been derived from the following countries:

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2014     2013     2014     2013  
     A$     A$     A$     A$  

Home country - Australia

     3,690,221        4,374,527        7,550,488        4,667,886   

Foreign countries:

        

Scotland

     0        1,396,357        0        8,597,428   

U.S.A.

     295,632        284,538        436,327        1,062,161   

Switzerland

     1,632,176        832,691        4,301,144        2,433,424   

Germany

     137,294        0        137,294        0   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total - foreign countries

     2,065,102        2,513,586        4,874,765        12,093,013   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total income

     5,755,323        6,888,113        12,425,253        16,760,899   
  

 

 

   

 

 

   

 

 

   

 

 

 

% of total income derived from:

        

LifeScan

     28     85     35     88

Siemens

     8     11     5     8

We continue to derive significant revenues from LifeScan.

The Company’s material long-lived assets are all based in Australia.

 

33


Table of Contents

Universal Biosensors, Inc.

 

Item 3 Quantitative and Qualitative Disclosures About Market Risk

Financial Risk Management

The overall objective of our financial risk management program is to seek to minimize the impact of foreign exchange rate movements and interest rate movements on our earnings. We manage these financial exposures through operational means and by using financial instruments. These practices may change as economic conditions change.

Foreign Currency Market Risk

We transact business in various foreign currencies, including U.S. dollars and Euros. We have established a foreign currency hedging program using forward contracts to hedge the net projected exposure for each currency and the anticipated sales and purchases in U.S. dollars and Euros. The goal of this hedging program is to economically guarantee or lock-in the exchange rates on our foreign exchange exposures. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.

Although the Company has a hedging program, as at September 30, 2014 and December 31, 2013, there were no open derivatives to be disclosed.

Interest Rate Risk

Since the majority of our investments are in cash and cash equivalents in U.S. or Australian dollars, our interest income is affected by changes in the general level of U.S. and Australian interest rates. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Our investment portfolio is subject to interest rate risk but due to the short duration of our investment portfolio, we believe an immediate 10% change in interest rates would not be material to our financial condition or results of operations.

Inflation

Our business is subject to the general risks of inflation. Our results of operations depend on our ability to anticipate and react to changes in the price of raw materials and other related costs over which we may have little control. Our inability to anticipate and respond effectively to an adverse change in the price could have a significant adverse effect on our results of operations. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.

 

34


Table of Contents

Universal Biosensors, Inc.

 

Item 4. Controls and Procedures

Disclosure Controls and Procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of its disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Paul Wright, Chief Executive Officer, and Salesh Balak, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Wright and Balak concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting. During the fiscal quarter ended September 30, 2014, there were no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

35


Table of Contents

Universal Biosensors, Inc.

 

PART II

 

Item 1 Legal Proceedings

None.

 

Item 1A Risk Factors

In addition to the other information discussed in this report, the factors described in Part I, Item 1A. “Risk Factors” in our 2013 Annual Report on Form 10-K filed with the SEC on March 13, 2014 should be considered as they could materially affect our business, financial condition or future results. There have not been any significant changes with respect to the risks described in our 2013 Form 10-K, but these are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition or operating results.

 

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds

There has been no sale of equity securities by the Company or purchase of equity securities by the Company, or by an affiliated purchaser on behalf of the Company, since December 31, 2013.

 

Item 3 Defaults Upon Senior Securities

None.

 

Item 4 Mine Safety Disclosures

Not applicable.

 

Item 5 Other Information

None.

 

Item 6 Exhibits

 

Exhibit
No

  

Description

  

Location

  31.1    Rule 13a-14(a)/15d-14(a) Certification (Principal Executive Officer)    Filed herewith
  31.2    Rule 13a-14(a)/15d-14(a) Certification (Principal Financial Officer)    Filed herewith
  32    Section 1350 Certificate    Furnished herewith
101    The following materials from the Universal Biosensors, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Condensed Balance Sheets, (ii) the Consolidated Condensed Statements of Comprehensive Income, (iii) the Consolidated Condensed Statements of Changes in Stockholder’s Equity, (iv) the Consolidated Condensed Statements of Cash Flows and (v) the Notes to Consolidated Condensed Financial Statements text    Filed herewith

 

36


Table of Contents

Universal Biosensors, Inc.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

UNIVERSAL BIOSENSORS, INC.

(Registrant)

    By:  

/s/ Paul Wright

Date: October 29, 2014       Paul Wright
      Principal Executive Officer
    By:  

/s/ Salesh Balak

Date: October 29, 2014       Salesh Balak
      Principal Financial Officer

 

37


Table of Contents

INDEX TO EXHIBITS

Quarterly Report on Form 10-Q

Dated October 29, 2014

 

Exhibit
No

  

Description

  

Location

  31.1    Rule 13a-14(a)/15d-14(a) Certification (Principal Executive Officer)    Filed herewith
  31.2    Rule 13a-14(a)/15d-14(a) Certification (Principal Financial Officer)    Filed herewith
  32    Section 1350 Certificate    Furnished herewith
101    The following materials from the Universal Biosensors, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Condensed Balance Sheets, (ii) the Consolidated Condensed Statements of Comprehensive Income, (iii) the Consolidated Condensed Statements of Changes in Stockholder’s Equity, (iv) the Consolidated Condensed Statements of Cash Flows and (v) the Notes to Consolidated Condensed Financial Statements    Filed herewith

 

38

EX-31.1 2 d798417dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul Wright, certify that:

 

1. I have reviewed this report on Form 10-Q of Universal Biosensors, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 29, 2014

 

/s/ Paul Wright

Paul Wright
Principal Executive Officer
Universal Biosensors, Inc.
EX-31.2 3 d798417dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Salesh Balak, certify that:

 

1. I have reviewed this report on Form 10-Q of Universal Biosensors, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 29, 2014

 

/s/ Salesh Balak

Salesh Balak
Principal Financial Officer
Universal Biosensors, Inc.
EX-32 4 d798417dex32.htm EX-32 EX-32

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 *

In connection with the quarterly report of Universal Biosensors, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of such officer’s knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. The undersigned have executed this Certificate as of the 29th day of October, 2014.

 

/s/ Paul Wright

Paul Wright
Principal Executive Officer

/s/ Salesh Balak

Salesh Balak
Principal Financial Officer

 

* This certification is being furnished as required by Rule 13a-14(b) under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code, and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent such certification is explicitly incorporated by reference in such filing.
EX-101.INS 5 ubi-20140930.xml XBRL INSTANCE DOCUMENT 0.0295 767471 0.0288 568677 175610978 2961245 3000000 0.71 0.71 0.010 0.06 0.33 0.33 0.17 0.17 39372139 2351464 23649417 -298312 -53356552 173959863 17396 93009607 4500000 4500000 1.00 25000000 1.17 175600605 175600605 260801 1.07 10606099 1000000 300000000 0.0001 0.72 0.01 0 2329440 1732500 15857966 14189708 17906571 974754 5422287 -298312 1160177 29683940 94955051 0 16732500 -53356552 957916 17560 54619699 15000000 1749167 15857966 14189708 24935759 19513472 2532500 957916 1732500 2549928 0 0 0 2549928 35789579 2920000 825800 3495000 38 54619699 23742422 4169 2167867 2167867 4207 33816691 18830120 9049283 0 15910120 147662 815655 -11633807 9479167 24479167 5363 575000 10000000 15000000 2600000 320000 0.49 0.49 0.49 -298312 -64990359 175600605 17560 94955051 0.79 0.79 8344277 31670256 14670902 0 -298312 -61723321 174785443 17479 93674410 175610978 8219892 175610978 253764 1.06 9914772 1000000 300000000 0.0001 0.71 0.01 0 2615730 1732500 16352515 14311721 19701816 957140 5964359 -298312 1412121 20619173 94736989 0 16732500 -64990359 979368 17561 46646580 15000000 1749167 16352515 14311721 26027407 20063048 1083125 979368 1732500 2600000 0 0 0 2600000 28957804 2920000 870573 2920000 78709 46646580 19830109 315036 2012682 2012682 393745 34470592 17688776 0 5850695 0 14768776 131165 815655 0.40 -8846706 0.50 1000000000 1000 0.50 2 8029792 23029792 127376 0 0.105 2000000 5000000 5000000 2600000 320000 -298312 -73837065 175610978 17561 94736989 201189 25869 69817 104597 906 0 0.02 625000 0.025 0.15 0.05 500000 -10179308 0.0900 -0.05 1000 724989 4361105 -8366769 0 2547278 -907 8597428 4975853 639559 194761 417022 0 -13740777 3495585 -23549 -8366769 -577192 5374008 -8366769 -1218518 469125 12093013 135252 4250864 -1915731 284844 4480101 868347 9545735 8677388 322673 0 0 469125 16288055 1890162 -9991887 -135252 0 18867 11807954 194761 0 767471 469125 0 1013372 0 0 0 0 0 0 -8366769 0 824663 917 1 82 0 0 999 194679 0 469125 UBI UNIVERSAL BIOSENSORS INC false Smaller Reporting Company 2014 10-Q 2014-09-30 0001279695 --12-31 Q3 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Restricted stock awards activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> issue&#xA0;price<br /> A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">260,801</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.72</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Release of restricted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(9,077</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.77</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,040</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2014</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">253,764</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The table below sets forth the RSUs issued by the Company since January&#xA0;1, 2013:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br /> Restricted&#xA0;Shares<br /> Issued</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Market&#xA0;Value&#xA0;of<br /> Restricted&#xA0;Shares<br /> Issued&#xA0;(A$)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> May, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">917</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> December, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">142,800</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69,972</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> June, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,040</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> 2040 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Recent Accounting Pronouncements</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On May&#xA0;28, 2014, the FASB issued ASU 2014-09 which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The core principle of the revenue model is that &#x201C;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#x201D; In applying the revenue model to contracts within its scope, an entity will:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Identify the contract(s) with a customer (step 1).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Identify the performance obligations in the contract (step 2).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Determine the transaction price (step 3).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Allocate the transaction price to the performance obligations in the contract (step 4).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Recognize revenue when (or as) the entity satisfies a performance obligation (step 5).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The ASU applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. Certain of the ASU&#x2019;s provisions also apply to transfers of nonfinancial assets, including in-substance nonfinancial assets that are not an output of an entity&#x2019;s ordinary activities (e.g., sales of (1)&#xA0;property, plant, and equipment; (2)&#xA0;real estate; or (3)&#xA0;intangible assets). Existing accounting guidance applicable to these transfers (e.g., ASC 360-20) has been amended or superseded.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Compared with current U.S. GAAP, the ASU also requires significantly expanded disclosures about revenue recognition.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The ASU is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December&#xA0;15, 2016, for public entities. Early application is not permitted (however, early adoption is optional for entities reporting under IFRSs).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Entities have the option of using either a full retrospective or a modified approach to adopt the guidance in the ASU:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Full retrospective application &#x2014; Retrospective application would take into account the requirements in ASC 250 (with certain practical expedients).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Modified retrospective application &#x2014; Under the modified approach, an entity recognizes &#x201C;the cumulative effect of initially applying the ASU as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application&#x201D; (revenue in periods presented in the financial statements before that date is reported under guidance in effect before the change). Using this approach, an entity applies the guidance in the ASU to existing contracts (those for which the entity has remaining performance obligations) as of, and new contracts after, the date of initial application. The ASU is not applied to contracts that were completed before the effective date (i.e., an entity has no remaining performance obligations to fulfill). Entities that elect the modified approach must disclose an explanation of the impact of adopting the ASU, including the financial statement line items and respective amounts directly affected by the standard&#x2019;s application.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is currently evaluating the method and impact the adoption of ASU 2014-09 will have on the Company&#x2019;s condensed consolidated financial statements.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Stock-based Compensation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (&#x201C;RSUs&#x201D;) and Zero Priced Employee Options (&#x201C;ZEPOs&#x201D;). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company&#x2019;s stock price. The exercise price of ZEPOs is nil.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to paid-in-capital are still available if the tax deduction is less than the deferred tax asset.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><i>(a)</i></td> <td valign="top" align="left"><i>Stock Option Plan</i></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In 2004, the Company adopted an employee option plan (&#x201C;Plan&#x201D;). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"><b>Grant Date</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Aug-14</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Dec-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Dec-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Aug-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Mar-13</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercise Price (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.17</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Nil</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Share Price at Grant Date (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.17</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">64</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected Life (years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Risk Free Interest Rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.13</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.82</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.82</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.54</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.37</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Fair Value of Option (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.10</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.41</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Stock option activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> exercise&#xA0;price<br /> A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,606,099</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">152,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.10</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(8,333</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Lapsed</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(834,994</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.02</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2014</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,914,772</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.06</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The number of options exercisable as at September&#xA0;30, 2014 and September&#xA0;30, 2013 was 8,219,892 and 8,344,277, respectively. The total stock compensation expense recognized in income statement was A$61,703 and A$175,623 for the three month period ended September&#xA0;30, 2014 and 2013, respectively and (A$219,061) and A$469,125 for the nine month period ended September&#xA0;30, 2014 and 2013, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> As of September&#xA0;30, 2014, there was A$201,189 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"><b>Fiscal Year</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69,817</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">104,597</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25,869</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">906</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">201,189</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The aggregate intrinsic value for all options outstanding as at September&#xA0;30, 2014 and September&#xA0;30, 2013 was zero.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>(b) Restricted Share Plan</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to non-executive directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company currently proposes to continue to issue A$1,000 worth of RSUs to employees of the Company on a recurring basis, but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The table below sets forth the RSUs issued by the Company since January&#xA0;1, 2013:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br /> Restricted&#xA0;Shares<br /> Issued</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Market&#xA0;Value&#xA0;of<br /> Restricted&#xA0;Shares<br /> Issued&#xA0;(A$)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> May, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">917</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> December, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">142,800</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69,972</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> June, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,040</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Restricted stock awards activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> issue&#xA0;price<br /> A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">260,801</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.72</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Release of restricted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(9,077</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.77</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,040</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2014</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">253,764</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Revenue Recognition</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We recognize revenue from all sources based on the provisions of the U.S. SEC&#x2019;s Staff Accounting Bulletin No.&#xA0;104 and ASC 605 Revenue Recognition.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company&#x2019;s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company&#x2019;s best estimate of selling price when fair value is not available for a given unit of accounting.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Under ASC 605-25, the delivered item(s) are separate units of accounting, provided (i)&#xA0;the delivered item(s) have value to a customer on a stand-alone basis, and (ii)&#xA0;if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following: non-refundable, upfront payments; funding of research and/or development efforts; and milestone payments.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We typically generate milestone payments from our customers pursuant to the various agreements we have with them. <font style="white-space:nowrap">Non-refundable</font> milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the non-refundable milestone payment is not substantive or stand-alone value, the <font style="white-space:nowrap">non-refundable</font> milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company&#x2019;s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as &#x201C;revenues&#x201D;.</p> </div> 1.02 834994 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Stock option activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> exercise&#xA0;price<br /> A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,606,099</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">152,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.10</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(8,333</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Lapsed</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(834,994</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.02</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2014</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,914,772</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.06</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Impairment of Long-Lived Assets</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company reviews its capital assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Total Comprehensive Income</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company follows ASC 220 &#x2013; Comprehensive Income. Comprehensive income is defined as the total change in shareholders&#x2019; equity during the period other than from transactions with shareholders, and for the Company, includes net income and cumulative translation adjustments.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> This expense is expected to be recognized as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"><b>Fiscal Year</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69,817</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">104,597</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25,869</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">906</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">201,189</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The aggregate intrinsic value for all options outstanding as at September</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Basis of Presentation</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> All amounts within these consolidated financial statements are expressed in Australian dollars (&#x201C;AUD&#x201D; or &#x201C;A$&#x201D;) unless otherwise stated.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company&#x2019;s consolidated financial statements have been prepared assuming the Company will continue as a going concern. We rely largely on our existing cash and cash equivalents balance and operating cash flow to provide for the working capital needs of our operations. We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. However, in the event, our financing needs for the foreseeable future are not able to be met by our existing cash and cash equivalents balance and operating cash flow, we would seek to raise funds through public or private equity offerings, debt financings, and through other means to meet the financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.</p> </div> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Organization of the Company</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We are a specialist medical diagnostics company focused on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We were incorporated in the State of Delaware on September&#xA0;14, 2001 and our shares of common stock in the form of CHESS Depositary Interests (&#x201C;CDIs&#x201D;) have been quoted on the Australian Securities Exchange (&#x201C;ASX&#x201D;) since December&#xA0;13, 2006. Our securities are not currently traded on any other public market. Our wholly owned subsidiary and primary operating vehicle, UBS, was incorporated as a proprietary limited company in Australia on September&#xA0;21, 2001. UBS conducts our research, development and manufacturing activities in Melbourne, Australia.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We have rights to an extensive patent portfolio, with certain patents owned by UBS and a number licensed to UBS by LifeScan, Inc. (&#x201C;LifeScan&#x201D;) and other third party licensees. Unless otherwise noted, references to &#x201C;LifeScan&#x201D; in this document are references collectively or individually to LifeScan, Inc., and/or LifeScan Europe, a division of Cilag GmbH International, both affiliates of Johnson and Johnson.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> We are using our electrochemical cell technology platform to develop tests for a number of different markets. Our current focus is as set out below:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%">&#xA0;</td> <td width="3%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Coagulation testing market &#x2013; we are working with Siemens Healthcare Diagnostics, Inc. (&#x201C;Siemens&#x201D;) to develop a range of products for the point-of-care coagulation market pursuant to a collaboration agreement with Siemens (&#x201C;Collaboration Agreement&#x201D;) and, subject to being approved for sale, plan to manufacture test strips for these products under a supply agreement with Siemens (&#x201C;Supply Agreement&#x201D;). We are also developing our own Prothrombin Time International Normalized Ratio (&#x201C;PT-INR&#x201D;) test targeted at the patient self-test market and intend to enter into distribution agreements with respect to that test.</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%">&#xA0;</td> <td width="3%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Blood glucose &#x2013; we provide services to LifeScan as required from time to time, pursuant to a Master Services and Supply Agreement (&#x201C;Master Services and Supply Agreement&#x201D;) and a development and research agreement (&#x201C;Development and Research Agreement&#x201D;) with LifeScan.</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%">&#xA0;</td> <td width="3%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Other electrochemical-cell based tests &#x2013; we are working on proving the broader applicability of our technology platform, including tests based on enzymatic, immunoassay and molecular diagnostic methods. We may seek to enter into collaborative arrangements, strategic alliances or distribution agreements with respect to any tests arising from this work.</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Borrowings</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Future maturities, interest and other payments under the Company&#x2019;s long term secured loan pursuant to the credit agreement (described below) as of September&#xA0;30, 2014 and December&#xA0;31, 2013 are as follows:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="58%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">September&#xA0;30, 2014</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">December&#xA0;31, 2013</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">US$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">A$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">US$</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">A$</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,083,125</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,532,500</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,749,167</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,749,167</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,732,500</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,732,500</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,732,500</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,732,500</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,732,500</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,732,500</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Total minimum payments</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">23,029,792</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24,479,167</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Less amount representing interest and other fees</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(8,029,792</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(9,479,167</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Gross balance of long term debt</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,000,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,000,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Less fair value of warrants recorded within loan (a)</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(815,655</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(815,655</td> <td nowrap="nowrap" valign="bottom">)&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Plus amortization of warrants</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">127,376</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,363</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Total carrying value</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,311,721</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,352,515</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,189,708</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,857,966</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Less current portion</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Total carrying value, non-current portion</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,311,721</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,352,515</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,189,708</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,857,966</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(a)</td> <td align="left" valign="top">The warrants issued in December 2013 had a fair value of US$815,655 as of September&#xA0;30, 2014 and December&#xA0;31, 2013, and are included in long term debt carrying value.</td> </tr> </table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Athyrium Credit Agreement</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> On December&#xA0;19, 2013 (&#x201C;Closing Date&#x201D;), UBI and its wholly owned subsidiary, UBS (together UBI and UBS, the &#x201C;Transaction Parties&#x201D;) entered into a credit agreement with Athyrium Opportunities Fund (A)&#xA0;LP (&#x201C;Athyrium A&#x201D;), as administrative agent (the &#x201C;Administrative Agent&#x201D;) and as a lender, and Athyrium Opportunities Fund (B)&#xA0;LP (&#x201C;Athyrium B&#x201D;) as a lender (Athyrium A and Athyrium B together with any other lenders party thereto from time to time, the &#x201C;Lenders&#x201D;) for a secured term loan of up to US$25 million (&#x201C;Credit Agreement&#x201D;). Of this amount, US$15 million had been drawn at December&#xA0;31, 2013, with a further US$10 million available to be drawn down as follows:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%">&#xA0;</td> <td width="3%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">US$5 million available within 30 days after the end of any quarter until January&#xA0;30, 2015, conditional upon UBS satisfying certain conditions precedent including that in the immediately preceding quarter, UBS achieves quarterly service fee revenues from the sale of the OneTouch<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> Verio<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> blood glucose strips (&#x201C;Verio QSFs&#x201D;) plus coagulation manufacturing revenues of not less than US$1,800,000 in the aggregate; and</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%">&#xA0;</td> <td width="3%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">US$5 million available within 30 days after the end of any quarter until January&#xA0;30, 2015, conditional upon UBS satisfying certain conditions precedent including that in the immediately preceding quarter, UBS achieves Verio QSFs plus coagulation manufacturing revenues of not less than US$2,500,000 in the aggregate.</td> </tr> </table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The term loan has a maturity date of December&#xA0;19, 2018 (&#x201C;Maturity Date&#x201D;) and bears interest at 10.5%&#xA0;per annum payable in cash quarterly in arrears over the five year term, and as otherwise described in the Credit Agreement. A default interest rate of 13%&#xA0;per annum shall apply during the existence of a default under the Credit Agreement. Other than as summarized below, UBS is not required to make payments of principal for amounts outstanding under the term loan until maturity, December&#xA0;19, 2018. The term loan under the Credit Agreement is secured by substantially all of UBI and UBS&#x2019; assets. UBI (together with any future subsidiaries) guarantees all of UBS&#x2019;s obligations under the term loan.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Voluntary prepayments of the term loans are not permitted prior to the second anniversary of the Closing Date, except in the event of a change of control of a Transaction Party. After the second anniversary, UBS can make voluntary repayments in minimum principal amounts of US$2,500,000 together with interest, plus the premium described below. UBS must make mandatory prepayments in certain prescribed circumstances, including in the event of raising additional debt financing, a sale or transfer of assets other than in certain circumstances and in the event of other specified extraordinary receipts. Extraordinary receipts include cash received or paid other than in the ordinary course of business, such as tax refunds (other than GST and R&amp;D tax rebates), LifeScan lump sum fee payments and Siemens termination fees. In such events, UBS must prepay to the Lenders 100% of the net cash proceeds received. In the event of a prepayment on or prior to the second anniversary of the Closing Date, UBS must also pay a prepayment premium of 20% of the loans due and payable on that date. If there is a prepayment after the second anniversary of the Closing Date, UBS must pay a prepayment premium commencing at 15% of the loans due and payable on the applicable date and reducing pro-rata on a monthly basis until the Maturity Date.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> UBS paid a non-refundable fee of US$625,000 to the Lenders on the Closing Date (being 2.5% of the aggregate credit facility) and a 2% commitment fee based on any available unused borrowing commitment under the Credit Agreement until January&#xA0;30, 2015. The Lenders will also be entitled to receive 30% of the net proceeds of milestone payments paid under the Collaboration Agreement by and among UBS, UBI and Siemens Healthcare Diagnostics, Inc., up to a maximum of US$600,000 in the aggregate. UBS has also agreed to pay certain taxes arising in connection with the Credit Agreement and other Loan Documents, including withholding taxes. UBS has also agreed to pay certain reasonable out-of-pocket expenses incurred by the Lenders in connection with the loan documents, or as may be incurred in connection with the enforcement or protection of their rights.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Credit Agreement also contains certain covenants, including among other things, covenants: (i)&#xA0;relating to the delivery of financial and other information and certificates, notices of defaults, litigation and other material events; payment of taxes and other obligations; maintenance of insurance; (ii)&#xA0;which limit or restrict the incurrence of liens; the making of investments; the incurrence of certain indebtedness; mergers, dispositions, liquidations, or consolidations and significant asset sales; restricted payments; transactions with affiliates other than on normal and arms-length terms; burdensome agreements; prepayment of other indebtedness; ownership of subsidiaries; and (iii)&#xA0;which require UBS to maintain unrestricted cash of not less than US$2,000,000 in a specified bank account at any time.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> As further described below, pursuant to the Credit Agreement, UBI issued to the lenders warrants entitling the holder to purchase up to an aggregate total of 4.5&#xA0;million shares of UBI&#x2019;s common stock in the form of CDIs at a price of A$1.00 per share (the &#x201C;Exercise Price&#x201D;), which represents a 117% premium over the closing price of UBI&#x2019;s common stock on December&#xA0;19, 2013. The warrants are immediately exercisable and have a term of seven years.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Other</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In January 2014, UBS entered into an arrangement with Pacific Premium Funding to fund the Group&#x2019;s insurance premium. The total amount financed was A$568,677 at inception. Interest is charged at a fixed rate of 2.88%&#xA0;per annum and the short-term borrowing has been fully repaid. The short-term borrowing was secured by the insurance premium refund. In February 2013, UBS entered into an arrangement with Lumley Finance Ltd to fund the Group&#x2019;s insurance premium. The total amount financed was A$767,471 at inception. Interest was charged at a fixed rate of 2.95%&#xA0;per annum and the short-term borrowing was fully repaid by December 2013. The short-term borrowing was secured by the insurance premium refund.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Interest income</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Receivables</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accounts receivable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,012,682</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,167,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Allowance for doubtful debts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,012,682</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,167,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Principles of Consolidation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, UBS. All intercompany balances and transactions have been eliminated on consolidation.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Interim Financial Statements</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September&#xA0;30, 2014 are not necessarily indicative of the results that may be expected for the year ending December&#xA0;31, 2014. For further information, refer to the financial statements and footnotes thereto as of and for the year ended December&#xA0;31, 2013, included in the Form 10-K of Universal Biosensors, Inc.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The year-end consolidated condensed balance sheets data as at December&#xA0;31, 2013 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain prior year amounts in the consolidated condensed financial statements have been reclassified to conform to the current presentation.</p> </div> 0.10 -1552576 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Costs of purchased inventory are determined after deducting rebates and discounts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">315,036</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,169</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Work in progress</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">78,709</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">393,745</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,207</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Account balances are charged against the allowance when it is probable the receivable will not be recovered.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accounts receivable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,012,682</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,167,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Allowance for doubtful debts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,012,682</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,167,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Asset Retirement Obligations</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Asset retirement obligations (&#x201C;ARO&#x201D;) are legal obligations associated with the retirement and removal of long-lived assets. ASC&#xA0;410 &#x2013; Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Our overall ARO changed as follows:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> <b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Opening balance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,549,928</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,351,464</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Accretion expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">50,072</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">198,464</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Ending balance</p> </td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,600,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,549,928</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Short-Term Investments (Held-to-maturity)</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Restricted Cash</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Restricted cash maintained by the Company in the form of term deposits is as follows:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> <b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Year&#xA0;Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Financial covenant pursuant to the Credit Agreement</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,600,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,600,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Letter of credit issued in favour of a supplier</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">575,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"> Collateral for facilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">320,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1.00px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,920,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,495,000</td> <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3.00px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="font-size:1px;margin-top:18px;margin-bottom:0px"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Universal Biosensors, Inc.</b></p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Inventory</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">315,036</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,169</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Work in progress</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">78,709</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">393,745</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,207</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Property, Plant, and Equipment</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company receives Victorian government grant monies under grant agreements to support our development activities, including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Our overall ARO changed as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Opening balance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,549,928</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,351,464</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accretion expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">50,072</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">198,464</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Ending balance</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,600,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,549,928</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Cash&#xA0;&amp; Cash Equivalents</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments.</p> </div> -0.05 0.00 152000 0.49 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Collaboration Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On September&#xA0;9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. In addition to an up-front, non-refundable payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement contained a further six payments from Siemens upon the achievement of certain defined milestones. These six milestones relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the up-front payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company&#x2019;s best estimate of selling price. The deliverables related to each milestone are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Of the six milestones, the Company has delivered on two as of September&#xA0;30, 2014:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">In June 2012, the Company delivered on its first milestone by achieving proof of technical feasibility of a new test strip and received a payment of A$1,522,534 (equivalent to US$1.5 million) as consideration. A sum of A$2,175,048 (equivalent to US$2,142,857) has been recognized as revenue from services in June 2012 in this regards.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">In July 2012, the Company delivered on its second milestone by achieving proof of technical feasibility of another new test strip and received a payment of A$1,438,711 (equivalent to US$1.5 million) as consideration. A sum of A$2,055,301 (equivalent to US$2,142,857) has been recognized as revenue from services in July 2012 in this regards.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> There were no revenues recognized for the three and nine months ended September&#xA0;30, 2014 and September&#xA0;30, 2013 relating to the delivery of the milestones pursuant to the Collaboration Agreement. Of the total amount of A$4,230,349 (equivalent to US$4,285,714) recognized as revenue for the 2012 financial year, A$2,961,245 (equivalent to US$3.0 million) relates to the achievement of the two milestones whilst the balance relates to a portion of the deferred US$3 million up-front payment allocated to these milestones based upon their relative estimate of selling price.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Research and Development</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Research and development expenses consist of costs incurred to further the Group&#x2019;s research and development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Research and development expenses for the three and nine months ended September&#xA0;30, 2014 and 2013 are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Research and development expenses</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,715,444</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,901,823</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,900,999</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11,807,954</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Commitments and Contingencies</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Our contingent liabilities as at September&#xA0;30, 2014 are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">we have a potential obligation to pay 50% of the patent fees paid by LifeScan in respect of the patents we license from LifeScan prior to the date of the first commercial sale of a non-glucose product that utilizes the technology licensed from LifeScan and 50% of the patent fees incurred by LifeScan in respect of such patents thereafter. In the event of the first commercial sale of a non-glucose product, the initial amount that could be paid by us to LifeScan is projected to be between US$1.6 million to US$1.8 million. We would have the right to make this payment either as a lump sum within 45 days of receipt of the supporting documentation from LifeScan or in equal monthly installment payments during the 24 months subsequent to the date of receipt of the supporting documentation. Currently the non-glucose products continue to be in the research and development phase.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">during 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> Verio<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup>, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by us in 2010 and 2011 up to a specified volume limit (&#x201C;manufacturing initiation payments&#x201D;). At the same time, we agreed to pay LifeScan a marketing support payment in each of the two years following the first year in which 1 billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The total amount of marketing support payments expected to be paid to LifeScan is approximately US$2 million. Based on the current volume of strips sold by LifeScan and that we have no visibility of future sales by LifeScan, it is uncertain whether we would be required to make this marketing support payment.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">we have engaged Planet Innovation Pty Ltd (&#x201C;Planet Innovation&#x201D;) to assist us with design and engineering for future analyzers. As part of the agreement, Planet Innovation will be paid a success payment upon the formal acceptance of the analyzer for commercial manufacture and a further success payment on launch sign-off for the first commercial sale of the analyzer. All of the analyzers Planet Innovation is currently working on are in the research and development phases, and therefore at this stage their commercial manufacture and sale and the amount of any future success payment cannot be reliably estimated.</td> </tr> </table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Leased Assets</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> All of the Company&#x2019;s leases for the periods ending September&#xA0;30, 2014 and December&#xA0;31, 2013 are considered operating leases. The costs of operating leases are charged to the statement of comprehensive income on a straight-line basis over the lease term.</p> </div> 8333 <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Related Party Transactions</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Details of related party transactions material to the operations of the Group other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, are set out below.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In September 2011, we entered into a non-exclusive license agreement with SpeeDx Pty Ltd (&#x201C;SpeeDx&#x201D;) pursuant to which SpeeDx granted us a license to use its proprietary MNAzyme technology in the field of molecular diagnostics. Under the agreement we make milestone payments totaling A$500,000 to SpeeDx if certain specified targets are achieved, and royalty payments ranging from 5% to 15% of that portion of our sales and licensing revenues arising from SpeeDx technology or products incorporating SpeeDx technology.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In August 2013, we entered into a consulting agreement with SpeeDx pursuant to which we provided certain services relating to the establishment and maintenance of a quality management system at SpeeDx. Consulting fees received under this agreement were A$77,758. In addition, a success fee of A$50,000 is payable by SpeeDx during the fourth quarter of 2014 as the criteria for successful completion of the engagement has been met.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Messrs Denver and Jane are directors of the Company and SpeeDx. Talu Ventures Pty Ltd, of which Mr.&#xA0;Jane is a director, is a fund manager for a fund which holds approximately 33% of the issued shares in SpeeDx. Until September&#xA0;27, 2013, PFM Cornerstone Limited held approximately 6% of our shares (this holding has since decreased to less than 1.0% of our shares) and PFM Cornerstone Limited also holds approximately 33% of the issued shares in SpeeDx. Messrs Denver and Hanley are directors of the Company and PFM Cornerstone Limited.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Employee Benefit Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company contributes to standard defined contribution superannuation funds on behalf of all employees. This contribution amount, formerly equal to 9% of each employee&#x2019;s salary, was increased by law to 9.25% from July&#xA0;1, 2013 and 9.5% from July&#xA0;1, 2014 of each such employee&#x2019;s salary. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee&#x2019;s remuneration to an approved superannuation fund that the employee is typically not able to access until they are retired. The Company permits employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b>Summary of Significant Accounting Policies</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Principles of Consolidation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, UBS. All intercompany balances and transactions have been eliminated on consolidation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations and obligations related to employee benefits. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Cash&#xA0;&amp; Cash Equivalents</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Short-Term Investments (Held-to-maturity)</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated balance sheets. The Company&#x2019;s cash and cash equivalents are invested with one of Australia&#x2019;s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Derivative Instruments and Hedging Activities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Derivative financial instruments</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company uses derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Cash flow hedges</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Exposure to foreign exchange risks arises in the normal course of the Company&#x2019;s business and it is the Company&#x2019;s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the non-financial asset or liability.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Derivative Instruments and Hedging Activities</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. At September&#xA0;30, 2014 and year ended December&#xA0;31, 2013, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2. The fair value methodologies described as Level 2 and 3 inputs are defined elsewhere in these notes to the financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Inventory</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">315,036</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,169</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Work in progress</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">78,709</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">393,745</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,207</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Receivables</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accounts receivable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,012,682</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,167,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Allowance for doubtful debts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,012,682</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,167,867</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Property, Plant, and Equipment</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company receives Victorian government grant monies under grant agreements to support our development activities, including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Research and Development</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Research and development expenses consist of costs incurred to further the Group&#x2019;s research and development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Research and development expenses for the three and nine months ended September&#xA0;30, 2014 and 2013 are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Research and development expenses</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,715,444</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,901,823</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,900,999</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11,807,954</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Income Taxes</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company applies ASC 740 - Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company&#x2019;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We are subject to income taxes in the United States and Australia. U.S. federal income tax returns up to and including the 2013 financial year has been filed. Internationally, consolidated income tax returns up to and including the 2013 financial year have been filed.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Asset Retirement Obligations</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Asset retirement obligations (&#x201C;ARO&#x201D;) are legal obligations associated with the retirement and removal of long-lived assets. ASC&#xA0;410 &#x2013; Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Our overall ARO changed as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year Ended<br /> December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Opening balance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,549,928</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,351,464</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accretion expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">50,072</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">198,464</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Ending balance</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,600,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,549,928</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Fair Value of Financial Instruments</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Market approach &#x2013; based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Cost approach &#x2013; based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Income approach &#x2013; based on the present value of a future stream of net cash flows</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> These fair value methodologies depend on the following types of inputs:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs)</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Impairment of Long-Lived Assets</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company reviews its capital assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Australian Goods and Services Tax (GST)</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheets.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Revenue Recognition</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> We recognize revenue from all sources based on the provisions of the U.S. SEC&#x2019;s Staff Accounting Bulletin No.&#xA0;104 and ASC 605 Revenue Recognition.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company&#x2019;s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company&#x2019;s best estimate of selling price when fair value is not available for a given unit of accounting.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Under ASC 605-25, the delivered item(s) are separate units of accounting, provided (i)&#xA0;the delivered item(s) have value to a customer on a stand-alone basis, and (ii)&#xA0;if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following: non-refundable, upfront payments; funding of research and/or development efforts; and milestone payments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We typically generate milestone payments from our customers pursuant to the various agreements we have with them. <font style="WHITE-SPACE: nowrap">Non-refundable</font> milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the non-refundable milestone payment is not substantive or stand-alone value, the <font style="WHITE-SPACE: nowrap">non-refundable</font> milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company&#x2019;s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as &#x201C;revenues&#x201D;.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Master Services and Supply Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a non-exclusive manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Collaboration Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On September&#xA0;9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. In addition to an up-front, non-refundable payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement contained a further six payments from Siemens upon the achievement of certain defined milestones. These six milestones relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the up-front payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company&#x2019;s best estimate of selling price. The deliverables related to each milestone are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Of the six milestones, the Company has delivered on two as of September&#xA0;30, 2014:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">In June 2012, the Company delivered on its first milestone by achieving proof of technical feasibility of a new test strip and received a payment of A$1,522,534 (equivalent to US$1.5 million) as consideration. A sum of A$2,175,048 (equivalent to US$2,142,857) has been recognized as revenue from services in June 2012 in this regards.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">In July 2012, the Company delivered on its second milestone by achieving proof of technical feasibility of another new test strip and received a payment of A$1,438,711 (equivalent to US$1.5 million) as consideration. A sum of A$2,055,301 (equivalent to US$2,142,857) has been recognized as revenue from services in July 2012 in this regards.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> There were no revenues recognized for the three and nine months ended September&#xA0;30, 2014 and September&#xA0;30, 2013 relating to the delivery of the milestones pursuant to the Collaboration Agreement. Of the total amount of A$4,230,349 (equivalent to US$4,285,714) recognized as revenue for the 2012 financial year, A$2,961,245 (equivalent to US$3.0 million) relates to the achievement of the two milestones whilst the balance relates to a portion of the deferred US$3 million up-front payment allocated to these milestones based upon their relative estimate of selling price.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Interest income</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Research and development tax incentive income</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has recorded research and development tax incentive income of A$3,561,209 and A$4,250,864 for the three month period ended September&#xA0;30, 2014 and 2013, respectively and A$7,281,358 and A$4,250,864 for the nine month period ended September&#xA0;30, 2014 and 2013, respectively. The research and development tax incentive income is recorded under the caption &#x201C;Other&#x201D; in the consolidated statements of comprehensive income. There was no research and development tax incentive income recognized for the six months ended June&#xA0;30, 2013 as the criteria was not met. The Company determined that it qualified and became eligible for this incentive income during the third quarter of the 2013 financial year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Foreign Currency</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Functional and reporting currency</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Items included in the financial statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates (&#x201C;the functional currency&#x201D;). The functional currency of the Company and UBS is AUD or A$ for all years presented.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The consolidated financial statements are presented using a reporting currency of Australian dollars.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Transactions and balances</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has recorded foreign currency transaction (losses)/gains of (A$399,417) and A$15,926 for the three month period ended September&#xA0;30, 2014 and 2013, respectively and (A$444,973) and A$724,989 for the nine month period ended September&#xA0;30, 2014 and 2013, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">all resulting exchange differences are recognized as a separate component of equity.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Commitments and Contingencies</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Our contingent liabilities as at September&#xA0;30, 2014 are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">we have a potential obligation to pay 50% of the patent fees paid by LifeScan in respect of the patents we license from LifeScan prior to the date of the first commercial sale of a non-glucose product that utilizes the technology licensed from LifeScan and 50% of the patent fees incurred by LifeScan in respect of such patents thereafter. In the event of the first commercial sale of a non-glucose product, the initial amount that could be paid by us to LifeScan is projected to be between US$1.6 million to US$1.8 million. We would have the right to make this payment either as a lump sum within 45 days of receipt of the supporting documentation from LifeScan or in equal monthly installment payments during the 24 months subsequent to the date of receipt of the supporting documentation. Currently the non-glucose products continue to be in the research and development phase.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">during 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> Verio<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup>, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by us in 2010 and 2011 up to a specified volume limit (&#x201C;manufacturing initiation payments&#x201D;). At the same time, we agreed to pay LifeScan a marketing support payment in each of the two years following the first year in which 1 billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The total amount of marketing support payments expected to be paid to LifeScan is approximately US$2 million. Based on the current volume of strips sold by LifeScan and that we have no visibility of future sales by LifeScan, it is uncertain whether we would be required to make this marketing support payment.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">we have engaged Planet Innovation Pty Ltd (&#x201C;Planet Innovation&#x201D;) to assist us with design and engineering for future analyzers. As part of the agreement, Planet Innovation will be paid a success payment upon the formal acceptance of the analyzer for commercial manufacture and a further success payment on launch sign-off for the first commercial sale of the analyzer. All of the analyzers Planet Innovation is currently working on are in the research and development phases, and therefore at this stage their commercial manufacture and sale and the amount of any future success payment cannot be reliably estimated.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Patent and License Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in research and development expense. Legal and maintenance fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Clinical Trial Expenses</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> These prepaid or accrued expenses are based on estimates of the work performed under service agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Leased Assets</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> All of the Company&#x2019;s leases for the periods ending September&#xA0;30, 2014 and December&#xA0;31, 2013 are considered operating leases. The costs of operating leases are charged to the statement of comprehensive income on a straight-line basis over the lease term.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Stock-based Compensation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (&#x201C;RSUs&#x201D;) and Zero Priced Employee Options (&#x201C;ZEPOs&#x201D;). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company&#x2019;s stock price. The exercise price of ZEPOs is nil.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to paid-in-capital are still available if the tax deduction is less than the deferred tax asset.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><i>(a)</i></td> <td valign="top" align="left"><i>Stock Option Plan</i></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In 2004, the Company adopted an employee option plan (&#x201C;Plan&#x201D;). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"><b>Grant Date</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Aug-14</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Dec-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Dec-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Aug-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Mar-13</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercise Price (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.17</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Nil</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Share Price at Grant Date (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.17</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">64</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected Life (years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Risk Free Interest Rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.13</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.82</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.82</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.54</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.37</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Fair Value of Option (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.10</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.41</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Stock option activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> exercise&#xA0;price<br /> A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,606,099</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.07</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">152,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.10</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(8,333</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Lapsed</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(834,994</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.02</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2014</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,914,772</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.06</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The number of options exercisable as at September&#xA0;30, 2014 and September&#xA0;30, 2013 was 8,219,892 and 8,344,277, respectively. The total stock compensation expense recognized in income statement was A$61,703 and A$175,623 for the three month period ended September&#xA0;30, 2014 and 2013, respectively and (A$219,061) and A$469,125 for the nine month period ended September&#xA0;30, 2014 and 2013, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> As of September&#xA0;30, 2014, there was A$201,189 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"><b>Fiscal Year</b></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69,817</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">104,597</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">25,869</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">906</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">201,189</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The aggregate intrinsic value for all options outstanding as at September&#xA0;30, 2014 and September&#xA0;30, 2013 was zero.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>(b) Restricted Share Plan</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to non-executive directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company currently proposes to continue to issue A$1,000 worth of RSUs to employees of the Company on a recurring basis, but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The table below sets forth the RSUs issued by the Company since January&#xA0;1, 2013:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br /> Restricted&#xA0;Shares<br /> Issued</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Market&#xA0;Value&#xA0;of<br /> Restricted&#xA0;Shares<br /> Issued&#xA0;(A$)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> May, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">917</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> December, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">142,800</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69,972</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> June, 2014</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,040</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Restricted stock awards activity during the current period is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of&#xA0;shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br /> issue&#xA0;price<br /> A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">260,801</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.72</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Release of restricted shares</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(9,077</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.77</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,040</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Balance at September&#xA0;30, 2014</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">253,764</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Employee Benefit Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company contributes to standard defined contribution superannuation funds on behalf of all employees. This contribution amount, formerly equal to 9% of each employee&#x2019;s salary, was increased by law to 9.25% from July&#xA0;1, 2013 and 9.5% from July&#xA0;1, 2014 of each such employee&#x2019;s salary. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee&#x2019;s remuneration to an approved superannuation fund that the employee is typically not able to access until they are retired. The Company permits employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Net Loss per Share and Anti-dilutive Securities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Basic and diluted net loss per share is presented in conformity with ASC 260 &#x2013; Earnings per Share. Basic and diluted net loss per share has been computed using the weighted-average number of common shares outstanding during the period. Other than in a profit making year, the potentially dilutive options issued under the Universal Biosensors Employee Option Plan were not considered in the computation of diluted net loss per share because they would be anti-dilutive given the Company&#x2019;s loss making position.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Total Comprehensive Income</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company follows ASC 220 &#x2013; Comprehensive Income. Comprehensive income is defined as the total change in shareholders&#x2019; equity during the period other than from transactions with shareholders, and for the Company, includes net income and cumulative translation adjustments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Recent Accounting Pronouncements</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On May&#xA0;28, 2014, the FASB issued ASU 2014-09 which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The core principle of the revenue model is that &#x201C;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#x201D; In applying the revenue model to contracts within its scope, an entity will:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Identify the contract(s) with a customer (step 1).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Identify the performance obligations in the contract (step 2).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Determine the transaction price (step 3).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Allocate the transaction price to the performance obligations in the contract (step 4).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Recognize revenue when (or as) the entity satisfies a performance obligation (step 5).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The ASU applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. Certain of the ASU&#x2019;s provisions also apply to transfers of nonfinancial assets, including in-substance nonfinancial assets that are not an output of an entity&#x2019;s ordinary activities (e.g., sales of (1)&#xA0;property, plant, and equipment; (2)&#xA0;real estate; or (3)&#xA0;intangible assets). Existing accounting guidance applicable to these transfers (e.g., ASC 360-20) has been amended or superseded.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Compared with current U.S. GAAP, the ASU also requires significantly expanded disclosures about revenue recognition.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The ASU is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December&#xA0;15, 2016, for public entities. Early application is not permitted (however, early adoption is optional for entities reporting under IFRSs).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Entities have the option of using either a full retrospective or a modified approach to adopt the guidance in the ASU:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Full retrospective application &#x2014; Retrospective application would take into account the requirements in ASC 250 (with certain practical expedients).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="8%">&#xA0;</td> <td valign="top" width="4%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Modified retrospective application &#x2014; Under the modified approach, an entity recognizes &#x201C;the cumulative effect of initially applying the ASU as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application&#x201D; (revenue in periods presented in the financial statements before that date is reported under guidance in effect before the change). Using this approach, an entity applies the guidance in the ASU to existing contracts (those for which the entity has remaining performance obligations) as of, and new contracts after, the date of initial application. The ASU is not applied to contracts that were completed before the effective date (i.e., an entity has no remaining performance obligations to fulfill). Entities that elect the modified approach must disclose an explanation of the impact of adopting the ASU, including the financial statement line items and respective amounts directly affected by the standard&#x2019;s application.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is currently evaluating the method and impact the adoption of ASU 2014-09 will have on the Company&#x2019;s condensed consolidated financial statements.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Derivative Instruments and Hedging Activities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Derivative financial instruments</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company uses derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <i>Cash flow hedges</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Exposure to foreign exchange risks arises in the normal course of the Company&#x2019;s business and it is the Company&#x2019;s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the non-financial asset or liability.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Derivative Instruments and Hedging Activities</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. At September&#xA0;30, 2014 and year ended December&#xA0;31, 2013, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2. The fair value methodologies described as Level 2 and 3 inputs are defined elsewhere in these notes to the financial statements.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Foreign Currency</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Functional and reporting currency</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Items included in the financial statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment in which the entity operates (&#x201C;the functional currency&#x201D;). The functional currency of the Company and UBS is AUD or A$ for all years presented.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The consolidated financial statements are presented using a reporting currency of Australian dollars.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Transactions and balances</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has recorded foreign currency transaction (losses)/gains of (A$399,417) and A$15,926 for the three month period ended September&#xA0;30, 2014 and 2013, respectively and (A$444,973) and A$724,989 for the nine month period ended September&#xA0;30, 2014 and 2013, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">all resulting exchange differences are recognized as a separate component of equity.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Use of Estimates</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations and obligations related to employee benefits. Actual results could differ from those estimates.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Net Loss per Share and Anti-dilutive Securities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Basic and diluted net loss per share is presented in conformity with ASC 260 &#x2013; Earnings per Share. Basic and diluted net loss per share has been computed using the weighted-average number of common shares outstanding during the period. Other than in a profit making year, the potentially dilutive options issued under the Universal Biosensors Employee Option Plan were not considered in the computation of diluted net loss per share because they would be anti-dilutive given the Company&#x2019;s loss making position.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The assumptions for these grants were:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"><b>Grant Date</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Aug-14</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Dec-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Dec-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Aug-13</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Mar-13</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercise Price (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.17</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Nil</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Share Price at Grant Date (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.17</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.71</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">64</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Expected Life (years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Risk Free Interest Rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.13</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.82</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.82</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.54</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.37</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Fair Value of Option (A$)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.10</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.41</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Fair Value of Financial Instruments</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Market approach &#x2013; based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Cost approach &#x2013; based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Income approach &#x2013; based on the present value of a future stream of net cash flows</td> </tr> </table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> These fair value methodologies depend on the following types of inputs:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs)</td> </tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> &#xA0;</p> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="5%">&#xA0;</td> <td width="2%" valign="top" align="left">&#x2022;</td> <td width="1%" valign="top">&#xA0;</td> <td align="left" valign="top">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Income Taxes</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company applies ASC 740 - Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company&#x2019;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We are subject to income taxes in the United States and Australia. U.S. federal income tax returns up to and including the 2013 financial year has been filed. Internationally, consolidated income tax returns up to and including the 2013 financial year have been filed.</p> </div> 1 444973 -3153816 -8846706 1638752 4584219 -8098 137294 6832413 552772 0 187247 0 -13905466 4815229 -390708 -8846706 -155185 5058760 -8846706 389538 -219061 4952523 691465 7281358 1934897 236446 4588686 150006 368304 218298 -1638752 0 42904 -219061 18489685 1847314 -3882793 -691465 1944995 15905 13900999 0 133361 552772 -219061 50072 0 -29520 <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated balance sheets. The Company&#x2019;s cash and cash equivalents are invested with one of Australia&#x2019;s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.</p> </div> 1600000 1 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Research and development expenses for the three and nine months ended September&#xA0;30, 2014 and 2013 are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>A$</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Research and development expenses</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,715,444</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,901,823</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13,900,999</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11,807,954</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> P45D 9077 2020-12-19 P24M <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i>Patent and License Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in research and development expense. Legal and maintenance fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents.</p> </div> P2Y 1800000 2000000 P3M <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Warrants</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Pursuant to the Credit Agreement, UBS issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5&#xA0;million shares of UBI&#x2019;s common stock in the form of CDIs at the Exercise Price.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The warrants may be exercised at any time until December&#xA0;19, 2020, in whole or in part in minimum multiples of 500,000 shares of common stock. The holder of the warrants can pay the Exercise Price in cash or it has the right to pay all or a portion of the Exercise Price by making a cashless exercise, therefore reducing the number of shares of common stock the holder would otherwise be issued.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The warrant is subject to adjustments in the event of certain issuances by UBS, such as bonus issues, pro rata (rights) issues and reorganizations (e.g., consolidation, subdivision).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company assessed that the warrants are not liabilities within scope of ASC 480-10-25. The warrants are legally detachable from the loan and separately exercisable and as such meet the definition of a freestanding derivative instrument pursuant to ASC 815.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> However, the scope exception in accordance with ASC 815-10-15-74 applies to warrants and it meets the requirements of ASC 815 that would be classified in stockholders&#x2019; equity. Therefore, the warrants were initially accounted for within stockholders&#x2019; equity, and subsequent changes in fair value will not be recorded. The fair value of the warrant was estimated using the Trinomial Lattice model.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The debt issuance costs were recorded as deferred issuance costs and are amortized as interest expense, using the effective interest method, over the term of the loan pursuant to ASC 835-30-35-2.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Australian Goods and Services Tax (GST)</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheets.</p> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Clinical Trial Expenses</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> These prepaid or accrued expenses are based on estimates of the work performed under service agreements.</p> </div> 0.77 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Research and development tax incentive income</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has recorded research and development tax incentive income of A$3,561,209 and A$4,250,864 for the three month period ended September&#xA0;30, 2014 and 2013, respectively and A$7,281,358 and A$4,250,864 for the nine month period ended September&#xA0;30, 2014 and 2013, respectively. The research and development tax incentive income is recorded under the caption &#x201C;Other&#x201D; in the consolidated statements of comprehensive income. There was no research and development tax incentive income recognized for the six months ended June&#xA0;30, 2013 as the criteria was not met. The Company determined that it qualified and became eligible for this incentive income during the third quarter of the 2013 financial year.</p> </div> P3Y 500000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Master Services and Supply Agreement</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a non-exclusive manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.</p> </div> 2018-12-19 P5Y 2500000 P7Y 1800000 2500000 0.13 1.00 0.20 0.15 0.30 600000 2961245 3000000 0 3000000 6 P10Y P10Y P3Y P12M P3Y 0 0 0 0 0 0 -8846706 0 8333 2040 1 0 0 0 999 0 0 -219061 2175048 2142857 1522534 1500000 917 1000 2040 1000 2055301 2142857 1438711 1500000 77758 50000 0.0354 0.64 P7Y 0.41 142800 69972 0.0382 0.63 P7Y 0.28 0.0382 0.63 P7Y 0.49 0.0337 0.65 P7Y 0.45 198464 2013-12-19 0.0925 4230349 4285714 0.0313 0.71 P7Y 0.10 0.00 15926 -683325 520295 1396357 4266790 123663 0 -5066231 1117229 -683325 4382906 -683325 2513586 4250864 1684703 236334 1993291 1756957 0 5586526 0 7547 3901823 175623 0 0.0950 -0.01 399417 -1894059 1741209 137294 3157820 103398 0 -4496410 1949297 -1894059 2602351 -1894059 2086591 3561209 1522175 127084 345382 218298 0 6237619 654095 4772 4715444 61703 0 P12M P3M 0 0001279695 us-gaap:ResearchAndDevelopmentArrangementMember 2014-07-01 2014-09-30 0001279695 2014-07-01 2014-09-30 0001279695 2013-07-01 2013-09-30 0001279695 ubi:GrantDateFifthMember 2014-07-25 2014-08-31 0001279695 us-gaap:ResearchAndDevelopmentArrangementMember 2012-01-01 2012-12-31 0001279695 2013-07-01 2014-06-30 0001279695 ubi:AthyriumCreditAgreementMember 2013-01-01 2013-12-31 0001279695 2013-01-01 2013-12-31 0001279695 ubi:GrantDateFourthMember 2013-03-01 2013-03-31 0001279695 ubi:GrantDateOneMember 2013-12-01 2013-12-31 0001279695 ubi:GrantDateSecondMember 2013-12-01 2013-12-31 0001279695 2013-12-01 2013-12-31 0001279695 ubi:GrantDateThirdMember 2013-08-01 2013-08-31 0001279695 ubi:SpeedxMember 2013-08-01 2013-08-31 0001279695 us-gaap:ResearchAndDevelopmentArrangementMember 2012-07-01 2012-07-31 0001279695 2014-06-01 2014-06-30 0001279695 2013-05-02 2013-05-31 0001279695 us-gaap:ResearchAndDevelopmentArrangementMember 2012-06-01 2012-06-30 0001279695 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-09-30 0001279695 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001279695 us-gaap:RetainedEarningsMember 2014-01-01 2014-09-30 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-09-30 0001279695 us-gaap:EmployeeStockOptionMemberus-gaap:MinimumMember 2014-01-01 2014-09-30 0001279695 us-gaap:MinimumMember 2014-01-01 2014-09-30 0001279695 us-gaap:EmployeeStockOptionMemberus-gaap:MaximumMember 2014-01-01 2014-09-30 0001279695 us-gaap:MaximumMember 2014-01-01 2014-09-30 0001279695 us-gaap:ResearchAndDevelopmentArrangementMember 2014-01-01 2014-09-30 0001279695 ubi:AthyriumCreditAgreementMember 2014-01-01 2014-09-30 0001279695 2014-01-01 2014-09-30 0001279695 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-09-30 0001279695 us-gaap:CommonStockMember 2013-01-01 2013-09-30 0001279695 us-gaap:RetainedEarningsMember 2013-01-01 2013-09-30 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-09-30 0001279695 2013-01-01 2013-09-30 0001279695 ubi:SpeedxMember 2011-09-10 2011-09-30 0001279695 us-gaap:MinimumMemberubi:SpeedxMember 2011-09-10 2011-09-30 0001279695 us-gaap:MaximumMemberubi:SpeedxMember 2011-09-10 2011-09-30 0001279695 ubi:AthyriumCreditAgreementMember 2013-12-18 2013-12-19 0001279695 2013-01-01 2013-06-30 0001279695 ubi:ZeroPricedEmployeeOptionsMember 2014-09-30 0001279695 us-gaap:EmployeeStockOptionMember 2014-09-30 0001279695 us-gaap:AdditionalPaidInCapitalMember 2014-09-30 0001279695 us-gaap:CommonStockMember 2014-09-30 0001279695 us-gaap:RetainedEarningsMember 2014-09-30 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-09-30 0001279695 ubi:CollateralMember 2014-09-30 0001279695 ubi:FinancialCovenantMember 2014-09-30 0001279695 ubi:AthyriumCreditAgreementMember 2014-09-30 0001279695 us-gaap:LetterOfCreditMember 2014-09-30 0001279695 2014-09-30 0001279695 us-gaap:AdditionalPaidInCapitalMember 2013-09-30 0001279695 us-gaap:CommonStockMember 2013-09-30 0001279695 us-gaap:RetainedEarningsMember 2013-09-30 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-09-30 0001279695 2013-09-30 0001279695 ubi:GrantDateFourthMember 2013-03-31 0001279695 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001279695 us-gaap:CommonStockMember 2013-12-31 0001279695 us-gaap:RetainedEarningsMember 2013-12-31 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0001279695 ubi:GrantDateOneMember 2013-12-31 0001279695 ubi:GrantDateSecondMember 2013-12-31 0001279695 ubi:CollateralMember 2013-12-31 0001279695 ubi:FinancialCovenantMember 2013-12-31 0001279695 ubi:AthyriumCreditAgreementMember 2013-12-31 0001279695 us-gaap:LetterOfCreditMember 2013-12-31 0001279695 2013-12-31 0001279695 ubi:AthyriumCreditAgreementMember 2013-12-19 0001279695 2013-12-19 0001279695 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001279695 us-gaap:CommonStockMember 2012-12-31 0001279695 us-gaap:RetainedEarningsMember 2012-12-31 0001279695 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0001279695 2012-12-31 0001279695 ubi:GrantDateFifthMember 2014-08-31 0001279695 ubi:SpeedxMember 2013-09-27 0001279695 ubi:PfmCornerstoneLimitedMember 2013-09-27 0001279695 us-gaap:MaximumMember 2013-09-27 0001279695 ubi:GrantDateThirdMember 2013-08-31 0001279695 us-gaap:ResearchAndDevelopmentArrangementMember 2011-09-09 0001279695 2014-10-29 0001279695 2014-01-31 0001279695 2013-02-28 pure iso4217:AUD shares iso4217:USD iso4217:AUD shares iso4217:AUD ubi:Warrant iso4217:USD shares ubi:Strips ubi:Milestone ubi:Payment EX-101.SCH 6 ubi-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Condensed Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Condensed Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Condensed Statements of Changes in Stockholders' Equity and Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Condensed Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Organization of the Company link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Interim Financial Statements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Borrowings link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Warrants link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Restricted Cash link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Summary of Significant Accounting Policies - Inventory, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Summary of Significant Accounting Policies - Summary of Receivables (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Summary of Significant Accounting Policies - Research and Development Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Summary of Significant Accounting Policies - Asset Retirement Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Summary of Significant Accounting Policies - Assumptions for Option Grants Issued (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Summary of Significant Accounting Policies - Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Summary of Significant Accounting Policies - Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Summary of Significant Accounting Policies - Restricted Shares Issued (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Summary of Significant Accounting Policies - Restricted Stock Awards Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Borrowings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 ubi-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ubi-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ubi-20140930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 ubi-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!^3Q`*UP$``*@5```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/& MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,84'^@Y&JZJ, MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N M);GWYIY2E^50"1=K`RK[?9HII4'Y3N^GD&&@T>8 MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@ MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E M6,S*L9B58S$KQV)6CL6L'(M9.1:S9M:`S/#O!]]C&.T*>-K38N M-(L63C^%7758[^Z8,`BL+V!?'K:5'GC0`D+=>TJ0+=FTZ5F'7P`` M`/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T M'4\4"_'L)MI<3_3_ MMCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\# M`%!+`P04``8`"````"$`FM$*B](!``"-%```&@`(`7AL+U]R96QS+W=O:G;X]5 M4*`2#)=H+Y'L*)O1V#M?G.7Z?=]DK\Z'NFMS19.IREQ;=&7=[G+U]'AWL5!9 MB+8M;=.U+E<'%]1Z=7ZVO'>-C>FA4-5]R%*5-N2JBK&_T3H4E=O;,.EZUZ8[ MV\[O;4Q#O].]+9[MSFF>3N?:_ZRA5BJW@4C%)>T/0F]F82V\7',[1OC#2M#*25-!T@'$A:#4$Y M+,TJQJR2/C,P/#.844,G5-:[\B'Z=&(,W[UU,HW:BJ1A11!6)`TK@K`RTI%L M8"1+)S(,9.F5@@M%TM80](:E8<405BQ]M&)XM#+2F6-@YIA1Z1GBH4D_Z8:O MG,\QBF!I/`UTTB<_$53/VY=5+57J_F=)4SQX`"#WS M"V/JBR#06<$JJH]DS02\64M540.AV@2Z5HSFNF#,5&40A^%)4%$N_#W"A7H+ MAERO><:^R*RIF#![$,5*:H"^+GBM_?GEFI?L<9^11^OZ.ZV`]TOI>R75YB;G MAN4S_QA"N66#!ZJI%PTOX>UY$B9^,.^3O%->SM:T*A@UYQ&L%Z1X"?(#P M6P7A/^W5$VUZG2($*D5NA.%F1Y9BKSZ74$*K^A(RBWQ/77"X42 M>47!9$#\7IGC]\&`''U.)PBF=0;.Z8?:4,'_M'8ES"ZF4A$[:#)(_QVL^ M)5+LY\CQXC00K.V!HD%9WVE+Z(<>R,[BOMH0C.;@-"-HC0,0KG[LF',:"/0] M`.'JQXYCIX'L'MT-^!3W?>P8>1H(].V!8EPU"$8:W;-,PKD!NG=E?XV='`\H M.$X>K<36A;T4U<6Q[F@E]EB,S0J!P_9_D\8Z'V>-ITWL>/4P;@].-ADM,SARV8L]L[1)!]V!<_X7``#_ M_P,`4$L#!!0`!@`(````(0!]+K.Z(P<``*\>```8````>&PO=V]R:W-H965T M&ULE)G;CJ,X$(;O5]IWB+CO!!L;FU:G1\-A=E?:E5:K/5S3 M">F@24($]/3,VV\9D^"JI`FYF>F$C\*_JUS^B9\^?=_O9M^*NBFKP])C<]^; M%8=5M2X/KTOOG[^_/&AOUK3Y89WOJD.Q]'X4C??I^>>?GMZK^FNS+8IV!A$. MS=+;MNWQ<;%H5MMBGS?SZE@+?5X> M/!OAL9X2H]ILRE615JNW?7%H;9"ZV.4MC+_9EL?F%&V_FA)NG]=?WXX/JVI_ MA!`OY:YL?W1!O=E^]?C;ZZ&J\Y<=Z/[.1+XZQ>X^7(3?EZNZ:JI-.X=P"SO0 M2\W1(EI`I.>G=0D*S+3/ZF*S]#ZSQRQ@WN+YJ9N@?\OBO7'^GC7;ZOV7NES_ M7AX*F&W(D\G`2U5]->AO:_,5W+RXN/M+EX$_Z]FZV.1ON_:OZOW7HGS=MI!N M"8J,L,?UC[1H5C"C$&;.I8FTJG8P`/AWMB]-:<",Y-^[_]_+=;M=>D$XE\H/ M&."SEZ)IOY0FI#=;O35MM?_/0IVB!X$[^B",S[F63(:WHRSLB#J!:=[F MST]U]3Z#JH%G-L?Z#H+`LFRY5U/5>1O8C/[T MW-A^`;'/>@;$\[1-Y%K'RN*]#&9$UGR!"LD!JNO1<`L;.)0_P4S*78-R/ M`I\-"-('36UZ^@R,EYXFHX\M`M5S+M]A8KNNE]PDTIM$-D8@><:B./U_O%$: MF*2/]+38(GWZF.;1L"JL.A=@2H;1Q=)S"7XE1.8".E0JT,-#D+CH'G$&)N*& MDNC&'END7WI<^9KV%1?@01@$!$A=@$D?;!PI3!?0H0[$L+B1-`8F9GKB.IJ( M(T.+>\:J"X0,-,EM@@@610&G:S-%2`#C]\EC,D1$4D@5#`L`2S2;^^3:9-8* MN/N"T[)L_GJF3Z`29N7C^4\0(KG/HV%T79`4$4)JP1D)DB&$2Z&XLT5AC<8# M3-=H'0/LJ^?F07M?S"PSUF!N(^EM)!M%L$AC!*:+M+8!)7)8!'TB+6,3*123 M0I`Z2YB+!)$/C80LYQ0A#!@_BBY2Z89A3/L*:O9<,UBFL03395H#@60.;:R7 M:9F^7F&7AH9Y?G:')`PAH1;P5H&1%"%0L-!6:-?!B-`^\X=]"XLTQF"Z2&LC MD$@RP[%YD8+&:T6&/%`A74\)0L"*A)(3!2E"F!8Z"NGRSS`30A[[]H#BF:J4(R6QD.!!88.$K MYR4`2S5>8;I4ZRQ@59Q;$-T$8C;F/OJRO8FDMZ-DHP@6:3S#=)'68:!\DLTP M9JX+87X07#@=3(`=""]6)HJA%7=V^VZ>,A1#,.7S81Q8H#$.TP5:FX$$DL'% MS+4B#T*IXAHOTJ10@8.2Z<-R1;G`@1D8)WQ*&(L$BHM.G5R0U-TDR#BUC,77[&_-!**W.8I3YIKI]Y^"!IB+F>-(1\D#3,C";M M+D/#K'66.#\D?T[[J'1_-DX(TAZ M.THVBF"5QC$X+=0<1P2P]8__+,6MS\!Y'':B/H\6NIJFI(]P]6(Z=C'[X")2 M912XJL;5=#3>_1C]%27NH:L#3L8NIF,7LP\N8C5W&18XEJ,=D]%%$/?0Z#Z' MF:LM$R/76R9AKK9,>PYHC\GV1?U:),5NU\Q6U9LYXPO`#IZ_/9\_?N;F^(A\ M'[/'I#O$(]^G<%[9?;\X7X#CPF/^6OR1UZ_EH9GMB@T\RI\KZ/"U/7"T']KJ MV!W:O50M'!1V?V[A8+B`XS)_#O"FJMK3!W,H=CYJ?OX?``#__P,`4$L#!!0` M!@`(````(0!DI"X?CP0``&\2```9````>&PO=V]R:W-H965T:_X!X;\!_).B6A M:>TV_0#]*NBE%3X;[8E=_FB*_8^BIC#:D!-/X)&Q)R[]ON<_06?K0^^'/H&_ M&V-/#]ESV?W#+G_2XGCJ(&X?B#C8>O^6T#:'$06;A>-SIYR5<`'P:E0%GQHP M(MEK_WXI]MUI:[K!P@]MEX#<>*1M]U!P2]/(G]N.5?^AB`Q6:.(,)M!C,"'. MPEGZQ`_F72R\HAXPR;ILMVG8Q8!9`_^S/6=\#I(U.',R#][Q.JZLGZ$"(S>Y MYRY;,S0-Z-Y"/B\[WPTVU@N,:3YH(M3`ZU7CR(IX5I%,*$+9)-5*+*"^HL.` MBNC388Z$7,P)>;@<.<(?1!S/M>5KB2G8Q),O/,)FW^W;B;WD MRU&6Q"B!U^ND512)9.+XKN/;RC1(=282'"R\V^&X6(!3KBO"Y@#90F]%`B79 M&!4ZMEF/5.-B`4U9,A$VCV@3(QZC0HT()R*#24ZMGF35&Z=@VU5MB(E#; MW)Y8KU:I7"6W083!.:[MK,*50AX/&EURLHWGA1_O2*G61N;DV[PP,WG=X@*[ M?H82+`[D%-5=81`A[]URFA>-M+PH&6Q6T[PZ&YF7EP`"[PPG%@PRIWJK(2@: M%B3L6OQ/SCX>-%K.>9M4:R-S\D)`X+PQ5RP?1%[?_<"+HC%7*)M]90G&1%>& M]&5?,D@T+JG61::%@15I9U+E:F6UADIB$4'1D*H3NJ&R>\:#0INI:`*5O')+ M2+46,B$O$(0\9PBQG!!S=$,BS\F('[Q@&`9"SR4D=!1-+&L"UW?@F"3[)++& M(\M5:"M[5BIK_*4?KH+W\91)>;UP.RE6%S*I-R%B"3&P)L:XQT36FGS3* M-+Q$$&AN7(=86,A4RN2)X*#.\QO+[D\"1-$0\BP'B`V/=^(4_DK@^*MK]#P``__\# M`%!+`P04``8`"````"$`_"JZ7'$$``"?$P``&0```'AL+W=O!^A4-0VZJ2UTKN3["23R>[,,V*I MI($R%+;=_W[OY2)2X%3I]$-WBY_'<^XMZ@+SS^]9ZKR)0B4R7[ALX+N.R&.Y M3?+]POWOWY=/4]=1991OHU3F8N%^".5^7O[YQ_PLBU=U$*)T0"%7"_=0EL>9 MYZGX(+)(#>11Y/#.3A995,++8N^I8R&B;?6A+/4"WQ][693D+BG,BGLTY&Z7 MQ(++^)2)O"210J11"?[5(3FJBUH6WR.71<7KZ?@IEMD1)#9)FI0?E:CK9/'L MRSZ71;1)(?<[&T7Q1;MZT9//DKB02N[*`I]^J3KPK7"V8A>=TO*[//\MDOVAA':'D`B#S;8?7*@8*@HR@R!$I5BF8`!^ M.UF"2P,J$KU7?\_)MCPLW.%X$$[\(0/)1&2WGA3P[L/;`N3I&N)+9 M#)0O]:$T3<5^53"H%(H\H\K"G;@.U$)!E]^681#,O3?H3%PSJSX#)="9]87! M1J`PIP-5.3UPW-B&4K9MWV[GQ1W"Z.ZBNJ(#H-W8'4V?.E;Z3!@,=8;?8D8- MHQF&[MUO&.&%"^I7?\-IHUM59D4,M*QANL6T$MQ$:.[A:^YWCS"<)VUGW4:O MB#&YMQ+<1&CNX4QMN\ M#+3V2+-[A+NU[YZ[Q)C<$S&FK=3''[U]W"2AF7]ZQ#S"7?.=C7%%#%F;3"9A M)]R:WC>$XR9"\\[@++V_\A7=<3_LU&U50ZW*ZH5=UX#)OQ'1`^#\:BV=^[8> M1E.OO?^'P^N^0.=O#1E\KNT(KY%F^QE>1YP>!$?=XT%H0%J"$&0,8D4X(\0> M!&?>XT%H4NI!>A.=1#3=*V7DQ7AS(3H47`>MJ)8>D'3$];S]?JS=Y7'3".VCF!%N%%% MCX!3\?X(-$/U+O26DVG0UA$(:983ZRTGDX8>`$?C_0%HD.H!.E^^8J9I6P>P M(MRHHD4('IK9%6W;E6KH]NE($>P(-R)ZA-^:VL&-J=V[8Z@A8Q32,2#XQ$3? MP*XW)A2$GH?0C7XFBKU8BS153BQ/^*PC@,O*YFCS'.8YP!ODSO$5F\%-.1SW MFC?@\<@QVHNO4;%/2_F`"FVI!#UCH12F/U>.%C2SAP4CU[P$>A`FX MK?<'`.^D+"\O\`N:1VO+_P$``/__`P!02P,$%``&``@````A`-&"N(41`P`` MPP@``!D```!X;"]W;W)K&ULG%9;;YLP%'Z?M/]@ M^;W<`B&)0JIV5;=*FS1-NSP[8()5P,AVFO;?[QB#@:2)LKTD`3Y_EW.,3]:W MKU6)7JB0C-<)]AT/(UJG/&/U+L&_?C[>+#"2BM09*7E-$_Q&);[=?/RP/G#Q M+`M*%0*&6B:X4*I9N:Y,"UH1Z?"&UO`DYZ(B"B[%SI6-H"1K%U6E&WC>W*T( MJ[%A6(EK.'B>LY0^\'1?T5H9$D%+HL"_+%@C>[8JO8:N(N)YW]RDO&J`8LM* MIMY:4HRJ=/6TJ[D@VQ)RO_HA27ON]N*$OF*IX)+GR@$ZUQ@]S;QTERXP;=89 M@P2Z[$C0/,%W_NK>][&[6;<%^LWH08Y^(UGPPV?!LJ^LIE!MZ)/NP);S9PU] MRO0M6.R>K'YL._!=H(SF9%^J'_SPA;)=H:#=$232P5;9VP.5*504:)P@TDPI M+\$`?***Z:T!%2&O[?>!9:I(\&SN1+$W\P&.ME2J1Z8I,4KW4O'JCP&UB2Q) MT)'`=T?B1TX81/'B"A;7.&H#/A!%-FO!#PAV#6C*AN@]Z*^`62>;07V,#YOU M7%3(J$GN-$N"8XQ@N83^O&PB?[9V7Z"F:8>Y-QCXM!C?(EQP8RV!C;&E]XO< M*VNP5M9%UU;NS8VQ3/"^S&PJHY.'9WO:R^E%4*%1B'"YL/S&@<&$(TQD$9.@ M`+D^J`8G&-+9\D5^:'F-LL',VP8$@Z\\Y)=-J`7'1LXWFH&$[8-]YSXS$Y?_H^\7G0LO[1U-?D- MQLH/Y9FD]^$\&<>_'+M%'PD'0T.-<`?JESTG?.B8O6MGV%W03B'[`$9(0W;T&Q$[ M5DM4TAR60IOA+1-F")D+Q9OV(-]R!<.C_5G`GP4*QZ'G`#CG7/47>LS9OQ^; MOP```/__`P!02P,$%``&``@````A`+(=,D?@`@``G`<``!D```!X;"]W;W)K M&ULE%5=;YLP%'V?M/]@^;T8".1+(543U&W2)DW3 M/IX=,,$JQLAVFO;?[QH'2DC;92\QML\]G'ONY69U^R0J],B4YK).<.#Y&+$Z MDSFO]PG^]?/^9HZ1-K3.:25KEN!GIO'M^N.'U5&J!UTR9A`PU#K!I3'-DA"= ME4Q0[`9Z5(>/RF>?^4U`[.A3+8`.RD?+/1+;H\@F%Q$W[<%^*Y0S@IZJ,P/ M>?S,^+XT4.T8$K)Y+?/GE.D,#`4:+VQE9+("`?"+!+>=`8;0IW8]\MR4"9Y, MO7CF3P*`HQW3YIY;2HRR@S92_'&@P(KJ2<(3":PGD@`>KPR>G()A[8.]$J>#`P** M>]E@_E#VZ[W0J;-@JZYCW;@#X.[E1I-@).42$\[.(:F#Q'&;1V\V<"?:!D$MAAH7\W,!&X>!LO5YC`W])R)]#W&6!;QFF,7[EEMP@L&@ M%V7!R.&-PTQ;]T(_&O7+=G@-WL[]$2!U@*B-7P0OQ3E3#3X/57?]_;YZ&S16 M'XZ\=QBG/O#'XK;#Z^EB,1N%P\"TKW@EW*EWT]!]J8*I/=NRJM(HDP<[Z4+( MN3_MA_!=:#M\=+Z!X=R.,M)?P'!LZ)Y]HVK/:XTJ5@"E[\U`DG+CU6V,;-KY ML),&QF+[6,*_((/OTO<`7$AIN@V\F/3_J^N_````__\#`%!+`P04``8`"``` M`"$`6?CBJ)T"``#K!@``&0```'AL+W=OP8$ZP"1K;3M/]^UW9"2-*N MZ0O$N>>><\^]MEE8JTLX9%4)QN\DV[2\,YY$\88:J%_7HM=[MI9=0M=2 M];CIKYAL>Z!8B4:8%T>*@I;-']:=5'35@.]GDE"VYW:+,_I6,"6UK$P(=-@7 M>NXYQSD&IN6B%.#`MCU0O"K0#9G?SA!>+EQ__@B^U:/?@:[E]HL2Y3?1<6@V MC,D.8"7EHX4^E/8O2,9GV?=N`#]44/**;AKS4VZ_.: M04.!)HQ3R\1D`P7`,VB%W1G0$/KLWEM1FKI`DRQ,I]&$`#Q8<6WNA:5$`=MH M(]N_'D1V5)XDWI'`>T="XC">I23-WF?!OB)G\(X:NEPHN0U@TX"F[JG=@F0. MS,Y9]*8U\&23;FR6RX6J-8SC:9E&^0(_00_9#G-[CHD'!`;UH020'9?P>E/W MRA9<('@.RLGD5-ECDA$F?5UYK=),,`1>Y)/!G[7GUN/N:`"@%SN MW8*M=]OO."+)B:@/9RZ)'[0:#ETM:\$CRT$?OTX>])(F2-']#,_N( MI@6/-+/!AM?T8:\9I[/L,/TCF]./2%KP2/+@PDOZ<.(ZFT>'@HX$[5T_.DG_ MW\86;`4/VYA$IZH>LS,:$3([=>KO*W^<>[KFWZE:BTX'#:]@)T?A%,:C_&WE M%T;V[M2NI(%;QOVLX:/"X4A'(8`K*_#X3.U_`<``/__`P!02P,$%``& M``@````A`#>`=U5!`P``ZPD``!D```!X;"]W;W)K&ULG%;;;IM`$'VOU']`^QXN!FQC&4=)H[216JFJ>GE>PV)6`1;MKN/D[SO+ MX`6*P)A,Y;W8I^?/[]F))'*5I MD]-*-"PE3TR1R\WG3^N#D/>J9$P[P-"HE)1:MRO/4UG):JI4-08:5?`^'*`J>L1N1[6O6:"21K*(:]*N2M^K( M5F?OH:NIO-^W%YFH6Z#8\HKKIXZ4.'6VNMLU0M)M!7$_!A'-CMS=Q3/ZFF=2 M*%%H%^@\%/H\YL1+/&#:K',.$9BT.Y(5*;D*5M=!2+S-NDO07\X.:G3NJ%(< MODJ>?^<-@VQ#G4P%MD+<&^A=;FZ!L??,^K:KP$_IY*R@^TK_$H=OC.]*#>6. M(2(3V"I_NF$J@XP"C3N+#5,F*A``1Z?FIC4@(_2Q^S_P7)=NO/##`.#. MEBE]RPTE<;*]TJ+^AZ"@IT*264\"_SU)$+O1+%XLW\'BH:(NP!NJZ68MQ<&! MK@&?JJ6F!X,5,)O(0L@/ZK"QOA8JQ&A(K@Q+2A;$`7,%]7G81,EB[3U`3K,> MJ+&20,98TLM)/GHV8./9)-U(N<8;8S>SE]V$4S<_]VP,8H)1"E36.4))8?%2!FWA4B M\.?P&T$F$B#@\R48HZF$V/=/)""FEQ##O!H`$P'SCP@P1J<"AF;"'"`&!5PL MPS"T`B?^H6?/3X`Q.O4_=!GZ1XSU#T6*7E9@EL0+;^#;76",3A4,$:("Q*"" M)`FBQ6+0.,E!\A$%QNA4P1`A*D!,A'WH^L-$F+@/8-Z`H%Z`?3AU;T;6^>YQT$W=#QGNW2/( M5N"5!H#=^1$%..BF"DZ'84<-D_78`T.",`>X\N8`9)7-9XH47;+;RMT+!DN],2 M/JH8K`W?!7`AA#Y>F,\!^YFV^0\``/__`P!02P,$%``&``@````A`&XZ$W?H M`P``60X``!D```!X;"]W;W)K&ULI%??CZ)($'Z_ MY/X'POOP6P6C;D:!W4WNDLUF]^X9H54R0!NZ'6?^^ZNF!>G"42;G@TC75Q_U M556WQ>++6UEHKZ1F.:V6NFU8ND:JE&9YM5_JOW_%3[ZN,9Y465+0BBSU=\+T M+ZL__UB<:?W"#H1P#1@JMM0/G!_GILG2`RD39M`CJ<"RHW69<+BM]R8[UB3) M&J>R,!W+FIIEDE>Z9)C78SCH;I>G)*3IJ205ER0U*1(.\;-#?F0M6YF.H2N3 M^N5T?$II>02*;5[D_+TAU;4RG7_?5[1.M@7H?K.])&VYFYL!?9FG-65TQPV@ M,V6@0\V!&9C`M%ID.2@0:==JLEOJS_8\MBW=7"V:!/V3DS/K_=;8@9Z_UGGV M5UX1R#;4251@2^F+@'[/Q!(XFP/ON*G`CUK+R"XY%?PG/7\C^?[`H=P34"2$ MS;/WD+`4,@HTAC,13"DM(`#XULIE[DZ-RLN=`V%9(YK.K MV4^!;&Z3"*<-B8 M?>&BD3W89_?K+IS@4.F7.7`[_D;+6F+@NVL%W+4/$>%#1/00$=]#*)D`U?U, MW,^``"]U:+!.G3=#55A+C-?L:\NP<4.TYBL%2E#8(L3!8!D>:N](-<^NG=T4 M($;FJ[>B&@ZO\:H%&*D./%1WB?E0M6K&FL+[YD@U#R0C\P>2X;P=+UF`5/R)K&%*,'-S9QPY*,F$6_D1G-6@UG5Z`TWD! MM5L*G6T;9!X<(\CN^(H2"VW`",$]]#@Q[(L.:*/QKDTN\R`G>3D@EJ3>DPTI M"J:E]"2F=`?^`;K5[@WBV15C$UI?BS<+L6YV!ACLC\F>_)W4^[QB6D%V0&D9 M8GRNY:N!O.'TV(RE6\IAI&]^'N`5CL`X:!D`WE'*VQOQ@.ZE=K+!FVY-D*U.8ZC'D:\9:H4[2K'/[XO M'H88&4O;DC:JY3D^<(.?BH\?)CNEUZ;FW")@:$V.:VN[,2&&U5Q2$ZF.M_"F M4EI2"T>](J;3G):^2#8DZ?7Z1%+1XL`PUN_A4%4E&)\KMI&\M8%$\X9:T&]J MT9D3FV3OH9-4KS?=`U.R`XJE:(0]>%*,)!N_K%JEZ;(!W_OXD;(3MS_X/,RY81`HT$1)YIB8:D``7)$4;C,@$+KW]YTH;9WCM!]E@UX:`QPMN;$+ MX2@Q8AMCE?P50/&1*I`D1Y(4U!_?)U$RS.*L_W\6$A1Y@W-J:3'1:H=@::"G MZ:A;P7@,S,[9X)_.P)*K>79%OA30!J:Q+;)T."%;B)`=,=-;3'*-F+V!&)PA M!/2=18+U2Y%OQWX2Y\`0,$9G<6GVA]<;F`;,XP4F.W?VB-D]Q)4V:'2IS068 MPH+=U^B*<@P]SAJS='2M8!HP6>KS'<*4L[\UWD,$C6&CP\`[NN*O5*]$:U## M*^C&ULG)M;;^HX%(7?1YK_@'@_0$("M&H[FA`[%\U(H]%GO/OQX[-Q3L9+V@?2H$O*_%>V;:W&S_]\GV_&WS+J[HH#\]#9S09 M#O+#JEP7A[?GX=]_\2^+X:!NLL,ZVY6'_'GX(Z^'O[S\_-/31UE]K;=YW@R$ MPJ%^'FZ;YO@X'M>K;;[/ZE%YS`_BFTU9[;-&O*W>QO6QRK-U>]!^-W8GD]EX MGQ6'H5)XK&[1*#>;8I6'Y>I]GQ\:)5+ENZP1UU]OBV-]4MNO;I';9]77]^.7 M5;D_"HG78EDS>#F65O>Y$N[\[7K8Z:;=O.O+[8E65=;EI1D)N MK"ZTV^:'\<-8*+T\K0O1`AGV095OGH>_.H_IU!F.7Y[:`/U3Y!_UU=^#>EM^ M1%6Q_JTXY"+:PB?IP&M9?I5HLI8?B8/'G:-YZ\`?U6"=;[+W7?-G^1'GQ=NV M$7;[HD6R88_K'V%>KT1$A\D)+#P>J];LK]OPIJ6W06<;6(>-4BCCMR%[[CS^Y0F6H5 M\7I2<48+W_=FB_GMU^)IE=E%Y1/7,C^%11IRB@N*QUC%MK4JS)KLY:DJ/P;B M_A?1JX^9S";GT1&*TJ2I>.TW2;@C#_I5'M4>*^A:W%G?7GQO\C3^)NZ&E6:" M+N.:Q+)+^!YAPB[CSDT9IA`1EJN+F9H,[\KXGF9OC\O[A M/0=1X:C+^)YOGCR^@4EN8%([8S@BN@##$7NB2%HZ(7LWV?*`?K"D'X3T`Z8^ MN(H>):+3!Y<,Z'@9W\`D-S#IB9$]__6=*CJW.^(B:='1&#E+[JQ`,>+W):]- M^Y>0""'!(,$A$4$BAD0"B=1&&%:($>D.*R3]/!09<`FS1WJL0#'B`BX,L0(2 M(208)#@D(DC$D$@4X;?CFN?,Z("3VA0,(\1`?X<1DJ9&+,PP!XJQ&0&)$!(, M$AP2D2+\:1M%UY^T/V9K8JB20"*U$8898H)PAQF2IF8\F)%2 M(1:_0BS"H`B'1`2)&!*)(FSM36TBAANRR+N>=]J'44D3-WPR60D48PGU$A(A M)!@D."0B2,202!2AO5#)10*2VD0,+QZ(%[?5`/(HZ@F=9"K&Y@DD0D@P2'!( M1)"(%:$BWIOL"=1(;81AB2S%[LB/%J=FD,HDT)#-#8R$&&$8X1B),!)K1&?! MHF>(2;!*:D5,5V3E=MUKW98ICBKXC"F63U-%0U9WE(X%";$*PPC'2(216".V MC,$JJ14QW9%5W"?<4<6?Z2,L&INBDY$S(1%)L$AJ14S+9/%Y1QJI6M5,([K0(A?EA:]6 MRR`28A6&$8Z1""-Q'^*318VD#S)[P-2*F+[(.O3:EQNG!JI\-?VA1;]CJW'; M\6F)D1`C#",<(Q%&8HWH'D`D3:>;@TU.K:HGC%'%K6D,N=#`L57`VAB(A%B% M881C),)(K)%S5T:F+@F62*V(88U+EP5NRYGV,#)QFY$+#31DFP5@),0(PPC' M2(216"-G:QPZ,\,:J14QO:&+`_91QNU9%)B183#0D-43O"B`51A&.$8BC:@A M1#Q?(19DS`E5C$42C*16Q#1%=$>?Z,M<>1A-&%I]:LAJCM*Q("%681CA&(DT MHK/!'>DU3+UV/'$ZU4^,11.,I%;$-.N^)0*W9XE@1E(\T)#%@25&0HPPC'", M1!HY=UD3TDO'6"/!2&I%3$]$Y(P$`KV:Q&GBT'K359#5$XB$6(5AA&,DPDBL MD;-MI!]/L$1J14Q+[EL"D(^Y=2PAM7"@(:LE>`D`JS",<(Q$&(DUHL>BOG\- M8)'4BIBFT/H?Y$E/W3^C=;\+B^`E1D*,,(QPC$08B36B:TPU])@SA`2KI%;$ M=$46K/>7,JZJ<\U2AJX`:,B:,K!>#K$*.R/R.4MO1$8X?O[Z?Q_.B$6G] MI1HW_?A

_V%/Q=7V`UO]0ZED0*,<(PPC$2:40/Y,[((0-EC#42C*16Q/!& M/HMM]&#V7&EQ,O^:7VQO5U@"#5D"OL1(B!&&$8Z1""-Q#^(]D(XRZ8$(DEH1 MTY?[JGVQSZ(S"9N3N7V@(:LO2D<-H/YL,9N3&S3$(@PC7"/J///9W*,W481% M8HPD&)%;5&3H^J.B/%%;4-2^AGU>O>7+?+>K!ZOR76XO<<2_&<^?JJTOS'D4 MCU7+1YC/7XB=)\?L+?\]J]Z*0SW8Y1MQZ&0DMW=4:N^*>M.4Q_;1^M>R$7M. MVC^W8H]1+A[NGHP$O"G+YO1&GD#NF6FW7;S\!P``__\#`%!+`P04``8`"``` M`"$`=)J%YL8"``!5!P``&0```'AL+W=OP8`U8Q1K;3M/]^US@P2+HL MRT/`<'Q\[CGV977W(FKTS)3FLLEPZ`48L8;*G#=EAG]\?[Q98*0-:7)2RX9E M^)5I?+=^_VYUD.I)5XP9!`R-SG!E3+OT?4TK)HCV9,L:>%-()8B!H2I]W2I& M\FZ2J/TH"%)?$-Y@Q[!4UW#(HN"4/4BZ%ZPQCD2QFAC0KRO>ZIY-T&OH!%%/ M^_:&2M$"Q8[7W+QVI!@)NOQ4-E*170UUOX0QH3UW-SBC%YPJJ65A/*#SG=#S MFF_]6Q^8UJN<0P76=J18D>'[<+E-L;]>=?[\Y.R@1_=(5_+P0?'\,V\8F`TQ MV0!V4CY9Z*?W.`$/(2W<]\-Q4&9ZE7C(/9B'`T8YI\\@M)49TKXT4 MOQPH/%(YDNA(`M M*7E`L/5`N6Z)W)QY@I8GL),=$&)&-M-LH9')C+=ME)&08' MAE22]':J8.,PES0Z1-HE'R>!_0T<$XUP:,8:+VNSX!-M\V3@=>DZ3.)6CL/% MB;];]_YM[1-EZ539=>[92:<*TQ.%#N.\.;&F*P':GR6Y)-&U-W=N!5,EV[*Z MUHC*O6U=(10_/!VZZGW4-<;A!72UEI3L"U$E;S2J60%3`V\.!BG7%]W`R+;K M"CMIH)]UMQ5\OA@/CPK3E&7ZNNK]O3)B:K)(ZJT[;=U:?G3?S/WY_OLCCJ MA_*T*X_MJ=K$WZL^_O#X\T\/KVWWI3]4U1!!A%._B0_#<+Y?K_OMH6K*?M6> MJQ-\LV^[IAS@8_>\[L]=5>[&BYKCFB:)7#=E?8I-A/ONEACM?E]OJT_M]J6I M3H,)TE7'<@#^_:$^]V_1FNTMX9JR^_)ROMNVS1E"/-7'>O@^!HVC9GO_V_.I M[[U%_:%]_Z>K=[_6I@FQ#G70%GMKVBX;^MM-_ M@HO7DZL_CQ7XLXMVU;Y\.0Y_M:^_5O7S88!R"]B1WMC][ONGJM]"1B',B@H= M:=L>@0#\C)I:MP9DI/PV_O]:[X;#)F9R)=*$$8!'3U4_?*YUR#C:OO1#V_QG M0,2&,D&H#<*`O?V>KF@FB)`_CK(VC,8-?BJ'\O&A:U\CZ!I8LS^7N@?)/436 M.V.0G_=W!EO2UWS4%XV7`KJ'6X:#'N((\<&PCV(P(AB#H&HP3JW4]/@30RQ'36%%\X-1(XY M)2IC"4D"2.%#*$LYY91>HB!RL,/;R6DP)L>22UB3-P,QY)B"I<.T^0!.DROE MA):_G98&![1(0,M`#"V:$"HSEX^1>($01*:9O$)-+J&FP0&U8.'<0`RU+$U$ MRC#W`@&HR!*7OF!F*(B4PD4H6U]!$JX8IF+@:BIDW.4Y#Y MZ=3@@!K'*@@2J8N:F=A6!ZBUR#&D=`G1>D)K<8DSTJM6F$@X$A@BNXY;O4 M']/3^GU[]HS:(WJ3WC,8VWN,$!F,3D$1`GQ9.MW$Y!8YAGYR#AQ#!(G)+<:2 MDTQ0>.:^9,:VGN\8!.ZH4R7=)C'!18Y!C6.@[`6+YQ9C"*KT'5G!B#E96>07 M=.H7(M",W&)LY\&Y%4NXZRN;/=]3B!*$\?1:>1=Y!IUZAG"!K;`@0Y`)3;GW MY&H)(@Q7\-#AJ0\N[R+7H%/7$*'C6@P?#P6"YBRN?(DHZ0.=V^=U1./'(,_` M3;38*S$I$(&4U2P$.#Z`%-2?"M9'IK@$&",2&% MIP28XB('85,'D:XXMKR^.]QE&9=I,NE#A`$'9"SS=`@S#"SDME-;-K62L,]R MB[')I'`"20*]+&8AF.8B,V%3,_$\WB;2-PJ:P(,9F1RIV3AF"U3)C*EK=_CP MS@`UXXUYG)J*##5[C/QV%'/E*1-AKCQEFE<2YL3^7#Y7?Y3=2)@/0WL>3^:?V@%>)(R_'N#%407']LD*P/NV'=X^Z%<>EU=1C_\# M``#__P,`4$L#!!0`!@`(````(0`7,['"YP(``%`)```8````>&PO=V]R:W-H M965T&ULE)9=;]HP%(;O)^T_6+YO/J!)`!&JDJY;I4Z:IGU< MF\0A5I,XLDUI__V.;0K$M!EP`3%^_>8YQ\)*J6[F^S*O M:$.DQSO:PDS)14,4#,7:EYV@I#"+FMH?!4'L-X2UV#K,Q#D>O"Q93N]XOFEH MJZR)H#51P"\KULDWMR8_QZXAXFG37>6\ZUBW7)!5#7&_ MA-=/6OI0Z+]@L7^R^M[LP`^!"EJ2 M3:U^\NTWRM:5@NV.("(=V*QXO:,RAXR"C3>*M%/.:P"`;]0P71J0$?)B?K>L M4%6*Q[$7)<$X!#E:4:GNF;;$*-](Q9N_5A3NK*S):&%[$ MUW/_&3*8[R3+4\FHK\C>421[B0]X>T:(_')&O0ABP>C`&.WM31A+*[D^DCB* M;$C10X3['",.IT^+4PS>![380;.2B*=:0TKKJ"3F_M[C^X5U7RRF-;SBV_NO3M]N?O5O:)9E_-I.5O, MJV_N75?-O7_X]K_^EZ^;9EWP[KSYYM[E>KW\W<.'S>2RNBJ;O<6RFO/-^6)U M5:[Y-:L5^5D_3_ZPW[>_R`-=7J]K/I??K[_:/`G3F\$\8TQ+TX37 MPVSC`_SAH#_FZ:J4N!4GUU=GBUG_V\_??7?<_RR(P-OJHA;#$8R?RJO!JCY_ M]]/Q'U^\/3E\57QW_/KDQ4\GK]^>%,<_'6T9[@@)6['Z8Z3F8_%/U77_N<\? M/7JT__C+9U\\>]K_ZFBS6DE`+>;%R7HQ^66G.+DL5U53O-ZL M3:EYO4_%T6+>+&;UE/FG#`TOY@W_^JZPR9%!9=/P_N_Z[QZ5S:5I]T3_J/ZTJ=^7,Q@Z$,#C^7L^7JSJJMDIYM6Z M/]#AQ""E*5;5I&*0L]E`+MZLJF5Y+54:C/YZ?0EK)V$SG=;^#*>+-4)R\S,_ M+>:[W2<&*WZS`B=7Z^N=8@EG'=JT[J4(Z\_YJFJ:HIR`@IN9; M@;\;1RYVQ[CFZYX/J.[3X6N_ZW/C_(N2,*O+LWI6K]G)`7/2+K)18UO(]ZL- M4EE]Q-8TU6`?GU?G%0HY10H0E\U`!%Y<+6>+ZZK"UF%,9I4)0[%<+=[7,H3C MRXX;FA'>?S#?]^RQX?JD!1"WKE[3W:+]88FK0]4VU5QQNUI=H]I]9XOX.6*O_*QI#K-\7 M==-HQT7-HD6O8E[/BGINMKRXCW$Z^)T^&F#3Y[_]^MNO?<(#-'8(`N&WD'3@ M!-V%J/TOG^Y\L?]HY]F77P7Z^S3:$PSXQ:.G`UH/IU.T8C$'999E/=UE>9-R M68,Z_06@!ADBG->3>H`<4=NN9=)GBV:P>_D8"X<_[,FJND2QZO<5A$\60]OJ M$F2'KJ$Z_*@N/_NY'GQV8"I)VMP4P)= M+,ZQTG.,60V#WRP:X_4-OMM`-)EMRB37-_U#1?VNSZ=Z4/_E:Z( M;Z6\^]BM9(\^/D[SZ*,W$CSJ?J3M:[1_#)I)Z+%):#'JDQS<.10XZ+/N[;CI M"!\7YZO%E2S&=#,9^A&=AYIJ];Z>#''3-6.+A3I:$%^QU(O%8MH4>&33XK^7 M5\O?8P3&1QN^T%]0?&+;"$[/Y-,GQFVNSS:"K"Y7;J'8G0YY01@^;)QF;L([ MVPS[VZH!R";N*T[9H=EBU&'ZOIHS[,RPIIQ>U7,+%-8`6I\KONI/H^(5..I+ M#>_A,_?']=4Y>CZ\']8S@*7C.9:]8JO'839]'=[O3Q*`+#*O_[71T/\P+-B@ M?GS6G_!-9"J*LXH8NRK6Y5T8TT3#)^Z"AI$:&7J^L8/_[KC]756;4:Y#DR MU^5-<%V.W'4IMKZ2^3"X[?)A[O2L\WIT7=NF^HY\P5PBEZ+9OC_KH' M;Z0(^K8W7WRL5I.ZJ21QYNP4BZ40DFUR1W:]**H0A0RV_9->CB3U:0^A_AVF MV_[DUK$E9V%%,0CKST_ZH\?J//,V,+?=Q^/$!7R^\;7!#NF-?$\'$PW>R.>Z M\36=5^7B"P4"L9EDPM2&&PF?#S),IK@Z(_:S[+X5MR26A'7;/_#EH_N M>'^FOCC69/$:<_IND)(W&QP]MMU+ M257AH9N6G2U6J\4'^33]PLI1\K+]L3>=X;IVHPH69=H?.ZUV7"/'UC$V MQ+2:X.5@L2S?<,=TK&VLA-%$HLW;"AS/DKEES6P>%8C^O"]0NHG%.4D1"0:J MXGQ&5+7Q?)CT&4D'`2P#;=)@LUU6!$40*Q^UOB!)8FG;L0S5-BK1(R!`JK2- MP->KBW(>@$E/B1#Y'"/Y]J!-LGEO2*"+CANR"C]7!7F+HBR:I?*X,^*3XJJ: M*HM(0%-ED+))J#)@6F$',8''03I$%0::_5^5\G)PP)JA.5@RO-(9)&,.__N4_CIX?-W_]R_]Z M4%R6Y*_.JFI>_&FS4/00F'>(E2,XK$L1@]28-2Q>1%.@,0Y/_MF&:%A6)7\B M4GQ@%'^Q1PD%$/Z&L$QKAW=FVDBW-E,=](QC"W$R]@,;+6Q3.OZO/J9%+.=Y`; M*E;:[OB1[;D)H]G6]66]DM.!W8D#50W\F<]4CS'[^T$^/AM?37=@4W`A;!W= M8<40AFN*::IE(S'9&Q/$`"PD0R%I6/'\%#]MNJ':ARPM>E3O2#X>\EBDO'BQ MD87D$FY+7 M:1'^/;9?C@3:;\E&):HQ6]3^#;PFU6P&PDPNYXO9XN):U2VV#L5E#0&K#(`< M>=(^H=;1!0,(33_@M!0D:)0C(-$3SA2*MU85`.7&Q1VX47_]R__NH]31HKQ0 MZ4PY*L&?J/=9BK_^Y=]!,$/C#XO5+_K&9.RD5KZX*7X@]%]?&OX];X$Y$Y[P MH,E.MLBRP"F\,!!&(UV9E%80,"X[L#K)B`M$+3>K9J.R(`.6*.-L5N(U./WE MQ:KR5':'3H.^SH.'\<$HUCL"F'^3Q678L\I4=BFO`800:3C)2)#JD7H@MR1F M,D#->NG[QB*0^[2N#65BK`?#+Y>(ZPT4GO@3'=+VBF@-9TT2DBA?J';Q9H6P MDF\]0XE.ZZNJ*\O%3^HT\?3,6['(5/K-Z>[Q3V]]4V3O@,.+2E"(R;8'UDGZ,GMP"F,`CK(R_94'%@)#H3$ML7%J`2`RY,79]J2F8ET'_9JHZ8_%@V M(O8D9(A-C_O\-M[`HJQ3>2=H"@J+9IMK$1_M;]GJP7V%Z%$(@$F*S4#K.<&6B/X MM,,F3V8;RUGX'#X?PU;S/U_3RE1/>.;J:C-?$'.5;J&O%L`?P++*_:NKBCKF M%/A"K*]XL*FJ7WJRE&DT/HK%CQ>FTPTZBN=`\X(89BLB76\)G/OE@J/ MI2+@@P9>3:U7Q>!1?V^L>HUXL,7U$N-=4,I6?4!8-9G((;5W)3?OYD:(L<#] MR7=[)WO%]X>';Y)*V,!ZN)ZS61NLMA)[:.5+&3IU;YF>')+3P%GC`\G=VRI9 MH)/=?S:\%<0\N9F!"'I;C""_B]9Y_Q\8S@Q9P!';_LS:PYXT>XTD MR.-2^A^%#$R-8QNB2Y//Z!BAY60B>8D36F6=F;3(-E`(?5!/]B03Q?EF!6VR M([SEJA+<1<-RR&Y%H-T"$Z)V(S5"A9!A$Z#/-]G7'$F`J@$%!Q'8^-)\T"I) MZ3]I'.3]/8T;[-5W-58)]5LU[MST=?\4,C73KDRC=C"UB;6*&H)TRCEJ$ROH M(BM%+P9Q2)B%+P@!\P?C%E%@C!EXK#A\TP42K8W+50!D#*"S1=KWBJ,8,)"% M6-DJE,4#%ZQL(KG9LJ`Q4C*)1+Y#X8@UL#>,HAV.NQI]UUR>!_BK*I=MZ9M, MZOO,/Y2Z!8H%/[Z5>!$=ND>IE9%$:AGOI`.)D:!<"? M&=IM^J&.2>=TL`;)QI$#^E__\C^5MLC$8Y2J5JNAS-$;L[JA5.OV.XR&N\#* M&0Y@V8!X"G`O\)Y5+L8RKN9F95<*FEC(A05/8-6&P.1C0"-+%DE=>CDJZINA MJ5%?MC&V/:;F=1VZ.W$3IR`!!E_]`C31G&8.U&%=%)C4^DZ,)6VVP( MM\@+X75NIXDYSS>BIS.>@R.U3S)T.)=P>TZ07*P_5#,F<+C;*WY8?&"^E33> MGN&/^7K'A@I[`-^_@O45FJR8U[+&DE>I&+V&>0`>G@TBIS_/FPEAI?7 MMB%[%SVC5:DP6NO&C.+I;RXN\6TM5X(X8K??XQ&%UC*839B-!`!3T^IL':'3 M/M!.Q@$L/H?TTFWS%8AD7&E9$5QKZW/;*Y!A5HXJSH6Q^##F1!CVBS+)G%,- M0\KW)9&UF`:TN0OA[*)/#[IJ\)G/9[.!HIQLKH@SS!$](6EI%6?D0:8>--(< M,7G81X`WK?>"N!TE!<-$]A^5-MZN@1%")4VC*LHT^BYJHGA;`YA;,E:6D\)I M05W-KY%W(5\T*!F*J[V!J8W21)"?P2B*@N*SQY8O:TGGL0$'WR$I4/8"5P-+ M.M)6`\D.*>X^A%6T@\K:)(<.,0+!]KL37^9BVW M/,9.N06/17E@S_I:@/)#U2+DR[JGB:8"79ZMBK&5XOFTP('('E&M_>U7[]_2 MOPMU9FQI<#^%J5'CM'=RDV$_6G5)BE1FCD,RE`*]I&70I32`5L^24/;#52%HWP=7>KB+17BX]! M%\R-M[Y>I,4S%BRLH;]7Z;V<*+'.XRC'X3Z8G>B=W5,U0*L^&@O4]W^@_+.[ M7NS&T0:]5?[B6B_FS!)3:?JFG>@6KGJ4I]=-[0/-(9C.6"GM[MIA[6&?.VR` MK9Y<4X\@+$[+^H`5Q$`M!X?R)-='AU4L/F+D(^2?OIFW=?.+R;9G4?2G:^X[ MN4K*F*O;OL]@DTB!0%\*;"B,F_O)N+KA0(79%A6LF+E%TFP/00;,WY+PDPD1 M75(@$0PRZ89O[$5W(90@M1`2%Y8Q$<)8,<#FTE\!%M2;L)JZN=#''92+;IT' M(6;8HTJY?0FY:9"A@V@'F:K/^LG/^"KFB[H\IJ,S]2 MF'(PR9>3^V0:$MPJB5SE5VD%-E:AWJT(K;8=40U;";%$@][XNS(&8^R!E4"> MZA'[@IW"?*LM30DH,`5#Q;D3%=W,-FR%ARY'XL``&=)P7H=Q0[TC)N:L36F8 M2VV%KAEHP7/HQ"]4O'YL>1@'0VWL#]645J\+(7=H=ND+??;RJ`CWG\_W>".& M3-O91P>0(E]"!@(%NTPFE!7C4[GGDG=9)D6#IP!@HRS"S.*&6BM;( M6X+IT2"&-P6<_NB2![5VBLU2$2F(SO*4RGU*$&VGES7HDEXTXT#M)B]UU44.H0 MC3J3S#'BA2AXX))1P$E_R8T+52+;WF'4;Y;#(F5[8&!97@@)MTF],![KQ'_0 MIL"$D#7$XJS<\V9+15?)668RA@:_^1I9HOK&2*GDKR:#Q0YU1H M],)2((;T[+<*"EL(RY?F`:H$YJ-'I\J(BSKK"1WU=KCJM5YJG&A"-8VL'%$" MB&GO2@TZ&6GY2>(@$)V' M=^XC5M;@(X@FQ6-&7-*XF:=^ZHXXHD/:S3NL,*-R2G%LLG9%DI5<7Y-\X?22 M#179F5,F9R0@`V]%KSY(8!@XZ0[)@/EN"PZ))=V/,P9I`3RUT.%,]C@=]C=+EV)W$3@0*Q> MLJ-)!MQB$3WY'*"]V"@/W<0:FH*WLH1/(!A8G@#+-_P_M_1L6\-^=!R[-)?[ M'R08^N?4(I`TG`JM=QR:=`\ M=H*RAI]00@*(;6(>1QE8[X&G-8:',IQ&Z=XO?C$GRH$*:QRMCF.5ITZ(U"[K MI27^]?8-+#,2UDH5)U#"Z"\X6T`V5.]NTT-V(@0K!$?0I6LI#+5SA>S:[F&- M41/0GR&4<^.#Q7;\R?)=3@UVX]C-:UA-_@1\)/?(11L7*+@<<2LTL1"9$_5E M3*CY,YF/G2UI&Z!V]2DLR:#G_Z7,'%-7H*PH41!"M$Z997XY**9>#?.+/("U M:KRN_@BJ<5621=`CXJN,.-BV`+)7=IP?%5]R`-B@4C/TGZ0^/WA6+&2L$#'A ME#2UY6X).-2NA$Y*3Y1J\;P[/2?28(M\JY5,UW61Q7*DA.Q80NQC;,N*O'1+ M,8[<]Y3TS9P$NQ4%9`\-IDV3(DZK>=3D,G+KE9HKBH.P>$<(>98I!:#KI9YX0'GMWJ'>`A6,8NY5.I2"(Y8 MVX-H]A*XY2&JQ1-<=87R]\7]P$!`W)/IP6)UF)P4IZ4\>E$4+D+>$RWS4[MD M^6#X#6/'J/RV82/;:5<+0S_PYK.,C+!)8B-58EW.8?$'#/&]>>R;TDJ[JB;T M@:@-3MN)4S:A?0C^MZ\8_7%3;8?("@#\^*MU1YA?F5>`,C;O2K>A8B,'NF)E79X'+7J'V\OZGVA-3J)#[ M5B6'7A7$AUH-FQZ,-VXOUH!J1^O0)P?>LX]2RC2&'P`U@JPQ059!&]Q_HFT9 M@!FDR-FS2NT*W<5"B;H]+/T4X0C&4LEAU2*>[N`5[0R^?-\K:AOR##J93%%% M`5G'8HG0&-6B?W,ZEFBBR,9WLH%XA<>0+-I!W,ZY"Z[B M$8_Y615%#9?>PP[&@9&$2'(RFH=M[B<$G-KAOK.(<$"B MOF$WVJ")@5;EA\0AI\(HC<]X#EOR"0(BZ-DFE>=:,OF]#:D.1EY59RS:P48U M$9MP81,H_TY@EK0&*:=H<'@1]B:$CG4GSH,Z##X9.J=G!5Z?J0H^9&/-C M8A(WYE$LC1H@@8S3`OU%=JW5P.1SZMF>,_'!"GNHHT.=A/&#@3QH3U9H<[8^ MWV!-8\8X@,09+R0=CFY>&S@GARW8AR!T`4)2%3^-JLC#+_;I4\%\F0PE6Z>8 M]GU=?=#4;5=U2Z:([V8C=[+^,#MX(1DTJZE0*%%B!EIL7*HH3YG#"?(F[FG!>0YW1]L23Y<+9'H>TCM*[9WG2/MCMV9.F43W7^8QDZ MJ]G*VG$#RX5DPD#!;4>[]69:/1.3=E+HVFZ3MW#,<7C./','U%7#9-+A.$]4 MXA](]9M4$GRCRY/<#WA!\+]4ZJVO'NW3:FT.3POO[&G#GL1D%*&<\)4[&&8; M=KQ2QK9GEZTL>0-8!]`',-0YW8C4V*2V7>V<["LG?=0Y*BQWSTM<4^^G3D+L M6L`8C))L0\_[%$M`_EPP%65(I M=;-@AU000P>WTIP6MU?\R)M4E0QTM`"U#M6JCV9RRBK:1APY6U@]GZ)HRG(`+ M[=_<EB(L@)8J.4V3N MA5J]9'/E#X8]ZZ_!I:RSG&A/0EZ^@Q8]C4HB M&^ON(_1IX[3#R76/SV9^>%SB$$S>LH9T3TC6F-Z'ALYS.:L5?>MF,;%6;:UB MA/NG49JD+;&O4Q+Z/6U+2TM2BX%I\GS0MG!C2XN21LZ9G"QSN40[)@SZ$';" M_%F&S?9Z`E38R1L.)R"C&D/@%#_-YE=EP'J0S>/*9"D2O!MYW/5&8<.VR;7P M_)R(N!1G=GJBB[QMA$"?!%D'76N,\I&Z:4QRBPP-B$96/%L&+K6(07@!=@D!@!EM`&2#!UG&2 M.(ER,8TF-9HQ1,D=&Y9Y4M>;&=)!`J?A<+Z&-^>=:MQ;'-Y;J>QKR;'7ID[+ MC\/N@1S\[*P%11L4M0QI96A;T9@BM@GO!2WBRK2'U8P:DR,6"I MWBJEORQ=0`6G[?#VM*AA"!J46GY@*<:;35=1W;HT3)Z6A#.FE9GR33>I?RDZ M:U%M/*D=3"#WD7AKD>ZYB;@#=3%=8#J+;"!)L1P9]S?T4NI%(0B&5B5U9&_M M9XB\6U#AJ[H9_;NSBCZ26+A(G$GQ/6:HD_(W#K3^\8V=9-0AX8P2BJI$B"JY MQZX*;D@'OE*@I.>"M)R,R26@7HO/KAX\DT;@!M/S"]0P]X`3'[V M](\5.7&X2-C4OZA@C)QS"1'NM`E\HYGD+5AN@W4>MD8XZ?F M/,\P]K3;=*)PO($S7,8L:9LB`&=EFXM,7UA.?I-:GC&72!1#0;>"_2'#>4)? MA=#05@=KQY=N;\CT55HEZ`^D6UR2ZUEMS)LWFM*UD[]BKO=HRN$68 M)XA(IRF"]/SMDZ'AV6Q],#\44&#Q4F/DZ^UWC_JS6YHH=>;O\.UK/Q4E\:PN M8%7>5MEW5<2?;#!QG(K+`MF1R*KN0=RCRKAC+6GVDZ/??GU"3**SD@/"]?Z+ M^?MZM3#OFE&RI3`RP0V@IR.A/SH$%X13GE.5RR%E8USDVW+R MXML8^#L_W5_$0P)HMG3)DLQ^KQC2#HWJK8Q"GX;)H^EJ(4Z=2TM8"`>]C84" MSJ4N!'*"+"BR,-!H3BX58\F!M*WKY.],G" M#B*`=A\P8%+S@.E]23]E,@UFFX`\P"B!)&*@P(J%75DNE_$9!$R0#Y(W:HA8 M!:T_0$KTAM=?JH/I MC[J>5QI*%I+(6][Y<=MPUQ]07$_":C4$O:H5)5^K=57B1U$>S:-:(LLC?<1G M-,8@3L&Z05?63^N=2RY4;1ZAI^*RC.P,-C(X7+&A.@@S`N+2'IDDDB2@1J M;>7*O"^'7WT8%\2^#(3U2$`55]"E3VPS3$#7+)V&;M@4X;SLR&16#\*Q:=T' MX1$';XQJ2(3_NO`"G)@ON&I"A4H.7S?T#T^&OM.Q>V#;J>O`F@EH//Y$"JXJ M[9X9Y3]2M6.0@SRU*Q`R$>N7^R1&48;:+5_S@P\&*%Y6'5Q>\0>_JB9LK7C0 M[M+HOCARF5_ON\UI/J]([O.52N6#SOCA'`UE=)(0,DI*-K$0S>7(73.V'H@VU#'Z,N]@2: MB'V-N47?VSROIX;$F-P(U]@T.V:E2:OL+-^!D1N-*3GV*#0+CFI M5V2O%4LK"`TGG67'0^$G`79;EY$.!X'3T6?MSIG.Z*F=7]9:9HHF"CLG'@K^ MPA2]YNOKNCD1E2WO&4IX>'JM?CE@`?U^58IG1[/LE1,K0>GVHF$1QCB%\T@# M9LLHBVW3^;WD;H0$8Z3.ZL,M=2&*SXC,8TNL?LHU:-FM<0J^HTR&=7^K,JTC M1%ZLQA_$M."5A!HXJ*?7;]J#U#54M8%6W$6YC?UM;.UN]&.93EN8[9PS7/3! MZW;-[6*5%A^PD'%2:(^-X&_42>/`+2EHSP6$PCGW/T,M\&K,'^LC>Y/ MFCV5)Y4ET_FS93`@V7LEN'Q[1'NQ9NIK#S^KP1^LWA),(8RU*__CJ%X#YB\M M$L)BY9B)P@#N<(EG+;/"PQ$?3,IV9/W#.PB"(\.0(^ZI6X8D'K]A>4I=Q;D- MX!+U(8[O1,^]PS]]&`["((XH92=-[#_R6679]8NF#DQ='EGH\6=-+&HNKTI7O0%&\\CE7%^UQ#=ZC)Y8)5MJ4'X2` M-I\SHW&@"Z?,$%(F6^Q-+84:(JN'A MOBER"1IOO)P1[Y<:^H;;>3@@)+8C*3@E0B4[)WK\WONE#)!%6.+IV>9:SCM* MG_TEBZU'^#Z<*.#[5:4.-=L,70VW4ALI:*9GQ7[MHT<"D4=(6!0'^M0H_5%+ M\?X\BP]P[;@")MX9(_%%:_E?@%TC/3+6=8H)EY@W0$^4<7?CFO33:K"-<:LM M7YWV@)$#0:JQ6OS+M7XL8T,^@!VAG8'#5&328)1<9ET_Z_>R`'$4JX"Z-%9[ MSP)99L79(?U@?IO6$/J/5&E4L$N(AU47]"O4UKH12-?867W;D&K*>?3@WHB5 MH>]1&]E6I2`)#DF:M0MQ\[=I%KD99)8XYO!DJ<0P)BAO#K0G\S(D`L=&- M&6)+H#2<[U468QIN#4PK,NVV);1BHK)F;&6S_"H>!!W81*H;,-'$RIMXX+?E MM;2'74'C`D7Y@S8=&TM9GKIU)$NCF/9E99W[MN\VO@`;3:>W5A MI).5^QZXH%=I<94'Z+&S<^1.2@>M/1.$'G6; M%ME&;?&-B\A$TVX58_=OA!!$F#M`$@YTQ^;4?-XUZ=8X;7:LG+0.$VK4RH(E MY"MN@D$GY!JE,0T)N,H%(N=C0M>'&H0V72YWI3DH*%G8XG[]X+=?M:SA*`::[L,BUE1]`GXKG$=> MU<&\:S^(*3>@!B,D%_=K#=R4#H4"63(J+-[AS9@W.R#*<1-M1H2'H M&$-%PMI^;2_G9EQ40H#,5):3E9W%Y$W9LQ;%M6D<5A*0+R.,[0'L+4 M1*O+(X9D^**[O"890?K!9IXE]%2.5;P,+Z88&M&5"9D?ZPISQ4& M4NIE:&Z,FA=%1)1^BIX.!/C'=`NAE5_`@Q`QMFD0U6*R'L"@?<%\V8;E>1PV M=*NPM%TCJM*.=">Y$[Y$J%2XC%>XLT;ZU5-++\0)F M>.I5N),<5U0N!#.12]8ID/F['1*3:6F%/5R,@F3;$6JF8:66RU/?61Z*QHR- MB-52L(^JS2-V9!A@HHV4M"(*?4I;RDPRNCQ,ZG5IH^5*RNGQ6B\;$"=U,N1J MBI4I0@_K#!JN^XH(2_Q(EON^HD3[:+%>J"?HYMG_"`/KDOD1X;S]#MZ^;W,\ M+_C=Z86N*^7'A,C,3 MQRDA:K@A,06.S)#F#3K,Y1VZ6()?L.A<9*Q^5O6Z:@>@EEV0I\H=6>`^Y^YG M)*'9LDR4K!6X.X:T!=30!=,N:'=9F]T@V3G-S;%?5@L-!F,`HOI8H?Y',MCP M]EE7B%7_R^&CXKG;MT]U1]T`!6R$\"9("J-Y6]]-#NCOBGW]G%AKSSNV2=O* MX41XD?/>-4/\S:P=-\L2`RH+P$N*9$R7NEP-&EC<'V@3H=7C!UJ\]TJVFZ-9 MV&'I97>L;(<*7?8Z\N*#(&43]74;W^,9&6N+<54[>(!GY%A=]+8A=B^"GCX*L?B(YI M71R'Q;,`J4+'&PG>9YH67E*]BUGB5'+47*/7GS MBI9MG;]=:18GH\3=(F3;73FS24$$,2&M=;$OHB#+TL4N2_5UI96E9DR[A^_U7\%00V.3@1Z%?[6PJQZ3IQ1HLB_[*T\Q+=GSG0/I179W(+U8!. MK4BEO':L4!"VLD@9?@-9PD6B:;/>?;%_L[C)T^+ M^^K]0EI8J4;@MZ8/Y$7S`R+SD%/:MFC)$(E!Q)JKJ#=^:W-3?VR=$-OOR)5M M#GXTIKC5-E;2(3=N>&8:L_T4.8`KAN3GZOGRV^H[_?J8.=J5]+,\K2LY*VF/ MN(QPG?;`%3)L5^QUC9O?MWG!ZXL6TW.0\JXV$[%0!@*( M4D011=RI&M?X3XD'NG+IB;VT#V&55A(YDTLA)]S<:`COI/LK33!` M,QA-^V,10X9X>=QE4HTD_ZVX[W6(G`XJUU[/T%&M+`(6(B:2K/P@875#A8:` M"1)9'1SV9@#W(R/[I9AWM"&:*`VMNXYL_7^S%1D`5,BS=C2@Z_1*2%N#R,K6 M'^082?HR;(O7+@QZ:'"H_W%##H1>W,?=@3N#6CF:TV.O!D!)_V]YXF MA-)*H[19E@N)P+I:3Y)03C\>_^C)5R.C\-V3QSM?/?U2/WX5>MO&-:YCMN0A M)X;I#XMYL+XJH@WLD'&7/-<=N,L/9/$;#O\)]J)52N6I6G1G)C\Y^&KGR_W] M$?9\"I,?/7VZ<\!/DPU-R7^*R8%OMS+YE&7KYG!#EN@F"**2L^>QJ9SDU2>? M)!HJT8&CGZ0>H!8"!%5)I:6D(\,TX!9C2M>QJWI(XJ9^@L//GNP\1GL/GCP; MX2_???64'7RB."DM%W'.H4P42@"S(T1JM>>GQFYV`_8>M6KF>&^9%0TW`K>" MG6S=:GX&+?1P;#/(QD#;XS$,7W8R@;G_D7R9A`UM!0S=DU<':.!RNE M@'J[:>LCKITWD#4,F19B@BYGJ?EAU5?6),-=0Y("3S%X)L16C.LN!`;*,:`.PIK^;NFI9B-P`07(QW8NBL2)^#,D^'GQWL/)5/_.B96293 MO*>/=K[ZXDG*#3I^D,/A]^!"]M9S*$.0>&*#Z(1+-]`)8W^)XN[O'#S]:NM< M[5G'OW4J=]L^C1%!&HR%G@RSS2FMT5,)O=?\O=)O7YCI\WU+QW$LB60E&7%T MHKIY17G4"#7+\G6ZGJJ(ZG)?#+XE>.71#.*@(GR/;`P/`6+ M3*]&7CBVM`NTJKQJ^2;QI3U\U=TZ\W[ES/%,>UA;J*-;L8./:_>WQM*[<3D0 M&Q=*;H=`];KM0Z_:$TB2GS;/:B-C/E$JP@K_C16CKUUF7)C.4/G690WO\Q@CG M&'2-2G]#1%K6E1E^368X*2";?O5!Y`?K.>BICQ*2EDX^)WL3JNR#64CK!D]E MC&?ME1KIYE??!9;UGM_ND(D+D*_#EZDJD$]HM^!W+U2S*U!,.L,U-3!:E1I& M,X]:^^O'D6+=TLH*^:CV=GHXK@>Q%SW:OEV4'@L3CF$YU?`9A/;?=%5K$+4/ M\3%OTJ?_%W-U1,].3)DYUG7Y*)]HF^ M?,R?7SU+,_T=S-08EUQ6?.=:M8LWSDF7<`5;>%*UQZ')P-M+4^H*B""9M"0> M@%ZW0CBBJU+J*&Z&ED%]QAY50G7\@H$MTL=F>WHA.L9V^;XEQ@-N,&6/@J!_ M^NTN*9`D/==)QST>Z@SY^SYGW0;;3H9^9\\&&]R'+Y,AN)6@>"E<3__NIY9O M&G#'5M@=4`V@\:QF;ADBET_<+2/1SR(6NL[YEYR2T!&!@Y*/SEZ9#8 M@Z[5)KBU*,W]>4 M-=)*^7FRC!,2E2VWI$(VWVY#&&Y(#5BWC+\@DITJ5WJ"K%KQ]-%_BXJU!#B0 MP?,*)G$P"O>B_9%OJ1(BKILONH^K7`>]1)UHF)GC5''%Q6,7@P!)I>*;YY8L M1.KC)36Q_==KW?&'?4,B'N6&`:%GPUWVK%,C3#WMS:U-WK(T8,#BRQN69\Z& ML\,F!*!TDV(X:1+RPG_;:CP"#H?9H[38"KF-T:OAD?<;2ZDD=@*7<$0=J8I# MK%AX%FXZ(3&RO_=%S,CH2_ODJ_@)S8CQI^),)"2:WCK)H_9+7):IC%G6T*)D M(#7C()\E34,!F*K0M+PV/P^5J>IEDH=PVY9,4/QQ=N\M[$H%(H$L@7*$)Q8M M6ZL?EF4V,S@*1)"X;F^7>?S$'U5W2;QSOB]8=Z2&"S0M$M$!2+%!A;">P%G6 M&-#AL+:S&7J-8]O2!DO\M?[9V=6W7Z^_#4M0Q\1.VXDPL<;J.05NAF=+)_SV MH5=C?)8+^A8PP.0&@EU?6M5U7/T6\%:9G@]KTX7 M-.&_]?\6;<2?'/OV=[!TWL/O_UZ0@^4]69>5=_@L#]T MRO&2ALML/Q1O%]2']>UY29[MVK^VQQ_:L.MO?_L_6^?:?_3WG*GX>#7[7;/D M7N]O[BV!*3JCJGO?%G_D^,EB*PG__R[W6S=IY>27^>(#6ZM;)0U"D!-L0CJ= MJ1^YF('QILCNH%A13"&H';DT_PI<<4%Z`W`"*J&GZA-@%F&!CTA4KP*,$*<($CG9X*'J02UA_RIM=CF M<4NE;[0HSTGL%Y2550(/?5;FCN.8=>VE`QP*_J0UL)Z_OW6ED#T-32/]C+_7 M]D<69#^-E)L&,R),G[C!-EOSA]\(@;YB(AZW!N([(`R_*"2C`]2$78))WE+& MJ;W>,F5G3?2BMT'B3FV9[>_$AU*J=S-F'@7>.6ZH#LW&*C^>EP18.YI$.-P^ M8YO;&JJM;`@.**#VL*E!-OYO_6TDK9I?<$_UU"YLQ`4^IA%?OWO%FM]P$<6K M-4IAK*D&_KR9Y6:J0V&6=@'$W`1ND+H#,LF?[:V?6? M.6YF2K?,[C0Q@96UVQDA)N;,;0?5#L0OJ_-+/5%R4XV>F?33X!0<:%.Q['L0 MYCBOT9)Y6:W@H3+L6]:9T9L#EH2>"*UQEU^*M;&D>5M]-WT99V;!A$0]JY@0?F>;H0\VZJ MK"E,BH+;XTU[@"-5(%I'WHU-*WIOW*76!*^"CZSK/H:AC]WYI,=TIRMNN.VG M>>+)795D!1?=CD/I(AQ8I?/,^6_`@N5VS3`2&^)XVVS/3B#]L%46X?QQ$@N7AOL/8(D3L7NK$W!ZR[9<.!T]U2_$NTTA]C.?+D*ABO0:)._$5M7K MLIQY(P6,.M)%,W..OW-1,JE./8XXB(481ON+UO%XW@;R](T\(^2P))#$6#^#F]HR,7.0A)4^2 M[Z^J/JSNM4EJ/(:!((`/U%YK=5=75]>YJ@?$P-#8A8;Y;A?W[=E-(VFO/'#+ MRM(IRSYF\0LI(F*$S.\AJ01^9K%]`-4Z,N,8-?]O2S,5XXHU6Q*4M:QRMX2P MY0$^BRL)TXM"?"EMEZ#3FB40;O@IB,Q:@([J"L;P&3QZX90*_VP?^^?EA`N6 MXI3C`PX?"!W&U406R!%LBM(2&ZS")',1BDU.:LC56;=+>]<71W]>\5T01MAC M8SPMXGZO;$L+^S!5^40`I4_$G+W7L;P!5=\*+2-M+Y:\FF5AD7BS+#T[4!FZ M*[TB0.L0:?0L1)EZ"WE$A_C;%YMN@_1-S&)*5)?< M50X^I*@!//,EG4EUPLXNT+UM.+LQPI>M[-74D'@VV64BKOF0.6](GKRQ9U"5E8&1\Q.1#XD+F4UGKC$W!*& M!97%"$+!^G?\++-CZ%#:!+^Y1$)I-D64H51-!`/),")Q%G3;S9DZU>X MSJ52LZ676'9.2U%P/)Q3+YX@[@34V.)84$C6N!/+-O>2V*CJ.3&RJM7[O1SF MTY/H7#D]7TD@2R2!Q2<#* M+E1Y)>U2*COGZ)7.05L&ZGS%;?KS^9D*U2!!1Z$&AQ\'MNP:YZ32"`.&)IDU MJJZSB]W(8PU[1)+HL^*O@UTQ@\MT3N.1(>A\KE@:YN""@<_FR&\V52K%S.ZT M/G0S3I`FQ$C2V)H.D?UL'*?&:BY94`+65Y0^^'!PB=+)YAJV+/+P9=`K!GM% MPPGC&^BW73M3;0=1FY#!B;8A4)O,?.SON83JP.G*>QRG*T%L*='`0&Y3K4X\ MR3SB"F*JCV52S923:HZI[EA/X8).FT&1DDLJFLK4`#BB]KB35W,<<)+.YXJ\ MZD)K#H`2@N,?RNO'%O=(.>\BG%*TAQ.:IE+A(O*P\+WRM>L,3%KV+JD4[:%/ MVR::S(/GLNV0RN&5]%-7CDL$QI:TJ_[!/4G=%L>GHJ2DI&$_$'5G<]J`1L#.040A=1,>Q"S<` M+?HYH))6H#R'@_`[7J`404F+8\'?F[3Y_.GB[>=/?G+:1?Z>+*?WR)#/GR)U MHWTA4?+G3T;*[>.G7+ZB6E-PWUN][4SNKSI"['@7?U85]^ZK1S\6<5W*\`N^%D;]-Q%)WUWU!8 MQ@CVX!VQ,=)AY$['V8!B?13VCEFDB)M$R!=T.%9#)O&7GT?(A#HN.D&U=/CU M9!=)`R\7%H--PRM::%]CI&8\E==LRY+E$8KG4S,'V+TM:V5\P<5E4'OI2S`V MC*M%T`?3^/=LJ`FHRMNAA^QG\7CPCGX[R4X3D;(W4-:L2Z04T<3@'7'$/*QR M-RMM\]S#_*XF>6Z72,E[.J!P6:U&'C&REPN;<6;-K=CRT9C]8S"#20C&HJ=. MFJ*RSAP8?@!KPCAP]0`CH+$.M+!`KPT+IMS,CCZKZJ!HP"0?OE!N^*+AA;43 M\OP>\1RL><]?B#C0$(,W2@575U>))E*`K--NSB(>E_WD1Z$NC6P&(0>/F)3.@9F1^%WFURI( ML`Y4;Q61Q,1D<@PV5.KS7CT14RHP4/9 M=>7-[1B]060G:G42#[.N%.;&.(3F:E]`@TL\7FC@`*,"433$U/OWG6YXT^\L M\O)`=_AU7&.?F76]E91@[N?"-'$?&MLHH&P?`^`@VK2#N&310GY[P*Y/2H_35S[J3K[1PLYT2?['0$2%F2)%('Z<=XE2R,Z<6LI6K!I"?W%_?_,H/Z6_G'PK- M3CV[$&>R3P<(]/1$W.X5M;A4<\Y%UA??<3C\AH M&"ON`JW3+X@E,H1\L&$B5V<_>B>?08^1N<;"Q!TO%>J4Z!A"(\R+?^**8R\3 M_))II:?>><7ME.2`PS:S.B"!9>E&%FN=6Q-$$O1I4",+4N[LRN$*(F$7U0C. MR\+'`;3:S5*(5-,!V`0`^7%U(W>0('CQWX^&$3H^C,1M)N(?E)B(!+)>;A)! MS+"+W$$R($@.5!YKOH]BBAV[_)Z$E9?JV,CB0\72\J9(AI7CTP^N9.QE]TY[ MZIY:0Q5]82\#FC)@+/U:`YJ0T-X`GY=#2?:S#E1('(\?/1]&[H?UAW[%U//< M@#;!\Z4LZ:YI!G)"9M.81/45J(W9'!P%F? M/#V%U-APCM#S)#,KO9_T)BA'Q"VR4!8`JP00'01?M3,G>,D-NP%!V"4^1ATY M6PJ72K7AWA16XSYSQD(:M_:A>JS0I(O+"+5TLY^&1[+SFI= M<#%#"NM."F-CZ,C4(TMGA+JAL,2UG>[ACKHNF--$%RGAR"C1W9W$._\[:B5J M6>:;'/G]ML=>(@;7SY5SEKY5#^61Y?!;)62E*T20*UXP83#JD!SY_=6*BLE= M.\,^%$=T7YU5(73XW"6*AKMKFKM!XZGB_AWEOMD'+59?6ZNUSY_6<>=AK48@ M9GNZ]S3I:=.]-_9D9?5)1.PPX,AW`5QB_5`RNA,05_MG$6FSO@$E"J*P:9'7 M.@8%,N$AM0@8EEN(SZ%`1`)<:N;+A"#%&#QBH>?1)+W5(5,DAY&A+!8HQ]J.`'O;0UP"52G;;$RN\G'RE!3S MGOX5,/>)N.%V-%>R=[+L<,&DL)MJ^QA::OGLB!03T7_"CUS0G;;\`HF%D>?! MN#2.VD3;4:KZ.B\A32_IS-?MV6`$#JE$A_D+ZTOH@$F[F":8^&CK_6A;T6*? M`\C[MF-2;#F$[F;W#S?Z#\GNL2[G"[X#2QKPR^![T$_#<8\DE41C5E6TQ)X= M@#7-$1N?`E\ZM>/3!A8V^UGV&49LP"((KOY*?4WHZXZI@MF4:WA?=Z-2Z3!1 MUR&8C!A$]UX>=7W!H3#7BAX:\ZD8V)Z<1693/+N@`HT0AC8`UAX-,.-(`J") M'>F!%G=AI6B@3JM2?]-Y,R4(MTA)$,!DQ.P;,HF5Z!F%C3?R+FOCO&M5DJ\0 M-3P1-4)+RA1NT!#0H\07-3CL(=6%+9W?$%%JN[JTAH,9L-F6?!VD2PJY M<2[%M[^9+*WS$BH]5H.I<]\HJK:TP8\HCX@M:P?@"U%$.1GZ%;M-;,ZWT0)! MAA:+H!3D!'02K1L/5U?65ZO61*E;IUB"]&RQX3YD))D+:J+4)/%GNV#EN^ET M)SF&H"?M3[[VLVH7+6OGITNVG4'4=Q$-<8Y*B$\"/&=V6G'ZC@TDDH4UESXH MXFSN1F$,LR^0!RP#;8U=@<63:NDB`E7]]&SDI4S#8H_QY=W2/+H)7\SY-LSHZC&!@:=ETX56>1 MH,QIQP:B5[NDA_0185*I9YQ']LBL+\7R.&8&H'&>3'#!;CFA'NT?$_ M__E?D]W!Q/535T?I?R/-0E.[;F&3!UF9TB/Q9JKBYNIDR23)4?".2ZD9:@-O M[O'C4Y`X@JI7:9U#'-2@"-`WT*M%)'O$U((OR%;7QZ(PB.-5>EZI0"[7T&J> M+&V-#TL3JM3`.,;0PXE18:J_9B>!F#QOM@CJT3-C?IISP3EPQN9'`0#U9@K6 MYE)"CR.+"*4.+"7)`Y+36;JL[3>-47AM98OF#`Q8J4T"2>?<*Z?=FH0"-?DK M\&;Z.NSN3=AN#`"RKBX@Q1KCME&QFGI$029\0CKY6O8BU)9@%YW1@O"8`N^$!P:M9)EHLAL M/:GA7%/%;E=(*NS/9EHZO7^"\,E2RBJ,K0G.+:O1I#`";L3^(`&3N(?-CCLN ME-J>)5CF33!Q=^/^=$E4)MN>V@1=^\<`DI[&WL!I[$TME!<0$M$)\J"\HZ\, M!&@O<2E7E+'VTDV47.L%I$*0JYA0H^D6)JL-NZ%=M-QR'RA-KN%H9C-"J$E. M*:F/Q03(M/1Y3Y!<<,2B!'5FVJQ0VRE+R^PII6$8_X6AZ\68PL"!$L-_PU_% MK3-VE#KFCH/48HD[I.5\G.Q71FF[L,5O3OXXY=($,<@_M1^A%M.2Q7C)5/"F!T27U2- M>;5EN/A)5D5$A">%9;4]TZ-(O%Q(X8;+WN7)R=9/@^HO_\E2K^ND)>S3'1\QY M.'AWCO&,U@WSS&(KES)HG58$E_O:R2/HLM1<)2+WZ:\V5UC-@T.:D=?X/R,7I$3E M$U8XRS5H$8$C1U^&--)L50.'`*]"#EP=]"D9VISE*93("-V[8X0QG;_#*!=5 M;(Q1A4YLM!FJD,KE3VGT?L]!.0"I6@?'3Z@GLW3S@ITRXS%^E&0#H$O.WFM/ M[!C4Y5R@Z\`;AX%;K%\*U.R]V4>L9K(Y21TQ@C2/_5N!6 M+4`.Q>FO2!EYM/EXT/:9XX1%X+YS!M*&B3R,.F"7X4X6UPWL5NY2M=H&,55_ M,K%'R4ZQB'RYG^1P3($8PO@T62=-V*A#!U-5E[;0[-T=:\O]"@<_KI0M^H#! M=D0]!/&@3-:6P^-IS,3R]5;"V3X,GXIO+HB521(5G23YO0TUX=455T3:D%)' M\IA(,OW3`A*^)^2HFQIM/_G!E\N1MZ3#Y/+9C8TX``@Y"PBF8"KG.\'T!G'\ MH4[\62>MQXES9_L58N5*ERK:/4,O50D-C;U7AN5PIH]3P^2=$E#FC)$U^[O]J,@`H$YA:!8/;?SUUROXV_.>":5RRDVS9R`3C= M,7]Z<75U\2,K[P*S6R>'9)]EP_0&2;GM_9T1A7//>)5"(P$"\Q!J7'IE_I>. MW5`3*(GCECG+YGVX0(&K>8@?E1/RJ"O9LX23U++%I1`BX4(AK>DD>A1RW``F MQ8";*C*V/1SNG?DVD@'5ZPJXGLE`+X.V;U`?WOZTKR"A*D9B M>D)<^]9+!?'"38I)X>:(:'@$^6)\[??D`:ZN/UE^]&2]>T+'LT?DESWL0LHH M,TQ:V5YEVXZAEW8@`W&8/4OD'`&(0)*):-TOP]]@VSU27K'T&`?#P\W-=NP= MKG#1\HF@_C4KVFGT]F4/P0QO@F[?,6"3)R>D__^V#V'S";C$XN!M MB1J-C\%\X%9-Q1Z$$PAP2^L+"-MU1[&*L'7-!S[<,1*0KOQ.2BO+,5L7R#,^6R'(+55FZX#*-(E_8 M693/_$=X(R:&;L15W..0(-ZI1?C537+I^@*M2IIS^H1?W:3$K5"I_-R%!QV< M>)D?T'&RM%@X-_YTA[P2\=)1\L)>7VJO==N?'$O;<"=2B'$YOMPQZ/-[4X<= M1G%PK*,IL\'<1`AD]!/$R(E\'=/APZD>F@8LYJ./D2521GUS\NAC4#P=@>*I MCU7&`=BT15-#:O[G4S3+P)[Y@RQ_R)#I$$AE,7M&?`A,>6Q/Q3S\P^M[8DTO M#6)'KHOSQ*-!])DS:E0#K\Q0)XS-U`K#":`A'2TAVG!+7;!`#T1!VZ7RG8Z" MQ:Z/KPY^Q`\TE@B-4JJ=+)T7-$1NI5U5?[&>0Q0?&^D82M,^C'-[>EUI#%ZK`\(=9\TG M1.8>MS#W5]**\WN6*'"$#QH:*]Y;\TB$[7-*YR_.S#6)S6C7*+>FR`0D.FQ[ MR2*9)?AX,]1N%=T7>\))`$*6U9'TP_]O=?1_O+/3\$HMY5Q>$BJ`E_V@L,'D M=WO;?O0O)7&'E^.P()9BSY^/5.[M6(#43H[O#KP./`!#2MOBUC8& ML)&R@E]2[M!!^J;YR$^4]2J.GD=#*PAFW\_YVF0J'-GD"J5;-%2R9BUFCS@# M1L[I2-09@.9[2KJ]9HL$#`2#R5@3BRR_RK\J4)2M=$F3MG)Y9`_=PUY_L6@M MLMZ39,>-$='AN)%9Z`+*2A'#@XLD55@9!QLJ7='6LKZ1V_Z$7H>*]36Y*+HC M\%J=,?.@>QY)QM_C[4:5GIC`S*!W5$WE&>M7Z!G!5^-2BDO^C&G0@87_$G($ MV?@EI.A(VF&*2#LCOHF[9*;Q6*F>U+JKW+,6\P_J4\(+KE61B0=I]#<#Z<)J M_[E54#]"H%EKZ"=U4M&-#$8;?\F+J];&W-DN](0=Z"6%`+0]:%^9*PSUOW14 M*=L6S]'RP-J9E/MRLMQ+;$J#!37<0XKNZO>CU6@&E*2M\',RPH].KPCU*>9@ MWNNBLK18HX&*F055/SR9D"F,=OX.#A!Z"!LE[_Y;CJ#0[4T@W*M@QZZ"9#"] M\:EV7O]NECVW]!JX.LA>=',.7HJBGX_^'CH8/KN#V?M)=B7*TVH=?,"JE$+V M,.;-(X_YYRWA&%YL723LWFT$;[6P[_;V;0V[_W1P=OG-5KQW"$>;84;E;G2Y MK:B4N7P,9'"D.^%T%M2&7:Y$^0+,L>GISJ+BF9.>[;AO<3H:H?K#VU>_$O)% M-#EUL MYR-I2U@TV>M/GZ[%D`*\!Z-5P&&26HO!I)K;..S!"B+N0,M2M@(W="#1O&6# MRP9MV4"$=VQ4@!OY>JB'=#N8KQ6,B*"1DZ?!$ M*UQ7MGV03-;VDC6.VF@5P[CKQ'DGZU_)VXW7UGS;FI8E8,-K5=A5Q0J;4W+/ M[X?);UE_5D1&*Z4CV;TSR%PVIL58Q;@1V&'DE"EOD!4'?4\V"FWI$&3Z9Y4C M421#:043C@Z2>^0U8%79D:*`@>&`O7LGQJNS^,)^2J?W-Z1$7;^WNRFW2E1K MF2S%(\+<;G9+G<.=#C./_5JD&1IO-P70,L<&W3X3/X+\7%DQ M`&ZR7335X5BK<.;U4J[;K0L$@3.7(@7T=?*UVRQ2'?;,[6Z(-R^-X5R'*,&# MICCC"A:=`/0A6BBN7-(4BQV(@*F%M]3Z$,+PH'?:T@6PF[,Q-5:&^RE&H6"N M=5K1I'Z0WD&F!?15AL2/T M8AH7#E/V$/302!(0'#)`SR_^,^E=EC]'6%SG+TYJ?65:B:N7O3JUR@,G2OTJ M`*($D='1FHC)6C`[-&M^+%WAC4P='E10CX2;7C3[)@DB8P%.3YD^JCS5;\"Z M-!-OT@@"08+??T4^X*D6Y%$C;VX+NF5MJ/[51%%L5>CK-!DY9V(1)WJ+<&#C MJ2F($:(_&GZ3\$W*--K'R3$YWPQ!(O([-,%E(ENSE-=O"R=9$1[,.>!?`,.V M1=:"?C)L5"E^KJIX"/>;##A$"FTG@*38I&0"5YO?DGXB=TZ8/A)6Q/_.V0IO M42I^2>'CR@>"@;B_)-J!^'".,QU@<-]E3ZU]Y*VL:6Q5%)3D84Z-';P_ MAWNE_8RPU^R#6"X#K:T]^DK;[WH1=HU-J#13+2]/@ZSIH8/:.E_`ALO*',2P MN$+E>AST;H!&+>4G>O:`G)G8PH+N.R^XZ=-K3!4UH#Y#(H%E5%Y\$%XR95P& M[:!"D"D-&GR-VOLQ6$D["++90FQM087I`PM[98//AX^6' MCQYI7^`99'MSQJ7A"BY"FRB,T(2UA[6=\R9YR=VP?O_QXX'#0;Q5(,W>$VY8 M88RS2HF1/#9WM])055?AQ7#[B]X7@)6EKG&[!3**\&`Z^?;)X156M]V/NG%' M_+Z/B+$N+8(M5K>C;A],G0TW8A;#5:C52I" MHFZ+4CDEC.[+E^#Y7WY]_6W=*?OW$>EL?]_'XIP\I73BSS?$U'?NP,WV4B`Q MN%G2>?(1_4=S,Y'ED%MU'%T4GN$-_2LX">>PD@6AP:>-2R[*]54E&U@4$=W0 M6HQ=$M72;\E/U#N,R647Y::WY&1H,U07?`JX6(P)WI"B$4^.=4J MU\H&H`8IQ9OCZS*88UF>4&XZ6VJ,Y4+QIKTQS^#\4/>EB`E4U7E:NT#(WK"L M4)''8TX@G3*S+%U*TEX0FF MC:"S"DX+%TJ3)=!)\-W2>27G4$U.U7(?KSF\__K*C*V!&B1X21[H-O8WJ=Q" M<_CJW+4I^XX%J\;@ZMBXOJFD,8[6O;:Y\NB!>R0X4)!"02!K4^4OL+MS<5"= M`/@QBN,^5]ER[117`5B%A5"M9L=.J,2<4DVJH=KIWH/_>5)+"8^D?1`:Q1%L ML%SH:?M&Q_3X@O1=;T$2/EQ9DG4&AKD$I,GB$<`+8!DKOO/#M):*ED`)!3DD MGLHBJFNN]W'8CO4U[@2$[3RN4)U+VP5O86V+34#(7H4\3LSH;5X4F8F>46N4 M'2-&6D5JPF;&<6":H"`O^?/)2]H[A=\!%-BY[!U=H5ZS>,K1+]<]L/W\FAQ(#`(+(/5QJ6&[M MBV/E].X]:M_&25MTW-UE*?W7=^VP3S6,] M:??S;YEO7PQUULWV@A17$GW4%.3[DRXMR5J>"(W)@H-)I0_LC%3=I=SCRU:3 M,*VETL+#S'`=)Q5W4&$^XM.I4+9KF<4&9KO0P&!*G8/H.)]9Q;7[1IWE(T`\ M]1^=!H,)C@J%(B/3W7G&ALA?-NG2*VLTF+RQ!MUW@/B<,3C[XCC.`R6P9_MC8P-;G5HHW M1^M7J,S;Z;1#OZG;RNE0Y^J)6,!D-PHTD$=O4ENY/1G-*S3*@"$,/IH60Y*F M$JD=)9_"XME!KS7NCKLUKPG6J2W1GU9EXQ^*+5LG?>.UX\E%U]\:DK+C`%Z+ M1/A93>1:%%7,T-:]:)?J]PSU4T3I,7T,%Z!>?49,2]ZY,L>"NPE7)M/CG,7T MHO(?+GG1S->3I5>1O/K'5Y88^Z?NV+8OM"ORF5^_E7DOEX;/_,>7JH.R*[:[ M@IV].9XS6!/\R@2"J-W^4(5QDB?LEEFPQESQK;@OKYW\WAJ7.2F4TK'2ZK3? MQB!OQ5([Z\/)*YN3PK,1>0-(-SZ^\2EWS[4%\E]WZ7IW"8Y5#W[Y.=ZS[ MQ#\\K[-]^&9O:[+4-X:MOWG0?D-[)@;TEF)=!C)T.LZRJL,[2;35CUQ`[4;> M<==K^PUVY6)HR`"_/]&M@WBGUMHO7T7891$TN6W-7LWK%KU]X_44BSY*1,EI MN8TH;SI`Z4BF9!+Y'M4-%^GY'M,,_?K#J?S?)D'#I9[E:HN6>QN+3E#Q?Y5[ M<[T8*`'`CYBL4C<@,"U9RI[$:7)K7? MW4L-Q[L'&^[4;'__GJLPJT!J>/S;MQ+Q%`,^7D3`R!4M;X"U65'%DAN3$11L M1_H^M\`?B41&#*A78EUCD8&08A+MN+LR[(F@AX"3#U1[$UPBFPFI0+K(P7:@ MK62LI%?GERM8QVQ"+#E-@;W2?KL]O#<>];Z$39I;V[M/[7K<$G"2SEU3DZZ^Q@R/!84>:33AI$V!P17(PP&C/"%%\.I MU6ESPVH+9Z*I7WQ@',)^>VW:L.`/,CXJ1+;PW(M;;MO?39K!5.2\0.NUP/\= M1\Q7V+9C[M`_F@TE)5]Z\N`L([41>G1+[ M#NQ91UUXQ6,G_PL;.:K\HG9C!U8T/018X<_MI`VX6W+[NP90W%6$C*^V(6-3`T%GPKB_M8 MF/BR_M4M?-.?8P6T@U3:O&&O\V?;CD7;O&ZK.2LAW6$JXJ@HG4ZH.CNY6<3X MR"THH>402U4F@_40E3,1/)F_\I=J(MI.FS0?`+Y-\UDA#X!8@ MJY7=O@LX%_!NT_"&?A7&\XM0;.B#$GQBWS40"?C8+.?N'A MRMJ#A48(!L7*VL;"Q_70&RU9V="+OZ4Y<@:K^Y:'-\UKWH&1"P@GM6&%_[1^ M;\=-IHGY"B8W61#VE>K38^2(J&!A=R'RIYD MM'X$0W^O3#=0]-\E"=ZIX;=^.7YC2//9SLD!^**P>E+S0" M9;:31O/E2+QUP+OA]-9A[HKB6P>Z$\9O'>46I-\]*+""_[7H5\.S$\($UI]U MJ%_*65L=Z)O=+B80_C.J[HSVRJ(2)]`$'?N=-]_O>!$]B_>3.3=&;%8W)WYR,V??\D* M;QYIP6IO_NCFE:?SN&/5X/O%LS*;W.K"IOI\1'\"@T5P-FGA%3%A&'HDA+1C>3+056=*Y MPT\[7+.LR7],DA-JH6?9^K?*2SK2?6K1>D>FN<5'OJ!;S<(-*%UK(-%H/Q,E M+H2F%=HF+$X&TJ<6:*+8)?JB7+,#$DIZI(++;]3MKO_^'K@@?@/GN/<4:_4,)XV1Q3A*/'8VV_<]74.UPT?3-W5 M78JYW.?IGT2V5K37:$'['=G+P(^[>.;]X@:-*]JW?Y!K2XT+O-3U]IX%[0#& M#RS+*0?#QC";^YOC9C"QDI$B=N=<[9ZW8R:6/E8^W+X[ M=)=?EEH1-B;51N#%6USPV0U8AF`T*SW`$B,^($<@#!!!4E59D_R9_?5W&,GS M<[YLF"8,I\)"Q5C:V49>0Z86Z"1:2\5';$&J86P'&V(5%:,N:QR;??A!":XM M$K`IPG.'-R,-HR_02:T(6N"+WBS`V?R9F05(!;]%`4U*FK%L]"3:VB&&RTET M8(F$7?E)/4D[SN\C@3Y9]9;RQ)[@M6Y?'40^O,JM=WSD\6Y5:]OA785X>7IP MJ*)59;]5/J+%*8IYPNR6(`9Q&F&F,7[2?X!8&^2ONQZX,#I>F7.6>K>"M3W( MO*02F+0C_HND'D^3)-9J)4G&`K=2FF31!,84_G82*8QMZI]G[=RHQU?#*'&G MW862+AE2U3/1)/JW#TJZY%ZD2R[4'DOFYK,HLIS4VA[J3U_;NDAL-SF8VU[6 M+`KIO_CU;';][?\*````__\#`%!+`P04``8`"````"$`D8J.KH0+``"R90`` M#0```'AL+W-T>6QET1G,2I9WYS7-G9Y?4 MU?]7N(\N8&=G$=K-X1/5E$^LIHZ5K@ M7'YX#*/8?O`!ZLO`M)V"-GNS0S[PG#A*HE5Z#N1ZT6KE.>XNRFEOV@-*UU?A M)K""--&<:!.F,]TH+VG9)Q^6,_U"US*1%]$20/SA/YLH_>YWV3_O_OCN7?_? MWW[WSQ_=Y;]^^F;WLY^^U7L%&T(3;-!,\[S?2!8^SBCW<@FNKU916`DR!*LS M!5T^A]&7T,+/P!E`//S:]57RB_;9]N'*`.$YD1_%6@I6!OG8E=`.W.P;"]OW M'F(/O[:R`\]_S2X;>($Y1OZ]P`,SX<5>QN&T?!X032'3!&%P,@WQ"I4I`)%L MO-@LD_WS'IDX7J-V7H?HC^/%I&B62QJO7;_8T>$AO$I;$3[QX\-,MRS((8-^ M']5*#78D9M-%'_B=C-G%Z&22#:VA-98J&>>+NW9#AD-+IBI;&%KOQSXB7;G M?M%^C`([1,7228U]FYN3.<>33[XP/']06Y]'R-79D\H5! M!KMUT98KR;%(*YN#/%8^]5(_&#I-CM09=T%Y>C[?[Y0II:.(:`JY<7\%B+77CT((W6O[Z_G4-*X@0UI6HRU[VO99O/\;V MZ\!@^A$;D$2^MT04CPNV;LGKQL7%K;6X97P),E$4-40M:S$^`M';^70A'^EB M.I5-U+#@3S+1]R/\DTS4@O\MI.DTKQQ,62!+>EKJ89^A?SZ>3J>3P<5D,IF: MPX%I,B4_Y![MA4OWQ<76@S0U[2(8`8+I<#*],`!(WYPP5B=%,`0`X]%H,AI, M#1/^SS+9\1'(UNE(5VU5@D"150D"159EY69/0N;/(P6Z?HICE2!09%6"0)%5 MQY(S\%BY50D"158E"!19E=7P$F,5NNF*8Y4@4&15@D"15:45GWD&GBJW*D&@ MR*H$P:FM6BRK%K>W%FO7[59F]?4Q6\G!VO$ABI>P%5GLKPUP]9A=N[[RW54* MJ\38>WS"?]-H#?]]B-(4-NZNKY:>_1B%M@\O>\6(XM^&D;"U";N8,SU]\IQG M8,8MC#.\&8MC<2@SD8D5OCDV^V-S9%QDBRA)K`-WZ6V"7>E*WGM]!=2(NFT7 MG.@P+)GD[E!U;WMHA=Q\@B.8J9FE!0>`3Q0N(3A"AHS53H:HC&2$F(QD@*", M9(2HC!`Z^X*KT.0RVL"N^K:!+6O2[[.56&=_V4^0`-_C,:UC=O79.F2/1EO' MB.JT4![DEYW8F!OXQRK6/9*VC-B5LV7`'BE;1HC*R/O-7HG+=@*FYSU(MO3- M??UM,(!1-K#`LY4$\_R$FUG9=I:P^^X7MY4\D1HH=)NN"AFVU+0K@PPF720I M@+6.:3)B/E_#].^XOO\))^1_K,H:`%I=UUBX;I!1.TBSUVO_]6X3/+BQQ8XM,1;L*O:MJW=S5JA4[]_[WF,8N*Q9 MIV=D?HBCU'52=JR*;0+5X1G6X!GDA$3P',+?K.$/>A+6QR'\H1FTUXB@%Z7\ MP;F$^F0A@R5\@`".H0(`'WG(=@'NJ0`!+J0(!.&B% M`.`T>,4A<3`@V0Q\H&()_(_%$G),(27'\HA2UJ5?X-\@I<6EWX/43/(M.'JE M9GC3`.`@EG4I5E6*(6:'2*M4`&\:5&#!K"MGRAO4Y7QE"B%)%S!4&H$TT*01 M>5Y)%/_5'M9M392!W6+)K![,3Q;/64K1[`%6TN1I33>8F@7 MO5/M*8J]7V"1B;<:.M!,=6,=;TU-/8=>^1+;ZWOW!9:BV;[3RZJ^UPM(BO[& MMC/R"&LQ5?RAN:YK79A+U\\!6`Y71*OD;%'?VIC?\@R^N=WJ(:T@L+FC&@/J M.L<@W04DA0A,4`5$8<^0;2JJ)IBLQ.)4,).T^@EECLK(F\UPF9NQ^"3Q53!O MV-G"I9E42:BWX1XU3AB^%'.PHL]#_;6SA$EU,[T<(;+@] M02%S*#G52=[0W#]I/AUN-P::N%NLE=]:@'3*B!K>F8-[)NV%*DW=Q\#=.B&2 MPJD#EOTU`1].;]`L.]W4L=@FL\N;%/C5SJMM7E1CN>921L1PM;,1#8(#3=6, MDG>D4^!YD^MT6-:^05T&Z25(45=K+L!Y,U_`U#*'1P%M+>5X8\WSGMA)GK:@BJ]?&ZDXDB!0* MPMEUC_=!V=5KZN!2AY,R^U$,K9HL:R_V.#-AH,=POV/AECZ1=(H3I0M5V4': M2?*&,X%-FI$W.2I[F(_GH*A5J$.^F13]^'),).6TNU97E+ MK27'>T[>4<3I2O6N#CN>K1P$>F8.0GQO260.K_4,.N\457=5I157]B4`MC$- M6]'DQA[^MIYRXUK#Y]/!\W3[O]?.M/<.$BT+W@$>9-AX/MRRCSO2>*C`V21P M9^H\NYAWUYIHE8M#`^*7TH(W.[661=7F'P7E&!`8\M]'9^/!$_`B? MI\].;V&/E@B$9W6%*#VYSK.V@)MQ2T)\/.`T*D+H]F7MVZ&=1O&KAB>V2G*\ MT4>"Y/X41:6.>`JXAA4!]&?X]0'X80,-]))IB/=AK*BZD"EC@5=CRYD8'1&AD^J6#^)D/D0KC>EA?A)J-Q`Y6_R+` M_[I)B1IQ%"&"9P)$B-Q[*3QIHPABC@3"$B(1P2G*DL161A&D\7<[#C%:N-#= M\M$:B:HSJ5#]+U^JV_F9WE/\?0YVHW^Y'@!%+=V5O?'3^_+#F5Z]_@M[A@TX M4_ZM'[S/46/K5S_#P``__\#`%!+`P04 M``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL M64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`! MP[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7U MVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]= MQ9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK5 M9B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<) M=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[ MQR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF M9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F M8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8 M=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM M`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SV MN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5 M!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;U MKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C< MAT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\ M:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D M1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K. M.YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4 MALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q M/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY M2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-= M`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV M#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO M-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY( M%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4: M.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965TB) M"LEXG>#0"S"B=;V@-=W(N*J+@4AQ\V0A*LK:H*OTH"&9^15B-#<-* MO(>#YSE+Z3U/CQ6ME2$1M"0*],N"-?+,5J7OH:N(>#PV-RFO&J#8LY*IEY84 MHRI=?3G47)!]"7T_AU.2GKG;BPOZBJ6"2YXK#^A\(_2RYZ6_](%IL\X8=*!M M1X+F";X+5[LPPOYFW1KTF]&3[/U&LN"G3X)E7UE-P6W(22>PY_Q10[]D^B\H M]B^J']H$O@N4T9P<2_6#GSY3=B@4Q!U#1[JQ5?9R3V4*C@*-%\6:*>4E"(!/ M5#&]-,`1\MQ^GUBFB@1/9EX\#R8AP-&>2O7`-"5&Z5$J7OTQH+"C,B111S(! M]=W]R(L6<1C/QEE\HZAM\)XHLED+?D*P:N"9LB%Z#88K8-:=3=_L#%K2-7>Z MJ"T%M(0XGC;Q?+[VG\#"M,-L+S&1C=A=0?PC\4'?JTAH?2AR`B%>M_\L4A>! MT1CU1"YL"5N#F?8Q-F+G0E@:X4%]C6YM&IQ@X.YI6]I/WAK,K+4W6L(;'P0V M8M='3*;+N(^PM$&#?6TZY''_=-%`XV*@8&LP+O]<"$LC++K_UZB+QC(V&)=& M%\+2.+,UNC/6X(%_\V'&!C-M,QYXNS/W3/[Q_.UPY[:H]X6KBP;B%J&]O+8& MXS+.A;",TQOA8,J,+T!=-!:NP;@TNA"6QJ6MT1VN!@_\NPC78+H7>*;?WV'$ M+H2E+81IUS?0+:Y%#]0M!M-WVX%&PO=V]R:W-H M965T&ULE)==;]HP%(;O)^T_1+DOB<-704!54G6;M$G3/J]- M8L!J$F>V*>V_WSEQ"+$#57H#)'G]GL?'/LYA29]XSDXJ+8NF30>A[K$A$ MRHO=TO_]Z_'FUO>4ID5*,U&PI?_*E'^W^OAA<13R2>T9TQXX%&KI[[4NYT&@ MDCW+J1J(DA7P9"MD3C5DF M@WF_D!%-3M[51<<^YXD42FSU`.P"`]J=\RR8!>"T6J0<9H!I]R3;+OU[,H_) MR`]6BRI!?S@[JM9O3^W%\9/DZ5=>,,@VK).FFY\L8XEF*:R<[^&*;(1XPJ%? MX%8(050EP"#JWRG,?811@B9,^_F$E@&B#6(QNB:B`PLX-/+.>XG2"-],70\U?NE/YP,QM-P2$#N;9C2 MCQPM?2\Y*"WROT9$:BMC$M4F\'TTSZ-I[\'#>C!\UX,)^+P=.3"SJ!+T0#5= M+:0X>K`]@5.5%#<[F8/AY2S`]%%[C^*E#Z0P005+\;P*%\$S)#NI%6NC@,]& M06Q%?%+@>@%#`P)3Z`^"8@3!Y4&RM;G1CALY<;N*8:.P0"`+;1#<'T/8FF]G M!@>!KC7O4>-N"(UBU%*,;47\EL(B!),VX=MD*%[Z,/MF129VW+51M,FFMB+N M*L[L%AE40'\R%-MDMW;6F".[?800IP[7M:;-%SDE$U_07./#P[H_GSG:VWR16Q7XAH0= M8/&Y)7M!8DX8.M%8&QS MM^DEZR:O>0!=64EW[!N5.UXH+V-;&!H.IO!.D*:O,Q=:E%6?LQ$:^K'JYQZ: M=@9]0S@`\58(?;K`KJ3Y&[#Z#P``__\#`%!+`P04``8`"````"$`_FZ`2L," M``!7!P``&0```'AL+W=OIX"T]*I26U<*DK8CK-:=$/D@V)PS`C MDHH6>\)"7\-092D8OU=L)WEK/43SAEKP;VK1F2--LFMPDNK'77?#E.P`L16- ML"\]%"/)%E^J5FFZ;6#=SU%"V9'=7US@I6!:&57:`'#$&[U<\YS,"9!6RT+` M"ESL2/,RQW?18I-ALEKV^?P6?&].SI&IU?Z3%L57T7((&\KD"K!5ZM%)OQ3N M%@PF%Z,?^@)\UZC@)=TU]H?:?^:BJBU4.X4%N74MBI=[;A@$"I@@3AV)J08, MP#^2PNT,"(0^]\>]*&R=XTD6I--P$H$<;;FQ#\(A,6([8Y7\XT71`>4A\0$" MQP,D2H,D3J>S]U`F!PH6KI9:[1%L/7!N.NHVH##MHUEX#_X,F&BLVEXHD M_DVGZ]G$=W3NS:=)BYM[_YGV+D#2#7>W/B',/"A_K$T7P\\]IKLK["<9K,Y_%L MK-B,%),T2K(W*@BOS_7>G/C,6QR.9UY[C?>6AN'T+-?-Z?-H/GO36/8>8TY\ M;NQL6Z^]YA!:%KK?V#HT0$=Y/59?4-_@_)LKN:[XAC>-04SM7/.*H"##W:&O MWL5]:QP>0%_K:,6_45V)UJ"&ES`T#*80C/:=T5]8U?5]8:LL=+3^M(8/&(N]PZ?Q-5?````__\#`%!+`P04``8`"````"$`0'*[@'$"```X M!@``&0```'AL+W=O M98->N#9"M05.HA@CWC)5BG93X-^_'F^F&!E+VY(VJN4%?N,&WRT^?YKOE'XV M-><6`4-K"EQ;V\T(,:SFDII(=;R%G4II22TL]8:83G-:^B+9D#2.@WM>C,@4VR:^@DU<_;[H8IV0'%6C3"OGE2 MC"2;/6U:I>FZ`=^OR9BR`[=?G-%+P;0RJK(1T)$@]-SS+;DEP+28EP(D:G5[HL6Y3?1<@@;VN0:L%;JV4&?2O<*BLE9 M]:-OP`^-2E[1;6-_JMU7+C:UA6YG8,CYFI5O#]PP"!1HHM3+8*H!`?"+I'`W M`P*AK_Y_)TI;%WB41]DD'B4`1VMN[*-PE!BQK;%*_@V@Q(GJ2=(]R0C4[_?3 M*)UF29;_GX4$1=[@`[5T,==JA^#2P)FFH^X*)C-@=L[&[SH#-:[FWA7Y4D`; MZ,;+8CQ-YN0%(F1[S/(8K#_96UQ]A!AH@X.NU^;`!0;N7MOH-+<`R7VJ:9RD^?1$_&J`2/+) M-'\G-O!WO30''DJ#TX>A+`-F[+7%P[W5Y;U!5'"OCO6XNS:"6?RXG:YHJ&M\ MFL@R8#[*;("XF%D8_C`;'=WP[U1O1&M0PRO0&4<3H-!A],/"JL[/P%I9&%G_ M6,,7FL.`Q!&`*Z7L8>$^+OTW?_$/``#__P,`4$L#!!0`!@`(````(0`13EB? M\DT``*KD`0`9````>&PO=V]R:W-H965T@\;[)!'*626HK`C%B'L\UBTJ5:"4R94RJ5/7V9SG"/7SX/8$$F^?B M2/W5#D<`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`Z?F?YIMQL.W]Q=7U_=W-WJG1S9\MYNJ7_:+0?W M+WK)@8+1]',[N+B_ M//$A#5PJS+^<^5[U\7>OZA/ULIX.7(K,OYS[7EV0!CY)+WVO+DL#'Z:7]M6% M:>@C\=(<#ETFS+_8=VMRJ7K M@5[HZ8_WYNHR^,&,YLY9W:OW9['G3F(Z\9A1_F:&^>FU/G*=GYYTZOW7SX.; MNQ_?_DMGRP^VYEVF)JX8N0IS/C/#CE,H4BA3J%*H4VA2:%.8I#!-89;"/(5% M"LL45BFL4]BDL$UAE\(^@+=J<=]GM?9[]-D,8_KL.O3.@6_\,&FJJW";C%,H M4BA3J%*H4VA2:%.8I#!-89;"/(5%"LL45BFL4]BDL$UAE\(^@*BI.IU_CZ:: M872O$1Z\UTD7WW4UYBK0'^'72:/[DK[3D`)20BI(#6D@+60"F4)FD#ED`5E" M5I`U9`/90G:0?2A1\]6*[]%\,XQ._KI&]XWEJ=L6'>M^7])W'U)`2D@%J2$- MI(5,(%/(##*'+"!+R`JRAFP@6\@.L@\EZK[Z%74_/\=PEV=3?6BR:\X[*[K! M>K[MH[[(;3:&%)`24D%J2`-I(1/(%#*#S"$+R!*R@JPA&\@6LH/L0XEZJF:< MT5-3'?>TDRN-'_3T/CE+]T5]3R$%I(14D!K20%K(!#*%S"!SR`*RA*P@:\@& MLH7L(/M0HI[JEOB,GIKJN*=6HCOKVXNDIWU1WU-(`2DA%:2&-)`6,H%,(3/( M'+*`+"$KR!JR@6PA.\@^E*BGFAZ>T5-3'?>TD_@XO1TD/>V+^IY""D@)J2`U MI(&TD`ED"IE!YI`%9`E90=:0#60+V4'VH40]U00^ZJF9!P^OW^A<>N9,V`P4 MM]N*XN1/R[?)_?6H+^K;#2D@):2"U)`&TD(FD"ED!IE#%I`E9`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`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`5'+#BE23&E)+ MFI"FI!EI3EJ0EJ05:4W:D+:D'6D?49R"\Y;=AEQVLQ3?Y]VFRVZ^RO5U3"I( M):DBU:2&U)(FI"EI1IJ3%J0E:45:DS:D+6E'TH_=#@=CM^@5MUJGY.]TVCYQ;K!]1OS M(]#CQ_YAR_@T;^GJKG^D,B*-206I)%6DFM206M*$-"7-2'/2@K0DK4AKTH:T M)>U(^XCB%I^W6'?)Q3I'A]^Z'Y9J1Z0QJ2"5I(I4DQI2&U'\GL];M;KDJI6E MR\L@RUV5*#BIW2?/%<=N0TU8_2.I^^215.&KW*FO=.1?L?(4CI6\8NVJXE=, MUE(;7^5>L75T>,7X\\LM!=G3PM??/G[XY[M'O3DE)7..N.S7\\TGE=P)6HH^ MUJXJH+&KTDDH^`R39SV%KW+OJ'04?H88OG95\?#)/4KCJ]SPK:/,!V;6)]*K MZ?D?F%WE"*ZDEQUI@=;MQ#Y/T5OL"-7/J1'56> MCKQ8[<H*$F'44?6H] M'7DC8SO69313N4^6*0M?Y=Y-:2EXQL_5AA5?**C:]RK]CZX?'YG3=M M5U/P^75DUHJ#`S!=I[,;FK7$H`I!M&/Y8[)P&UX=LGDYN+ZX3,8N78FZ]OS8 ME:LZN@>UKW(?7N.HVX.KP4UR;]JZ@N=>/PZLF::>$5@[JPT/\X[,_#QXN^F2 MF(FE.:'JIBVHP@?>5[FW6]@--?$SQ^?MW>U%\GY+-[3.Z<\/7;FJHSM0^RJW M`XW;@;NNX\G4OW5;//?J\:=M9HKAIVUF+N>?:[OY9K@Z?=E1DOID7T>NZFCF MQK[*?0:%H_O#9Y!TK73_ZW.!.]QW5:[JZ(O7OLJ]>.,H^^*M^U^?>_'X\S<3 MLO#S/W%ZMO.W,.T=Z9[5[=_HLJG(\+6K\L,WI-91 M]Z>?PC^I<75D-O7RVZ;#*/',RI$_AXXLZ8)SY!V-W8;^HRCU(^XCB%NO6+3K0 M3_35E"=',?[\S$0Q_/S2.Z<7K?+IN[GX6#N*/E;0V&YHUC&"SS!=Y?-5[AV5 MCL+/$,/7KBH>/ED%:WR5&[YUE/G`OLO,4V=.?&!VYNDG'B-;=>K^OMM0JQ5V MX2UY?X4=1@7N_95^9$>5I[`5B&#Z8DA?7^!&;OW(HCA]YTTCKSB-M!2 MCKR1L:TRJPY!\I)94.&KW+LI_?".*D_A6/CH[/3VZ"LV?,76#Y]^?M?I9//X M&?]0'I_Q+47K'9?).6SDBHZ?#WV5^V`*1]T2F]:$AS=WR<%=NIKX&$T^O,I5 M'=V%VE>Y76@W:1S35?SW"Y$F;T^-==\T1GS,$K2BFZJ&:W_Z2-+ M;J7=AL=GG[[*?1"%)7T;P)PFDL^W=!MH'X+#(:FJ7-71%Z]]E7OQYNB+MVZ# MYUX\_OS/F[E><^9J*9S3>SKR]L>NRI^B"U+I*)C3>SHR?.VJ_/`-J77$.?VU MF8O]GZ_EAU&29)J!M0@2/-2W568=[/F\C&V5G@ZX)!2.CIX2NM3.T:\[0'(4W3L.+ MY,9SY*M\J^U8?MFI8%5)JD@UJ2&UI`EI2IJ1YJ0%:4E:D=:D#6E+VI'V$<6M M-C.P\`)TXJ@VYZW]!1P:J25)%J M4D-J21/2E#0CS4D+TI*T(JU)&]*6M"/M(XI;?=XD_9J3=$O)M3KYNL?(5[F^ MCDD%J215I)K4D%K2A#0ES4ASTH*T)*U(:]*&M"7M2/N(HE;?I.L)W_R%\,-( M\;G=47S`)W/QD:_J4T`J2"6I(M6DAM22)J0I:4::DQ:D)6E%6I,VI"UI1]I' M%*?@R`K'\2OZ3;>$$9[F+6D-T/5S1!J3"E))JD@UJ2&UI`EI2IJ1YJ0%:4E: MD=:D#6E+VI'V$<4M/F\1Y8:+*([BHSG]HI2O:D!6E)6I'6I`UI2]J1]A'%K3ZR*G3B:.[60**CN:/H:`:-;T`%J215I)K4 MD%K2A#0ES4ASTH*T)*U(:]*&M"7M2/N(XA:GZT\G^LIUIIN.PL!DMBR3>R"E_E3LDEJ2+5I(;4.O+KK1-/?K^P]U-7%>[](/W1S,Q7N;V? MDQ:D)6E%6COB<]^;=!GKFQZ4'T9);HN[1:JHW:"QW?#$@W)?Y3Z=DE21:E)# M:AV%O<6N3EU5N#([N$]69F>^RNWJG+0@+4DKTMI1II%FI2@\0+^MD6:4I)$= M1>?0GHXD?WS353W_`-\7N,^JM!2\6.7IR(O5?JQG?J;C"]R+M7YD1Q-/1UYL MZL?*?S5AY@OXD==^9%%\'C]O@>N&"UR6@A:- M/!UY(V-;=>*K";[*O9O2#^^H\G3D%6L_5EB5K,4UOLH-W_KA'4T\A6,E3Y*G M?JRP*GG%F:]RP\_]\(X6GL*QDE=<^K'"JN055[[*#;_VPXOBC*0K8]]V*N&" MV4U'T;ZV^^L]KJMC7^7>4>&H>P!Z=3NXOKI*UMA+5Q.?Q9-= MJ%S5T5VH?97;A<91MPN7]Q>#NV'R1*=U-4=W8>*JCN["U%>Y79@YZG9AH'VX MN$^_OSYW14?W8>&JCN[#TE>Y?5@YLOLPN+NXO;].6K%V1<_M0Y3)V]P27OC+ MJ)<]BSX,$U_?+(7/HCT=2Z"K\@^+"U+I*'@6[>G(\+6K\L,WI-:1'W[BZZ; M5^=ON9[G2/>B_<5D.$CNVD>^RJ?`CA4\9&=52:I(-:DAM:0):4J:D>:D!6E) M6I'6I`UI2]J1]A'%*=!%)IJ_G#C@37ERP%N*6YUW?95O-:A@54FJ2#6I M(;6D"6E*FI'FI`5I25J1UJ0-:4O:D?81Q:TVJW+A5/5$J[M%O'"]]M92W.KD M!F/DJWRK^PT=%:PJ216I)C6DEC0A34DSTIRT("U)*]*:M"%M23O2/J*XU;JY M.Z?5ICPYJCM*+N/)_&9D_JB3-HPNXZ""526I(M6DAM22)J0I:4::DQ:D)6E% M6I,VI"UI1]I'%+4>,NE1$=Q MJ].'[;[*M]J.Y0_T@E4EJ2+5I(;4DB:D*6E&FI,6I"5I15J3-J0M:4?:1Q2W M^LB*X(F;-ZX"WG84/FPGC4D%J215I)K4D%K2A#0ES4ASTH*T)*U(:]*&M"7M M2/N(HA;?I0MLQ_MZ*(]/W);"!P.D,:D@E:2*5),:4AM1_)[/6V2ZX]?`+(5/ M.3WY%0.KW"NV MCOC,\2ZWN2O.( MH$7))+/Q56[XUE'F`S,K#>',]YN>K-S9]0J_9OG.4G3L=56B35(SMAL\_ MI/4%[OV5?+'*TY$7J_U8^4>9C2]P+];ZD47QT6OF\N&'>>*,9:?^X:?64?2I M]73DC8SONJH3CS)]E7LWI:7@%2M/1UZQ]F.%55[RS9R1JU(>@^,(0;1C^6.R;RI7=?RGUK[*[4`3[\#@ M_B[3"/NI/+<'<2/,!/*,]-OY9GCVZ"A\<'C7TY$TCEV5_T%T02H=^4=OE:NR@_?D%I'?/1VE\[KONTBQ>G>86#]S1U=:OMC=3A,G\C9JA,_P79CA:>+ M[A7U7_XY7%UN+LS_B__,0.DV>^Y8[?X4Y8MVH79C^5UH'!TY8[6NYKE=B%-Z M9.)UQD^P[S@+LQ2EMZLZ\1-LMZ%_LEN02D=A>E\R?.TV],,WI-81TWN?SF,. M3Q-?\M_H/&P9WX=:TI_-<>>A$6E,*D@EJ2+5I(;4DB:D*6E&FI,6I"5I15J3 M-J0M:4?:1Q0=%/=F'O;R4_>A/.FK&>'PN"`\$R57M)'=,'RH0"I():DBU:2& MU)(FI"EI1IJ3%J0E:45:DS:D+6E'VD<4M]I,R\YH=3>+"^]1[RWIRAQ<=))I M[\A7N0-]3"I():DBU:2&U)(FI"EI1IJ3%J0E:45:DS:D+6E'VD<4M]K,5\]H M=3>]C5IM*?A-WCUH3"I():DBU:2&U)(FI"EI1IJ3%J0E:45:DS:D+6E'VD<4 M]]7,E<.^F@NR^=-(QZ?K]]T4.^JO)7]/,7)5X2WEX#IY6#1V5?Y.K7`4;C@< M^JE=_!9TKQ:]A1.[;LJ3"XZE,)J@\3VH()6DBE23&E)+FI"FI!EI3EJ0EJ05 M:4W:D+:D'6D?4=S7W&3\!='D[/O>4AA-2V'",M&T56$T,QL.AWZI)WX+9L89 M'ETGHME-4*.CRE(83=#X'E202E)%JDD-J25-2%/2C#0G+4A+THJT)FU(6]*. MM(\H[FMN$MY]F^)$ASGOOK<4AM/2B7#:JC"J] M):4ON'M+SN\C7^7OWOH-'16L*DD5J28UI)8T(4U),]*?;S777U\D>PM.!5E;)RQ(F-EQJJ,U1EK,M9F;)*Q:<9F&9MG M;)&Q9<96&5MG;).Q;<9V&=O'EK0[G8,?EEFNW^@.YE3CN[EW>`D:7%@+SE"] M'3]%]67!.:JW<--A\.@@>2LJ.^,2.K@P]6ERK47)A2FY,"47IN3"E%R8D@M3 M:Y-Y< MON"_"SJXX)RSMRBZMDX[T5^U>.O7;QI%-[/I<.@?J27O)9U;G3KV.*D:7%B+ MH@M3=&&*+DS1A2FZ,$47INC"%%V8H@M3=&&*+DS1A2FZ,$47INC"%%V8H@M3 M=&&*+DS1#2UIMYD?AC?[+S_IVIEE\/AJ<&$M2JZU4\FU95%R,YL.+_T#F.2M MF$E.^%9.)==.BJ(WT%G\U7#\E>_!15_F;@459IC"#%.880HS3&&&*U:.9PF2[Q]YOZ)SP*1[^I"XS"`5,X8`H'3.&` M*1PPA0.F<,`4#IC"`5,X8`H'3.&`*1PPA0.F<,`4#IC"`5,X0DO"8::983A. MG1[LM#1*0&?)Z2%=^1]<]&6NVTH`3`F`*0$P)0"F!,"4`)@2`%,"8$H`3`F` M*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0&A)0DX;^U@<,'%@]Z4L_X^;'CI%WF[ M_^!W4!8D@.L'F3HE`'5*`$P)@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4` MI@3`E`"8$@!3`D*+$V"^I'3..>!0G\S+K"7G`+^6:A/@RWP":,6`5F:LREB= ML29C;<8F&9MF;):Q><86&5MF;)6Q=<8V&=MF;)>Q?6Q)`M)%AA-7@4%F:<%9 M?`[P"Y8N`7;3\#[`;^I2H02@3@F`*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0$P M)0"VRI@2@#HE`*8$P)0`F!(06I(`,X\_XSY@8.?]X7V`LS@!Z1KRP)>Y;H\S MI@38E_!)40)@2@!,"8`I`3`E`*8$P)0`F!(`4P)@2@!,"8"M,J8$H$X)@"D! M,"4`I@2$EB0@7:XY=0[(K-$,K,4)2+Y*/!KXLB`!_:;.E`"8$@!3`F!*`$P) M@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E`"8$A!:D@"S('+..<`N MH$3G`&MQ`ORRFKL*]&6NVSH'P)0`F!(`4P)@2@!,"8`I`3`E`*8$P)0`F!(` M4P)@2@!,"8`I`3`E`*8$P)0`F!(06I(`L[04)N"P+'#]DB5;/6;`8KVU\`>( M`YHZWVT;U*GS,'4>IL[#U'F8.@]3YV'J/$R=AZGS,'4>IL[#U'F8.@]3YV'J M/$R=AZGS,'4^M*3S9OTH[?PW_5&!P:!;BM*+N6/[76_1:>'*KUFZTX+=U%_R M%0Z8P@%3.&`*!TSA@"D<,(4#IG#`%`Z8P@%3.&`*!TSA@"D<,(4#IG#`%`Z8 MP@%3.$)+PJ&V?:]PF*'2N:.U.!SISQ4&@[[,Y4KA@"D<,(4#IG#`%`Z8P@%3 M.&`*!TSA@"D<,(4#IG#`%`Z8P@%3.&`*!TSA@"D<,(4CM"0<9FGI.YTYNE6J M^,QA33O@EY:NL+P\Z,N"<,`4#IC"`5,X8`H'3.&`*1PPA0.F<,`4#IC"`5,X M8`H'3.&`*1PPA0.F<,`4#IC"$5H2#K/J])W"81>PHLM*OZ@5A@,KSX.^+`@' M3.&`*1PPA0.F<,`4#IC"`5,X8`H'3.&`*1PPA0.F<,`4#IC"`5,X8`H'3.&` M*1RAQ>$8GKGN>*A/KAW6S'^@/#@]8.79E_D$T(H!K]S>C`_OT]O+)S%UPXL2ONR M(!SA4MGA[E3A@"D<,(4#IG#`%`Z8P@%3.&`*!TSA@"D<,(4#IG#`%`Z8P@%3 M.&`*!TSA@"D:P,3AP'JU+PO"T6_J3.&`*1PP MA0.F<,`4#IC"`5,X8`H'3.&`*1PPA0.F<,`4#IC"`5,X8`H'3.&`*1RA)>$P MRU@(QTM^?3K0?TV:9XK.PM^?NKK`QAE3Y[&M.@]3YV'J/$R=AZGS,'4>IL[# MU'F8.@]3YV'J/$R=AZGS,'4>IL[#U'F8.A]:TGFS?!5V_L0ZM7ZFSG9WEMPU MX$F%W51E[CA7`OI-G2D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E`"8 M$@!3`F!*`$P)@"D!,"4@M"0!9ADK3(!9I;R\>V/^>^_G?J/);(/;!FOQE0%/ M,=RFX6(53>GHAW.)43I@2@=,Z8`I'3"E`Z9TP)0.F-(!4SI@2@=,Z8`I'3"E M`Z9TP)0.F-(!4SI"2])AUK'"=)PZ/]AUK^C>H%\+"V<5>(IA_@9,=POA.JOS M`TP)@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E`"8$@!3`F!*`$P) M@"D!H24)T(%[5@),?3JOM!9^67L(4[MA:C=,[8:IW3"U&Z9VP]1NF-H-4[MA M:C=,[8:IW3"U&Z9VP]1NF-H-4[MA:C=,[0XM:;=9?@H/^,-#J\'52YY:#>W2 M573P6PN_KNWJ=$/:+S-D?FC@RL*O:SL+-QU>^T`HG:?D=W#MLEIRUF876=A`#/9=65A=IV%FPZO_9.9 MY,V8N7R87?-FONT9XJ5=%@AC[4QG@OX8'%[C28`O\Q=E6C&@E1FK,E9GK,E8 MF[%)QJ89FV5LGK%%QI896V5LG;%-QK89VV5L'UL2#F4H"L>)$]NEJ4_3W5DT M;4O_PY"C@=TRFK71%(!^-!<4!0"F`,`4`)@"`%,`8`H`3`&`*0`P!0"F`,`4 M`)@"`%,`8`H`3`&`*0`P!2"T)`!F2A^>'4X%H%L"B!X&ZN_4VAON\!2`YSV^ MS'5V/*`I`?UPKDX)@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E`"8 M$@!3`F!*`$P)""U)@)G2GY.`;@D@3D"_+!`F`,][+OLRUUDE`*8$P)0`F!(` M4P)@2@!,"8`I`3`E`*8$P)0`F!(`4P)@2@!,"8`I`3`E`*8$P)2`T)($F&G[ M.0FPT_SH-J"?^H<)P$,=\\>JT[DY30E`G1(`4P)@2@!,"8`I`3`E`*8$P)0` MF!(`4P)@2@!,"8`I`3`E`*8$P)0`F!(06I(`,VT/$_!_N$>T*P!1./I5@3`< M>*BCO\+-<,`4#IC"`5,X8`H'3.&`*1PPA0.F<,`4#IC"`5,X8`H'3.&`*1PP MA0.F<,`4#IC"$5H2#C/)#\-QZA;!+@I$">@L_B%2^H?*1@/S%\5U>E!9<(&` M*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0$P M)2"T)`'I6LZI!&36;RX[BV8)PVLLW_NR(`']ILZ4`)@2`%,"8$H`3`F`*0$P M)0"F!,"4`)@2`%,"8$H`3`F`*0$P)0"F!,"4`)@2$%J2`+-8./M?958)G>D:XU<);_QRN_VE@2]SQ[028(?S#W25`)@2`%,"8$H`3`F` M*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0$P)0"F!,"4`)@2$%J2`+-^=,;9_ZI; M;XJ6"*S%U_\;OVCM$A`N51U,"8`I`3`E`*8$P)0`F!(`4P)@2@!,"8`I`3`E M`*8$P)0`F!(`4P)@2@!,"8`I`3`E(+0D`6;]Z)P$V/6F\/I_U:]!A><`/"GP M9<$YH-_4F1(`4P)@2@!,"8`I`3`E`*8$P)0`F!(`4P)@2@!,"8`I`3`E`*8$ MP)0`F!(`4P)"2Q)@UH_.24"WWA2?`ZS%5P$L%%_U9:[;.@?`E`"8$@!3`F!* M`$P)@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E`"8$A!:D@"S?G1. M`NQZ4W0.Z->@PG,`%HK-.D&Z3$A3`E"G!,"4`)@2`%,"8$H`3`F`*0$P)0"F M!,"4`)@2`%,"8$H`3`F`*0$P)0"F!(26),`L$IV3`+NH%"7`6O@U"'-38-KM M30<\3.V&J=TPM1NF=L/4;IC:#5.[86HW3.V&J=TPM1NF=L/4;IC:#5.[86HW M3.V&J=VA)>TV*T)AN\VJL/U&Y[\'5^\__/#+?\8/3Q\>/LLOS!<]?_[Q<,OV MMX&^GGWH:-1Y:[K+Z.<`^,;#J-_4?^-!82_3;K&.%^G]K9;MTC MOE19\Y'4GL&T9S#%%*:8PA13F&(*4TQABBE,,84IIC#%%*:8PA13F&(*4TQA MBBE,,84IIC#%%*:8AI:TVRQ:A.T^?%O'_`G<4WVWJQU12*V="JDMBT*:V71X MXY]RQ'M]G:ZGG-C90WVRB.(L#"EM/*`5&2LS5F6LSEB3L39CDXQ-,S;+V#QC MBXPM,[;*V#ICFXQM,[;+V#ZVI-UF=IV&]&7G4O-?Y#!7QS"FSD[$U)6%,746 M;CJ\\;^R2/9;9=%^GXJIJ4]WUII.XOV)?WB#I?_KOLS?]M.47-0IN3`E%Z;D MPI1#K MOBQ(`$P)@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E`"8$@!3`F!* M`$P)@"D!H24),'/"`:IG;#U&Z8V@U3NV%J-TSMAJG= M,+4;IG;#U&Z8V@U3NV%J-TSMAJG=,+4;IG;#U.[0DG:;.6'8[N[K0-K@U+G? M3B:COEO3%:8_]V>F?=>V++I5R6PZO/7/#)*]-I/$<*]/[:R=5$8[:RT**4PA MA2FD,(44II#"%%*80@I32&$**4PAA2FD,(44II#"%%*80@I32&$**4PAA2FD M,(4TM*3=9D88MOL0TOMG?VP>+D]''T:?:/UAVV0VY>Q$3EU9 MF%-GX:;#6__\)=GQW)1U^.SQI:^7]LM_-YDIJ[7@#S>,!K1QQHJ,E1FK,E9G MK,E8F[%)QJ89FV5LGK%%QI896V5LG;%-QK89VV5L'UO2>07DG#/4C:E/8]I9 M/.6[Q9,>NZG*_`T_30GHAW-U2@!,"8`I`3`E`*8$P)0`F!(`4P)@2@!,"8`I M`3`E`*8$P)0`F!(`4P)@2D!H20+,;/",:]1--WN,UJBW_@-;_VBO?W& MAR]SG=4YP`X7?N>'I@2@3@F`*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0$P)0"F M!,"4`)@2`%,"8$I`:$D"S&SPG`38V:,_D-\-;CI+S@%^1=PEH"\+$@#3.0"F M!,"4`)@2`%,"8$H`3`F`*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0$P)0"F!(26 M),!,$,])@)U01@FP%I\#_&*S2T!?%B0`I@3`E`"8$@!3`F!*`$P)@"D!,"4` MI@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E(#0D@28^?A5_)WB'Q?^;OBQ(`$P)@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4` MI@3`E`"8$@!3`F!*`$P)@"D!H24),&L;YR3`KH5$">@L/@?<^95<=Q_0EP4) M@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D! M,"4@M#@!M[DEK&_[$S*'H9(+A+/X](`OAOLR'PY:,:"5&:LR5F>LR5B;L4G& MIAF;96R>L47&EAE;96R=L4W&MAG;96P?6Q*.[#+A]1O=5I[[9Q]O,\N&SN)P M^#5+>^;P94$X['#A*@+K%`[4*1PPA0.F<,`4#IC"`5,X8`H'3.&`*1PPA0.F M<,`4#IC"`5,X8`H'3.$(+0F'66(*KQV'AS0O6D.^[5:GHB4E:]$:,FT\H.FT M\/\Y.],EQW%CC;[*A!^@1Z3VBO%$N$JU=O6^_!_[ML<.+^V8Z>O[^O>DL#"! M+ZLHM1U1;1\`!)EY!`*01.7=KLD&,B^,S`LC\\+(O#`R+XS,"R/SPLB\,#(O MC,P+(_/"R+PP,B^,S`LC\\+(O#`R[UF7>=M:\IF?>:MCF[>B_*PA,_M>J)LW MRAYR7&W::.Q.S'8\_(FE-[>_:[Q*FR>MHIFUXY7L>6UK-3=>"<-:85@K#&N% M8:TPK!6&M<*P5AC6"L-:85@K#&N%8:TPK!6&M<*P5AC6"L-:85CK62>';89X M.>:LS9LGC;5U0\5;*WM>VUK-&2`,`X1A@#`,$(8!PC!`&`8(PP!A&"`,`X1A M@#`,$(8!PC!`&`8(PP!A&"`,`X1A@&>=`;89?.D,:!NJ'@#9,]K6ZLY M`X1A@#`,$(8!PC!`&`8(PP!A&"`,`X1A@#`,$(8!PC!`&`8(PP!A&"`,`X1A M@#`,\*PS@*&[,>#XAOU)3SK86M-^=9,87V`H6;X:]9EWC9! MSGGMYTV3YK6?F7_6ZU88Z19&NH61;F&D6QCI%D:ZA9%N8:1;&.D61KJ%D6YA MI%L8Z19&NH61;F&D6QCI%D:ZA9%NS[ITVXZ'3[=[H7_[V]__\H_+KTP[6=P$ MDX#E]&&7;=HX:6>!B?$[.NY%7]ET5QCVW2XH8J1J]K0V-^GMMLMQI58K/>"* M,%P1ABO"<$48K@C#%6&X(@Q7A.&*,%P1ABO"<$48K@C#%6&X(@Q7A.%*8BEK MK2N[:`ML2#>%,UPY'J:[0636N#*Q28+`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`IQ9J99JC%A=J-FMU=Q78^VJCW<5#;U>ANPN\I\%\M%]Y[2 MO:M6+N*ALF,77=QLW^\,;?96OX];8FW6-U.@(E;K58N@+AEMCIN`@^+#?_==R],(IEK^?6" M=$!PI0."*XQ(9I86*,.+1;<.0,"9#KM0VT+\G%#GA?LDT.6P3\R>_%YCN%QT M?$.2TS6Z43L^>KURM<+KHE,7%.U=CVG:I)(%"Z5BN! M0.G,N!NZ'KJ7,Z'.U?C'5>OV4G!:>B#4P@AU9LGI+K$$.A?S3^W-7T\7:%O7 M^$!_YR";ET>-YXEUGG+W6YZ)9(Q#\W]:HO%QI_ MZ8'X"R/^M=?CJ^M%/TJ2@J##9U)@JPB?@KGA.Z\ZFE@GQJ]4E^@0V,JFZ/BS M.&Z#(W:N-GUL!K&%$<5ZN-(%R@HC9-*6D`DC2+YM)Z7-KGU$OE/*-$EO!X7$ MNOM<=QLB=JF:_393-2N*73[:-&4D=IFE^]Q^SX.TW6.ICD$GF+G24R_28S7B M6T^CQ)SX2I_$-[-ZF^OD)MHS'78)L/G]%/]=MI> M&2^(*MMRZ`;V*U>M7-4A8-`O0S88\!>!>QUP-X$[&W` MW@7L?<`^!.QCP#X%['/+.@-L!>-?*W,&6/W>@,Q:`[H%%`;4:LX`81@@#`.$ M88`P#!"&`<(P0!@&",,`81@@#`.$88`P#!"&`<(P0!@&",,`81@@#`,\ZPRP MI9DWP-VNYF1(JSI_BQKM*?H(XO?Z`L9K7^J1>6%D7AB9%T;FA9%Y861>&)D7 M1N:%D7EA9%X8F1=&YH61>6%D7AB9%T;FA9%Y863>LR[SMGCTF9]+=UILMNG. MS$W=QH4PTBV,=`LCW9YUIVMKL'-.-Z_9W.U[7"1FOUGD;E;]1D&IQDHVK+C.Q((/=8X+6P*=YHB;_4X^T%FK4--%9IH4=)FU%< M:).<:O*C"-*1%E*OF+CDW34GF=Y']%;O[ MS.D;HN,B+07:0.3E0C@BT:IKGZ%MKN#[$GD\3#>3 MS(R?E2[QOQH+XX2>93/7G_MIRTM MQ^-Q^HNW8_,>D;^5YGJPYR\^-W5+R]+%=GJMP"-AUP+@":7L;L+N`W0?L(6`O`_88L%QVP-P%[ M&[!W`7L?L`\!^QBP3P'[W++.`)MZ>0/,[9.>WCP.>=;F;\B9^2=OE'J.D?G4 MUC$R+XS,"R/SPLB\,#(OC,P+(_/"R+PP,B^,S`LC\\+(O#`R+XS,"R/SPLB\ M,#(OC,Q[UF7>)J,^\W.O_31Y;5_[B=F/`[K7ODP[AUJMC/`8(`P#A&&`,`P0 MA@'",$`8!@C#`&$8(`P#A&&`,`P0A@'",$`8!@C#`&$8(`P#A&&`9YT!-J7W M!MAK/__8V)G/9!K10K:("FOO##)%GZHY._+AIKL%=@C##F'8(0P[A&&',.P0 MAAW"L$,8=@C##F'8(0P[A&&',.P0AAW"L$,8=@C##L\Z.VQIX^V8&Q_R4JBY M'636&B`KEJ%6ZB36;A(,P[@S"R+PP,B^, MS`LC\\+(O#`R+XS,"R/SPLB\,#(OC,P+(_/"R+PP,B^,S`LC\\+(O#`R[UF7 M>5O=^LS/I3NOAIO7?F;-RD88Z19&NH61;F&D6QCI%D:ZA9%NS[K+MW7P.9>? MULT,IF7\NAR'O):>WF>]"5,]D M.IST2MSJX:9JRW':O3MN.1#*6JU<*Z&L/<#:4([]OL&,24-@NEABEQGS`>=][IV7"M,0 M0A!S(]9P-2?!"W>J5OHCB+EIV@0;Y,-TA#37\`GW!^^B;.O(,T9$BY%$.;'F M6T[+L?\0X5B:SNQ^3=7*51/EW$/>L5_9EX#ZK;_2;MKW)-#Y;)_M$H%KM=(E M@6ZZW.SW_0=GB'1NAL-A&KM(VWKMG$A;_7[`3,Q27'M M@?Q&P52M7#:1SDW+)NM*XYQK-$*?TB%QKM5*A\2YZ3`4NG887TT79EOXG!/F MO%":+N=RY&-#Q]`SCZKQ6XZROIVJEQNP=P%['[`/`?L8L$\!^]RRS@!;^'@#3E_=V!`FK[G$ MFM5-KN<8F9=Z9%X8F1=&YH61>6%D7AB9%T;FA9%Y861>&)D71N:%D7EA9%X8 MF1=&YH61>6%D7AB9]ZS+O"U\?.;GYJ1IH=1,[_F@^E$!O[I11KJE'ND61KJ% MD6YAI%L8Z19&NCWK+M\6/N=ZK`STE8UYP0ZK8*:URAOGMO0WGX)9.RV M7PAT;OKLH@%!:S47Z,1LK*F2+<=NHX)8YZ;$:*K6?Q2%6$L/Q%H8L:Z]ID?5 M;;M+>B@U[`,#M4,_@G>QMG6-C_5WOOKS\FAZ!5^.O.R/*?`K$_V^6:DVZWHZ M&M5<"C)[>@&3S\%FS&$PCJ,WT9>#$WUA1#^S8KH\$:/6>*K#+OJVW/'1GYG$ MV.<5^SEK9@Q<)3!HG>K98/;T9:-UKC8MHQD_A.%P/5SI@I`)(V32EI`)0U'? MMHL(@6LB\IT^VF'ZL3X8L^WFR7PS1";6_%3:!^Q#P#X&[%/`/K>L,\"6&=X`>ZU\UT^E MC7QN4L>KS`CX-%XMNUD:XU6MYN00AAS"D$,8<@A##F'((0PYA"&',.00AAS" MD$,8<@A##F'((0PYA"&',.00AAS"D,.S3@Y;<7DYYH:'M$)K!\S$VN%AV;W9 M@@&UFC-`&`8(PP!A&"`,`X1A@#`,$(8!PC!`&`8(PP!A&"`,`X1A@#`,$(8! MPC!`&`8(PP#/6@/LIZP:`[Y_>#@>JIO.%-8.#_)^UU1MDD/9]:CL)F"W`;L+ MV'W`'@+V,F"/`7L5L-Q.PMP%[%[#W`?L0L(\!^Q2PSRWKY&#^U\@Q,SSP MZ'FY0636#0_R7MQ4S1F0#D?3PC!`&`8(PP!A&"`,`X1A@#`,$(8!PC!`&`8( MPP!A&"`,`X1A@#`,$(8!PC!`&`9XUAE@*_DS;A"VE=$O:0IKQP!YCW"J5K)] M&)5A0.YB^L`F!@C#`&$8(`P#A&&`,`P0A@'",$`8!@C#`&$8(`P#A&&`,`P0 MA@'",$`8!GC6&6"["=Z`XPWBE!_,'.WA,B)#8N[C^%>EGF-D7NJ1>6%D7AB9 M%T;FA9%Y861>&)D71N:%D7EA9%X8F1=&YH61>6%D7AB9%T;FA9%Y863>LR[S MM@'B,S\W^J<-DV9R:-^$18%N])`O(LSW;`O M1TN]#0+MZ-^]'\084*N5;#,&",,`81@@#`.$88`P#!"&`<(P0!@&",,`81@@ M#`.$88`P#!"&`<(P0!@&",,`81C@66>`;2V=8T#:BFK'@,Q:`[JW!#"@5G,& M",,`81@@#`.$88`P#!"&`<(P0!@&",,`81@@#`.$88`P#!"&`<(P0!@&",,` M81C@66<`:3O+`*O?KP(S\]^[Y6Y_K#9,>6L.X;#NAL.<"%7\V^E%>:;+I?3NYG=I=BNA[^4N0M( MNR3MV)799"D7((RS%8:YPC!7&.8*PUQAF"L,7,+\_H%YI9JWMS"?-/E MXZ+>`;`O0K8 MZX"]"=C;@+T+V/N`?0C8QX!]"MCGEG7IQHJSTFWU>U\S:WS-C'^>&VG7N5KC M:]!TZ3YZW5V`+2+/\34M.EM?,VM\%8:OPO!5&+X*PU=A^"H,7X7AJS!\%8:O MPO!5&+X*PU=A^"H,7X7AJS!\%8:OPO!5&+YZUJ7;5HP^W39'R-_FGAMJTV*S MS7QFC;J9S:F;JS7J!DV7[D=2NFNQM8^_EKD+R&LE/\M99]:H*PQUA:&N,-05 MAKK"4%<8Z@I#76&H*PQUA:&N,-05AKK"4%<8Z@I#76&H*PQUA:&N,-3UK$NW M+71\ND^>WJ[S$JE)?&:-N9G-F9NK->8&39>KZ"X,SX7AN3`\%X;GPO!<&)X+PW-A>"X, MSX7AN3`\%X;GPO!<&)X+PW-A>"X,SSWKY+#5DY=C;EC+JZW&@,SHQ1D@[]NL M:[62;0P0A@'",$`8!@C#`&$8(`P#A&&`,`P0A@'",$`8!@C#`&$8(`P#A&&` M,`P0A@'",,"SS@!;*9UC0%Y9-09DUAH@N_?K6LT9(`P#A&&`,`P0A@'",$`8 M!@C#`&$8(`P#A&&`,`P0A@'",$`8!@C#`&$8(`P#A&&`9ZT!FWY!/#,&'.MW MRXK"6@-D]WZJ-AF@['I4=A.PVX#=!>P^8`\!>QFPQX"]"MCK@+T)V-N`O0O8 M^X!]"-C'@'T*V.>6=0:;VI)N8:1;&.D61KJ% MD6YAI%L8Z19&NH61;F&D6QCI%D:ZA9%N8:1;&.D61KJ%D6[/NG3;HMT/^3:Y MM?V=N1=^7NS[H7^3F9_:%C8SM2W5_-2V,-]TN9HV?;L+L;6GOY"Y"\AKU>8" M_/HU?_]M(PQOA>&M,+P5AK?"\%88W@K#6V%X*PQOA>&M,+P5AK?"\%88W@K# M6V%X*PQOA>&M,+SUK$NWK=A]NH_["?;`X[F\YZ5^D_?,&G&#+8%@XW:3JS7B M!DV7JZ?>&R,%P6ALO"<%D8+@O#96&X+`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`]\CS@LLSSPM=>PS/+`MSJCLM'Z2U\PESR,UA_/KPK;67_Q M6#Z,UE\\E@^CY8]GO(3'M!SQ)(^H;+!V\7V%WTFPLCCO@QV3QSQ&QQPM[SPL M,2RS_/'TOK#,\L?C+**RP=KQ'(*PS-K%]Y5AL#S$]Y5AL#P\<5^Q^_00WZ<' MNT_S)SR7A1V3G_6)SG-A[5@OA666!WY*)2RS//#[(F&9Y8&?Z8C*!LM#^E)Y M[^">L/"KP4&K/1?.SZ]&)9PB/W@9E7`2_+Y@4,)SV>S\8A<6EK=XKK"EK_@. MO"48VS`66\YB&Y[%GI/@1]6#\]NC%3_?'95P MVS#>-H&)YR];,A'/7FSR$L]=UD0G7@'832J^1]GT/Y[]VV0@G@O85"">"6RX MTG@>8,-Z/*K;33*^1]HM,KY#VLTZOE>OB0YO`P>9LYMX?`\_3J%#ZVW0C<=< M&W+C$7-0&WIM`VT\SHYD+AYE1[(0C[%V MRXKO6';#>N)^19LG1E<;".-QT(;6,-;'@37,W/$V%8X]QYM4&&L;0J(X[*_C1<_"D/Y^'V$HR.9"_`B/."B7+(,\?LRD-?*1NL++H2>YHT M40G+>.3F[H*G`T41XY'0NPN^T!Z5\3RUW05?8H_*>(;:[N(F+K.GRUWPI?:H MG3UESJXAMV9ED5_\-._B@C]1MOC%Q!7G&<\G+"X$((J9/5F<:P_+>,#Z MGF.&VME[^*RCU;V*2Z[VW%YN_#J=ES< M+KJV!]H\A"6'W?+B>A>-0'>4W(1=6'+)E5Z&5WI%R558AVUN:',3EMQ2`97E%R%)0=*KL,K/7"EUV&; M&]KU%J\8!'YPV]__]7>KDW_Y]O7__`!HC_\ M\.>OW[Y]_=?Q?_[MRR__\^4WJT#EOW[]^JW\'Q8Q/_[?U]_^<7SC[.?_%P`` M`/__`@```/__`P!02P,$%``&``@````A`!JW54RJ`@``"`<``!@```!X;"]W M;W)K,U4)NHBQ3]_W%ZL,#*6UAFM5,U3_,P-OMI^_+`Y*OU@2LXM`H;:I+BTMDD( M,:SDDII`-;R&+[G2DEK8ZH*81G.:M8=D1:+9;$$D%37V#(F>PJ'R7#!^H]A! M\MIZ$LTK:L%_4XK&O+!)-H5.4OUP:"Z8D@U0[$4E['-+BI%DR5U1*TWW%<3] M%,XI>^%N-V?T4C"MC,IM`'3$.WH>\YJL"3!M-YF`"%S:D>9YBG=AJ0<'O[[AAD%"@2:(8L?$5`4.P(JD<#<#$D*?VN=19+9, M<;0,5G$\7ZR60+/GQMX*QXD1.QBKY&^/"CLNSQ)U+/#L6"X70;R<788@^@\2 MXCUJ`[RAEFXW6AT17!J0-`UU5S!,@/CMB"`4A]TY<(J7&(&O!JKPN`T7\88\ M0NI8A[GV&%A/F!Y!0+17!K7IR@[LE%UNG2O7WC"4B=Z6N?P?&0=.,:PGY^,3 MKU?VF/D`L_^++*,C% M6,EU1AP&[E:_?Y7%49Q-3!394(6JVW]@-O M%SF?7]OGR:X=A*3_`(.HH06_I[H0M4$5SX%RUB9+^U'F-U8UX#D,$F5A`K6O M)?QQ.'3;+(!ZYDK9EPT(D_X?MOT#``#__P,`4$L#!!0`!@`(````(0#;WQ6C MA0(``&<&```8````>&PO=V]R:W-H965T&ULC%7+;MLP$+P7 MZ#\0O$>TY%BH]BQ&_ABB-1P9G:6 M*\_O]ZHF6S!6ZB:C<32@!!JA<]F4&?W]:W7WB1+K>)/S6C>0T0-8>K_X^&&^ MT^;95@".($-C,UHYUZ:,65&!XC;2+33XIM!&<8=+4S+;&N!Y=TC5+!D,)DQQ MV=#`D)I;.'112`&/6FP4-"Z0&*BY0_^VDJU]85/B%CK%S?.FO1-:M4BQEK5T MAXZ4$B72I[+1AJ]KK'L?C[AXX>X6%_1*"J.M+ER$="P8O:QYQF8,F1;S7&(% M/G9BH,CH,DX?II0MYET^?R3L[,DSL97>?3$R_R8;P+"Q3;X!:ZV?/?0I]UMX MF%V<7G4-^&%(#@7?U.ZGWGT%658.NSW&@GQ=:7YX!"LP4*2)DK%G$KI&`_A+ ME/0W`P/A^XPF*"QS5V5T.(G&T\$P1CA9@W4KZ2DI$1OKM/H;0'%G*G!UUAZY MXXNYT3N"[4:T;;F_/'&*Q->]H`F/77IP1J>4H(S%_+:+>!+/V1:+%D?,0\#@ M[RNF1S`4[951[79E#_;*/A5OY2%LG,HDUV6&YS(^]"&V[OU"_2'$G18Q>>4/ M#@)F=((97W>`D-L+]6#L!3;T-;^+C`/H!FFDN5W:@SOI/N2P,_N/E[-N3LZ5 M?,S)#!V^G[,_=2YYW,$.G=0_O!XL7L33ZKIYBL<1NGY?U9\[5SWNG*N.WJB& MP0[3H\"4\!GJVA*A-WYH$YR'?K?_GBP3?V7?[H_297>56?\"Y[SE)7SGII2- M)3442#F(IEB+"5^*L'"Z1>/%7[0`4=BX`LOM'8O"Q1F_5_$XA\` M``#__P,`4$L#!!0`!@`(````(0#H#H=?7P0``/\/```8````>&PO=V]R:W-H M965T&ULK%?;CJ,X$'T?:?\!\3X!YQZ49!0"/3/2KK1:[>69 M!B=!#3C"I-/]]U-EC-O&3-*SZI<0#E7'I\IEE[W^\E(6SC.M>N@YODBI+"E;1C?M*N?ME^]NG]9753_Q$:>,`0\4W[JEI MSH'G\?1$RX2/V)E6\.7`ZC)IX+4^>OQ2EHU+4E-BZ0!_?R4GWG'5J;OH2N3^NER_IRR\@P4CWF1-Z^"U'7* M-/A^K%B=/!80]PN9)FG'+5XL^C)/:\;9H1D!G=<*M6->>2L/F+;K+(<(,.U. M30\;=T>"F,Q<;[L6"?HWIU>N_7?XB5V_UGGV>UY1R#;,$\[`(V-/:/H]0PB< M/0D:!9C06,E)6@`#X M=5_K15!58IE M+%G@*5G(7&.YX3F1GO#LQA\MB+^:X.@W_*;2#YZ_."+PBHCA*3TG\]%LX4\( M).A.P%Z;/3$94=(DVW7-K@Y4.*2'GQ-<+R0`EFX6V@#4O/QL6B"32+)#EHV[ MMZ2&5E[SS#_J;0)!VQ,BWUG@1.$M%$?B#7`@P!4%#!]'Q`%LF`4 MW?AA![R%->Y)[BPZEZ@/Q!I@2(:Z^0#)R+)QX5=+?$]CV-H0*#AE-.N%H4Q4 M'!82ZX@1"1!_0"3(`D4(-:A4VC4DC6Z%HDQ4*!82ZX@1"HRNAS*\%W5%C\9" M<3=2*)'YK1CVRJASBRPDUA%#(%#K`G&Y3I:X0_7/T?\4ADBI>(*7[:$Z^,E'@+B77$$(_GCMY&.9^,WC;[ M=V<>B4SQ$C'%]Y>H,E+B+236$4/\RA8_GHU^O6J0Q]0N$5/[O)=X9:2T6TBL M(X9V`D<+/?.W%Z6P-B5VT%)M['L;BFPH-B!3$S:B7C60%1&U?$=?V\+:DY7H MI$5Q1WG;R0SE$M(S M:T$1L:#8@$Q-V&8T3;C#R4WBCCS9G]JS(AX?0B(A/;$2`DFW$BNM],0..JY^ MDEAL,%H0=Y3+=J0KEY">6`N*L*7C$>`L+=K!;<7F'`5 MP*8".TX?)S[<;(1RZ\L8OHP'?:;P93KP!:Y)NV$/`+X,H)\`[JF!X?IU3H[TCZ0^ MYA5W"GJ`U/NB@NKV`M>^-.P,4P)7$M;`O4O\/<%%F\*:]+'I'!AKNA<<0%W= MMS\```#__P,`4$L#!!0`!@`(````(0!VN"JWP`4``-(6```8````>&PO=V]R M:W-H965T&ULG)C;CIM($(;O5]IW0-S;T`<./1I/-";*;J2- MM%KMX9K!V$9CC`7,(6^_U52;/MA#<&Z2,?P47U=UU6_W_:?W^N"]EFU7-<>5 M3Y:A[Y7'HME4Q]W*_^?O+XO4][H^/V[R0W,L5_[WLO,_/?SZR_U;TSYW^[+L M/8AP[%;^ON]/=T'0%?NRSKMEP\=V%W2GMLPWPT/U(:!A&`=U M7AU]C'#7SHG1;+=547YNBI>Z//88I"T/>0_\W;XZ=>=H=3$G7)VWSR^G1='4 M)PCQ5!VJ_OL0U/?JXN[K[MBT^=,!UOU.>%Z<8P\?+L+75=$V7;/MEQ`N0-#+ M-8M`!!#IX7Y3P0IDVKVVW*[\1W*7,>('#_=#@OZMRK?.^-OK]LW;;VVU^:,Z MEI!MJ).LP%/3/$OIUXV\!`\'%T]_&2KP9^MMRFW^I*;@W(2/X^_/]6;?K]RF?Q,DI"1D#N M/95=_Z62(7VO>.GZIOX/1<.*QB!4!6%`K^[3)4TC$L4_CA(@T;#`SWF?/]RW MS9L'NP;>V9URN0?)'40^KPPYQK5^M%18HPSR**.L_,3W8!4=U.?U`59V'[Q" M3@NE65_1V(KLK)"E`+R1$59N,E[/^AE%BB6*K()D6^,%B#VR4>>]EXHD'B46 M"61H/HD40Z6-%Q.JXR(<:KBA<=*632DL-@@RGTV*5SXL?$R*$..2$0TE\5#- M19KR.`D=^LR6L#A.8AW%@H-M;L+);<8_;*!S*>5#;@(3AQ(U`#(NQ$W@E,)B MC&W&Z6TFQ78""4T=-M1@!DG*$T:XKFQ0:M9>9OFDV*739=%ZPN M:E1U*1%A3!PV4\%C83:TA29-SI@@TVA2[*"QT'[Q&C6(EH;"R6J&M_FP+T6H M]X,%)6Z!DF(7RLG&&C4(Q>"UH8ME"BB+N$ZX!4;`?,QTR4Y@<&TZ;<-3+J+> M*EA2)5+[C3%V45*EP-SIM-N`<@K/KB?!F6T-.<:<@BK15)-.2FP^.:WG\^%L M-P<=84X7K@F*5#.P5$3,K:XE(92`[6J)S2<']GP^'.\F'W.W'D&-JFL$;W9' MG*6(DH0(O3=L.#FQY\/A?#?A"'/>O28H4IU!('7$M0E+LN"P+TFHP]B`IRJ[)DN0`3CJ7`D&3$E"R)(!$8W3@`;]":O(-?, M0G>=`C3=8D&BB$;&E[=!DZE`F.H%"4DBF#&_;<2;G(/@U+?'GY[\"A%%D^-O M2F+QT9_RC^$IQS^X-@#D5"*5)G!\'CO-E-D2&`8T^F#2T)ML9%"[?'H3*3[T MFDD^2S+))V?^[$%#I=KY*LKURA4?BJ;JK.)'_OSL2;5;73W+5/90I*I['<^2Q$Q$D>XUF^\F&Y$_ MGR_XG*V_5B+7)@;X3-U$>")X8GSULL%N,A)Z:23B(F^H47DC,4L3HR<5'FI< M=IOLITR$7C$1U\C62C2-:+H(HS1.]/:U.1T/F6=V](J7<,?)UDJD.%F:4C"* MTOJW MT_"4@QDY$&LE0DPB4A:2T%F*/&&48T)IY'F("'72D12/$/&$K2[;79F5AT/G M%73Y2>5CE7%_#D>9P_A>,-^!$\93ORF]YNZN.G7FA[.$H<_]W!V7,)A6+@$\;9I^O,'>=0VGD8__`\` M`/__`P!02P,$%``&``@````A`+Q(Q0NO!0``-QD``!@```!X;"]W;W)K]`>%=H+@UMU)/#;?JU.^T3_S1O^V_?67]7M5OS2'/&\U\'!J-OJA M;<\KPVBR0UZFS;(ZYR>P[*NZ3%OX6#\;S;G.TUVWJ#P:EFE2HTR+DRX\K.HY M/JK]OLCRJ,I>R_S4"B=U?DQ;N/_F4)R;B[E=`!%QVK<[W&_T[6246T8WMNA/HWR)_;P;OM>90O?]6%[N?Q2D'M2%//`-/ M5?7"T1\[_B=8;-RL3KH,_%EKNWR?OA[;OZKWW_/B^=!"NEV(B`>VVGU&>9.! MHN!F:;G<4U8=X0;@52L+7AJ@2/K17=^+77O8Z#9=NIYI$\"UI[QIDX*[U+7L MM6FK\C\!=1%=G5B]$[CV3HBY)(Y)'_!A]S[@VOMX8+'3+X;K)0IX._/N(OIG-7DS[Q7"]?/-L_0R1BRZU4=JFVW5=O6NP7T#MYISRW4=6X)CGU+F; M4T@F7_.=+^J6`MU`(;YMB4G7QAL43]8SP1CCR4PXQO@R$XTQ3&;B$8:8,I., M,>3*&"#'51.HK:$FX_5]T8+#&QU>O[0@UM5OIU<@&-HI93/;LXB-0@B'"/%L MAN2,AG9FFR:C)E(S'B(+U[9=ZKKH3A*)L9@/>^]ZKY(&L#>&&O"ZL*%CJ+7@ MB[`6]M6_T$(PL&6N>KDR$0I"J,6E<)E/D9=HTDL\220J0M(";G:HA5H##LL: M,)3K0"`BP(5O4^I1A(0"<;J*094<*6SQM.MD?+D4,#2`8<#SDL\7R8$3XLBI M#033IY8Y'OW:@5UUA`(0DBU>+@:J9:,VZ2PH?\]'C9?A,-& M%1T(!H2_6_."$,+XED-O"G[213Q))"I"$L*3A5`7/(>Q`*A[!8+I\VZ:*#>A M,(NLHXJ(AC:&MU(\M"*OR;A-"I2/IH/33QTHAW&@J`<'@E%E^D+P4Y,1M#ZZ M6.]62CQ))"I"BAY&C_G18@N4*)(9Y+$1!)`'.8ZYHN2G@L,0OJ M,&;:+JK11(:45<$'HH$4\XY](L8H61)T<@<]I*P.X>=2':"(24W4/Z)I/_$T MDB@1N3K@CH>2J`\(PFEYH^`#*^@9$>;"]QUH&C! M'#>?EAXO!3%C2:5P,P+R)P8@TNC]ARICI#+&*F-RQRB'S*>CQT,6,Y4<,JK: M@`A(Y-RW;=3SP@E[U-L5NR>>1A(E(DO!)Z>!%!-5+^8L60)4T@$9#F.HCX4J M8R09;P=`R8R::'+'*`?+QZ7YP8KA2@X6#7$!44U@XG=.CXB2L$Q\/D33+N)I M)%$BL@I\@)JO@ABW9!7P,$@$U'CXSV@FAZ?:Q:G]PQ2F%;#\V$ M'2WW=V*AS1STT"6SE,"0CYA08OCICW9$)`'P.]FFS$<'>RPQ"\_V;3A)4.M) M9$AU^EL/S80=C:7`O_9[2-&WPAX1:G5*F,Q#E11-^XFG$?YH7!P\7[/;EUJB M*L2C;_%\])P^YW^D]7-Q:K1COH=YSUQZ<';5XL&W^-!6Y^XYZ%/5P@/K[NT! M_D&1PT-2&ULE)5=;YLP M%(;O)^T_6+XO8`(A1"%5$])MTB9-TSZN'3#!*F!D.TW[[W>,0PIA6[N;@)W7 MC\][CGU8W3[5%7ID4G'1))@X'D:LR43.FT."?WR_OUE@I#1MM[WMRM*6^P)2SE6QBB*'C&4I$=:]9H"Y&LHAKB5R5O54^KL[?@:BH?CNU- M)NH6$'M>$>J%*?><,@V5`F4X"] M$`]&^BDW4[#8G:R^[PKP5:*<%?18Z6_B])'Q0ZFAVB$8,KZ6^7/*5`8)!8SC MAX:4B0H"@%]4>*[+!,_F3AAY,P)RM&=*WW.#Q"@[*BWJ7U9$ MSB@+\<\06'&&$-_Q%R$)YZ]37!M19S"EFJY74IP0'!K84[74'$&R!+)Q-H/\ MV#@N7O]F%3P:R)VA)#C"")8K*,_C.EC,5NXCY#0[:S93312.)=M>8C)HN&D_ M\<(EXR6[7F'*!Y8NOB!;0U]_KE0?OA&;\/M]-W8"V!<__GC?[501S<>2="JY M@NRFB@%D9&?V/W:,&,HXB)Z$5UMOK"88:*Z+\:HB?56Q^Y=BY`\">7NYC#C! MD+R7ZA!OG/R-U&ULE%7;CILP$'VOU'^P M_+X82$@V*&25[6K;E5JIJGIY=HP!*X"1[6QV_[YC3"ALTH:^ZE*],R5%K).<.#Y&/&:R534>8)_?'^\N<5(&UJGM)0U3_`KU_AN\_[=^BC5 M7A><&P0,M4YP84P3$Z)9P2NJ/=GP&KYD4E74P*O*B6X4IVGK5)4D]/T%J:BH ML6.(U10.F66"\0?)#A6OC2-1O*0&XM>%:/2)K6)3Z"JJ]H?FALFJ`8J=*(5Y M;4DQJEC\E-=2T5T)>;\$<\I.W.W+&7TEF)):9L8#.N("/<]Y158$F#;K5$`& MMNQ(\2S!VR"^#WQ,-NNV0#\%/^K!,]*%/'Y4(OTL:@[5AC[9#NRDW%OH4VI- MX$S.O!_;#GQ5*.49/93FFSQ^XB(O#+0[@HQL8G'Z^L`U@XH"C1=&EHG)$@*` M*ZJ$/1I0$?K2WH\B-46"9W,OO(V":`%XM./:/`K+B1$[:".K7PX5=%R.)>Q8 MX'YB67C1TI\%UTF(BZA-\($:NEDK>41P:D!2-]2>P2`&XLL902H6N[7@!"\Q M@E@UM.%Y,XO\-7F&TK$.<^\P<.TQ08\@(-HK@]IT90NVRK:V-I1[9QC*A)=E M9O\C8\'0G$'PL^A/^$[98>8#3'19&2#3$[1@Z`&575^HU5.\NJ73O#J5A=D)C#,?_W8%JOL4!G M&:V(N%7K-E'%5 MVJ_X;6BK]=8^C[=N]9/^"ZS>AN;\"U6YJ#4J>0:S&R@=AA_TH# M.[=]+.`GRV&_^/8H95*:TPLHD_ZWO?D-``#__P,`4$L#!!0`!@`(````(0`$ M^.`NX0(``(4(```9````>&PO=V]R:W-H965TS^_8=8\+&2=JE-QPF M,_\W,S;CK&^?ZPH]<:6%;%(OUL?I'K4)><&@4*C4UP:TR:$:%;RFNI`MKR!7W*I:FK@515$MXK3K`NJ M*Q*'X9S45#38*21JC(;,<\'XO63[FC?&B2A>40/YZU*T^JA6LS%R-56/^_:& MR;H%B9VHA'GI1#&J6?*Y:*2BNPKJ?HZFE!VUNY<+^5HP);7,30!RQ"5Z6?.* MK`@H;=:9@`ILVY'B>8JW47(719ALUEV#?@E^T"?/2)?R\%&)[(MH.'0;ULFN MP$[*1^OZ.;,F""87T0_="GQ3*.,YW5?FNSQ\XJ(H#2SW#"JRA279RSW7##H* M,D$\LTI,5I``7%$M[-:`CM#G[GX0F2GA:15,X]EB&8$_VG%M'H35Q(CMM9'U M[]ZKUW(J<:\"]UYE,@]FBW`R0H2XC+H"[ZFAF[62!P2[!I"ZI78/1@D(7Z\( M2K&^6^NY\[YP'7PB08/`M"!#+3Q9.MLR;:W M-I4[9SC%Q-)X3NYFHQ7Y=Q'V4]C/@U`X=];R8;YT-[B0Q=# M\STH;,'3^KKO,9J]3;5Q/K6W^-3E=:H=YR??RMA2;9@/[2T^='4=NKJ$+A9V MS+S18!OG4WN+1UV%UZD1>)W7&HWI/)1SW'"9=:'=U+J4YO@"9 M#'\@-G\```#__P,`4$L#!!0`!@`(````(0""@Y.EE@(``+X&```9````>&PO M=V]R:W-H965T>M-,1+%[''32D77 M#>1^#6):'+S[P86]X(626E;&`SOB0"\S3\F4@--B7G)(8-N.%*MR?!?,5BDF MBWG?G]^<[?3);Z1KN?NB>/F-MPR:#=MD-V`MY;.5/I;V+UA,+E8_]!OP7:&2 M573;F!]R]Y7Q36U@MQ,(9'/-RK=[I@MH*-AX86*="MD``'PBP>W)@(;0U_Y[ MQTM3YSA*O23SHP#D:,VT>>#6$J-BJXT4?YPHV%LYDW!O$@']?C[TPDD2).F_ M78@CZ@/>4T,7:D)QXK5.XILD!#@&R`A^BGDQW!6#"$P&N""Y*STTFGB$TTR M5.XCKCY2C-B@T/5L5IQC\#ZR3=-QY:73I'U;HR#QHS/!ZE00!^FQ\2,N"'<] MEQ6?>+)62```9````>&PO=V]R M:W-H965T7[Y\OH]#XX_;R8KM;OCPLG]8OJ\^7_ZZVE__[ M\M__?/J]WORU_;%:[2Y$A)?MY\L?N]W/N^OK[?V/U?-R>[7^N7H14[ZM-\_+ MG?COYOOU]N=FM7S8S_3\=-VZN>E>/R\?7RZ+"'>;_GE;GYZ]?//^[7SS]%B*^/3X^[?_=!+R^> M[^^FWU_6F^77)['>_VCZ\KZ*O?_/2?CGQ_O->KO^MKL2X:Z+!3U=Y_YU_UI$ M^O+IX5&L0?ZR7VQ6WSY?_JG=9>W^Y?673_L7*'Y<_=X>_7VQ_;'^;6X>'ZS' MEY5XM<5VRK?`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`795(0*0O;RO:9GH;1V\K"S,XP\SJC[ M&<8^-5#>F=8?PZTY,W=G"&"4^-LM81BAA%@B)%D34)*1?% M)9&4B_F9I"U.PDO94L,SS.@,,ZXQ[1MY:QHU1ET>\PPS M*H;):HS^NO-*J2FN/*74;$[)7$LI633(*:D<](:5JV'TC(?*[/E^)&YI!LNJ[<;@T*TY20*$8HQJ="UY5K?N,,8YX:Y?`Q M03%%,4,Q1V&AL%$X*!8H7!0>"A]%@")$$:&(420H4A19DY"2,G]*IPXA\XU_ M/I>:E,KXT:`PQTEYDB[#4Z.DP@C%&(6!PD0Q03%%,4,Q1V&AL%$X*!8H7!0> M"A]%@")$$:&(420H4A19DY!24CQ`^T!*YG.I*:DDTZ`P4DJVE(O;X:E1HHQ0 MC%$8*$P4$Q13%#,45*Z-H^9:SE7TU09 M^1^4J#%-BS@-9,11QDP,)B:3"9,IDQF3.1.+BC/EFFC1--$] M3'P=$E2RQF/B,PF8A$PB)C&3A$G*)&LD$Q\)@&3D$G$)&:2,$F99(U$3M&\).'XW`DI6E0P')\S>R=WGX4I=]:^ MWF_UE9OU8?Z>')'I)=&T7DNM9!Z5I&$W&S,QI([T6ZUSTI$ID;;>[W1NE4NT M"7$Y])P"1D$C&)F21,4B99(Y%3-2]K^$"J%M40QZG:ZIRD:H'*W:`CAL=O ME&N>H79,Q)NP;VZ[2I1128K1)N7*;7R8^.8UDR%UT6O=:NV.4>[C!OG[_0^WG>U^7]>4>[2A)+1.7WW/R*@$#5?/8R:&U(VNZ_V>)Q\1G$C`)F41,8B8)DY1)UDBD M+,T_\N(#6;J?31WA51ZH#4K4*<^"5TH6#\OI#2DX8C*&7@R8;G(7$R93)C,F MCM#N;BH#-&0Q&/HQ8#I)G$Y])P"1D M$C&)F21,4B99(Y$S5%RLGIQ#=?$$H/D13"N?33V'*G=Y@Q(UI->0R8C)N"3E MDYQNS9-)@Z.83"9,IDQF3.9,+"8V$X?)@HG+Q&/B,PF8A$PB)C&3A$G*)&LD M(Q\9D$3$(F$9.82<(D99(U$CE5Q3GOY*S*[Q)MY;,I9]6N M,@([*%'C6;6(TT!&'&5<0_2N4BQ@G(/,&J3<3T^83)G,F,R96$QL)@Z3!1.7 MB/]R;?X+H2;JJI8(E:LC%(9,1DW$- MT;O*B*YQ#C)KT$FZ%JO>L%93CC)C,F=B,;&9.$P63%PF'A.?2<`D9!(QB9DD M3%(F62.1T_5CA4FMFL(D]>'GH$2'427EX>BPG-ZPXX^8C*$7`Z:;W,6$R93) MC,FZ,LX2YF\1!,F4R8S)G,F%A.;B<-DP<1EXC'QF01,0B81DYA) MPB1EDC42.6<_5J+4JBE1ZIX\N"E00ZH-RS@-9,1D7)(B8<77%.7_Y".#P5%, M)A,F4R8S)G,F%A.;B<-DP<1EXC'QF01,0B81DYA)PB1EDC42*57S@=\/#"_M M9U-'@]4'-R5JR,,ADQ&3\8'D[\=21X&;)IJ'B6\^6YHPF3*9,9DSL9C83!PF M"R8N$X^)SR1@$C*)F,1,$B8IDZR1R.FI%BDUESZT:XJ3>LI9:U"BQK3D^B2. M,F9B,#&93)A,F)Q\1G$C`)F41,8B8)DY1)5D=>QU?D M'*TK4\I3''*UIDRIIYR\!NT"->8JDA%'&3,QF)A,)DRF3&9,YDPL)C83A\F" MB(Q\9D$3$(F$9.82<(D99(U$CE%10I\Y*8TGTVY*57?-S9H M%ZA(U:XFOKI8'M092D!\?$BWI8A1*1KSM.BE@1A2/W^(5+Y1"YA,B>C=OOA. M8GEA)[PH4R8S)G,F%A.;B<-DP<1EXC'QF01,0B81DYA)PB1EDC42.4WK2I/X M26J[IC2II]0R#$K4D$!#)B,F8R8&$Y/)A,F4R8S)G(G%Q&;B,%DP<9EX3'PF M`9.02<0D+DGUY$#3U+);_8_93)C,F=B,;&9.$P63%PF'A.?2<`D9!(Q MB9DD3%(F62.14[*N#.F,4:.:,B3UV\<'[0(5!Z"\KD&^:AR6TQM.KB,F8R8& M+(C)(29,IDQF3.9,+"8V$X?)@HG+Q&/B,PF8A$PB)C&3A$G*)&LD,L`\:!>H++[O7Q6? M#KVO"LI_:.,_3D9\L5)I5`9M.`:,F1A,3'GI;Z[4SUZ;R*!_)3Y02?IWLGI3 M[G7&9,[$8F(S<9@LF+A,/"8^DX!)R"1B$C-)F*1,LD92I/'U]L=JM1LM=\LO MGYY7F^^KX>KI:7MQO_[U(KXP6'QEU%'SQ6;U[?.EK]T%VJ7X7O,#+]I#[2ZJ M:T^TN[2N?=*Z$]_7?AKG3^WNS[KV@78WK(LSUN[,NO:I=F?5M3O:W:*NW=7N MO'W[]6'%ME\^_5Q^7]G+S??'E^W%T^J;>$UNKGIB-&WS^#W_\)KB/[OU3_%: M75Y\7>]VZ^?]GS]6RX?5)@<"?UNO=]5_Q`I?_UYO_MJ_[E_^+P````#__P,` M4$L#!!0`!@`(````(0`0FO8\&1$```M?```9````>&PO=V]R:W-H965T/'[]G#<[9\_7HZN M;BXOML_W^X?=\[>/E__^E_>/V\N+XVGS_+!YW#]O/U[^N3U>_O/3W__VX>?^ M\-OQ^W9[NB`+S\>/E]]/IY?E]?7Q_OOV:7.\VK]LG^G)U_WA:7.B7P_?KH\O MA^WFH59Z>KP>W]S,KI\VN^?+QL+R\!X;^Z]?=_?;]?[^Q]/V^=08.6P?-R?J M__'[[N7(UI[NWV/N:7/X[?%TOPR_/>\/FR^/ MY/E#/4#_V6U_'CO_OCA^W__T#[N'9/>\I=&F.*D(?-GO?U.B MX8-"I'P-VEX=@>)P\;#]NOGQ>*KV/X/M[MOW$X5[2AXIQY8/?ZZWQWL:43)S M-9XJ2_?[1^H`_?_B::>F!HW(YH_ZY\_=P^G[Q\OQY&HRGLYO1R1_\65[/'D[ M9?/RXO['\;1_^F\C-=*V&BMC;<6A[C?/G=G5='[CG&-DHHW03^[*C1@9:)WZ M6?M`/W^]]9DV0C^UD>XX#+0^UXJTHL[K]D(KTD^M.%J\R]\1S9(F:!25MK.C MR9T=46B;-B7&[^TN!W8DD7WGV*J9W+0J81F_;U*,."[J M'V>.+X6R:55B.KEZ?7ROFS55+]'UYK3Y].&P_WE!>8_"#7P;!#8(;1#9(+9!8H/4!ID-'!_6N M(9/!<*U:(59;`W&!>$!\(`&0$$@$)`:2`$F!9$!R(`60$DC5)48L:(-S1BR4 MM!D+3$!](`"0$$@&)@21`4B`9D!Q(`:0$4G6)$0L: M1",6S;[M:D[!&UXB2M$,2T,FM^W&8`5D#<0%X@'Q@01`0B`1D!A(`B0%D@') M@11`2B!5EQ@QH.VR$8/A@5?2YL!K4I^>Z_WN"L@:B`O$`^(#"8"$0"(@,9`$ M2`HD`Y(#*8"40*HN,0:>CJ/&P'AUTAH2(6=FN9:V0MSK#$@.I`!2`JD:TO3:B*VJ'/S_P:VMF-'5J#-0 M*T$R"#!2:RTUI8[)EF]FG5U=D>*Q\L0\(Q]1((IB?K2P-OFA2+&M"&W%@KJV MK*@F8DND'-NA5*2XQ4S,,\H1%:(HYL&A4J385F78,B>%.AIWRQ0]*YL*2[RT M1\U)FC;I;/M.(Z>3;#6:RGI?(W(1>8A\1`&B$%&$*$:4($H198AR1`6B$E%E M(#,6ZE1\1BR:0[01BP:-QW6A:'PSFIC)RQ#.Z77C?LLY;13*$`4(HH0Q8(&6DQ$BMU)&37NC*?.>'IC M+>:,90;=R5E*W"D0E8@J`YGS0)VTSY@'^F#>79,-&L]X'EBA6JF*KGI'=S-O MSSQHI7C@7*TXGC?S8#Y9C&969<5CXY0KAN8!&`]845))B"A"%`L::#$1*78G MU6C(G8S5!MW)64KZ7B`J$54&,N>!.KN?,0_T4;\[#QHD^<"J'*]4^>L=^:"5 MXH%S65'G@WG/`O)89G`!^2PE"RA`%"**$,6"!N,X\4.+6#JU!D@^L);M25;=WY(-62N:!MLSYH'<>:+7!!>1+ M%]AX@"A$%"&*!0W.`W`GU8IM/NAQ)V/C@^[D+-7-!]!>B5*5@+HYH,&23ZP:T0C+4"Y^?74O18I#I7+2"^@67]"T-9I'%ZW[K,I64$!HA!1 MA"@6--!B(E+L3\IHR)^,A0;]R5E*_"D0E8@J`YDS055.NC/AE\[IZL-1.U$T MB!*%C)NAQZG4D8X5!1W*6$D<*1"6BRD#FO%"%G>Z\>.,TI^M`W0S1(.,T MUZ*!05JKC[AI,CERYG,1>8S$9Q]1@"A$%"&*!0UT-6$IZ6J**&,D77X"MK9@[0(VLQ&Z7!UAJ M,'&MV;RL#)<5*0FTT\N96:=.CQ6[YIT;ZTSBLRU9G@$K2HLAH@A1++:D7S#M M$U1,6=%TR.IJQHJ##N5L2QPJ6%$<*A%5!C+G";5X1MJ@TJS]IM>HF^@%#0S6 MFJ7$&Q>1QT@<]!$%B$)$$:)8T$!7$Y:2KJ:(,D;2U1Q1@:A$5!G(C)BJJ;T_ MT=,6'2*FJW)FHK=/9E,;BL:*9"ZV,XCQ6[YGMR M>]-[6B8\D@$K2HLAH@A1K)%:'?.W'I?>BPRN-Q\Z8%,$F@N9%NR`B-$L=@:G"1@/F5;C3=3V%%G+##H2R[M MLR\%*TK'2T25@N"FE&N MF5L?H*_4BX&B-IPHUUJ*/A+BF>JRHB[N3IS1:#ZVK'NLU\V3D(9]-B7A"%A1 M&@Q92C'-K88NX'6*#508 MKQ.`='\E:&`YKEEJW)E=VI8@CZ7$O(\H8"2*(:*(D=B*!0UT-6$I,9\BRAB) M^1Q1P4ALE8@J1K4M,Y*T1S$B^4:N5^)6KF^0D>L;U/UZ!E5DE6('N8@\1#ZB M`%&(*$(4(TH0I8@R1#FB`E&)J#*0&0N[5/=+1?%=B/KS*T:VTI+ MO;4OT]5`V5RX;'[16W3GI_1F;QOO2=^-66J<7PX!*TI+(:/>EB)^.MA2K*6& MW4S8EC2>,NIM/..G@XWGTCB[6;"BM%0RZFVIXJ>OM63,*5J6YZSO6MQ@@9"N64I>3BXBCY&D.1]1P$ALA8@B1F(K%C30U82EQ'R**&,DYG-$!2.Q M52*J&&%&I@\XS(C]4A:HK5B!5(9IEV;NY>PZOE9\8R_'YF4H7%;D;4WO7H[U M7MMEU-_O]=F4#&'`BM)@R%*#>SG6&VPP9E.#4@G;DCZDK,A.]^[E6&_0>LZF MQ.F"%:7!DJ4&]W*L]UJ#9H90E:WN7FYX!^`TA;#N(4$CFM*1QTC,^X@"1F(K1!0Q$ENQH(&N)BPEYE-$&2,QGR,J&(FM$E'%J+9E1JRO MM*?K-V\$#VM[3H.Z?T.":(W(1>0A\A$%B$)$$:(848(H190ARA$5B$I$E8', ML*@:3WC<&Q-% MB5NOCP9-S->'=79>.:T4YX(U(A>1A\A'%"`*$46(8D0)HA11ABA'5"`J$54& M,L.C*BCVW&FJ]6?^.;_3U&*,Z:01'8?;'3B43E>L*']EOD;D(O(0^8@"1"&B M"%&,*$&4(LH0Y8@*1"6BRD!FY%21H1NY-Q964Y,PPJ-1YZ_X'$!K1"XB#Y&/ M*$`4(HH0Q8@21"FB#%&.J$!4(JH,9,9"%1FZL:BWSN/YVQ]Z.4UYP@B+1O(N M7[%4-^..IM8'I&N6D@.=RZBKZ,Q%T?3"+@.\,:/PO*_.MBI[=V<4H#5*N8@\ M1#ZB`%&(*$(4(TH0I8@R1#FB`E&)J#*0$8N)?7RN9]0-Q7$X*+6>^?YDU)E/ MC+K3`N<32W7F$Z.NHC.7&K+I`VU!<%4T'_>]X872M+QH4'>[.`&T1N0B\A#Y MB`)$(:((48PH090BRA#EB`I$):+*0&98*'@0EE]ZY4^4)2M,&M%[I//*MSY2 M7[%BYY6/R$7D(?(1!8A"1!&B&%&"*$64(1@NBCE M(?(1!8A"1!&B&%&"*$64(L`-BE.GRYY](Q4W^(_X)TK3 MVI`TB)[P@*^T5`>M$;F(/$0^H@!1B"A"%"-*$*6(,D0YH@)1B:@RD!D6^Y#; M$POZIE`;"SS9TN9=A4=%OMTS'IU MYO2D3J:@A[0F-`A9.>)Q-U*W7] MX9;=@\F8GM1?5;*>T$76G_OX'9GJM42&>N5I^/M&__-D^9E"W]=9ZE$?I['J M'2H:J=Z!HG'J'R;5H[XNK4:CI;J/!OM$5](LU>TR^(0NF%FJNV+P"5T70R/5 M]V0UOEVJ+U:A#GVW:JF^)H5/Z)M22_6E)WQ"WWNBD>][LEXLZ8HKU$@6R[*/ MT^5,2W7U$FK0O4I+=6L2/J'[CY;J=B-\0E<7+=7%1/3DNIU;=!7YR^;;-MT< MONV>CQ>/VZ^TH&_J[[D?FLO,FU].^MN*7_8GNH.<-BYTF3)=.K^E>\3H.NC+ MBZ_[_8E_40VTU]A_^I\`````__\#`%!+`P04``8`"````"$`V)X0FG$"``#5 M!0``&0```'AL+W=O>>\[]8'7S MI#KR",9*W9ZDGU3TA_?[R^N*+&.]Q7O=`\E?09+;];OWZT.VNQL M"^`(,O2VI*USPY(Q*UI0W"9Z@!Z_U-HH[O!H&F8'`[P:@U3'\C2]9(K+G@:& MI3F'0]>U%'"GQ5Y![P*)@8X[U&];.=@CFQ+GT"EN=OOA0F@U(,56=M(]CZ24 M*+%\:'IM^+9#WT]9P<61>SR\HE=2&&UU[1*D8T'H:\_7[)HATWI5273@RTX, MU"6]S9:;.67KU5B?GQ(.=O),;*L/'XVL/LL>L-C8)M^`K=8[#WVH_"L,9J^B M[\<&?#6D@IKO._=-'SZ!;%J'W9ZC(>]K63W?@1584*1)\E&&T!T*P"M1TD\& M%H0_C?>#K%Q;TMEE,E^DLPSA9`O6W4M/28G86Z?5KP#*O*A(DK^0X/V%))LG M13Y?7)W!PH*BT>`==WR],OI`<&@PIQVX'\%LBV0SK$W1$KW^SBO(\R:UG M*>F"$@RWV)['=9$M5NP1:RI>,)N`P6O$9!'!4$V4A#*FDMXN\C&S!_O,OE)> MRB:\F*;)WTXS^Y\T'EQ2Y([BB^PJ\H;,`5-,,/.(^,,@0LXWZ,'8DPEKD5U' MWI`Y8,[(C-,VS7SL]K]+[(-.O.?IB8*`F2HH\M/VAO4*TZ?`-/`!NLX2H?=^ M=3(&PO=V]R:W-H965TJV795K2E?7+Y(@WP<)(,&B?_SO?W_ZX]6_/GSY^O'Q\T^O!V\N7K_Z\/G]XR\?/__V MT^O=MORON]>OOGY[]_F7=W\\?O[PT^O_?/CZ^K]__K__Y\>_'[_\\^OO'SY\ M>Z41/G_]Z?7OW[[]^[]_>O]5(/__XRT>]`_.QO_KRX=>?7O_/X(?]\.[^]=N??SQ\0ON/'_[^ M&OS[JZ^_/_Y=??GXR_3CYP_ZN-4HTX)_/#[^TY0VOQC2QF^Q=7EHP?++JU\^ M_/KNKS^^K1__KC]\_.WW;^KWM=Z2>6<__/*?\8>O[_61:I@WPVLSTOO'/[0# M^O]???IHLJ&/Y-V_#__\^^,OWW[_Z?7ES9OKVXO+@/#UV_E1S/DZU?O M__KZ[?'3_^N*!G:H;I"A'>12>\]!CFQX93?42V4V?.:KW]A!]$\[R.V;J^'U M[=WA+1QY]5N[H?YI-[SR;_W(=CIX#I^9_FFW&P[?W%U?7]WJ='-GRWFZI M?]HM!_?/>LF!@M'UR22D^XR?^2X'?8OU+V>]SX'KJ_F7,]_I0%GH=MB'8CAX M79`&/DG/?:\N2P,? MIN?VU85IZ"/QW!P.72;,O]AW:W)R)+I#%P;S+\_JRMMNJCG,7.-WW][]_..7 MQ[]?Z7R@%_KZYSMS=AG\8$9S`?721[W)7WW M(06DA%20&M)`6L@$,H7,('/(`K*$K"!KR`:RA>P@^U"B[JM?4??S]QCN]&RJ M#TUVS7GHY.IHVT=]D=ML#"D@):2"U)`&TD(FD"ED!IE#%I`E9`590S:0+60' MV8<2]517NV?TU%3'/;427H4-;B_B0WG4%_4]A120$E)!:D@#:2$3R!0R@\PA M"\@2LH*L(1O(%K*#[$.)>JIF1#U]X?6U&2:=I6^3R^<'6Z0YHY_*TW-T7])W M'U)`2D@%J2$-I(5,(%/(##*'+"!+R`JRAFP@6\@.L@\EZKYN)*/N'Y^E375\ M1'<2S])IVT=]4=]32`$I(16DAC20%C*!3"$SR!RR@"PA*\@:LH%L(3O(/I2H MI[K5CWIJCNCA]1O-ZF?>,YN!XG9;49SZ`WAPFUR)C_JBOMV0`E)"*D@-:2`M M9`*90F:0.60!64)6D#5D`]E"=I!]*%&[S6H?^FTNE\_L]F&<9`J_NDB:^^"J MCLWAOJ9/`*D@E:2*5),:4DN:D*:D&6E.6I"6I!5I3=J0MJ0=:1]1'`JSS!(N MFQV?V,UR7G*H6TJF]LOD8LU7^59W8VE#1P6K2E)%JDD-J25-2%/2C#0G+4A+ MTHJT)FU(6]*.M(\H;K59?#FCU=U:C28(UYX'LV)ONA]/ZU=IJ_LJM^'8;^BH M()6DBE23&E)+FI"FI!EI3EJ0EJ05:4W:D+:D'6D?4=QJL]82MOJ%%^OF>4MW MN(?G\>12_,%5'9WJP]4?NR0.*OQ(+BY)HY)!:DD5:2:U)!: MTH0T)1$4[VE>*J_2:?ZOLJW M&E28:\SNM.&J2E)%JDD-J25-2%/2C#0G+4A+THJT)FU(6]*.M(\H;K59L`E; M_=*IWB[\J%?!+=MMW/`'\QS;M/+H5-_7N':/_6:."E))JD@UJ2&UI`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`-<"=D,_Y8_]ACX%J"I959%J4D-J21/2 ME#0CS4D+TI*T(JU)&]*6M"/M(XI3D"[O=6>!-^9W28XO_V@Q-[WQMW1UUQ_" M(]*85)!*4D6J20VI)4U(4]*,-"?CATM+AYY<.Z_<^F/+F;Z4CSIYN( M1I<]!5L/(5C):]8NZKX%9,%]L97 MN5=L'1U>,?[\G*_9,EB[[ASR77!6R%'VL755` M8U>E*2;X#),'@(6OAO7$CMWYD492^J_/6(@[E\=%K*?S4/!UY(V-;98Z,('G)VG7AJ]R[*?WP MCBI/X5A)GVH_5EB5O&+CJ]SPK1\>GU]Z@Y\Y2O48R#V+O>)=O"7SD#_X&-+% M6U>E*_>@*GF#8U_E=KUP='7(YN7@^N(R&;MT)?$QFHQ=N:JC>U#[*K<'C:-N M#Z[PDRNM*WCJ]>/`IO?2)S[P_I;9[<_#54?FB4WP4:;KI+;*_&%D4)5\*&-? MY88OW/"WAP_\]N[V(KD6+]U&RL+30U>NZN@.U+[*[4#C=N"NZWBR'M2Z+9YZ M]?C3-G>*X05-<,WZ_)/357>_&7X#P5*2^F1?1Z[J:.;&OLI]!H6C^\-GD'2M M=/_K4X$[7'=5KNKHB]>^RKUXXRC[XJW[7Y]Z\?CS-S=DX>=_(NWV_BVXH+SJ M2$N4;O]&GH[D;^RJ_-FP()6._/"5IR/#UZ[*#]^06D?=KY&&O_)F5CVB3^9E MR32C).&CF.8WI_DW[HV\<_G[I6#<^"O.\Q MCS+4B"BF/1W)T=AM.`P^=;NAI])5^4^F\G1D^-I5^;$:4NLH$U-S(Q,>P-TG M=O;W[O55+1O4<&^3,\N#JPIO3Y+`C7R-B^F85)!*4D6J20VI)4U(4]*,-".PH64:]"85)!*4D6J20VIC2A^S^?= MBU_S7MQ2L"`Y\A2>VI));>RJPBN=`99^?94[5$I'_O*^\G3D%6M7%;]BNOCF MJ]PKMHZXDGG]7>ZN#Z,D4>INN*./%32V&YK'&<%%1+KTZZO<.RH=A9\AAJ]= M53Q\LC3:^"HW?.LH\X&9FUE>39^Y5GYM1DD^L(ZB8Z^G\--!#KNJIY=^[8L% MJ[&EI>#%*D]'7JSV8SVQ].L+_(?9OPU1?/2:&]WPPSPQ8YGRY%/K*'@CH^N> MCKR1L:TZL?3KJ]R[*?WPCBI/1UZQ]F.%5.KW/"M'QZ?G[G-/./SZ^Y* MPT6PZXZB1;#+Y/'5R!7I``N.4N30#N4/R<)MV*V[ZJG$\";]PZ[2U:AK3P]> MN:JCNU#[*O?A-8[L+@QN;N]NT@4(5_/4+L29S=].GSL!]#?3;D\?KCN*%H7U MD267TK;JQ**PKW+#%V[X;DTV:5[I-M#9_E@7[%X?7Q!V8_F5CN;HB[=N@Z=> M//[\S[MSO>:=JZ5PHD?3^=E;,?2GQ3Z&'8;ZD_0[`DD-R78FJ>.QVYQ MW`YN'BP^O0LU=Z%Q='1*.+$+421OCMQ;'1Y1/&]-\C!,_,E;"J/JZN&:Y&&SE*T)HDXC'R5;W4WEC9T5+"J)%6DFM206M*$-"7-2'/2@K0DK4AK MTH:T)>U(^XCB5IM[M?#X/W[A?]/=VH47KHYT1=(?T\.+Y%YXY*M<7\>D@E22 M*E)-:D@M:4*:DF:D.6E!6I)6I#5I0]J2=J1]1'&KS=W?&:WN;A:C5EN*6YW< MQ8]N^BK?:E#!JI)4D6I20VI)$]*4-"/-20O2DK0BK4D;TI:T(^TCBEMM[KS/ M:+4I3ZYW+,6MQKFZK_*M!A4WH))4D6I20VI)$]*4-"/-20O2DK0BK4D;TI:T M(^TCBEN=KCR\]`*N7Y((I_'DZV$/-[9*QW,_V2,4?8T/!:CP([FJDE21:E)# M:DD3TI0T(\U)"]*2M"*M21O2EK0C[2.*0V&6!\XX_DUYDJC#G^7_10 M^88+-([4YOYPQ]>&1K[*I\".Y?_$J&!52:I(-:DAM:0):4J:D>:D!6E)6I'6 MI`UI2]J1]A'%*3"K).$!_^R'RC?=^DITF==1^%#95@4T)A6DDE21:E)#:DD3 MTI0T(\U)"]*2M"*M21O2EK0C[2.*6GR;KFT=OU,[E,=SNJ/X:$Z_9^NK^J.9 M5)!*4D6J20VI)4U(4]*,-"W'>&M@MU\`L MA=^Q\.0OG0;XJT57%=Y/#=,_$BE\E9N22U)%JDD-J77D'PY-/!W9^ZFK"O<> M7[R9^2JW]W/2@K0DK4AK1_R&R*U9=7KBHNCY?[!R&"694LW`^H*Z_\!&MBJ@ ML2.M?O07SX/[]"LUOLI].B6I(M6DAM0Z\KLZ(4T='=W5F:]RNSHG+4A+THJT M=I1II%E`^O]OI%V&\H\6'LR?VZN1T1S:4]BUY"G]V&[X]%=]?('[K$J^6.7I MR(O5?JPGONKC"]R+M7YD1Q-/1UYLZL>R+Y8L[\Y\@1MY[D=VM/!TY,66?JS\ M.UOY`C?RVH\LBN=QL\H4QN3$%;)=E`KST%&4AYZ.O)'Q;5=UXDM,OLJ]F])2 M\(J5IR.O6/NQPJID+:[Q5>X56S^\HXFG<*PD\U,_5EB5O.+,5[GAYWYX1PM/ MX5C)*R[]6&%5\HHK7^6&7_OA17%&S(I5F)'@1OF,--]V%'U_:SA( MWM'(5>D2(C@G)%5C7^7>4>&H^ZK$U>W@^NHJ.3)+5Z,9[.G!*U=U=!=J7^5V MH7'4[<+E_<7@;I@\YFM=S=%=F+BJH[LP]55N%V:.NET8:!\N[N^3OW29NZ*C M^[!P54?W8>FKW#ZL'-E]&-Q=W-Y?)ZU8NZ*G]B'.9&X)+_RZT/.^M7++]3M+ MX;=6/!T)R=A5^:^5%*324?"M%4]'AJ]=E1^^(;6._/`33T>&G[HJ/_R,-'?D MAU]X.C+\TE7YX5>DM2-^Y^8VOUAW]M\!'L8Y7)GZO1T.DN\I/KBJ\"(]F4)' MOL;%?$PJ2"6I(M6DAM22)J0I:4::DQ:D)6E%6I,VI"UI1]I'%$T"=^_KF%202E)%JDD-J25-2%/2C#0G+4A+THJT)FU(6]*.M(\H;G5^S?'L M:[N[;HE1=YCAM5URW?;@JHY=V_D:?_S;P8.?]V552:I(-:DAM:0):4J:D>:D M!6E)6I'6I`UI2]J1]A'%H5`7SSG^37ER_'>47-LE<1C=]56^U:""526I(M6D MAM22)J0I:4::DQ:D)6E%6I,VI"UI1]I'%+?:+`2FZTLON[;KEA3#-:8[2_%9 M(/U2EJ_R*>@W=%2PJB15I)K4D%K2A#0ES4ASTH*T)*U(:]*&M"7M2/N(XA2H M0U$*3ISP37ERP%N*6YW\O>3HKJ]R?1V3"E))JD@UJ2&UI`EI2IJ1YJ0%:4E: MD=:D#6E+VI'V$<6M3A?O3K2:BW1WEN)6IU_+\56^U?V&C@I6E:2*5),:4DN: MD*:D&6E.6I"6I!5I3=J0MJ0=:1]1W.K\NMTSOI9SQR_960J^@S,BC4D%J215 MI)K4D%K2A#0ES4ASTH*T)*U(:]*&M"7M2/N(HA;?G[<*=RB/)VY+P0.]$6E, M*D@EJ2+5I(;41A2_YW0YZO@,=L\U)TO!EQ]&GOS]"[_^XJK"^Q=\@:3P56Z> M*QWYKS54GHZ\8NVJXE=,UDP:7^5>L77$;R?!@EB5*W)A-]K*"Q MW?#$+[?X*O>.2D?A9XCA:U>E^XC@H6*R\M#X*C=\ZRCS@:7+(2_[P+A*^]."KW+LI^8J5IR.O6/NQPJKD-KCQ M5>X56S\\/C]S@WS&Y]?=3X=W9?<=)4_^DZ?2(U>E/`;'$8)HQ_+'9.$V[)XW M#Z^O[N^'R<5AZ6JT]=.#5Z[JZ"[4OLI]>HTCNPN7UX.KFV0&:%W-4[L0AS9W MEQP^\7[6?^?@GG?(EN*?;ADFG_+(;:B3_=,?U]A7N0^B<,-WOZ![?7%QFSQ8 M*=U&.DD^/73EJH[N0.VKW`XT\0X,[N\RC;"?RE-[$#?"W$">D7Y[OQG.'AV% M7S&X[^G(9S!V5?Y'5@I2Z<@_I*\\'1F^=E5^^(;4.N)#^OOTONYE)RG>[AT& MUG<.=:KM$S(<)D_M1[;J^&^JC-U8X731O:+[69>;"_/_XI\N*MUF3QVKW<^Z M/&L7:C>6WX7&T9$9JW4U3^U"G-(C-UYG_*S+/>_"+$7I[:I$OC^9*U=;Y;\# M4KBQ/)6.PO0^9_C:;>C':DBM(Z9W<)'>R'3Q/?LY1#?0X;K4?QS#83+M/?1E MNG#H4YV?&%X%]Z:3?S\##-,OB"H!=M/@&77&E`#4*0$P)0"F!,"4`)@2`%," M8$H`3`F`*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0&A)0DP]\GG)*"[KXX38"WX M=;K!!4Q3/DSMAJG=,+4;IG;#U&Z8V@U3NV%J-TSMAJG=,+4;IG;#U&Z8V@U3 MNV%J-TSMAJG=H27M-C?X8;O-Y8'Y<>?CJP>#BVYA(&Z[-7^1HZ/;R1O1!63T1DZ]`5.?GKNL1;F%:6]AVEN8<@M3 M;F'*+4RYA2FW,.46IMS"E%N8<@M3;F'*+4RYA2FW,.46IMS"E%N814X[F",+BP%B77VJGDVK(HN9E-AT/_M9+DK9@;V'.2 MV]WPQLFUI@^L/ST,A\GI06>1OBRX6X`IS#"%&:8PPQ1FF,(,4YAA"C-,888I MS#"%&:8PPQ1FF,(,4YAA"C-,888IS#"%.;0X`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`OM:24TD2D]'`E_D$T(I,79FQ*F-UQIJ,M1F; M9&R:L5G&YAE;9&R9L57&UAG;9&R;L5W&]K$E"4@7+DY<3.@;L+C;=Q:?+_S3 M*'LYZ-B1W%0\#5W;T?.&+@JS8 M\8._R`X&;0[[ MLB`!,"4`I@3`E`"8$@!3`F!*`$P)@"D!,"4`I@3`E`"8$@!3`F!*`$P)@"D! M,"4`I@2$EB3`K$V=DP"[EA6N,9B_/C&IB!.0_,V.S@)]69``F!(`4P)@2@!, M"8`I`3`E`*8$P)0`F!(`4P)@2@!,"8`I`3`E`*8$P)0`F!(`4P)"2Q*@MIV5 M`%.?S@'6X@3X1SON+-"7!0F`*0$P)0"F!,"4`)@2`%,"8$H`3`F`*0$P)0"F M!,"4`)@2`%,"8$H`3`F`*0$P)2"T)`%F`2J<`PZ/)ZZ?\]AP:->NHNF@L_`O M_0>V+K!QQM1Y;*O.P]1YF#H/4^=AZCQ,G8>I\S!U'J;.P]1YF#H/4^=AZCQ, MG8>I\S!U'J;.AY9TWBPGI9U_T:_W#(9V92I*@C5%SR\^7_GG9FY:Z,N":0&F M<,`4#IC"`5,X8`H'3.&`*1PPA0.F<,`4#IC"`5,X8`H'3.&`*1PPA0.F<,`4 MCM#B<)B_"/M.X3@,E9PSG,7A2/\N<.#+?#AH1::NS%B5L3IC3<;:C$TR-LW8 M+&/SC"TRMLS8*F/KC&TRMLW8+F/[V))PF$6H[S-S7-KUK'#FD[A<,N8$7AL!:'`T\I+ONR(!PPA0.F<,`4#IC"`5,X M8`H'3.&`*1PPA0.F<,`4#IC"`5,X8`H'3.&`*1PPA0.F<(26A,,L2*7A>,DS M3?U.C+T1":\NDD<5#P-7IE60_B($*Y2^*,B*'3]8WXQ*EVX M+KC/,0(>;US`&R0..AX'Y63!3IKFL/\]P(NF+@JS` ME!68L@)35F#*"DQ9@2DK,&4%IJS`E!68L@)35F#*"DQ9@2DK,&4%IJS`E!68 MLA):DA6S1!9.)*>N,[HE-:7)M5']M\ML2F3?_^%5$I-14.8VU6S1;^I,"8`I M`3`E`*8$P)0`F!(`4P)@2@!,"8`I`3`E`*8$P)0`F!(`4P)@2@!,"8`I`:$E M"3#K8&$"S'7&Y=T;\^CLW._AFA^QPH5&O\X6I@//R-RF_CM42D>_:9`.F-(! M4SI@2@=,Z8`I'3"E`Z9TP)0.F-(!4SI@2@=,Z8`I'3"E`Z9TP)0.F-(16IR. MJW0I],3\<*A/UCN=:18*Y@<\(_-EKMOC`:W(6)FQ*F-UQIJ,M1F;9&R:L5G& MYAE;9&R9L57&UAG;9&R;L5W&]K$E"3"K7>'\<"H!=G4L/$-<60O_'(VF=J-. M[8:IW3"U&Z9VP]1NF-H-4[MA:C=,[8:IW3"U&Z9VP]1NF-H-4[MA:C=,[8:I MW:$E[3;K5V&[#X]$!U?/>29Z9=>^HM9;"_\@S=7I?^HGA,R?4KJR\`_2G(6; M#J_]@[7DS9@%EO#-G,JN79")WH"U*+LP91>F[,*479BR"U-V8F[,*479BR"U-V8F[,*4W="2=IO5E+#=YV2W6XF)+FRO MK$79M18&,)==6Q9E-[/I\-H_]TO>C+G[3]_,RYY0FV^III=ESJ*3\C6>,_FR MX*0/+NRXZ<+.Y9_R*S9`J:LP)05F+("4U9@R@I,68$I*S!E!::L MP)05F+("4U9@R@I,68$I*S!E!::LP)25T.*L7)^YX'.H3Q9\K$6G"_WG+.+? MIA\-?)D_7]"*3%V9L2IC=<::C+49FV1LFK%9QN896V1LF;%5QM89VV1LF[%= MQO:Q)0DPBP/A;''B@L'\*&=Z=^$L/E_@DM&7!0FPP_ESB!(`4P)@2@!,"8`I M`3`E`*8$P)0`F!(`4P)@2@!,"8`I`3`E`*8$P)0`F!(`4P)"2Q)@UFS"!)CS MQ>U7@W=:8$P)0`F!(`4P)@2@!,"8`I`3`E`*8$P)0`F!(` M4P)@2@!,"8`I`3`E`*8$P)2`T)($J&U1`KKEA^<\4;PVFZ;306=:[W`=U>P/ M&V=,G4>=.@]3YV'J/$R=AZGS,'4>IL[#U'F8.@]3YV'J/$R=AZGS,'4>IL[# MU'F8.A]:TGFS)G7.L6_7L*)COU_7"L[_-_Z)K_U3RNN^S*5""8`I`3`E`*8$ MP)0`F!(`4P)@2@!,"8`I`3`E`*8$P)0`F!(`4P)@2@!,"8`I`3`E(+0D`6:E MZ9P$V)6I*`&=Q>?_&__F.%_`QL/:&HWZM1NF-H- M4[MA:C=,[8:IW3"U&Z9VP]1NF-H-4[MA:C=,[8:IW3"U&Z9VP]3NT))VFQ6A ML-WFEL_^4<&)-<";;C$I^OJ!,^6K/__KOB-]H.C*_)?N%`8[7+CI\,8_B4KV MVZQCA/M]:F>[=8]X9ZU%,85ISV"**4PQA2FF,,44IIC"%%.88@I33&&**4PQ MA2FF,,44IIC"%%.88@I33&&**4PQ#2UIMUFT"-M]6)DP__'44WVWJQW1]&0M M3%HNI+8L"FEFT^&-?R*6[+6YX0[W^M3.=C?H<4BM12&%*:0PA12FD,(44IA" M"E-(80HI3"&%*:0PA12FD,(44IA""E-(80HI3"&%*:0PA12FD(:6M-O<78?M M/F,NM3?F44RMG8KI_[)VIDV.Y-:A_2L3^@$C+K6Q0V\B:E]ZW^K[/+FUA&6W M8C3V^_OO7"8R$\"Y55ELVXYH20?(1.+>0VQDD:5:HVERZ>9D'H:[YXX]8?W< M2YH.>\A6T\*(SC3P;TYT]'\R5:L6?6*8*X:Y8I@KAKEBF"N&N6*8*X:Y8I@K MAKEBF"N&N6*8*X:Y8I@KAKEBF"N&N35K#3CMM_[#P>_AGSO;WVA_)E!KT)W_ M7ZS':DSYDRWS3%^.B>9*LRMFU]7-QGHW";M-V%W"[A/VD+#7"7N3L+<)>Y>P M]PG[D+"/"?N4L,\)^Y*PKPE[;%GG2NP>#Q@M3LMNLQ[:"FO?*C[I-+E.#`/$,$`,`\0P M0`P#Q#!`#`/$,$`,`\0P0`P#Q#!`#`/$,$`,`\0P0`P#Q#"@9IT!L:$\9`PH M&]#Y!5JJ-9XFEVY.YW?!N@>/'67]X$L/6W:@S<,65I\2G(KAJ1B> MBN&I&)Z*X:D8GHKAJ1B>BN&I&)Z*X:D8GHKAJ1B>BN&I&)Z*X:D8GHKA:O$[W?J^U6[_(T[*O;U*?[/4S3TNUQM/DTLWI_%Y=]^"Q?]2#\X+\\W\= M]J.QIV4CRJ73#+`Y[=X@8H%0JCV_29PJC8M!)!=#5ZKC8;8':=U+M)V&W"[A)VG["'A+U.V)N$O4W8NX2]3]B'A'U,V*>$ M?4[8EX1]3=ACRSH#8O]8CQ9+!@S[S>90\:PP!M-JH-!!T5RM,F"Z=&08((8! M8A@@A@%B&""&`6(8((8!8A@@A@%B&""&`6(8((8!8A@@A@%B&""&`37K#(C] M8VW`CQXJGI6-:#M?S&^Z[-?E%^NQVK/SQ5QI].*JNG!DN%+:G/\F!5?$<$4, M5\1P10Q7Q'!%#%?$<$4,5\1P10Q7Q'!%#%?$<$4,5\1P10Q7:M:Y$IO/VI6E MT:)L5NN%T-G`NOFBTX3Y8JHV9AL#Q#!`#`/$,$`,`\0P0`P#Q#!`#`/$,$`, M`\0P0`P#Q#!`#`/$,$`,`\0P0`P#:M89T)\Q+!F0'"V<%=;.%_/;7F4#/U>K M#)@N'1D&B&&`&`:(88`8!HAA@!@&B&&`&`:(88`8!HAA@!@&B&&`&`:(88`8 M!HAA0,TZ`V)O?\@8$/7[-6-AK0%Z&_)LJC9FFS%`#`/$,$`,`\0P0`P#Q#!` M#`/$,$`,`\0P0`P#Q#!`#`/$,$`,`\0P0`P#Q#"@9IT!<6Y2&_##*X9R`$-3 MU<*Q>W_I8GU6JN'D5,VKRZE2Y8H8KHCABABNB.&*&*Z(X8H8KHCABABNB.&* M&*Z(X8H8KHCABABNB.&*&*Z(X4K-.E?BA*5V96F^B/K]:#&P;L70:7*Y/INJ M50:(88`8!HAA@!@&B&&`&`:(88`8!HAA@!@&B&&`&`:(88`8!HAA@!@&B&&` M&`;4K#,@3J\.,:"<=C5KQL)H91H!-F=Z&_)LJE89((8!8A@@A@%B&""&`6(8 M((8!8A@@A@%B&""&`6(8((8!8A@@A@%B&""&`6(84+/.@#B`J@WXX?FBG&0U M\\79_,;2N,.<#KQF6SQ?3)4J5\1P10Q7Q'!%#%?$<$4,5\1P10Q7Q'!%#%?$ M<$4,5\1P10Q7Q'!%#%?$<$4,5VK6NK([\$1R7[^;+PIKYXM>D\OU7&TVP.PZ MJ7>3L-N$W27L/F$/"7N=L#<)>YNP=PE[G[`/"?N8L$\)^YRP+PG[FK#'EG4& MQ%%5/UK\V)?E[,JI5SV5C*R=2N8W_UBB,;P(= ML\R<44[&9G:5,#*O>F1>C,R+D7DQ,B]&YL7(O!B9%R/S8F1>C,R+D7DQ,B]& MYL7(O!B9%R/S8F2^9EWFX[BJSOS"+G-7CK>:U_[`XA3$R+T;FQ3$R+T;FQL2?=FU1]L52_TW__V]S__^\5WEH;L?!,-MM-&9;A-.P.,;+.>-RH5FU>S MG+JT?^%_-5:+7\:M%KW=6RO75;5Q\KA)V&W"[A)VG["'A+U.V)N$O4W8NX2] M3]B'A'U,V*>$?4[8EX1]3=CCR(:L=:[$`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`V)Q"@SC[D@9Q5C?'63&<[1KL?QL-;5_2(-KJYF@KAK9=@]MNQ,'S#,+9B"N&N%U[ MR6KV)0TBKFZ.N&*(VS7(9TR;_^M>J7C\DO;Q6&WAL1@>=^T?=1M//'Y)@WBL MF^.Q&![W#79S,AXO--AY'.?=AW@\G(^WV[+":+@:_?HWM#:KJ=HHZ%7"6!FH M'IZ*L5050THQI!1C_!3#.3&<$\,Y,;02PR$Q'!+#(3&L$4,1,1010Q$QI*A9 M9T`<@=<&5&>72T=,Y?2\&=0&5KUYQ0@F1N;%R+P8F1(]Y1&^IN34VHRZ4+&Y2Y6A7J MX=+-Z1#J8]YD[88G`EUNSXCT="8)]/04X^T)M!B!+DT^L2,A M<1ZVF30R/B9Q'MA1[>IVU9TZ$N>R0ZVKR3B&@JG:V`)*%\9B8(KA=M6]G`EU MJ48$JFK=60JA5@N$6HQ03ZWNWR5K!P\"G;16]Z<+=.QKZD#_X"!;MD=-_`?6 M>=Z]`(E_N73)\ZE:%?^!;5B&5X'MMDC$OUQ:J[Y=.?YJ@?B+$?^IU8@_8THW M2I*"I,%G4A"[B#H%2\-WV74TL1[8MEDP3FR.3OT4^W%-:K.[-EPC]4V4SBN M-V8W$YM?#;<)NYO8?+_[A#U,;'^_+E*QHJ]577CQ\HDC;7=&QJ@QR;9==S/V MY6:N-LIPE3`B4IJ8_SB'B(@1$3$B(D9$Q(B(V.N$O4G8VX2]2]C[A'U(V,>$ M?4K8YX1]2=C7A#VVK#,@=C"'&##L>)I1*8:CV`2W!G0;*`R8JE4&B&&`&`:( M88`8!HAA@!@&B&&`&`:(88`8!HAA@!@&B&&`V*>$88#J88`8!HAA0,TZ`V)K M5AM0C99+PT%Z:=8\;>[!#'K?LV>J5)M/[WD1:J2:K;@E,#X9J,4], MU;3`H5-#M6U]-QV(T,^IVCCPT<^I!5C7S]@"'=+/8CS;Q:G:^.STI[!AC7BR._,'.L]?CV'$XVLB2U7+6P59NK53TN-R]'$JNCXUVW$R2CY?9/.=-U.?8/AW1YV&^T M21X88WOIERHO3'*LX>L>5_/,`0>B MFV$KT`:B;`^FW'?)(1#EJJ7<3]6J0)2;#V=#NW[G31C*12]+/#N'-@P+@^Z^ M?C?'%M9L0F:6O^+*?GFL5N^7S6XV(TLV#=M8/?_/$[F_3=^QN'7\)N:T1;K< ME'I+F]E2C?%L3MW(BL.K-5]:TQXXT=&AR1B/7S!2;6,=]5S?7[BUW-^G[_RP M1B/R8P_H_,3RIQNS6JK-6\'KZ=*9T=GI=C31#DB\<]#V;,G+85W1O`[W]Z!7 MC(13++?])Z/H5+ETWN)=)8P>J!X]$+M-V%W"[A/VD+#7"7N3L+<)>Y>P]PG[ MD+"/"?N4L,\)^Y*PKPE[;%EG0"R]>K3$R+T;FQ3$R+T;F MQP0 MPPXQ[!###C'L$,,.,>P0PPXQ[!###C'L$,,.,>RH66=';&UJ.Y;&A[(5JO=G MV\):`[1CF:N-V69\F"X=&0:(88`8!HAA@!@&B&&`&`:(88`8!HAA@!@&B&&` M&`:(88`8!HAA@!@&B&%`S3H#8JM7&U!MWI9D&':)[7`PL.:0D$7_?F:8U_YD M7HS,BY%Y,3(O1N;%R+P8F1S/#19,X@L(M,HLK`UE.328.WJU M&>LU/5AWGZT@;N72)FZZ'7$3(TC3M7,LMWT3!&FJ5@6IOET7I-BAUR^W:J`] MX)0L/K;2K]`+:V-7#@2:V!7&:K%RKCLX(793M;%C.*?;$3LQ8C==6S6QZ=XQ M)'93M;$)!*MOU\4NS@;JV"T)5LX2ZJ$J/F]%X.+]LKGS&[U!,%:C]E1-+R0T M+'>;PTO<"AL^[;#SV?E887XL@CC=Z)GVB.M4;0P802QL.`1;Z\-TA+34J!-> M=Z:+_U._GXET[-<.B?2POVM6 M6O']V?99V_*Q&B:D#U;.&>=J8[>)=&EA/&0]FT[HV/@<$N:R49J[<[&)8X^0G!7T%+_M1OO;N=K8'<:(Z=*1$5,Q MQE8Q;!4C9&*$3`P7Q5XG[$W"WB;L7<+>)^Q#PCXF[%/"/B?L2\*^)NRQ99T! ML?&I#:@FW:4YI.R9&AD&UNQN.-X,02I&YL7(O!B9%R/S8F1>C,R+D7DQ,B]& MYL7(O!B9%R/S8F1>C,R+D7DQ,B]&YL7(O!B9KUF7^=CXU)E?2O>P46J'V,+J MW0UYWH\',R/=8J1;C'2+D6XQTBU&NL5(=\VZ[L?&YY#NEXU28_O`VF7EQ.;A ML)[GQNFD5&-6G$;-3?]7%01IJC:.D`1I:F%D!$F,($W7SDTD?^XT5QMO1]SJ MV[5Q.SYP5[BOWZV!"FOB9G:U&=F\1[E.V,W$YK7F;<+N)E8'?;OI#N+NJVIS M1,9'V3?1122V-+5)U1!ZP+[E>-@9-:^OPMI`U3NH8M-8;Y:30)5Z,R-0NI9` MB1&HZ=I9'7VZAT!-U:I`U;?K`A7[ESI0"R/.\;#?:2,RL':3TG^0_W)3+EWZ MB,]<;>P`<2LME$7=R>ILU>W.B&.IPV)K>O7J14YH2[792T(K1AP+&_9%JY^] M>AYK/-5@%^C8U1P2Z&$7U`9Z8+'GG+JXW73'+P2Z7+JP3YFK58$>+FW_"&33 M'500Z]("7LT/TG\4A5A/#S*V0*S%B/74ZOZ/<'X^[;KT,-:(/_F<&JR3V\4Z M]C5UK'_PU5^V1_.K]6)S/+#8HTX/LEUIJUBJ+;H^W*WYE,AXZ=,;F+'&4^+M M!R"BKYL3?3&B7]AHNK\18ZSQ5(-=]*G61']I2(GZ_6PTL.;#)\<3FT-?.S". MNZ7:O(UF_!##X>EVHYR$3(R0Z5I")H:B];5=1&)O\[_@8]DB-3X.K#VZ\)_@ M')=J3[U^QMB5%N9U(K$KEPY'%[P23T^Z_3JQ+-<]>WO".SW%&'+"JR8);ZDW M_OUC_U5Q!'NAP2[^L>)^+OXO_)C4\;!R;\?D@;6F3NQY4TNU^2-11%N,Z$ZW M&\-&*,4(I:XEE&($K[ZVBU0LSAVI/_QTZ+ONQV65SXMB'B$?4G8UX0]MJR3@\5`,SP, MB_##IY*3N-%>C5J#;O]WL1FK/3N5S)5&+ZZJ"T>&*Z7-^90#5\1P10Q7Q'!% M#%?$<$4,5\1P10Q7Q'!%#%?$<$4,5\1P10Q7Q'!%#%=JUKD2F^T#II*387/> M3"6%M5/)MM.$T6*XE&ICMC%`#`/$,$`,`\0P0`P#Q#!`#`/$,$`,`\0P0`P# MQ#!`#`/$,$`,`\0P0`P#Q#"@9IT!<010&_`_F$K*"<.<80:'PMJI1.^CS]4J M.:9+1X8<8L@AAAQBR"&&'&+((88<8L@AAAQBR"&&'&+((88<8L@AAAQBR"&& M'&+(4;-.CCBAZ.7@Q7_PKN1D..J(2ZL517=Z@RVEVO-3R51I](*!1`Q7Q'!% M#%?$<$4,5\1P10Q7Q'!%#%?$<$4,5\1P10Q7Q'!%#%?$<$4,5\1PI6:=*^2V M<65A5W(2]?N%Y\"ZJ:33A*EDJE89((8!8A@@A@%B&""&`6(8((8!8A@@A@%B M&""&`6(8((8!8A@@A@%B&""&`6(84+/.@#@;JD>+)0/*65(S7Q36SA?=N1<& M3-4J`\0P0`P#Q#!`#`/$,$`,`\0P0`P#Q#!`#`/$,$`,`\0P0`P#Q#!`#`/$ M,$`,`VK6&1`'7+4!/[SUB!MIZ]$=4#%?E&J,2M.TTE7"E:E2Y8H8KHCABABN MB.&*&*Z(X8H8KHCABABNB.&*&*Z(X8H8KHCABABNB.&*&*Z(X4K-.E?B0*]V M96FT*`>`S6@QL&Z^L`%3M\3]B%A'Q/V*6&?$_8E85\3]MBRSH`XFSI@##@M9UGU+#"R M^2_&2'>I-[.KA)%NU2/=8J1;C'2+D6XQTBU&NL5(MQCI%B/=8J1;C'2+D6XQ MTBU&NL5(MQCI%B/=->O2'0=1=;KGTZ:EE_YPA-4,_J>%S>^:D_C"^(]I0E@? M=\,!+I1J\Z>1<"&Y=+N=/X/3=26.3>JN+'6@'+,TYA8V6TH'Q'A:,9Y6#'/% M,%<,<\4P5PQSQ3!7#'/%,%<,<\4P5PQSQ3!7#'/%,%<,<\4P5PQS:]:E.TX^ MZG2_W-QR9M(DOK#&W,*6S"W5&G.32[?;^4W_KBNQA:^[LF3NL.5O7WJ%->:* M8:X8YHIAKACFBF&N&.:*8:X8YHIAKACFBF&N&.:*8:X8YHIAKACFBF&N&.:* M86[-NG3'?OV0=)?]?>-K88VOA2WY6JHUOB:7;JL_&.HZ$)O(0SI0-IU-!PIK M?!7#5S%\%<-7,7P5PUI`V2LUZA;6J"N&NF*H*X:Z8J@KAKIBJ"N&NF*H*X:Z8J@KAKIBJ"N& MNF*H*X:Z8J@KAKIBJ"N&NC5KTWW6[V=?O$C87]GM;$=6FSNR!7/':K6Y(ZLO MW1[-;\5V78E%?&WNW)5#/Y)X5O8#M=0C8QB8ENG;([W3,U>;=^UFUQNSFX3= M)NPN8?<)>TC8ZX2]2=C;A+U+V/N$?4C8QX1]2MCGA'U)V->$/;:LDP.'&CD6 MAK6SJ-_;75AK@-[I&2^M/V1FA@'3[493,$`,`\0P0`P#Q#!`#`/$,$`,`\0P M0`P#Q#!`#`/$,$`,`\0P0`P#Q#"@9IT!L5.JAXG\V5:L,$,,`,0P0PP`Q#!##`#$,$,,` M,0P0PP`Q#!##`#$,$,,`,0P0PP`Q#!##`#$,J%EG0.PY#S&@[%$;`^I]Z_Z/ M82XW9V*\X,5(MQCI%B/=8J1;C'2+D6XQTBU&NL5(MQCI%B/=8J1;C'2+D6XQ MTBU&NL5(MQCIKEF7[MBTU^F.%6'\U>O2T%\V^TW:"VN6MLFA0')R>U:J-4O; MY-+MT7SHVW6$X:;IR%('HGZ_>BFLWI2=B>&M&-Z*X:T8WHKAK1C>BN&M&-Z* MX:T8WHKAK1C>BN&M&-Z*X:T8WHKAK1C>BN%MS;ITQXZ]]Y9?3EL6MVSU&W$+ M:\1-C@0R<4NU1MSDTNW14V\YG,7.L^[)DKAEI]ITH##B56V\YJ/B<0R>JE53 MKA@NB^&R&"Z+X;(8+HOALA@NB^&R&"Z+X;(8+HOALA@NB^&R&"Z+X;(8+HOA MA;=7L,EET1X'V&E9M,=A85H6[7$:DY6=K2GC5"`MVT39_H\_NVVXC[WQM>G;= M-O+.%VJG99%WODXY+8MX\D6[:5G$C*]BS> M7;>)F/$;1VE9Q(PO&$G+(F;#5RC(P6V4#5_5TI6=\^,;Y(^_A4[N&66/_).6 M[7""[QW(R^C#>I?V8;VC#_R37\=SKG>I2WS'2Y2EN5WOR`/_Y/8P]?I''Z^/M[R+.ES7D39(_^D]SP./_F:DZR] MXX@9W^Z1EH6#?!E%6A;Q?&)\B?EHS7<)I-=%K//Y:!WS$?^DU\6>W1QP$66/_)/>_]3;ZP/=T9\]R%'W@ MF[+3LN@#W\&_&Y5=MXVX\#-++B,N\5K)UP51QG7Y ML\0Z9)VO0]:Q#N&?I#UB'9ZE[9VO-S'GI,]Y$66/_)/>.997^:HE-LKY^BF63^GJ MZ9Q)^SQ?(\1TGL_F1SQ;.I=?Q'2=S]8Q6:=S]7ELC=.(7L0B)5VC7,22-E_1 MQH(V7\_&4<@3)R'T)Q^+-_0G'XEC(,['X2U/G?$:+R36? M6V-JS6?6F%C3>?4\AN7TV2[V@W(Z4L20G(_(^TUX.G;&-)S/PC$)YW-P3,'Y M#!P3<#[_;GAEY;/O!GO3N9>E`U-%/CKS;.M\3.?9TIF5G0(EV=W86M!./N/& MA)O/MSSU$[,MCJ9W.^<%G.:-6Z7S##=*GPK5L_LPM\94GL^>/-,3*B9\7BA)?R<*33-%4ID M:ZT+A,A\N(A)(+D_W_,<_4[7^91MHBQ[7F*R(B9I&5_JOWO%8676?WZ_9_>* M;TG+ROBB[]TKOADM*XOOK7YUDY?%]U>_XIO2LNOB>ZRC#YE;Y'P5.<\<>MBL MU_0O?3W&SY?SG$^,"<2%`&0QB]\NHN]I&7U?<<]T+T;9.LJR_E&VB;*L/6*V M(F9I&3%;$;.TC)A%7-)GN8BX\$_FZF64\4]6=A5EUWG9393Q3W;=;93Q3U9V M%V7W_)-ZS4N=LBPN7+>-LNR>5QO6ZU_Y)[DG9=&'=+U^%V7W>=F;*'N;EWV( MLH]YV9/P]CX]NWW@FH>TY&JW?76=GNG>47*?EESMCK@F M&X/N*+E/2ZY.3UY=GZ;C$"7W:4W*<]O:*G]^DU#USSD):\IN1U M6G)WC/'IB=H=!ZGWZ3GJ`]<\I"57'+!>I^>K=Y3I^>N=Y347*<]O:*GU^DU-UQSDY;<4G*;EMQQV'B?GC7><=1XGYXT M/G#-0UIRQ1'D=7H">4?)?5IR%=-A.@/=Q>24EESP!!?I$UQ2I]?<<,U-6G)+R>U0\L?I@.Q?O_SIG[_^]=O;7W_[Z]__\U\__>/;7_@` M`M_2S^?&?OO[7^,C8A!8IBVUXKLAP+L2U#4C:[;]^A>.8H2ARD M%_7FT_`G9S@DA]+MUY^GX^1'V;15?;Z;6K/%=%*>BWI7G1_OIO]\C[[<3"=M MEY]W^;$^EW?37V4[_7K_^V^W+W7SU![*LIN`PKF]FQZZ[N+-YVUQ*$]Y.ZLO MY1F>[.OFE'?P9_,X;R]-F>_Z1J?CW%XLUO-37IVG5,%KWJ-1[_=5409U\7PJ MSQT5:GD5'CIX[EN M\HE^]M=!1Z0L$^:W?8#^K MH]91/P-_-9-=N<^?C]W?]4M25H^'#J9[!1X1Q[S=KZ!L"X@HR,SL%5$JZB,, M`/X_.54D-2`B^<_^]Z7:=8>[J;.<6;](P'+WAOX92*;ZT763&0C M1#XP$I>)P._'1V)!.M#9(7G!0O]NA^9TJOO,"?(NO[]MZI<)+$>8S?:2D\5M M>:0+GC-TBD46O99$D#U$Y1N1N9M"E"!!6LC\'_>.Z]S.?T"V%LQFBVTLW<+G M%B0UB6Q@@M`$D0EB$R0F2$V0*6`.81&Q@1S^C-@0&1(;[M66`QDLVP@$M^!- M`A.$)HA,$)L@,4%J@DP!6B!@'7Y&((@,["E:DBQUS[?4QEHJ1BO=Q!&SB6\KQ+H/!G=B2\ER-#R^,.+-`D1"1")$8D021%)$,I5H MOL-AK>..$FO=44;ZHJ\_ M#WU$`D1"1")$8D021%)$,I5HCD)AA'P0!,X*] M1FR5EFO4%*$PXNLA$MJ4"B.NG0EM(%K02+6E14U9 M$MVA*IZV-:VV!]+&@1*+%5Y$18]F+PSGK!).C`*.8`$JT3,*D5!:<8]O!XP4J>IZ^EC`:/5'ARPO,NM19%-;S*D\/0E4J-C MI$3`K)QU7_':"\OP+Y0&O+-(*G,42S3262*U2'D-G1GU=2H-N'(FE0'IP22U MGAK,@2R#&YM(,UH::E&C2(N:0"..!!:U\\Y9UO^LY7FQ6:^HRW>FT$>MQ)46NFO;7J:]D'+T^@HR; MO#8"?29(J:W.Q!N'%JW,8;)Y3+861=JF*]"(=P%O*+?F$*.(([FGQQ*-R"?< M2LJG&&4EOH4<@; MTH5INX,9R9J-BL=<:=0J85:P??'Y3WE#.@1GZ0YM#F\,04])4M^/!?Y[?8$= M]*U;KD6O"5JJLIN#'+W/K"![1W(IX%:V<#O$*.)(RL<2C<@GW$K*IQAE'.%4 MMN?O3](&@8Z"C^VDJ)_)YRBH0NYO!:;?RK8;#UZLP+HUN;V`CVA]5J$GXO.:\<2W'(^4 MR%@-JF2/%+SX"7RK^];GEZ&UA4[Z3=KD-@QK0&<+'0SJ+T%_4&CIP=M3/*#M MRH,WBP-\[<%;-\P3UX.W$0/<6GCDWHV?9"ZX-O0`[KD>NK)UO>W@`'S7\P38[F';%WTA5]#/Z_2/SJVQS_4'7P7[;?[`WP& M+^%-PH+&ULK)U;'__WW]V]O_G7W^'3_\..7M\F[SMLW=S\^/7R^__'[+V_W MN_Q_!F_?/#W?_OA\^^WAQ]TO;_]S]_3V?W_][__Z\-?#XQ]/7^_NGM^0AA]/ MO[S]^OS\<_3^_=.GKW??;Y_>/?R\^T$E7QX>O]\^TS\??W__]//Q[O;SL=+W M;^^[G<[U^^^W]S_>6@VCQY?H>/CRY?[37?KPZ<_O=S^>K9+'NV^WS]3_IZ_W M/Y]8V_=/+U'W_?;QCS]__L^GA^\_2<5O]]_NG_]S5/KVS?=/H^KW'P^/M[]] MHW'_.^G??F+=QW^`^N_WGQX?GAZ^/+\C=>]M1W',P_?#]Z3IUP^?[VD$QNQO M'N^^_/+V8S(Z),G5V_>_?CA:Z'!_]]>3]_[S_/[G_7W4#L_NF#U^.;SW9?;/[\];Q[^*N_N?__Z3/Z^HB&9D8T^ M_R>]>_I$)B4U[[K';GQZ^$8=H/^^^7YO8H-,_W3T]Y_=&Y=LWG_Y\>G[X_G]6*#&=:I1TG1+ZDY50A1=6[KG*]*>K MG+P;7%WUKPM3$DG/IB\>1-/%`?WG]2!)VJOF+4W.Y0Y(^#X7^")Q*T_(_X52CAG8,WL6;7"DOCJV,F3*_X)YQLU-/G3 MZMHXMM_IAZX=.Z$V[S!9$!R(`60$D@%I`8R!3(#,@>R`+($L@*R!K(! ML@6R`[('*;`R[.1/CJ9G3-V)%RQ]17="'&U%$@&)`=2`"F! M5$!J(%,@,R!S(`L@2R`K(&L@&R!;(#L@>R`'GP0^I90E\*G=B[TSR4^[>TW% MT+V6]`?-0CT!D@+)@.1`"B`ED`I(#60*9`9D#F0!9`ED!60-9`-D"V0'9`_D MX)/`EW1A!;YL=Z"1#AWHR/'8X+@7G@!)@61`U@CQ4')05``IFUJ^:K65J!HA5EW[B@(KF4.0OV^F MHY;03@YU[?F7R30G@OS.JSA(G53O^ICB=CN)&ETF`CR\7#0S*@2U-%:*+I-/ M4V,ZX$2`-=>BF5!H3),9OOQ"-4=(*KH<"JQFI0BU#"1U%7LTAW@QIS8;F4CQ M:')LL1#DZU)^*D67+Z5:K$2*6ZQ%/=C/)&$7V,_F;+2O9MWCQ")SRN*9X3J< MV"8L1?M^3TH-,!4I5I\QZA]CLY=<=7I*=\XBX<6O=!)DF]PB[JT2'NFO`D[-3&'FR;2:;+QI)114I'B MX68.=6^.!K\9W'34>'.NU'IY%"S5VH%2I+@#%7=@8#T^"`=6+2!\EK.I:<"[KB0%BS5 MVG@I4N(`UY]HXS57.-5X:'^2"NP?6?KI7@ZO_29?UX:VJ.=M&9T4H5:KNHJR M&F9<45#.2-07@EK4ERPENBI$-2-[G\P_N4S,'OOO1Z;=J5,S[+WQ43%=^!)- M$X?.K6=.EY@BXXIV+NC1':N^6FUR;N[4Y>ABT>IN[T')NJ0'5=B#?K>CYKF: MZYQJ/PQ'L]]O,_KNX2>9+KI#]S2'Z M@Z_3":(4488H1U0@*A%5B.H`A6.^+.TUVWP]9HO\4RDG14@F-3SB8RE_C<,S M/I%BD^:,9&-7"&IIL62IL$5][")2W&+-Z-AB:#^37?HKP*OR*I,7:;-:%)@5 M4.HJ]OS=1#+4QWTBQ2/*&?DV!/4E2X7JU:%8)5*LOF84,9C)J?Z^P8P6-:=: M1*'.O9AT&]02%:F3.GWH)P*L.1?-C`I!+8V5HNO$H9\(L.9:-!,*H\^D=KXQ MSZQ$1EQ9S:+`:@UJ&4A*68#1=>;03Z1X-+E#7HN%H)862]'E2ZE=<252W&(M MZL%^.O<\8S],,LWA$YG!3!#-_JVG[E-,6(@NL$8H,A\Z57))9ES1GKC1$7'W M>J`N[IQER!^GE1!4CUX7D^F9PK5-/ECG5A3!F39[GQ^SK9DR; M+?I;:3JH.[J"S-@8@DP6GII-G-29XT"18D-DK-Z>QNF3**YP*ONVV3]+M1[8 ME"+%C5>MC==F2\R\,Y&C8IHKO=OUC$BX"=:(P:PN6DW9 M^)FK2&N"6T!B4X*K=NIZ=,%HI7JM72BY/>E"Q:AU2CC3A2`DS0%FJ^%?=AIU M5!,N;P[YH2JHS?(L)<=%&:*J@EK4ERPEZBM$-2,,U9Y.5>PD>O%IU%'/ MT632VWY'G=Z/68JV4TVPJG5W(C(;Z_H;XEZ3_O)U.D&4(LH0Y8@*1"6B"E&-:(IHAFB.:(%HB6B% M:(UH$Z#0%R;9O<`71EQM1"PB=XLO&B2K*FX!S=&.R;/]M;>KGT3(1(K5YX@* M1"6B"E'-2'H_%=32^QE+^;V',[ZY2''O%XB6B%:(UH@VC(Z]#_UJ4F[?KZ_* M1>GD"-QM4>!N0*FK:/K7[*OP]$ZDV#HYH@)1B:A"5#/R?0M=G;%4:U?G(L5= M72!:(EHA6B/:,(HX\A\Y5#"'6?JZ=8<*DE-.G)0Y4_>\I@X$4B=%779YFCHU MS42`;96+9D:%H);&2M%UXE11!%AS+9H9306U-#837?&1S46`-2]$,Z.EH);& M5J(K/K*U"+#FC6@F%%[OEYU]4,(.\6"1=WHY<5+GXL&=??A;ZV2HLJC,Z:(1 M\&AR4<^H$-1BNE)T^5*JQ4JD6'TMZAE-!?FZ5,S/1)^K.2=GF7`65UTH6*JU"Z5(<1CO M?^AXKV_TJ..];J*FQS%+^9MT)3,1&8Z3%%&&*$=4("H158AJ1%-$,T1S1`M$ M2T0K1&M$&T1;1#M$>T2'`(5!<=GQ7A^/]QCY>Y!NHDY[)R(EKL;C/93*$16( M2D05HAK1%-$,T1S1`M$2T0K1&M$&T1;1#M$>T2%`H:MIS3FU!VD_!NJ;FFJ* MM\@_WG-2'DH198AR1`6B$E&%J$8T131#-$>T0+1$M$*T1K1!M$6T0[1'=`A0 MZ&)S..=O,\_XU8@KOUKDIR)]0"FB#%&.J$!4(JH0U0$*QTR;G4O&;,35F"WR MSU7Z#6I9D5.6(@-YVVKU<$`F4CSUY8SD>*00Y.M2N^B2I<(6U7:X$BENL6:$ MIQQ],R.">#=7S*)E(\8AR1KX-H<62I4+U M:M]P9D)_+]2T*KKT&^=9149&ZBJ>/A42`QY=C8X6@ MEL9*T14_/*E$@!NK13.A\.J][/"$%A>X>O'PQ$F=.3QQ4N9@QXL\M4?-1(I' MDXMZ1H4@7Y?R4RFZ?"G58B52K+X6]6`_D[/[P7AFQKVKWJ#X==M3G,62:\2)7R@J5:4^=2I+@+%2/7A=Y5 MTK]6,T#-,J>Z$`3MU;G,^44_Q3]J":=,A\RC;TU(=KO*$!.NV/K`5RI2;(B, MU=L?G%UU.C=JGLVY4NLQ=,%2K1TH18H[4(4=2(8#=`37.M6#T!$ZI6V/_JLF M<^4>C1WRCRH$B1/P%AI+R1E^ABAG),E^(:A%?#:UVU5[GHFK:,ZCFD".V-#IDB4\\Q2 M_J9:+&I(T64(#(+BS&1OQ-7T0[1$=`A2ZNB4G/>-UFP+Z&]PKBV@/S?Z<($H198AR M1`6B$E&%J$8T131#-$>T0+1$M$*T1K1!M$6T0[1'=`A0Z&*3V?I3_!F_VD0X M\*M#LCI-K@"EB#)$.:("48FH0E0CFB*:(9HC6B!:(EHA6B/:(-HBVB':(SH$ M*/2K3NA?M_'$//\*\WQ!LKQ'=IFV8O!`5'>@$MS,Z2(IGB5R1`6B$E&%J$8T M131#-$>T0+1$M$*T1K1!M$6T0[1'='#(GE^%06%.#_R+_75!8<\@@CG`'4M( MFC2Y:E!K4%@INC%F3K'ZR>!:[?@RIX*:*95#RA>BX2K'J!>I:(5E*1#:*.2-8BP:HWJ&>+:"<5K>J;1*6+>Y%@ MU8=`3Q!,U_KTI7WE.(J'^T"'PAQ6ORURPE*4\;1D4B+%7<\8N3<\O4O43QMS M%J!=Y6G-!4M):EHBJAA1:#:ZNOJEEC5+M;8X92EI<89HSHB'UU=3Z8(%6AM; MLI0TMD*T9L2-W:C0V;!`:V-;EI+&=HCVC)K&U,@.+'"JL3!.+SN8<8N:=XCVT!B$Z)G&PA#5 MIX1GIE)[7NQX\"ANB$Y8:DS4RD>!W)%>T5JR^9<[%^/W:%:N`J6DHN_ M1%0QLDU=JR'47-S:U)2EI*D9HCFC>%,++FYM:LE2TM0*T9J1:TJ99L/%K4UM M64J:VB':,W)-J?W4@8M/-14&ICEF]#>,9P+3GDH&@6F1FCM5IR;7KN*9N;.1 MDKG3J;=S)RSPKD+K]%)(XZRV1%0YY"9.U5+-%5I;FK*43&0S1//6EA9.&$IN=I+1!4C;DR_0J1F M@=;&IBPEC$3?6 M4Q?X@05.-1:&*$E=,FT:<94:6:2F3=6IR;6K>&;:;*0D1)WZ9LNI;NVQXE,7 MI(M04%QR19D-*H=:=IQ.36MC4]0\0S37C74'QSN7S7_4=F+!*EK;7K*4C&J% M:*W;[D..])*!;E'S#M$>&E-+ZH'KG!I9&+#Q@_Z+7SEQW1S[RYS9U\<,8Y9J MN]$G,ART*:(,48ZH0%0BJA#5B*:(9HCFB!:(EHA6B-:(-HBVB':(]H@.`0J# MXK);`]=X:X`1E31+:'>H'CN:B)2XVNF2G\IE*)4C*A"5B"I$-:(IHAFB.:(% MHB6B%:(UH@VB+:(=HCVB0X!"5[?<+3BSO<([!-<6^3?Z$*6(,D0YH@)1B:A" M5".:(IHAFB-:(%HB6B%:(]H@VB+:(=HC.@0H=+$Y-+\@E;-G[$$JYY"L@I-K M0"FB#%&.J$!4(JH0U0$*QGQSV1'U43S1 M7GK!G>I79Y5R1A#TI=7Q5L)0?O4V_N,6* MI6STJBN@YE*_)=^3H77C.>3Q$Y@O_S#>39-!J=GOYKK^(V=MOME:=H-IFD. M^8\O"Q*C^#TX'@"E+"7/9F2(^;.*DS3]JS+KDH,T9VP1H.D_X-_!R$94Y=A_8X3KK`ET[)%:6]BE&S M7JF)HV:!4XV%5C<)@#^EZMW2RYZIOW%YA+]/L"@(R@:U!J63DH?>,Z>>7KG( MELD9^4'9J&>IDJ6D8H6H9H1!.=`)B#7/Q>=J1SW'I4A&WD_4IFG,4K1$-PN# M6CPF(L.#3!%EB')$!:(2486H1C1%-$,T1[1`M$2T0K1&M$&T1;1#M$=T"%!P MS0QH6@^NF?83EJ-XN`UAY)^K]?5MIHE(B:M-TZ3+.U=#J1Q1@:A$5"&J$4T1 MS1#-$2T0+1&M$*T1;1!M$>T0[1$=`A2ZVB12)Z;',UZW*9A__C*PR#]70Y0B MRA#EB`I$):(*48UHBFB&:(YH@6B):(5HC6B#:(MHAVB/Z!"@T,679<0#S(@9 MR5(T090BRA#E`0K[:1(W/Q3/Q)]+$+T5>6"1>05$L[ST]"(T<5)G?O3MI((W MG\+11"92/(/EHIY0.$"3W5PP0".NIE6+:*=G]N7XA>C)P`GXZ1_NBD6*>YTQ MLIN\Z^$`GD5E"6JA,:ZO.ARJ3K7.^!)SJH%%='_9#17V"4VB%.^/30"<&OK@ MA@S5:78'!)W^U5"E:CG7>E%Z,[@LO3F**[?:C$?3"M9,D^NB/[NN3OJ$:-VNY3_>3/ M29WY035+2<*6(N!S(E+LUA11ABA'5"`J$56( M:D131#-$F9L?]1S#5R['/KR' MD:7\S9->]R7+T%#NR7VER!&_O7?2_260Z3$U4Z7EYNC5(ZH0%0BJA#5 MB*:(9HCFB!:(EHA6B-:(-HBVB':(]H@.`0I=;3;SOJN]U>O,K&]JJ@7+(C\W M'P)*$66(#GOL$F#^#J=($H198AR1`6B$E&%J`Y0.&:3DUPP9IO"!#.81=Y3 M"9-A@V2-\[-3M^5T4OX:U].9;L:Z9$G+&3L#,Q@]G6T*+`?H!2E@JZKM_7FXD4=SUGY!L+U)1/FR^^P#6VF%02<2[YD1!,GY=DP9433:I/V]!)U'RX3*1Y1SDC4 M%XA*1H%Z_4*M2J18?&+=7-@T])R5 M;7+I1Z#508]LT'0OP:6_;T!6=E7;STD\,1XU6=E6Y0=G^N:7">I7%RR3R)$# M&?HE39*A&S%ND@P=-'D]'.H;RS6+4(LR[A9+7Y8=)QU,CYFI>-;Y<2/6&E^I M)\;#)DO;5OG==9T^VME)!`'M6&N#9.=&C!LD.P<-1@.Z:?!%9J8^1";:B^\: M)QVC"%)3E8N,&S%_K="YJ2?$`R?K._VRE)/U@=$$`HSB&A@9%Q@9%QA%+;!I MA,TB;!YABPA;1M@JPM81MHFP;83M(FP?88>0JIMT,+]MF-S!HUT.)+WD;F#D;F#D;F#D;F#D;F#D;F#D M;I^IX9MTTP_\<]%NT]-PW^=25LD-:/@-D^G0WQ/99+<1HRNSF37Q%QZ>&,^: M9*2F!69D)&!D),?\)O!7'IX8JR.[^>J4W4RV>(G=;'89V@TR3K(;,`H;QX(= M`C"R"-0EBP`CBS1UQ>B]KMK14"0U8IY%?'7*(O](9IMT,+5EYB6R9"C(=\E0 MCLF6E*XO8&0HJ$N&`D:&:NJ*H>`!"S)4(^89RE<7&HIN]%\4.D=YM<`X%B8` M^A'H2<)BM-5K+J_(52AB/("LJ>KN=:26)SO&":=$S]7D2]A(!BW:6'YV*]$?-)8_[C`AZ+QX!; MQ;FJ'+G0_&&;Z`FC^<(Q"40R&3`R&=0EDP&C$/7K*HN8O;YOD5?&HTL9`D-9 M%AYSZ1>Q4SPZL5/7#]O.M2`V(=NYJO;QK^Y5[T9_XX-LZ>JUJB?S-KW@<"?S M0I-D7B?'+S/1KRO=W7-Z^WS[ZX?O=X^_WTWNOGU[ M>O/IX<\?--\FM-GQ^)O'NR^_O/TX[(T^FI,RZD!3Q1:-J$ M.E=4<@QM54*-F):HUQ%]INQ@CE.B9=282;2C9=2<2<6P[./U]>@C_0($2^@] M)R/S>HU8R0V5'&_TJ]Z/KP=4BCO1*U=:CDD,2\,$Z&5!+U M=I>\T(UYX6./[$;?@\4>C*GD8)<9W8,>VUE!"=K/IA"HQF_[1<4N/+9F$ M<$3_B?7\(W4OZB'J7-2GU+6HO.E89)0?R9WV%R>JPV/R9MR9Y+&(HK&YGB*< M;G:.S*U,'#;=U:.2V*#I#O#(W+K#.F-C*OI/K,P<#HR."1S6HQSN9G1,VK", M\K:;$?TGIM.D_J-C$H?US!&`<6ELJC#)L"F+C9M>\S"JZ8?]J#$=]$?FN7HL M&9-%QE&+T.W_D;DCBW52*C$W]&,E`RJ)]8UNY%))3!L]!S`R=VM1&ST.,#(W M;;&$'@$@#\=Z,"8;C*,VH%=XC";1$GIMQ\B\;P';H?=RC,QK%["$7L\Q*J(E M]):.D7D'!]:A%U=02>SBHIT=MZ159E%[4C27T$O21>580J\@'YF7C&,)O4&<>A`KH0]BCLSG+K$.??F12F)7+7T+K=1TJJ:(E M,RJ91TM65+*.EHQII./H2"=48K[&B2.ECYK2>&(6I4]U4DFL#GW/=&2^QXG: MZ+.FHR):,NM=4:]C[/O]__>'KS[>X+)6AT9$8YW>/][^9@P?[C^>$G M)6YOW_SV\/S\\/WXUZ]WMY_O'HT`"7]Y>'CF?Y@&_GIX_..8!/[Z_P(```#_ M_P,`4$L#!!0`!@`(````(0`A6-%^,@$``$`"```1``@!9&]C4')O<',O8V]R M92YX;6P@H@0!**```0`````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````````"< MD4%/PR`8AN\F_H>&>TOIC-E(RQ(U.[G$Q!F--X1O&[%0`FB[?R_MNCJC)X_D M?7EXOH]RV>DZ^03G56,J1+(<)6!$(Y795>AILTKG*/&!&\GKQD"%#N#1DEU> ME,)2T3AX<(T%%Q3X))*,I\)6:!^"I1A[L0?-?18;)H;;QFD>XM'ML.7BG>\` M%WE^C34$+GG@N`>F=B*B$2G%A+0?KAX`4F"H08,)'I.,X.]N`*?]GQ>&Y*RI M53C8.-.H>\Z6XAA.[_1H]TI>9[=WFU6B!4YN4I)GA:+ M#5G08D[)XK7$I]9XGTU`/0K\FW@"L,'[YY^S+P```/__`P!02P,$%``&``@` M```A`%#1JZR\`@``$`D``!``"`%D;V-0&UL(*($`2B@``$` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````G%9;3]LP%'Z?M/]0Y1U2 M*&,,N4%]2)4:2HX7"F^+$#:\'`\/@[AS8), M(-DK6X5!K?%T98F3$ M.X;M,!C]8083+N8*18VX!M1DD6)MT&MI,5[T M3M;9%JJ+O/7A4DFC)+ M9CY$AI@Y]$)[T`LFQ7M5AU2EU&:`@2A*)M=>_CMI08N"W@B)(1(LIQ^09+\X MVGA=,".,TSS38+#'*DM>U?&R*)A>.]Y8+*3`SL2:I.>-/ MFC>F]#Q)A/-]`+2Z53_ZN@W7;FA'`^S\&"!S/$#FYP"9DP$RO[PRC\`5+C`< M)+$;FOZ\;S'Y$[W%Y$_3YTW@2L*+\*)M!'JSM$L-])[A!\L'#+T;(.+WL6.F M*4X<&,U,]III>K"MYH[`)T-\JS-I_]ZUTEL]6\OFMY"OYJFK<*;G,F%Q`TO#\3W"[_[G^P8D.CO;'DS&N]_ M,M$_````__\#`%!+`0(M`!0`!@`(````(0!^3Q`*UP$``*@5```3```````` M``````````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``&``@````A M`+55,"/U````3`(```L`````````````````$`0``%]R96QS+RYR96QS4$L! M`BT`%``&``@````A`)K1"HO2`0``C10``!H`````````````````-@<``'AL M+U]R96QS+W=O```8`````````````````+D-``!X;"]W M;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-&" MN(41`P``PP@``!D`````````````````@!X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#>`=U5!`P``ZPD``!D` M````````````````LR<``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/G&TA/_!P``^C0``!D````````````````` MP3$``'AL+W=O&PO=V]R:W-H965TS:7`8``,\:```8```````` M`````````/0\``!X;"]W;W)K&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`+"@Q11T9```W3`!`!0` M````````````````HT8``'AL+W-H87)E9%-T&UL4$L!`BT`%``& M``@````A`)&*CJZ$"P``LF4```T`````````````````2:L``'AL+W-T>6QE M&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0#,'H`8 M%`,``+4*```9`````````````````+V]``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`,4I2B*.`P``2PP``!@````````````` M````",$``'AL+W=O&UL4$L!`BT`%``&``@````A`$!RNX!Q`@``.`8``!D````` M````````````QL<``'AL+W=O&PO=V]R M:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.@.AU]? M!```_P\``!@`````````````````,AX!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(9L(\#``@``_`8``!D````````` M````````HBX!`'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`(*#DZ66`@``O@8``!D`````````````````M3&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`-B>$)IQ`@``U04``!D`````````````````J5P!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(R:'=T'(P``ZL8` M`!D`````````````````XKT!`'AL+W=O XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Detail) (AUD)
Sep. 30, 2014
Dec. 31, 2013
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash 2,920,000 3,495,000
Letter of Credit Issued in Favour of a Supplier [Member]
   
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash 0 575,000
Financial Covenant Pursuant to the Credit Agreement [Member]
   
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash 2,600,000 2,600,000
Collateral for Facilities [Member]
   
Restricted Cash and Cash Equivalents Items [Line Items]    
Restricted cash 320,000 320,000

ZIP 13 0001193125-14-387033-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-14-387033-xbrl.zip M4$L#!!0````(`$=[745`#%T!-_D``)YK"``0`!P`=6)I+3(P,30P.3,P+GAM M;%54"0`#5C]15%8_451U>`L``00E#@``!#D!``#D75MSX[AR?D]5_H/BAU12 M%=BX@W"=V5.\;J9J=CWQS)[=Y,5%2_2868ET2&G&/K\^#5*V*)F2*)FDZ.1E M+R8IXNL;NAO`Q[_\]7$V'7V/LCQ.DP]GY!R?C:)DG$[BY-N'LT6.PGPC M?!XFDW":)M&'LZ=7_*T5H),\I.6>52]?I(IE&( M8$2MKT1?,G')V7]5[TX?GK+XV_U\]"_C?X6;L4#P!!M=GU^?5X#]\^A+FN1P M]^PA3)Y&]G0ZNC9/Y:/K*(^R[]'D?/FCC[?9=`0R3?(/9Q5XYL_G:?;M`E[! M+N*E=,[*.R_-U>F.^Z=Q\J<1W\O]Y@]K]_]@Q=U$:WU17'V^-O`OSV^*YY84+(U6$"6+D M^9%)M'I1,:(\&I]_2[]?P(6:VQ>WZ^-:)+$QVW!Z&Z=YE.1IEA>&8Q2.-<.5 MD2Q:S>'"?S[,)HY`+NB+)X_/(`^.'^9]($;3RWF&=;[5Y?P-4S\-C1 MJ/#9Z65>6/9U=#/4R-F1=_"[-QEDZC9JY:/'&?17<02&]C M]&R8YX_YY`A';AXC+DI42\^[]*+;N0G'61&'/R;S*`.]7$-T_#*'?TP^1]D8 M+H3?HM$XA:N/\VLSY"B=WGSV)<46E@@1#C'T/S"8_\V7K]X-OC%JQ91:-^!H MX(KE,P^+#-X_B<;Q+)R"QWW\-3@;Q9,/9_'D1@HL+*IN`N8YU`LP\@2V$.>: M(CN@`=(R8)IR3W+NWI`; M%34^%C,^^TE)Q179AGDU]IY4S`$VZ4;%]%G%EC48%;^&VZZ*J5&QD)94JJF* M83*\])-Y/'^"Y&.6)E_FZ?C/+_$Y0%(@>Y]T0D,4--[A!PU1+0OE:Y%I#<@J8OWUI">92O0"3%?_$6ROX,L_/A MTXQEG!(0*DS$(P$7I8+4:_+F(7L:I:E!>0:F!Z)@RQQ0*D),6A8B=96'R+3+.[3RM;OD M32?.TW4T+2:.,)L_?4R>"[A#Q:D->N-CG*E'31G,%`?.B4S[@0BH0);%/,0E M!OJ[$KBJC2"$[3(Q?'02J7T%(K(Q=<8OK'9*@K^7@$>EYTD*^ MKS7B2DED2U\AY2G']@-/,-LOY5"F![)E,7R)`/+$B[-H/$^SE@2A-0.-'B:' M)O9`7^3`V`XY;,&T1Q)!G.7S`0BBB4'0%\?8*8AZ2"W-0WPCJ&*%F6F;]!14 MEX9`U#N:ATXN,EPKLB[GH>?WF/SV/IU.P$C]_UE`WGN@Z"BAQY8B$A,IO,;O@1);"*/"-T4M7(QL[&&&F M($7'2H!R2\Q4&M"2@W=4++\1G&Z,V/B_T-0D3ISQ+DU:&)-&5$/8HOJ+.9V`U2>T&@9%9;L$B4S*$&86$.JV!RH.PWS_.KN]]!,TO.KK%AX M^W4QNXVRJSM(?1=9/(^CW`VGTPARP.5]^?+&_-"$%N2RKS6&Q"L94%5(02%I M.9#%,N(AA[H"^=P51#O2E@*FVY<.$1<;K9,W@AR`Q,"..*?X44O%]<'RP\KS M+`]F="$"*(>$#2F=0S$(,5#<)I;&3)<=\A.(;BW/>[G8E;PV<^+EZ_8GQ8TD M:`+-^5[Q[4&\+K-/<0+WN%DTB4W[.IZ""_\2/L:SQ1"^Q"@?`OR)RT\9$DED/0@69#:L0-+EO*A8K.Q>0C"5=6] M6JRXNOL,N6:\F%TE[C3-X>ZE8(O8U[),]I?<#4W%3+YE\70`F`UW:F_-@KU* MG9LE&S;6'G9M%S$;5,YUP)%-)4.8!@ZEGK2H"=\0FH[E,\=28E5$2AA`&_WL0X6QK@/PO'*)I6.7 M>LSCRR2>?CB#449'&YMXM1?A:+$MA5/!^GMDIJ)H8G^/,HA*;UHNV565;^E+ MO8ZJ@F+E$L>!:84&B!.MD44#B=S`9:[O:,^U5O8$S._3+/[[ MX*8$9@2TD?#L!K!GXALL4NMES7HM`=X^_JU`/X?9559N22GZ9I`=%<^V%G@@ MH3V@(=Y(`,7:/5/%JAJNSF4-"6R$L9]-^>'!L%[:\*<)\2$1($N+)6I6BO"<->F>T*4N_7HFFY7KXM>#4SZ;J`UW(" MWTY.Q5_E5)_2Y-O7*)N9?62_A/-EN^,Z>BB-*#?U6IR,XX=P:M_-H^P_HS`+ MXN^M:G9W@Q`K6SN.;Z%`VI!I!UHAV[84PEA;7%JV#*A3-@@%Z+)2=A^);)=J M6P\>;2F6O%*L/1[##TX^Q>&MZ3B8'E:Q=?O@C:O'+SHU'#RQS(H3U9Q7M+=U M^$>;[\?$:/CK?18-TGC+Q0K3/3K*A"OHMDL(@OUXH$9`S8Y/80FEI:P7P&KP MO0)L4<7$),N<6%IAZS",X`V+V:+8K^1%#QF,ID@`X+^G49$))!-[EF;S^._% MWS]G*4R6\Z?/4YC$X9K)`AYF0U0[*1IG&DM1W>_7%MQ70C0[HW/(C\+;:338 M<`A)ME8'+`T@5[(=@>6,..]3Z"P(=D6_.85_78-?1 M/(R3:.*'61(GW_*U].`N'L?#"WBH89WHB$<0.I.*JE[_="W M]D0[J*Q;`,;DTH/XD6Z73G_VWQ0UOR%D7^NA M!SQM:I'L:S-LC5F#"T_4]`:Y9D*)^O"T%UU0X1,M"./5-9[:L1\=9ZZC M&60:$[.+,8CS<3@UKCE$:S7;8\3Q.6,MSIU)U)`-0^[-HUHPC66:G2X&:0^L MC3ZX`=?PW-&@`P4SSL&UII5`W@3)ZS0[GA>2,F=X`"1D,!'(:X@!7Z^5U3N& MOMW^>R^3#L@UZ-8URKV]@;9AM9ER'`BKK5.`;]!9HU.`Q1X!?(@3UN`<;%<6 MTA!(K"PSXVP@J^_`%IWJ\OJ`@Z:Q1:KI>E%7._17*_T/83SQ'\W^FL&V6L39 M3Q85UL9VN]<#W^R@Y?,L'L^C2?U!SOY@.I#V,DH`9F`1Q,'^D.:8(D-$0SBS M?`<'RZTY8)U?D^S/S^:9<)QE/>(U?65MBU'(->U M,.*N"3&VZR!+^32@7&CMDK*1S"JAI7[4=7%E<,9)>%TSJ1QL]\>C>TA.S$85 MQ2FGE;KMB*/1+RJ^#G]`/AME,8QK<'9ICLL1J6LLLSKL^C7VU9+'SUF:]S\# M-ES#,5,[DH__2S::NW$=@5@"TV"S<,#AK,%9Q6ST141[LY MS6_9+%)H>7#(H!QBS")2ZK4]JKLPU$T50\[73,5O60P3BC/!7$2Y_?1Y.$ MU:G=[7M:!NR!U"S<'KO>,O05MF>.7+#G(C8%4?2\QW"(;2:S,Y*KY?KD[N&O,%:; M41^3\71AUF_?&7##R<2KR`\%M1)'=>/L"S?#$#&;K<&"R25C7^VP^VARO#`E M,,R(Z*SE04W+PVR/56_I>-3M72A7R,`\6J#36!-(0SH-)(]DTU@V@' MH>QMKTJO@J$M;5WIS&FDA;DAB8&0M[?GLB?92%+27)^&]?`6T4]Y+\;S5#TFN-6;B`-+: MEJAR^B"^%`4?)*TE:NJ:^7(?S-852LI>S?H&[=[MMEOJ2_&\I?/U>9M&9GO< M%R#8^ORDB5YCZN\VVHKE1S/>U91^:I'A6I'U-:6_@0UI^=/%VM-13%#FLVA' M\/XHH@/M,HF8-J2K/K:0XQ.)S+>(M.VYS,+.RP8@BT&&IEHDW7J%NNT@]4HJ M[88E9AC@S>(4D0I3<0#U<"=+_\>C;<2,7I; MK4^2@V_B[#0'9R8'-S@E4=0T-GI,P3>`=IB"LR(Q+8@MN+($YSV2S^^#V;H^ MR8TN@1Y23K6.LM,,G)D,W)QP95)Q3@XH-=K\Z.*164XS*K07`N/E!Q>;`!A6 M%GBL?)IF@>7:,27:TFWP\C7+`MMAA>[8=)Y9H?>9SGMBA3Y69(U8H0MK*D[V M,%7]LM#_"5;H[9)K@>B.O!]6Z-=RZ(P5NK`G7K!"RTXR[??#"GUTJ&O""DU> M6*%!V%H3KEJA:#T!*737,\)P2*&[1CHX4NCM<:<;"EWR_Y84NJ4(WX04^CEC M:.FKR.^+%/H$%CTL4NBN4ZJ3D4+OU&P[VPC)0$FA=P:/MA3;'2GTGN&_>3DT##1JVH[?,"D MT#WXOFE&:H6)527"&3`I=`\B404S$-F@R.^>%+H')S>[WK7D;`O#UPE(H;L' M/7Q2Z!X4CPN>.DJJ@:]O4N@>5&U(H;$D&F;R$Y)"]P"TV*2FF-16E?UA0*30 M;Y!!(T(!\KY(H7O);]X-*70/#D)K=Q^?A!2ZAY3%+)DKS61E4;`'4NCN@3V3 M0M?W.[LGA>[!4`$AEY)+8>':G.Q$I-"]!*QW1`K=3X$Z-%+H-]A_4]1+$HB= MK8<>\+2I1;*OS=`6*70/A4/1&\14<5S_':'V2:%[`*5,F8`E9))6+:B!D$+W M8JW%9Y=-<;S%]X9#"MV#8=0I2:%[L8?W0PK=@SVPFO/NIR2%[@'RR4BA M^\DU>B>%[B?E.!$I]!MTUI04NEB9:^Z$[9%"=^]K)@TQE-`6YAO(NB.%[J$9 M<4)2Z.[1&5)HA46UO]P_*?0;8#8EA2ZW36^J\02DT&\),4TX%HNJ6X%.Z]AW MV^:%[L'[>%T_J2]>Z![R$[->;1A,J_HZ$2]T]Z:)S:E?@9FLLF*&[7\@Q MI%*84-#PR9FA>^CW-@+;`3-T#\UZ,%;-%!\YAXJ\>2>N1 M&[J'B:,H_,%1E9*;$\>VE&THI^O?$J,:GJXGISE=_V;V[>X-QWS5U!)8:E&; M[G?'OMW]]'M2]NT>7)Z49-3K+G\R]NT>DD>S0X(1(L5IV;??T!-JQ+Y-CV+? M_AQE8P`:N@?%[LU&P.H&V^\1Z21L,W;EF&$$9XMJD# M*IH42TTV&?T*Z]`F[&9`5\%4[YFC^N3<8KU2>H%1@Y!#;='`I1K8/R*45"*PX"QPE M*VN,SR#K!EVUVR2[)>MVNW_T*ZSEX6.(5?$49)(FT5+!N1=-X^]1UL+Q MM9>?WG=DSU%^8,-,@K1)AKFO*#*G)9&O/:8(]5U?^LM:O82Z?_!=?/N@E]44 M!9,GAB)`T^%\^Z`7X.;;!ZR*_+3?/NAGZL'FWNG M#^OJE[;P?*#YV1BN(;Z5YW176=@;Y;#)[;\9M>O"$'40$R)$@!TYL#84] M"Y`/N5,02"*IM"IQFU0Y>YL#6YGY+U`*SA:SWY)L389..#5[T5L6P!;KKY,# MLP-B8\Z0XR@+<<\$=I``8I:`@(X=S\+X96ZFU1QD-Z)*O#OHRQ!?%K?_'8WG M7U,W3CI>W^/5&1JH)^^R1NR4CWP6Q=H>6AHXVS.;W;;;=LI*KX'H"N.VJY M#^ES9_G+_[+WI+V-&\G^%<+9!#9@>G@?XTT`B2('WIT9>VW/R]M\"6BQ97.7 M(@62LL?OU[^J[J9XZ*0LT?+$09#($ME=55U==U>3]#$OA2VY$F2J=JBZPY,T*CV0.QY?5W43-N3=%"P?5=E MR2O<'3:SNEZ!/MTOSN]A_A"BC;W]88O.E@>V"8@4V>QV>6H4>K7=\P*_I9O% MP<2HI.EVQZO3/,#7^=3;'TKI;&E4O.S;>(UUF3_4<&)!NBSS8@ MCR1*:`E!A31XEB3UT;._(NDH2<=>DM)P-%-6?5 M:UVVQG!U)`WL20!\&@>8F&B7-MR((!OG(C:D"QH$BKXR3#:'4DL*=,89\9OSQ%^"_$./-/>E-T%9KD?.JK%R" M3AUKK!_WLX>K-'D,`Q+TG[]E:,5<@N[WL:"D-\S#1];JBQ[IG,)W_$>P1%J0 MQE2[N!-,^5/6CWX394DV8:)*6.UE>,X=4\?60%13AW=3VM@P\F,>NTB_^/GP M`1,3U=^9Z-D!O9K[19LCE":I`TOW-+!&9&";@0+F\8WNVI0W^U&CII\B%R&;X+`A=LI[2`UI3"&^%"6M*O=@- MZ'(7;13.U/`>06-6BK4U8G7"@"%+PON8%20.GV_!Y,W`T(7G/OEAC$6)?0(& M+VG5&O+E%/$DVX3!!V!@F%CA[5BP<51%-)V^YKGZP.O)&K`%;!=3T6JAW18( M-8O:ARD!8@T(^S\>'*0G0XL6$MPM+>IFVIX@[$[8@K[5P/>K54=LA]U<(X1F ME\WV;4-?3H9-18:%5;>J`;]7SQHNQZ%Q%'`.K`N,A%;'902XX]KFHWA^R M!/(Z?O20$VC>49OV?YTM'O8MTC53J2;A*A`W4.$;^S)&XQ*[F52.0&S1O+FS MA4.KR*YV9MH,DX9J0X.:FY'T2$NKLRJ=K2@()4NW34VIIE47@+[@`!7XC$EA M$K(MRX75(:()G*O9IF[IE18#J[%H1M[*MCS;M4KK3N[`FAJJK==;="X&OX4Y MAK_5;_W;M76Z*VL,SR/9FCF70V^#V?S)NBQG!8S((D49XR%R.D@O338E1?G[ MAW7@+]C4:UIV7V$9;Q+W6?L.=@F)/L2QDE*;^&:G5NHC\(* M>+Z0_"$)2@%TB)L$J\OF79(.:;+.XYUO97&`#(E'/D3=-&5;6>7?SN/2"+*^ M):O2/OI-1^%:BYYN9E""/'H=S;&Y':4NVA8UN-@)V78M%]\V55W MDM_$!A"ZHBOST:[U"!U$A3QD&PS3*IHER=7K;M>@T;H@;O190@UVM-Y%;A,!21`\4.^QK:YBF:ED+L9M' M:4GIQ2QC].9*3+!"0%44H]K:]V5(;AZT!#,R\K,L'(5#5D(\,U/1%^]=.A>7 M\0`,SD?=K MDX*26<27YIS1_F:J\!#U':ZD;"B6)>GZ@IAU$X-FP5EYM6[C1MT#7$WT%"T; M?.^*Z[0"@TUZ33,7NLG^!XB[0O/LMBU;5M6R:8'41KJ3Q5G?HN[$I+78=*Q? MAN6"IC-9-L4>))U7T6PJ#.HYO#F0FXJ+1=X/V%_!6D'+JEY&UP!ZDX#(*^!G M.S:,9NFB+&'?<==T14L&3`U/DCQ/4@>2X[(`ARQ;D@E6_;H(QT)\Z;4`)*#I MDE>O.=A4DBGS%0=K\6C$DFL-L@Z^MJV^*50AK/77?"7%OAW5FK7)8FTS4FT7B/N)$'> M)?;U?)#S1MW22RK;D!TFT!^!?FTUU9@&K8">_/R:?\D.F3YM'_LVY;S M'+Z8VC_-#E!,L:9W^]F#>^SC1YM18CY,T0Q#7;L+5V#9ADK[D>;[)A,F165S M4QJ]5)IW0Z.=;T[:6'W3(QX'J?$Z()&&&^Y`55X'Z/\X)GD'Q#I`7;=7`;77 M+J<:-O`"`67;S?ZF;TM$[9]([+2>86Y*I\[%U/Y)\`.)J?T3Z]7JSP,2?KQ- M?>PS??,\ODNBUM2:7;TR=Z^*J9J>XXFNW%=$%,9BS[)DT95LC,8/=!VOMT+T MX9^CW[[U+_[^80Z:$D@WSFGW_WM:]QCG7_UQ^Y7=!:PRP/KUXG_9Z%_ M<7GC?KVYO+X1+KXZ#(%%D)9X]&!%`UJY%/DM.I2O04#1-75@.`-1[7NVJ%F* M(O9[?4N4\$8Q%WC-`DZCW;%&P*N$`5H#I4EI+XQ(ZO@YN4_2%KVW=TAHD*$W ML+,`#.&:X*5FV-(=^=R/GZN4KD%:HC%(AO1V%B_,AG[$NG(.I^U%YPM)KM(> MUQH#>`E,\T#?/D]VQ]T;0DJO7A/_58<4`9D'CTD4-PX&0/:NX508147)%E6I M#FT-KB9'.P0/'$07<4"^_Y.\#D]C.1\\H)@VO01W*7`E[/SZQI)C=DWU-N!C MM$V4%1&/*ZP";MDN9.OS*OL0I,F_U$6[L`)3PS`=/I!@BJU1EJG9V>V$:+[U MXJ#QS3?0MADO77J^I:?N`>%^!#_M#'L+;/&>[BBB:>HF8*_KHCW`:W9L67(E MW=$-N\_V]B]1?AZ$C[_`)OXU$;+\.2*_'GWI77^Z^"KV+V]O+[]\%*1) M?BYXEU]OQ9N+/]R/@EQ^X?6^7'S^]T?A-AR33/A*GH3K9.S'YP(?XO;R"IY7 M\/E;]W]OQ8NO`_?K[4=!^_F(3US2"&9'2OBTA[_@LH^(PX?)-@A1`*L@PQ,%@+_XX\GY3]][TOG<^+1S0C%' M2P+U+Z\'[K7H7'[^W+NZ@9>&@(4_R6I'X]\0/@N+OIS#( M'WX],HV?CP0_"N_C7X^PY1Y)CX2[)`U(BD]5P4RK?P3%^Y;)%H&BE0?U9Q[Y MP'=)GB?CV9SZ\E=V]?VK3?VA3J=TP<):Z];U:"4J=-XZ.ZU!OO'&ZGB76&*BAUAQ_8O9TE$,FH_,RBPQ2L MNTU7]L7D>`TB_$["^P>05B48_B-)_7M"GTB%#QR<$#W[\J$)MF9O/-+[VV[I MM0$#KY=,($/N@10)")&?',=U/6\)3^?)I/K+9$LYR*7N9]<#M2"3<4-1B/!5 M,4UQ-:*?"P,R)'5F5.53`7WU.2&]TRWV8@XN6"M%+J+O*X9T:DGR1B_'R5/J M3WX]8O_O&/1=("N=F17<_PG#)&!>GUKS*V<2IKT5Q'BFOWZ3#[YOH&Q MW0'C-+<&MSRI&UF:G=^YV;F`_FVY?*\3=L%1?SVJO36C9&,[_(9,\J8A+E%# M7-M.@L,OHR3.%_O>J_<\#`<2[--218E575$S755T;*\G@A/ZY9N6(ZK#@XJX7'[0`26.+@C4?(D MT)L\1DF:/]`$R`M M$R#6>P+D/0'RL@1(5(OHET*P?.AF%JRK/,CJ_B@2W:5+7I=X7_STOR0O@:!% M9SNDY>RAX][?3G9+V;P"U_?H7H[08HB M0_A&&5O6E%-K)RO^!I`U[%/[;>0%#U>&_V,:DY<$WGZ`U,D;0+5S,=X^AO!2 MSWZ3EI.5MM_]Y_(1WD^=#LYN$;F(8>XIN],+^X'>/O@Q/Q=#$X791/ M)[0\X*JKNJ)Z>D_LRZXB:KH^$'M:SQ,-4QGT+5?M6Z9>%"5KU8/X'1&B>4KH MB3<+QP-&:1+#QR&=+KL":W[XS/Z[^[",#%\//,<2)A3',Z\-`>"$Z MO72GTG)7&"WH\\AZ[<`MT?;*B_SN\5JX#KB3\.\:U9`"D9!017#%:=0TR)@QX%,KXZ\1&=7RCHJD*)L/)+<'H3GO18!K/GHN6)9RQW%VPH2.3P4+ M8WCA.,O)1)!/SEH;3^^<\Z-SSH3=/4/K&Y([>)*U%(:A0,9468MSD?+.1>]< MA(\-2$[2,1A3I2)FUU(*M/2?L0N,I;XSS#O#X&-%@]DE_`*6%/P`8RV12$OD MD?;.7N_LQ?U9YBO,K.N: M[4+J9I>Q`WC[)@?WEIYD=9)@=E'-F>"0-/?A+>X``I"EZV.?9^BV/8+SC#O< MCS)T=:@K1.4!]^XR?#E.XA'K0>Y'L*)815+WBL5L>I?E/BL96?`T\_00R3C) MT6=*IOEDFN/8,P>J!AH,`[L(1DF?B].Y2-ICU6G!6I2%0`#0RRDS&N,! MF8#,&.<1]=I]BF,09L,HR:8IBH`[8(1%T9<#P;W8VB'L6MJ]&\-4&%SPXW@* M[)/.>H.P8^*PSK-M0@.;IJ4#8 MXT$RX<\*[)-?C\/1>%"!PQ26,14NO.N;[.1`ULDMXH4/_B,S0!ZB7)CX&G1)&&CKB;*-S,0Q\\1[N M^4N8-]X\RU0V6+EB&.\^%ZZ7/2@\)=,H$'+_O\A#R%M,BW#[B$M.F@!`'D-% MH>B2<,SD+E?E$S0I8,"(AD&#$)]^-\/?^10?^U((L(UY]1L5Y2C-YH1?-;1= MY@)J`SCGK%'*>!K1NP^YCD2A&Z(:!ROXN1Y,V[+X_F(5S$Q-IH4)2RH$Z/F60'$SEY.DE@PX+DP1 MW&E<54_`4,$2PZ`0_#/C%FT<-!_9EKTC(TR[T.GIC&'&@8-7F,T^#$F*!8D**DL)8+1V18V9OH&:?955*SPRM M49`_0&].S46A@!-0"9,%;0,0(`M"E8V@D#)4A;T9]PWK'M^U>5X.UYV<3@!^(;[ M(>A8@$R<^C.JC@DP>4`)Q>G.Q450FH2UY#2L.3,;D[AZ`J).+^#*`"\K"AB_ MT^IDO+!IT7IE\T;Q?"%,VV*)32I=6(U&+\9K'7$+/)(K8$4^WNZZ?AFF:IB. M+CJ>HXF:U'?%7E^21=UV!YHF*9KF:)T?@K%6E5O04B*1GE<2JO0ZV#*+WY&- M?72169\R#ONPVJT9)-,]%N-0Z7G;* M14D1N&/A79!FA7HF_`(UG$K`9J)85R92401SH:/XR$T'?D]FH7]+!8WSG"$R M!31,?=8`8GW8V-;,N*_&7K]-PS@9X\[Z[.$U0C%V#":$RUL-H%2I:')**V6,([KB!Q8,'' M0'\^7E:N'@R`5`=_GP)2F;6@Y*)I:Y-2&%I.6TR*LIBN((;I1B7B09&78O)W M%'Z?\62%69N\NE#@LLEI>H+-1WAK:IZR@&D9ZBR\$48'$HGXG86Q@%8!OQT; M'+[O11B4AHX87S#K)J2>93:-T&2%UP,23(=L!5%5`6^'M',U'02,X6D:9_7- M7M32)".JFFK]W+.\W.%L27!$5%33'#OKTD&IJ5JLQ7^F:9@%(4L.P;?,3'PB M!:1#0LV.$LXS81""Q0&Z>$CY^H[D3QC1I#;@`@I4X$%BE.IS9L=C&FJ:3A*\ M2AM!IC@.<[3U<9S9S*5Q'38I1;UII!7E2K8>1840EVKXN#!DG:QYZ1#)*/=/ M_'3&W"&3F/5Y\5$29$M13-(RH08*EQ2%3N!(/(;)-(N>JU08PMLAJV::^&$@ MAK%8@`7`4Q<#2>\_^F%$O>J%,($\CA!^F&B>]BB+$;07;!'K!X\#;.S:%S;% ML7_2,!]:N>IUVX1K&0'-M56COI)=OLI4N8C!DI9X`6AAGU-;FTJ7%ZP490+/?/J7)%&LEJ)V#(7(_QAW+;)SCIP="X\8T:@Q&#%A:(!]R^A$W M.GTK2JC40MT'(B5#245?1U<2O42.^CV(SJRF=+'<$,TJYH!B#FV8AG?,04_` MT*(JN:F1F3K,$Y00\?^S]V;-;2/)PNB[(_0?$`X[PHX`.``);O:9C@"W'LWG M[5AV]YS[X@#!HHAI$."@`,F<7W\SLZJP<)$HF9)("@\]8X%`+5FY5:Z4)"IX MOY+\Q&LDW&0P;IJ9>1!@R"QXBK=7]Z<_3^=2@@CWO_00`'`"]SKCOQ^D*>%K M*AUOXO[ZK[)HQA%(..-G>""9S,;KDR^6MZ(GE$Z(7*'$W`B\4Z7B30LF?5`_ MG"U#TVU\3#Q3.IE+!@,%(%1B:(EC1@(#V"VQ*9A&C5J3%T[U"?$=/&R"&RDQ MV_>0[4!H1W(/,?E:?!:K8.98&&W(NJN.)D?\7']#K0`GI#OJS(49!*:E"\1H MR]26,+`0E96M,J(""10GJ&GGTQ)G%!8^P04RXE5D*B:D90!3NISI MY)G"0`FI(@J[V[)@@8`Y=&0<<,TF1[XN8Z_].6@+,>D9E,SAE>Q18CJE9D2E M)>I2P-%)OA0(9^'^Q:_P(>).P_QZ,F_M\G2K1 M`].V.OJ&:VL!(XA2N79-.\[OW5([5W90AH)`L(+LDKM^Q15>2+SD(OJJ[,E+JW-C MZ0[*,-2PD<>*4?;AZVJ<.N3K:YF^-QV$DUX:,L'[\.\;/_7B%ZI'IG`5:5D%J&.J@F'6]E++Z!&JK4?T0801Y@%N"Q,>G[(_GK8\#M5J/:WA%O[]X=0XYC>\T'V=YI*<5# M*I?%)MH'?PJ*,'G]CT\7?B:*<+7-:IO5-I^7\OO5YW]I(XS(.D<+/49N?57N MSV-BT8V:==K:5*/6N7?A\&J#A['!YFEKQ(U:X][<^!GIQ",,YOM#!?/)Z/MC MM1%7G8!/;J?USG/9J?UL;,3VO8T5]U&3#R-I_Z*0DZKJN"VU21JK"&A53DSF M#F.]"XQU#H+HFC^WZ.9?;C'8KEH,WE%E>081GV6$4I`:XS\VM!C,_LVS[G>G M$!)W`Q#^9,BCBSW]W"L6NY=T_RYT_E/Y+OE[E/BR\I;S:K\@.W7;1Z&]^WJI MPX9UK`W53+UEMG2S^TP45JMF'H4-\/&POG$CUO\NDCN/#Z^;]8?O*78H2/WP M-^OC9^XWH[F*E#X^1'_3T1N->QNSWQX'>E<]7N^"S!_P+G>,F-RP]6[WWE;O MH\!ET#\.H*/KXN<.M\5'0)E5FI!7)[*#Y/>FG_+>M`'^=\7O!YWP,3#J^4'M M^%6/G>^5%VR1K%XLS5_I7@R_3*,PV6Q.NIEZ\;M]F09V88Q=O6O9>ONA^UWO M`U!/`1Z0&ZU*;MR%(36`(4VB=!RPQV*!]Y_QD"3'*<'M$!U-WTKUE%05(FFS M=44;GUN$@6P7M/V-!M;XT3IZW>KJG6Z=*B'!/=&V]7J[K1?*<@=+53],%%$2 MM4Q+M3E5'>7T^(WS"C=IMJRW$BK.*[O5U:UZ,YLUQ$K`ZY/> M-.79BRV3'D@)*(=*V]VP`:H$A9VZZ%#@B6YUNM1C)LP/\NS%MJ,.7%G(+`VQ M/INJ^+6ANC-"*N_6S@L%_%8*$\NJ<=^P4X":B"KB,A7U+:H>%LO`/EL':ZOS MBP[6SMT=K/:)>#D#Z2X;^1R;S_P?KKMI;COZ\BKOV]UN2?>_`SVA M10OD4.>A\Z*/S71YZS$WC^Z8+=/6F]VC..>#)O#6T9U\O:EW6D>14'U`Q]P^ MNF/N5K:7ROK\F&QWYW,,CL?`*^^@%2%5QCCQUZ$8X]S+RYA=BDKM2>R'W/<0 M>*ELGQP$F9$N2A/J44=MC[GH`7";W>HV(]U_61P]?K>3AP*V66YN)OJ/C-\6 MFEVIRE?K_4.>NI79YS3.;5;Y*NF45)L0V3^A1_T3HJDVH&Z&4#&XH0:N5,I^[,79*>.%U$LVWDZ2,UE6,(@##BECQM#@I<; MS>R8,,B&PZR5NCSF+1X7<23Z0@<>X9,L2.S6`"U51(-9X.E.L8X)S^Y MO:S[.'>Q$16<$\_:.U#?5`22;,L*`VSIN(9K0(@@=A4P(XG="?5R2?Q`=9>2 M'45H\>C[D2^MBW MH=C41_7ZR^`:4X,*W#3V@^4\\GRR>E]BFQVY57@3>]4_&G^Z55@)L_28!=&U MIOJTR:XLA$FR88;D4VJO',@`]_Y/%_`B7N:"08:M/S?S^B_G+]W#O%[E+U7Y M2\7\I:"4C9,K2/E+%UEB4^'%G`<'#KR/;OP72_)%_('*^1YAF;V4 MI=57;ID=S7D?W>61)CYU]^*8.8*-6@^?!W-:)FJ5W7>DB&W9=;VSEQ,_@LVV MNGKWH4-&3YV'_S,-V:\$&3^E_TTW[6>"Z8_.Q@_#0%LP')9ZU>]:H0.&>*8A M9%6-CNJ.^]1WW.S?58V.E:LGV>GREZH"'56!CBTJ3LL$=?[9E!X[#F7^\5#^ MYDSOKRQ`?P'Z6^ZNMF^MU'F*+*_`;^K,-%G68]F7S?5HT#RAZY^ M>FI17J<3+OF8B:JG`[5C4TJJ@@8[Y08T]/;]NQK]$L^_$YB>`C@/WW'OU&3$ M*44"/Z:4."6XW6*@_]O$O\(__^=O*3>IBSW2^D;(M\;">#9J&8[9'1FO8;'3Z'^L_.^I._>#Y;L;1&IF MAJ.`90D7K0`8.H$\FCDWVVUT.116VMJR4`2KX8<3.*)W]NM[+?S/0CH]_$NL MF6(N,:R=1VGLP6%R&9Z+[XS3)8L)*H6_.$]Q#13>Z_._N`1-S(3C#VNF7(Y^ZE'*#,XJ<_H*^E,U'XYO-B-8WK&6S:1>\H3UV.V,>N M?)C4DR>$<>-Y)0\1_0VHG(V60R[&^BDQF^B28V`3)L\P#E%!Z MAO?,`Y%%O7/%TEP>X1M+.D88KU;82>'X<(;0\Q>!#`'ZS`7J"=DU MGC'`*7:])'6#TDX4@KD+C,Z/,`)X2@!UY`Y%YK"%,9Y19'^1%Y8YH?#U^S`?SK(L(P$E5V3' MAUA.;("SA1OC2!0`,1IL@DJA]"?P7&RG6LL$$`.!!`#C*LJ#4B@CF M2`$O<;@Z3&XH30T?PZ0B]8486P`:&Z4XN/,(OD8^%W$&>FZ\ MQ`EH.3!(21^@6D#(+#@+`GQ+D+L$YMI6<`TY:14H#[1&"H?8P)YSYDSO4::' MY+#E\4$)*2Y"<(,"Y:8*DQG]`#%C'!9)\%\S!?2(O& M_Q8EG@I,,2;UQX\G(+9BX%D%=BD75UB,+OGKE>L'@NM%<3GCI*Q6C+%Y(OSG MST6NT@I\:3#72=\I@PK4/E3ZC'I32`M) MCD@+"9N_X6_I$&_&(\DVD(#>^`5'S^;Q2$X)J`$68>Z4DM.42Z51"J?A!DC) M,I>**HGYQ:%]<<0%>CJC9+(@G2#>:9=";]#(I"'\;\#UPIQ<)`*7EZ<3JU+\ M*$99#*4;,1!P`C;&H%(<\-AWCCA(?M9@L#PY%811(MK1A M*\"7$)MN9DWZ*L,L\G[B-@QYY)AH"[,D,='H,MC$(#-60'7F;N-4Q1I@7AQQ M+G6[E?G]<'5G"-3H2A8@4]154KJC4,:'H;+QQ5VN5"WCK"P"DN4"&)>`+!T^ M"0"8A21"=D,2,6:PSW>44AFS*8PHV$"Z`*4,H]+D7$`[J4@AIJ^+4N]O)%YS MP<>FF-T%7R#P@-1@0SB[&NGI21SN!3F`!$D`[JRO5.BEA)B2%/'X%BEJHF&B M:`7DD!^EO*B*7#-!SM>^2'*;U[15X^;U#,C$P(`X]JY@)?Q4.H:2D7/3`BGO MD(Y#WO($9GDS'\Y#8-:4\!O0$O-+\07FS4+<^]]B=ID"V4?Q$D:8I?$D8`HW MMRHU4G(7@4`J;/%VF`-"L"@A[N")RJ?-:/\*M>Q8I'H6R^7WB7XU,J_)3% MR#815)O!((7_.HU'BQ3*"%'Y=I*(4HF(UZD0H?;3`FG+&3LQI`VMZ>FK] MZ(:N9).8'0YXPYJ.V8-8X%38OW%6P)2 M%5[+KF`\P&LD)U*(&K;S3=XAR$5ZS+"-'$NZ`PTZ@!M M&4KBQ@%IP$3241!=BN*B_"\_"$@=5K5$5VPTL(0Y):<1;63&@@R>*O_V&L8I M;WPE?UP*P!73DLC/WF!>BC=>]Y6(E;59@028CW#%MXJTG7,]%.V>X#4R#[J( M`2BULS,4ZK":6"P%WT"PKB**Y%9<7*F(@4M-@"A-P!*-+6*A\&)^9OWW<@Z> M/QN\7R>>=6/WK;;JLFE[LVW<*0C_WC)_1VH*#AJAA/V<#W\N?$DHY^$7XA@J M^M,1,9^JJ\P74NGO;2E';8J^\GEDUZWV#^?[X`<N MVM7K9KMO]7I&IU4?&;;5[1J=^JAE]$?]1G_8ZP[ZG>8/ZT?CY6_8FN(VU\'# M@>>.AW/WR?<`_W5XGW\:K4'<:73,AEUW#&O0=PR[9]:-KC7J&]:PW;0'=;-G M-DV`N(W.(@![IV%WN_8=`'_WK:_`UINQ21JPS]/-4U$G5#F8(],LOB&#V[_3 MIU?O-^I#0$F[A?\S&G8,I]TSC:XS[`VM_JC9'/9O=?I476*K#)0J`Z7*0*DR M4.Z4@5)UB:V24'8-UZJZQ.Y[I\<6\GF:4?E5E]@#1.K#33ZINL0>-'I796ZJ M+K&G@N'Z,C[W,\\/DBXF[P>?HA"B\_H`/?X5CI^YRB-?SP\CQ, MW)#JU8L?A)?[H?*RG&:GT1GV^T:]/ZP;MM/M&)U1NVTXPV'?=DRS-^RT#RLR_I`BA-V$HC=$ M8@P<._92A37[LI7., MUZ*D$1$3P@I106XL`L1%7P<5["$6!E#!P"`93#I-,1(0@Z]D)%1-.P]5:)7R MD8I=ZBNA12H6BX(Q?2[#16!R/M.FZ#X5T2Y9D(T(V2Q$XYR]$$L64:DB@E;4 MP>>L"+,,8C7-"8L`"R("QW64!I.53K04CIW'DY96.$TIDBE?Z%FYIVW,>!HD M>41/RED)A+0F/'$ZIY1"I";$!7P5#QM@I""E']QV'BIN#]>`47*=]P MJ")2&N.P0KF>+**O<(YB^7ZR]70PYF<5F"(N;\YE@&W>[TG+[5]@WC5ZW9QLC:S!JFD.S,:R;CQY#T2GW`2HSZ6_4:KP$*$U`ZF[\^1%[ M`Q69M(SFH,R&>MTLQ*XUWF_<%4::EY_+P#6K'_'D M4R3;EE-@%'^@Z*7!H-FSK+YMM#IMQ[`;[8'AV*.^,1J-;*MO]9S&T#JHZ*65 MWNM5Y_6J\WK5>;V*:*DZKS\+=V#5>?VY1C54G=N7@*OYU"(U]]MEY?0T^-WCL[FTV*MNA>E@XY/.T4/UN7U:E4<\:-AKU MKF%9[9%A]YM#HX>NMU;;MENM=J_;'MA/[G"C[:/!_HNHEN!F%1`/PJ>&;;Z% M1YP/K%NM6NX/^! MFACR1QA`.D`W-(*?LP2]?ML!C*2V&<2;`*PC8(1[%F;_BYRK+M`/K2&Q$`04QA/"BS)D; M4KG*.6,"ACE(8APSEB4Z$<&)QZ(,@E, MK%6&WOXI_1($N[A2UH11659]C,W"&C6'?<)JCAF%;+=MP M6IVFT6A8]7ZKWVP,F]V["*MM,N%79-7G^-(%<2^<5.5"%8]>AJ">^)XH22B4:+%@XJEQN!:C\RD_BJ#`L ME5LY>Y%56T$R1[ZP,68/-(K."U*8;6LG6RDIB68#_`LT3.,'Z+]6O@,]&" M4@Z,(2WX6_\?PXL+&)T"-ERJ`76.;@>`Z8JBT!^<\[(FD-=4_4\:)7G5Q5SE M($772V-1A&7X4_J&RPK(Q;_*PW(?6<]Z`JK5D'MLU;3/N,%\9,6]90$#D(RP M@(E8$2*"L9Z]D&5OQ"C7LPBC?K`LKRA'YP-JQ4N).?X<_YUS\RLV\[V` MX4*^]RZ`I;N\?&XDMT6E5H;PU`)_[HLJ;@+WBRH9RM"-QUFG7%O3JN$LB,TB M:@B/=2.I2/:?$\M*^1N8]",+QO`]=LO-YC\(W"&ZH8X@#*A$E?%2_EI&2J$K&)N1%->7@&(WUG=1B/-%,,0Z1*+#>$8AM1N%I ML(;;IA($*FJ"`9L4C#!FQ5%D-6(`4$"%&/,:AXCX4;X_(F:OIJOR?.H';9@" MAF+5-2J@J`I2]4&J7VJ_S\?_4%P@)+GC!KH&YPZ*#RAT@4^A6/#Z/Z,9:+\A M@4;^^R`02C!VJE&(JAN"*H[@"CTG>82>\V*IK$7@)L0,92E>HBF2*5('58@$ M.Y[X4SJ$1'(0+EB(*IM"8DUH45@^"G0NN/FC6AQ=WQ"(D&^RM9_+42D$836F M0/WC1F"N0KX81+`6>K`:FB##`BS3?%TRF&V..%#1`S>;P>3+C=**"(AJ>IO`D7*`5;7HLQQ?K,B=G;A MHQ[.M7\P-TAFI)@,2WY29%-"^0F!7HY)+I>+V>1FXLA;D%58O5UVL M;NF6*Y#B#K)"@J7UE]6%4M521WVQQE5%%6XJ8"SN722Z5%4]7#(6D=.13D.Z MRQ040@2UAITC%Z)5MBJ"NA)F"WIINEA@I?:-ZUX#K7AY\Y)KF;(;\`S:BM>` M%(+!OL01WL.PLBR9&,NL5/N$=1H#"E3ZBL]6I_^"!L>O*P>+&TWPTD\ZAKC, M@>RCRS5GP=202K`\/@K*A5E#$GL41R)*Y$Y\!-IAM?45;J8L1DC#JI!C00$1U4O)T#"1(>34 M6".B_]?+7.8,:WQRQ-2+8DW(56HL$\N&+_#.<1,%2_5P]:*95P)57ZT2YF#E MBZ_JBRWS2)I2P*CHZ%G3T6>Z/*QHHP9IHY080-8S5#I72:RH+E`[$:`X:3H> MQY%+`DYV**#N)'@%(0OM)BVWF(DCILNR$ECXW^4<1(J'$MF?S],P(BX:7.4MFT408?^?PHC)KDKS!05#BK!2%+I3@U%%TPV7B$H:"JXLO M,GC(_W"3F"H**;Q0BVVXL2_Z)XA$%5_DPL1_W9WJUBV4ZR;(LHERP,;)P.=> M$&&JR/Y#M5M#JSEL#/J&W;5LK,EI&]U&:V",K$ZWTQP,ZR-[\.1.-?P')3_T MHCBF:O('F;`V$N;^.1ZI+._L2WM7X8Z_6"NM?[:E$T80$27%=\4'>>\J$(;W9@/^VU`A]AD?TB^K3X;&-(TQ?U-MV5[=:FQ,8 MGR%.5D=T\$?T#/2/X\N&!2RMA%MU1$=U1">G?QQ?=G6%D]41'=L1/0/]HW-\ MC*15H6EU1L=V1J>E@5`"HCM--N7#'SAJ5AA9'^Z$_3^=9S.?] M%)"@7%%K/5)G*Y$\>D&MAF[6NWJ[N[D-T4-+Q[L`ZE[@><+WC@4#;-UN/YU? MZ/@QX+3N7A^PG)/LQA&SA:B)A;D4&P+CIXR=/(-\T_E5!GF?-IW'3Q7'?_#= M7^6+S_/@J]ME==^H;I?5:5>WRZ):]7N,3<1442; M#A!)JWGOS(OG>=^HCOU9'ONI*XQ?@I3L<'%2J/>K6.2I0Y8E-OM#;GU5>'7YG?*H-,97X[C"E/Y[1/ZW(I0CD\4):65*8=;Y@GKS+9 M>L.R]';=.DW!^>LAXXUF76]:3U/7X*CPR.IT];;9.7A`/0EXFGJGV=:[K0>^ MG)R(&M<04E;T`GPDR;Z7.1]+M%>PJS"PPL#'AEU5B>MY&5/)VZ0:LV#_(-7B M\X0O!"?J9SUYJ%3P>798L@@D+CF>FUE:&[ M,G3O"8\J0W=EZ*YD:*5]5+KOD<+P,+9Q@)"[>R_)_3;^.IYFDB6E?JT_I,HZ M6#WQXGMKUX)O,Y8G,_B91+*.<>);=*&`D6L4O-"9]P*:"U#?026;+V$_G6I_ZYQ4ZK>*R\M:" M3]A0\'.XX3RLKNS'5VZ)'434HW+@)BQ_/GC_5M>^]\Y%T^:$&E?.HB!88CMI M.$">CKD_\=UXB:]=:&^2Z))1,0;U$3S598_"XG3?`!VYZU$D^1H1:@U!GTDIHB8K/$TABEMW"DR\T-?6%`+6#8KE$0P0VKAE'>]'98 MM]9;F2>?`S:N7G(D5>9?:=D)$?RP2:FHGB&^Y=H"3F.))Q8S@'S6&!D&R5HC MK\+A@_BTO"#L>.YFC2>)PBES"KA(NA"C`7NI-S5`X`#1H(R.JS15'+NF?9Y2 M'U59&02;PL)85CX6,K,Q8Z$VB=WK$)N2W\27!"1@D&D:"^2%PT! MUY'`_I,"3<%C0%4_T/[IAO#W`=+#B[@4?SX':@+&#GQ;O(UOR%4)QNUZ,Y]= M,=R"?!XL5=MT+*RCQ?!KF`(.R2;&@']N0$J"8.Z?0_8M2KT9`I.G&W"_TP09 M=@7+I][2!-YWJREGO'8RGG!R[R')M7^]V*TPM$6 MF`/E1>YE&E`*%`P&I)1.08RE,4(T@Q%`)8P28*F"R'() M[.T2SN4]LNE]J,T5@ZD8S,$SF)R^UDAJ5X(2`I]J;A=(*B>H7[@V[/\.NDGI M-Q].Z"#BJ@16[X47VZ=C,@57;,7%`:\VIL MB6:9M>;K?-P%BQ%MPU"4L22L1OQR^:P@:N`)W/QHK.A*(O@45>\E/*/MZ#0* M*=.DL%[[P+[S-N42`U;UQAJHP!,V==-`8*]<9BS!8#7**Y7KY#,W"#1WL8"5 M300J"H[-?H*ZSV3-%%>-G'=BWS#_9](H20JXB/T\G<.YPXG*UNJ"/$"7102/ MV7]2G_3E",[L+Y8W>X?Y%K`0SU^X`6JJJ%V3\@L_I0E/`#2XS'PE.0H(KJ!0 M0-]X25>G7UM!G^T[@R7C;J1^/U[271"6D?@NW@\1@&A!R*^!.>YT0=YQSA)> MP]\1X=8O)=,4ELOR"R;SY=`1YG@ M$=,*HE83"RSVW%"@[56VQ<(.8?ZLGFT!E3,TGI9Y>ADG%.GJ0F;@.@!ZLI+T'8 M7E;F%E_R!?/\J<\FQ)I@`M"Q8&H"N\?\!5+8<.-S98,C/@Q?T_,KV#TL=.'Z MD\+2U-S9&%Z4QIQP9IP"`$`FZ\37O!DRY\3]":--@?)`K2Z,\OO%-]K)5Z)6 M_&\@WQT#DO*W.,8'?\HN$(F"=+Y`3DE7C^S$\/,+'[D/)SJ!Y1"&8N'/FG8> MJE40E+B>8X$X=C)@P$:DN4)#_5(13,@2!8I%''F,37@&$QRZ#'VW@$@:UD*( M,]*4@F)7TLR6Z`8\PIV2':(PND1R_+J>+U=3 M8<=!Z5):LKM"RQO6"8-L62DM!LAK%U\'30;8U`SDR]CE/I>B#0D'T&8]R@!=QRY1#ZA-P:&6U1 ML4)<'^,-)O&30&@[DMC@IE.BR8P825X!Q$$$1&&!)Q"0"^N+`MA0%`O&D"\3 M]!-A"05I`[LCJ[32311+^0=S@V3FH=@=^.YE&/'$]X"-G(=>38?+$B[3I4O_ M3Q)B\A2W74$(!TC]QNV2Y9IV"DO'8Y&L'E@@LOB81(DF+EXA$Y*7!-]&J(N] M".[Z`?6T000"0W"]7&#A][,H$-\)K)`%%:5K0GT<`["C$@T38QH:BPB M[R\X#?9S`8!B)#TPS`OU/JF+*.S=L@-2)B?Y(E%]Y0!)(&0FKI5BO"V?LQ`4 M7D_LG9AME,A7!*[X>,>@:!'^]+3_;>.)(1*@C@4`YH5;-H@4MWQL&9(JX0G/ MX/?LU7?:&[_@((@97IWQA`4;F;``6?E24(S41$`QR>MD^PC,N:`0?(J+`2W" M0S&,,7R`]4P2G+S@P&/@*U*K+HP$@\!='@87$O>]ELG$J4`X>6<3;Q<4N9[Z%4#GQ@1WCVJ`3&OI<(PX/`&U7$TFA_"A#;AAU?PS5RL-A[H1H*=9O+*]!T M"JP<3Z2L)`+X0SR\0#I3Y]P(6'B)9`(*$0PU3F/`71[-6>XLPX/)Q+40R@H3 MBEM&EU[,9_X"7RA>O-Y+?@,GLW8TZLI*G(5NK3[A./#DPE;IMB^,.'B61;MH M715B)!M`KM*"I`K_TES/H]KO;D(""_U/3T_@#L\\12LW#[B=@&Z4"G.U: M,S\G957D,Q!M7-[*2W=FJ2;@.PEP>B7+D$W@Z_W!.:<30"U7$(WS"N-&\&HJ MAJ5+_(I; M#//;W=Y"(\D`3?$(!?,E$XM&X2>9U\Q%#["XF"-A(*\CL]1-HJ:`59W'MR+^ M2E@#V:L.)X0!KEY2N:0H$W$/*0<'D.D0S1@D>HA]?G&1B7CP_1=Y.4'?NI22 MJ(H38OT>1^FBC$F9'%*(2.A"I(:D)3M1"*F*)4%!B7%>-5L=O=5N:V001U,+ M4!M>&J6QD0QE0+4@4":"C*;^3_BG,D+6:YW.1C.D*]?)9U&<&(B`Z+_*5'34 MX\C)/4W1XH8JW;W!'P M93"6((YGLBR'4]U\""M'0!K*ED-8C[R;^%?XY__\+>7&I>LNW@U`@@]\CDP2 M!OT&%-<+@`W^!A]H_Z->^BH<*5_AMG\9DB:300EU4OCH*YO^_26+@A]?AJVZ MV3%;AF'9EFG\+TCFYH^+;X,?]7;C!Y*@V6V8/\R7FC_Y^TM_\J/5-)N=>OM' MS^R97<>L&T-GT#?L[J!C=#OFR'"L1MWNVF:S;75^6/#A;[@/N8U5GO+1^?K[ M^2>C]_G;M\\?WVG$)$:?/WTS+L[_O^$[S40WS[_`7> M[Y239HBCY709@MQ@N["Z/2^+V.6WX;^^&>>?!L-/W]YI]NN@P`>3`*RO/B%'7U1&BY@A*%IB2O8VPZQ0L2.E!\%DR4J87T,-+Y\1^HN5V! M6AINNC6M8]IV)%I%-KS*HP3E7T`Q]I894NX/V?K]?L-JMHU.N],3)HFBCXZ,D.L;65T)S#EAPI1,-PYA&R// M2,RN?``AW4T!@?Q)ZA86.Z6+7Q``D;EC,KKIVB6#^Q,ZO\@_YZ6DM!+A8:1) M]BDYSA&@"Q?V.4GEHE3>'&J6M`LRM9"*/_DWVEV3VV&H:SX%!.A"YUBM7"X7 M**Z.Y0C'@F5'@C&_UF*<9P+_E_FI@#&!G)K!!_BI8%0US9%7-=E5@N[^L,M, M`E^BY6-U&]"7U>`8&6_2;KW.@E4\4L&*(36W1\FT.J]W3DS*YMS^ MR;Z>/]G4VQ*][G*N.Z2!/5Q*3CDZ2^&Z3.#0K$4B4CK6V.3E@1<8]2$;-P0#M_U#L;8+-QO#C M_8*FPNA;#@?UR6>%C7@5K7#L1G&S(R2=5P>%.`>RBQVPX?;KRX^"?8N-5JZYTM_5+WMO']T,#!8/SF^R5Z">_9Y>4),6!SF;031OD' MWO`NJ+[X>9BU,:2.1;?]7,&2:>\/D6&_UPD?5YUX?O![&D5FYW,,RL5YRLKV MS4?]V'5ZGE;=."I`'8QZ M%$2YL1Q*#>]39S+MT),?*O>8"#(I!GY2H!D%]#",=@UIN>2-+(68[N*JOPE_ MRYC^ORH%:.`8HTZ]-32=9K/; M:]V*\P]8V8<0E\(:_+F6@42[R/!@%_1^G,@X\F1[$JU$[J>;3GP*MRTB/";X MH&]WL@VS<[RC*&$9AH]#QQ/AI*6(9&$,4SDY&2?(O-[X!GJ`LF2U[R$MAF"W M4F+A>^VB!L/\[CA?UE.*LZA_]!?'J:2.)-)&&(^*V":*Z&#=AX#!@S,*:?[* MLBSR"^-?9,#PY4'F-%^(?1<>:TQJNPPH*Q:F7*KX!<409!JK6$TY;'X:10F\ MRGB6M7M&D6"X-]J9#!*8`Y@2MI'O9)EET<(/13;#&165<"]EL##E(9/_7YS5 M&SQ:&=]`\=04"QYC0%FL,OA6;RO#@ M3.7Y8^[;YP6+18(!O(NY`/0]Y>?X(1/Y6!BO/*']WU@@3.:SJI7XE/<]P<0# MC"/(\L[4/!0H(5)$*#Z!(LG5Y)07SD1,YT;G&@R$L]80:[)P[<(9ZAACQU3* MWL;C.7NQ3CDXE(;M8>< M@0(A!B[G(H$AH80?"J+/\D*SZM@%PMM%H.\FILNB_0(#\WL8TX1*"^R`7G;R M<%W>6^;O?!'I(PG!\B6^$EX(7G`X_CY-Q:T2::=;/=MWH]H].J MCPS;ZG:-3GW4,OJC?J,_['4'_4X3M`GKY6]FS3)S:#XB9,I'\HDE?9?/OL31 M%;#E26_Y'<8_#S,>ZV#,)A6#`PT.'J3P3/Z(,G"O4"Z"=EU1Z_?K;;/3-HW1 MT.H9=JO?-1RS9QIFH^W`XW:SW\((2ZOY\C?#:C;KS78KA^^O;7,%B[T9FZ0! M^SP]#S'++(J7?4%$W_`>]P#7LGJ]8_5;/:,QK#NP=,/I1US6!Y&Y01/*>"-(D5^'8@02FG<8N3CV\ M[JM[G560.+[HHH;5U,W&YG8T)QQC9.M6J_NPFSZMD+H_HY@**BSBZ#)F_/@0 MO=W1V^8#'_GA[;JQN0_7@2'YX3+W$687SMA$NXRBR?$A?14[6L4A/8_8QPI^ MAQ`[>C/;WOG4@N,)@&QT&WK;WMP6M(H3+>C;=;.*$7VV$8X5!/?+GW>($=W5 MX;C-3:FR!C]AR`@69^5..!FIBN!Y!.K^/9?]`5X"G('1;MI#PQXY/:/7<=J& MZ?0'`],9]80[_&`\EZL50^Y4+^3L1:EB2%4OY.E=FE6]D`,VS5<.S0,$6N70 M/.##J1R:%8X=B"OP-'9QZC;OJE[(_A;_!!L_F(3>\%9JHSK`W']#([+3K]L`V+,=J&':G;AD=I]XV;&MH]8?=]L!N6$]> M8`'_0<5"""Q:#A>M`!@ZD9U+BCQ.S06QWCA?;['9=*G"@?/U<_XG53:(LXJ;UHV(?,9E_TYHUATQ<'*`3``K"B5?=`# M7S9!$+4%0K&RS7`JN_!4X\>:]B<^IEYHV6`^YF/[LJ&X:F:@%\NPP`B>N_!A M!W",7*9NPN(4>NSK,M!OOJ)6/D$.Z)Y MLO.?ZH"6;T2_HNK>X.]0&Q.(J-`=>ULJ;YI22]>4F)-T M>#\8Y#*P':++^[FC=78X!^?R?I0M/Y+3^^2PK`3'RN6]$RZLV7SOB!V6N14] MMKG_I"H7L&E"](`>O:+R::B']]%`%RQ$O5B&<-[+)O2T7M^FW=6[]'[TU3-]N;G2TGC.Q6 MM_/$J"[P;/'S_6&Z3J321/8*U)A^;M*8]FOYW_.4CZM./$\8GKHR,Q3E9']) MEPG*+N5UM?Z`/,HM$Z2!N3D*Z*&EP3'!Z5%4Q!,1'PW!AX3_]I%XWU[F/"@! M=G-_M&-_V(TZ`661"?'US]8,/D6?703_'N9/]^SX]T9]3O= MP;!GM+O6P+"=YL#HC%H=8]`;MIW!:%@?#3J/G7QI=6YJYW$QB^+$^,;BN8:9 MKEF)>0088(0QER![2R=SB,T]Q`[0S4+2/D*!Q;[U&H`870WU'^< M()3"$CU8(LSBAUC/7E2Z+S:ID=7LJ00]>K8!)^'["5M$W!%M/8Q>[6()6CWM&+6C^_K*S M73?)7\DW9N_G]5,W#.>-`+&84(C1P8LTYJF;W>2T?LPF?J(YEW!IQ`O?O:PS M3^L0?DIS\.EO_+0\X1]8@IV$X%+I"<3W.4]%5[NI>X5!VI08P-/%(O!!/SLV M:GAV5-!L-Y^`!DY,3O2Q2EN"\?B4"3)U/9E\<73XWZ@_2UGP*-L^$4_?B08Y M5#!\@$"1O7/UG<\M.*(X@^X3,MWC@5-#M[M/H:L<)Y<^V4B""HJ/$(^QR04( M6%_VQOY<2&5.@#:_B]2SYFLC%"#F8O/Q5/TN>,@ MC"?^G$;E+`@P@&1!?=2%QQ[&`#[@AVZ,\4EIS"GM?YQR/V2<4_[ZRBB>:@+M M1?-%0#D*9Z*I\^H[(?/@Y/_)AY2=[_3U=/ M`G<,.Y:+QU(2.!1\!"]JBRBF[`O8YY4+CQ"L^-K4_XGU#&!!,^9B<0M*SYCX M"1"F3/EWR5XU9A2K$P`)BA(((D!B['*?H!=&\5Q4Z%"MRK%"`USCDZ7<`2PU MPH(/03J1!2>2V`WY%`:GJ"&,\4F6HE0'AF!0%?N_`8_`3<-T_TD!(:9+,3*? M:5-`)VW&)I>,RSH'6&4@P@.0[;QI87&A5V+MUI;?9R]V:/I=M?RN6G[O<^ZC MK_5<5<@_0*`=8KF`"J,/-?2CJI#_7(,F3F,7IUXAOVKY?81.L:KE=]7R^SG@ M>=7RNVKY_9SPO6K_L-4-<]KM"RKX'4+[AYO9]LZG%AQ/#X.JY?>.^G;5\ON. MI'Y*30HJ".Z7/^]09&*;E[[LR_\B"\1_P?+P3C@9JN+P#^7;[SG]OM5Q!H;5 M`/+)'^2[GB MOUXN^4^N?]5U`)W_K@<_<9\\T.C3UF$(T-D`(Q(\-_#D^E/5,0&^YDGLHE0R`C]DRL6?-27(`PNR]@17C)?Z$_#: MF:CEO^%=TS)Y>^C"H0;3^RWA>ZBB>0X0<:9_&5[S$N$'(242][ M^0Z,XB=,M#5P5?L(+<3:'QOJASQ%WP95?$(T086W_O`]C"QQ0^T2X4\M1[3+ M&#%Q'H48<2*"2N@1#.*J'#HJNX(I1!%V9D@QAN&*!9&D3B_QKRBY0L$/C\_' ML!?@OR'S1+,1U5)%14I0U,2F_AY?U$,8H(2'LGL'G"$&^LB37]T)U8/)=B"W MI1@(->0`%D*Q("*(:)67\!P3`XEOFVC5%5$;:ZT\!+6IR!T5%+)+/9E=A5I9 M%!;Z(FVMS_2MU`YI;T)Q8'=:PT:G:71L&X1BO=ZHTW':9KWW MZ`%O]1NBR7ZI2<##J0)O*AP[ MD)"5T]C%J?MF3[M/QPD[:6_NTW%@L0F'@NTGW:?CA)']ICX=E>_KY/WJ%?P. M(2[A<)68!^C/<JV.=A+;A-%I=HV6VA[UV<]AK]AJ'$TM!K0?*R(O_44L" MK0`M.ID#BZHH^H"Q$X<_8>@+OZD11R&/'1VV9Y@Z#[_["99TT),C MBF4EA$@;,Y%-GW?8H-"#$;Q"S]%INOJ"*`RPVL"C6+G@K-B<0YO`?[+8*T4/ MK"PLXEB]@2=Q2EO:Q?>Z$P64B6;HQFC'X5]8?#%S8]9SN>_!&`,_2$6-AWN2 M2PK0IJ]\'MEUJ_W#^3[XL6#Q#X[3\)?:A'D`E8"396[5)VN.K$9K"-0TSTQ M&2>.T:%*4.\M\W>^N$M\YER[\>3S@MC1\">+/2P_<1["A'XT^9.*'+.)(VI9 MJ-^_4"V.IX%ELVZV^U:O9W1:]9%A6P#&3GW4,OJC?J,_['4'_0ZV2ZF__`T@ M:1;8\:,"YXX'<\O4OV/<1#;O[W'$^1Z@OP[M\T^C];Y-C8[9L.N.80WZCF'W MS+K1M49]PQJVF_:@;O;,I@GPME'\6B]_L^!\[@3VNV]]3[`=4B62\YPE?0;6 M%7^;N>'&J5=.FWX<`!<<`0?\@QC@$]%#H]-OM^MMP^KW3>`MCFET[$['Z/4[ M0ZO5L*S1R%3T8'?W<##[AMMJ0:@O<805>+XRSER0>LCL\K"F/3*ZK*`QJ#JY6VA_9IM4$1GW;AXQ^DR,@(-T`` M]Q(C,A$<*L@+%!,LX8-A0U@?"30.$?RWB&`:(YH:'H5"8MFD^1@_QFI`]*PX MVIP:B'$L^81ZUF0B@M!PG:&6+HQI'&$H;!B%1LRF:3BA4*&%(!!4=9Q7=;W; MLO2ZW80!WI2;FGV_>-700#L,8,RWNH3)QK,E'*>N5;@,;9K&2&8:]W^JR;BH MJ*2@DRYD;">&C#(1_4D5KUB,XYQAS:,I%3R"^4&SC$(FVK2!8H:CYD\E1'&] M4P8*QQBK-"\QG#=FEPIP/!W/?&,^;J]9A;LXOR[@Z M)FU=G9XQ6IG`DS%:>D(!+;#PAF<='YL(IQ6 M7BBP<%HZY@DP6_A8('V,`;08?DF#BY!M.'G8]]3W,);2#SUQ0P6B486OE$J_ M"0@US>&;,`X?%;#)%\H*;(M1]"L#4Y[*TP&T(4; M$J%1^;#HDJ*&]U18Z9PE&58JF"CN,H;OD<.)JF@40BR+@>%$OU#H:Z]1D0*, M9<+42TP4Z49"2`9V7T<($:JMMCE""SFQ??]PRM8Q5C*S3//UW0(HFZ_O8G9% M.[_ZLIY';F(!_>(P=;->WWT@Z^Y+6)WW/-3^F0);@".OEQ$G0QH8"=`&6QU. M_1BK%&:\9+R41"V8401430T2O5D(O"(HR@4Y` M9&4!:>G->EUO-NR-`M*J-3,1J0G9D-,O\!S@;'.!Y"AJ+6S,8'0?Q$LER4)*JO`)D[AGH!*?W42I<@O8K#1=W,0U6U'6JU!4L M=Z,N#E@73GZ)O$(2P'VBU=-*2!)A-I@WKW9>67K=9B\87=7L`$^!WR`7SM-P#K[[1:E M6D&$CGV:-0[#'#9=8IN\/6VZ.]7,'&N%)LSE7O"6M*Z&HDI4V/_US`]DAI'T MDA='<5$WSDOH"EC*^T+QXK9^-8MWP;\6)[:%=ND_"L-?1<3 M^4[FDK*%9?.;0Q$(MF?[2K\SZ)K-0F88^LGM&U[('1[`[:==MNUT<= MY["J;ROH$-T5X',W3](C&EU*"RXF`,K0/LG:>:)*)E0)9E64!T?WW.$H7 MY2MJO&W\/,%09@6J+$T.E!7+Q]EUE\(M<-, M@:V0O/3IE'G9!TZ^6:@'!,>:>VWK:: MNFT_<`[FX6V\H7=-2^_4&\]MXQ;NW-2[W6=7[]^"\S;;>K=9)1P_VZRG"H(5 M!"L('CL$[YR[N(./>"59,9K/?9&LAAE;Q7C,A\I8=,Q!KSYJ-HVVV6@;=F/4 M,7JMOFTT00?=8S[4.5[`:7<0'F119BQQJ,T M]K).RUDP-Y5U]671V6A,SBP*%W=A<+'(91Z%E'FYA5>T$`E>J$XL5J=Y;BC" MP%T>813P,J]L7,,"I6AV1!>8"MHGL5A!5]M$B]M$A+4.]9.00_EN$\.:A!C`( M=P,F@W.CT+@,4@^S<&5>AB"=-`%,_J]JU8T!B%$072[5Y$@YY?F12K=L,*.X M\B:)A+-M\M2;J7WB"$!SV'\;\VU$V?2K0O@6[8F(+PN@N'%/(A)3949+04M!7OE#B*O^&98KLBC'&JB37R$HH7K(%8Z@`,!5#V5%/:MJ? M3+NF&0A%*)T!;U+XZMS]BU%X(XR@(L:83YP.V8<6I/,%Q5MBY`@@A=V$@UV* MON88W+E0\,`C%>6^D=E.(H\2\`3VE4\)4`0&8MA-740J!(B8F'_M!@$M($LB MFHA0%(K)LU7N.":/P-G^% MT36L_+*02Q!4!-T39 M!YHR#/(F#T;LOR_'S@DN3T>N>%G^\N#]6]B5B/3E[APY#NASL!>0J^5=Y)N3 MJ9\XMFJJD*4>AI20IF`CXHJI[8;4ZA0'%4(8?\%OKF<^L#!+&TNQ0:!!*8`Z M(<=.'45)*;@U+,O.Q:L(ORYMG/CXVM;AG8E,&%P-V5[;5BZ&.%GB"Q*/9..* M5"R4_`!6CC'_N22L:90?KMJ**'J3IXCBGK:\OEFEE`."*K4JC+0K7Z4]X+\&)%"O"Z@>8_RXB'/-97`.CER:*G!4NL@9L9T'2T#G#*,K04A?*-7F`PQ4XCEK+Y9X#'$O3M'5P-YDX"^FU*I& M*>$EW'09\2N\.TN,=H%G+O_+8I%!NW#C_$ZJ$C!TN408I+!(F00KR-1%71K# MAS,VE:6`3ZE1#HD##ZZFE.B@9I!STWHV!B;+=&$5&$YD4IX'9I&IWKA7(YI. MLRC9U5N(TM?5#5S.#AN'G:PLB6\X%A1#2HW$:U$4_X7`Q`SB>$=MD>NY"2!F ML%"FD5B$H4$=OF0R)>,&6-`>-ID1,-]+<:D5&`&?0H6%V!`:#&CYN55A#T:Z MW6UN95L=]8EZL)YL9J/9K@\'QJC3[AMVV[*,[K#7,D;]WJC7['<=:]@ZG#IB M!(J)1@7:#K)86(%*-A80H'9<>8SZ@DJN<(Q)%P+NMK#TCJ8!^F>E*6!+,0-%G6,JE!]B7CZ1]DIKM;$++#9K M3G;VHM"%;)5^KN6*4>O(%)-3R6^R&W*6V87S@%P9%M#T^GU&[?;]1^-@T@(:00BK0BC0V0G`P;*8VZ MB'`.Y.9^N.P%>&.BQGU2IH/6Z8U%+HGNG'(.:[E%G2?*3")LRK"7%@HP)&3T7L0^(`;#^^,GY[U+>^YY=/>F> MBO+">=44A9QQ66+5>,G-2A<5S`,)BA/5U%*D^TZ$'RF.EFX`X%+#HZ'21?5; M>J6:KZE?9E->K4$#+*3Z8O-$<]MK;-^!J`>\050NH:^9_YHB[PQUR$QF8#TH%3GJ9PB4`M8A-)"#S&RDU M=;6ZXQ[B;G>$#[B`A%O\'B!:7FB M^)H7B]L.$(FH"XQBVZJ9*V.\)9AN7P9HJM%N(,@!4*"G]4/^AQL&;'GK,<,8 M*XM22]KE#G`'378MLB73:^0@?;SR/-0%>M0?]D;-5L,8@L)OV(-AP^CV&Y8! MJGZ_83M.K]<8'%98RU"E]O=$:K]&\#G8>):5^MM)[(]360`$Z^5-W'B254K, M?A?E47B*FG`8IM+E"BR!XWUUS&9N0"5\L(RW*G5`%V19_*XPB+`>Z62C8S&& MFBB[?Y?HARK?J3'*MWVJK+`$F:H2]25%CY=:X%[3$+4Z:#BDHV!QG9S!9+=Z M(+AN3;X#@VQZR\Z60<[ZF]:"3/>B#!7BJ"AU4F`46"C2Q2I'I&>"*CI'2WW, M8,5RV%CY0XK6^O^_O7=;;AM)UD;O':%W8/3NB;`C"#5.)(#I61/!8X_7=K?] M6_;,7O]-!T2"$L8DP0%`VUI/O_-052B`($4=2$$6YZ+'DDB@,BLK*X]?4GI) M-]`P/5*[C#1:K)<%MA_#=))>^DH8B!L;5@!,*D@*6'%^LT)X!PK2$<0DU18E M%#_-<``WZFWXTHU8*F+Y5V`L5P@A2':G$@!\PN0ZP>2EOBH&=<"4I0!JW%@D M[:ZR?23$H10B-G\Q!DSF2>7WI8GJ$O\06](DB,24P1Y4)";;&HHA,2.J&3-1 MVBA[@;?OIS\*_%J*5)3E-,0WRU5K`I8W*FR?%G_J_+6XIOZ]W`% M^4;1X>WTB]=1**6T2!&%E.&598',I+N]G-$@,T-'*J9((9P4+-P! MWMABN`]'.+6?1(TGLW0"463CJ:H:&G$FBDJ M3U39?I!Y/$_G%)R&\CRI.%W@4HU/8%"WWFH,?_V/:#XU\L201+QIK#PQ!9B@ M+(D,BE8>Y^!O[I:M,XE$AP^@RT'LFE`#FD#A[GZ+YE_E+\@IP>M^4\EE]8L" M]Z<,M$GU$"4Y:HI@@+F(??G%'3P`I1SGK8]Q]H7."\TBH1_EU?=9EHCE36ZR M&6P[\'R5L5DO@\_DG!:HCKA3ZN;53K/,VS*BC*) M-ST%2RN+A6,/:Q/9UHW;IO;1,8;P.=L&OR;AF,]!:F2#%<5V1;&;[.O($TTT M&W.-#(%%7QEF5QM7Q#'G:$JIP9Z"#'UJU:"345U][?&N+/BI-9@N2FLRXF]9 M/PK--=:IMT34#(\E>B,X=B9)(ZRBC+YS#7HY^ZHJC=I"+XBQ+X4BQ)_5SI;% M?)I$+.=XD*E/!N596^U6=4I%5FE(IQ]L/U0B\.Q_)-]`9:1M[0D<-0/=.TWH M391IG-W0`YAB?5Q-JGX4>.$<=1,O>AKK;!?H^6UR*2*D"OM;F,1P_0!'T*2` M9[!1T;HH=1E)VUE\EU.F=5)T]FKC?>1P3N4;Y/-QWZ\P4RS;5A-N1EM$(4K: M0KQ8LY?C$GI[O%C`_<#9+7$]L/NG1W4T$:#0MBX(.[>>!RHI6F4]*;M_Z(26 ME@XZ/1+I!NJF"@4TL?!IT2,&CX*R?M3\\0!I\1L'W[NA',E>FLV3;TQMTY3A M:)`, MOV(Q$E1:4\&ZS?!+A(&)S$;X*3)?&*,!_T2D/;[O@D%1N!F#5A&DQ M9K#:WJ\@!,JL6K)]AD*=<85*:8`"QIE0%\@OH/:@P@3A1*J.>,DN/2[,88-H M-HLFM%[1BK84,Q!VTLF;JJV5D_BL,B,:%GF./%.="1NK MH\RJO`GF-RH`IJK[RSJ2:NB*E4C64.9._T/!*MGN+S#:06@7:S%_H41PS--* M%B2*9&KP^H4\B@EUZB;@ZPH+H/$),MVU\W%UTLLB'"K:)/FG)MZW6> M'#2B0\V9YYPCX^")B)XJ>3'>@>TEIJ,M6+"]9$ELNDNEY`HY*S5Y3/%%;`04 M`66JUQ/%\B+:K'*M\!2^0FN%M172*NPW1*S_2@1EI*C M(6K=VRW1-B%]@S3ZFGR)"K6M)7IH5\[$^$6,YE_'*VXGEG_<(B[4981M6U)! M\V6<3.#F%-'<+<U%M7M&EO%1_BU;4ZHTJP2MN)3E5"*R;HE#F-ZZF#J M#EW&*Y1S@HNX$?(63%ZNO9`V_9*2^WAQB9M;!);^*/V^B!V11I(]ON5ASF([ MR6O;VMDD"[/UIZ@&RZ*27\3SJY]91EBLB$_&2>EQAA'*\RK)9S1=#DNP*"8G M-;O6T`!2CT.7K[BW4X@SF\?X8BW73!\XIWI?OG0II,'^G^HB`V4B?H.C!DEY M44Y+%$3"E[">1*OU9*^8.Z[%D&8YO$M8'7#D,?K%YA-8&-@0P;&O8A"?T'RB M=70F(BQG>AOK)$0,!'1/B0(J;!=>7E:81ZKZ0M@FRFU&0R;[ID%.Z5("I;`A-\4KW@E].NBNB"6ITILG[9E!)T%O\"^(WQZ&ETJ/2TG>#]$ M.SSRG*GCP%9XW8<-FNK>8]"493[=S*7#O_O93Y`X]-".9HX/:CC3_@ MU-K5C\N:DT2?YNYL$'R:N[/[OCG->CFL-#SO62^:&?O\YKHX5J=M.MV]OOP# MC?APVU;WP'--'D?NFR+E_TI2JA2D9D9PMI^=H'M^VS-?W"@;QW\.0MY`\US#_$J)=[O_"XMO++X]\QK)6] M=PW^@J@Y]7[C[HW%[QW._ZJY8`.G[;F=)]&SSXA-;MLVO9-N?JESN$XW\L6I]H54U,?']*PVE4VT@HVS6H(TTDPN/EUR2>%'@"7/HBVEDN M>;H!@M=@]I>JOB6R)S4ZX-;GB#VG7L>I<7C$)7Q%Y:TK;7'H\^AZ+;I]-0JHKH?)KE2F5Y3#P$"RL_AH#"^&%\7(:?XVGV':O'LG`Z'K/ M6[MU%2'($.,#S9()U<]PBIG`?>17>1H9@?,`G5/9@R+'(F#MT-DKA8>*^$+3 M?R-48GX[#]L(B!DN;]I%82.906*!G%J?8AD5#T1!S'L)JZ#8N+WNL[YV M3N+**-R1LU`:6+LN+F9*QO#=`_UX2U]W3Y MZH._^MDG7D[IZ@8R[92N;O#FG-+5)QEK2*+WQZ#B1\]H]#8=B'NYPT\9Y;?; MIF6WN[Z]U]=_H/2&W;:Z7MOO-B"4]GQ2U[UZ_W(:7>:GC-Y+)_A'BQK_.!FI M$_^:D-&[JR&S]S[.GT_RZFG-C6?%J,:8)\])9_](>:H3!Q]7;S:%MK$Y-^',KIUNPQOO9$!#"?P)^Z)I@Y/A!JBQM1P(B`=$.4G M0M"7^-AH\KN1Z8HE87*N!LJ;Y@F'\XD@@O-XN9A,JH\<%5VO;"[*H>ETYAD##&3G+1I:2AB%\8+` ML0JPNW"!S;+_6S2YEI9^]FIC\03\RYW-#*B$4")J4BNC#(-/J-8-CZBL7!%Y MWOI=&Z3&`#VK,$YK9H]H8R-#@F#'+.BTK>8D",PS.<6-I5+DF`O`=H9Z)]RG M2;B*<;0]8]\U1.AT;$DQ&RYK_3/&*59QN&Q=X28L:9=I$".B-&,G-C=;TZ_. MM'F)/(9(3*5/"(N@F&9=0%I*)C+ZS1EE=)?11,P(%Z`OLH.8$NN;1^&<=9B< M5*X+XPH':A,>)3;`B^VO4B+@%04%@JP*]F,I,5S1*EDACA(6O^[`AMS-K.`< MY-S2`IGAK&BH?DCF^)%+0K2)Y,-B#QM[17S<-D)=50\4@--B^^2)YM,NIL73 M'M%P6'&YJSE-6YY?"+601*D>:,"4'%@A=WUC:D);+*:`&3L3V.D34(8XTZF5 MTRQ;?`I>#_*WVAK:.(T);X0DQ?H._9C)91MR`1*)0/%E^P(8>*68)(^,*Z]) M]DMM?X98)96\U$^H9X")9$)SC,_A)BV4"^V'%,IU[%,O83UFU?9MYZ41;B'E9CL(7ASVB@7[ M;7KMH'-@83^50S0WF7_BX(F#)PX^=PXVLB3G+<_5^83SV&E93N3ZWG+G4>LL7(YI1:W!P>IZ5F>4;2V2LQUX7;V65*E28_R;J5832+ M."LDHHZB,O*G4""MP?R4OIK MZS+*OT5ROMCF>(2SC9E<5'I08`FH19:7R),F:%ZEF'.++?&XMDO";J=13@I, MGD?V+)EN`5]`KSU[)8=H;.?.!F_$A,JIFM01+4.>M0/?XUD<^O@=E*D;GL/S M70Q)T0=?T=:0%*@I5PG5_2QPCD=Z4^*F3.7*9^N-^6`L)AA M)=)T#]JPC@?W@V>6X/(4/1N#C,HTB+E=8J),"::?>$,.(2(:-*0NB*<$,OS! M(DEQTM<7'&!$0]2PQ(E.8884JMD'*4V%Y[*8LU>U#"WC)80T4JDMYIQL?/KL ME3AHT_6$A[6%>*N(63(*J:$Z9$;'T#C#V7RS63R)Q;!4?MBV-\HI)0+2@VBD MA]2S(-'):,K&,22*FI6>E)6G$,?/RQC/QT6NYBVH:>18!OCY_.*\-8NFA,E1 M?!]H!06WS%KK%1U;-5903A3'L&U)X=.X(1S-?8D:;A;3N7O+HS%QLQ"3I%T& M]%`C:O=]X>;KOD;T/EK)O#E553T:!O0QRF,QO/<]W)%77&/8V+N?%YT6BTZ* M1;=>%S?NX-?>Q_?%C\-?WY`BDF/=7R28.2.=,JBXJIHL7#:,23'#@MBYK; M^F0H,@>HD!24CASCF.6H'>')H(QD37"MU2`!;+B6:E4NK*X66+ZG`EP0G'9Y ME4P$ODHK#"KNQ#A7)9C,,9PL'2OTG&+U//BGJ-3""U;6_&XOX/U$3U'ST"-U MZX)-^O%]Z;K>J+K4I%!<+M(8:(;RQHL,B>!)7W)8(PU<7*?(U`6-*%(#MFJ& M):+BC-*%*D^E&FFQ@1%P,")U3.*=Y4E:3."D<4/K>"[FD:U7\.*OX43,_>$I MJ?3ZAO`*1YVAN*#-@3QC`9R^W-*R$P[3JJ^LR%-FM^UVQPW:@7W@`2--)-SI6&VWVX"L M_C/"8)I,4IK@*TN7GIV\=\RVZ;TXP#$K\)LAZL^I@.7'P1`Z\>\Y8C`=3ZV# M-_I@&V;^G/"-NB9<`^;3@/`]*T8=Q3C\T2Z.'ZEFZL3!Q[T\[E]UYC<.36![ MHGL5$W5M0&R5]I24=X M1+A:I%:5N-VU,*\MI M,5&YPD=DV2C!C`2'D^OH`2FW[N-FW/81B8>GW"S3_,L=\1O^K&6U!#51` M7M'S:%8R%6S3MO=_D'7W)53?^WN8?HERM>_EZ@MM5M&"/[=*XXFL."3IC9?J3DESM")X? M3`N?A/09">D`BTMVBZ@:*)51I1QA?*41RQC=59.\1MH83%`K-#RC&MG6;+V< M<%$;BOHO"$D'CTD6\:257()G&F43K%$]B>=)/*]4Y?]>`EHJI^("-%%K#D(: MA0O\%6+=3<+LNC7#VI?#&:*/7.^41;J-P]"/R3RYHK)]LF*D"5/8&_G-*E*= M`:MU?C([7L:1^3_KA,L6R9Q`E5O8!V%\# M,5TO5J+:GT7*.;A(/7*+Y0(1GKDF?]9ZA\T$[ZB9@-H$FAV)*J"9<>1O1K7U M$D>:-8B.I;R";5MJ#8L3`?%*:JC@`I;%1UAH#_]9L@[BXFG2/Y<8[P$/!_VB M.)VL%]B;.:&_34&-Y1$+3$V'026\W6LJ,!2[9IWO';)7;%82!` M5I@SE=5VAT(@U[""C#I(L7=`V;H<0@`S>KK&CE'&IM:`5LY>%+8>:NWU!F&S9'PD&_)>CZ5#86BT8]:##3$='V%PD0O%GKVJM2:J/>P MBIZ'$@NYWPG61ONTICX:>/PJ$3#4L7!%J2'MMOT`?LOVCZCHE9-[FM5L:N%L MR.X6>"%LY]DK?1]Y^7&^=7<0&+W*3-%4)[M$+V^$E[W1NJ+64#`%.]KRK-22 MTR[\I=HE-*8!3/;8+5N_)Y"`,AC`W7K]6\7G]XT5B-]1$%(2?A?-GFMP&-,X MOR%]DE_3@(1,=J[J6.Z9WNDB@SXHW1JP>TG0T-@J?4E2?4ZLD',7F0>K\$;\ M0$ZY[&2"#UK#1('%XF'L'MK,B]TLU)\"XX%Z\U-SG`W M$34 M>-71PAG`8#YO9C`9%O`C!#B[R<#:3 M8T%1<_;APHW@7ZT_DO/"8K1,!N+N70S@<5VSTZKA8$,:O#3[ITRKY%T:B;A8 M5F9G%LYE>$@:!>V"E7B>Y-`.D0\#YP%<@9!<+!WIGQ)I&M:_&G/1$`YMERC) M@L(J$K<[MG/"?W)4.9/DR&B$I;%IBDY0R4,"@IG"!1-VQ@"/&_]!A9JRLWA MI-/C,@$%5>0-XTM7;%,QP$>6)XLH;<@N?2QMC)2\\NU$9F2(]G"V#NG*`%-X MBMD"<6O"7],4;72!'!AG*-3J:07[4D3B3V73,,4AV-J:Q=]1L:0J4XRZOJU. M`%BE6A,R-O;(6,BP(R-:HTK*-J1[(?U06NJ[8HBS/"#UECTDH)'HW97&@ M(2MJ(U'>22MD$>;6\DBN5Y4DH&,")P#%1=+%)X$)*20H(]4#`5N%?^*_>SS.<]4B2?*[MP@!==0AF(29Q`\8+(F:[1UH:L9`@JUOU"X MY>>#=:(O@O6"=H:YGJ0$J1!F^@?`'8QB$@]8Q!0CL>`SQS-*H_Y;X!@5ZC$E MNRA.IV2JW^B*4RQ.6TQ;:-JO83QG_:>*7FI-C4MP[95[SX=!YR\]3$M?D;JB M>*U\`<-#M*Y@S)V]$8@)NX1) MZ`X\1:_C-X4>K7\>75O,.DR_XSTA[FX4[)!AP8QPCL<9Y#T64]9>Q_JC8^%< M%8?J3$-8`MZS+=&BPE9D/X/*%&=&2'%Y>5Q%)952*D-5H299&&BJ4A1GZD3S M3+`TN>3:`52TZTND2,![@.Y&E4XW8S(7NJF&%%!.(HBV0S^UJUI3OP#.7HG8 MU^*2#A@.)6OA*9S7:4FE#_(DIYC33G6EN]B3%&,[;.]5WB]<2OU125HWGU"S MQI.E@,U"V^-#>,/JGL-['+PKW0/YS0K3+,19GL$E:M;H6E#^DTHC_Q5.ZM)( MHQD\D77!>@4V&JQL)=[U*Y9T(IXCN,8R M4D]JR#D'AZ'@$I\+$*#-Y;*M2M(ISB/NX6J-UBGC:.4$N06;L\YTH^1;Q&=: MHI$LSHE8O>+]7_]X^VED7'SH#49_;6G%XG^4-H/X)0O>:U:(X5C"@E-.H)C2 M=QU'7R,9[$B`KVA\5^8-%HXLP:_44,1WE;@0(TW49'RW(M2;K"NB MN-I2"!=/4[8BK(K/VW?_EG?9/VG8"P0VAGRJXX,P!#85!>Z#II(%OA[\=26& MHTJ-([>$XGF:ABKT>RGHI:F4AAS:W\-E*%0F5ON"!A:QO")D3PJNF%D15,-1[%^?88#SHU M9'-=)0A!E[$#`28V`D>IVS>=DTE,QQJ+AG@R;?8%40;1/I;H5)5`#LVRQ2P[ MG1`53%#\E%DW1"LL$UY:L;H,*_$GLCKK8E!I;21`7K<"9T],89W2I_#MF]I9 M9&U$9)ER@IH$X`U>0)\F'.CE%_-2\!/(UJJ@")V5L8]%>EQ8!73*8RY0SG!M\H7/Z8DU@HSVI%BKAXJ<.$K]=MMY/ M\N02EFV;IE?*A=+ZW\6SZ`+]54)OD,9@V&):SU[MIK8MS">)HZK).B8WY4$% MVVD2I11>4&(*;U'OCB5:;32?HA!=SA-0OE?S]00\U3,>IXL3A(4QB>,ZR>;$ M.R+Z+K,BVKE*ZYZ"V@0+'..5T!3[[&?K6YB)NXWP=[$L)ESP>$J^9E1V!IYW M@UP.RJ?ZFAZ@J]D]WYQ=BP1QX1&)D!4%7G!PYJZ@`@C2&Z66*4915LRXS1G- ML-7W@=4%\>9D$]UH\FXK&92,=CO9=7" MQ8\)T2(R)A1P7D1%++C,I,L(;YM,Q*]E5J8(83,7-BW,;Z'NB@NK)ZR8O?+# M\M58JI>J1*UJKBI1H-VG&L"D[?`>R@4Q25IO>;3/=&APS+4H>F;H^V'$95*$_6;)MBP.0WX_Q%YN=G=C MS.TD>F"BJ?;#^V4=R%Y`,YBMTH5?L1]*Y*&V*BY4].4O8OR!A%'<22#"(0D] MLD-#E&698RF_3C*N55N!1.=&,C,FH4@ZA(M+>6(F')PJGB9*8+&D`Z5K.HTE M#"K<>>N505&:=M73E6<9;J?>SW8[Z%IMV^U0J/X_ZQA.I+A$/U_\[*"^F,,S MWT@#JW9O98Z%S-]0S8C/XN^52(GDSC:O71A3[/)2"$[I*S9MX/[$IQ:_%1S% M];A>@AX65W3AVXCP@]@\"7^OV3QUCJ7D M==EMIP!WV92IB2!*]&*]\B4L>?U2F10H_9N:[&X>>UE6.4,B]^1^(7YF4R68 M*:4=-3->>L7EPY*L+AW]JI'QH/M?P75,.&_ULBUQ(EV:2G;#F4#W54U$5%_8 MEB68MU[H9Z\JFR4N;7&?%T,@MESIF+RJ7NKE*[T9!MM[D4`J'K13U,3NJ6'I193;@S?_W^LEC2FPRX*CA`:SZHR9/HM3T$2% M+L%Y%W2H61DE6&(S*T+8^KV`#\%H]Q(VK?##I!KF<%)8OB"M=L>VVQW'K;T@ MK?..NB);FB%-YQ=T#FBV!0LY7K66UVF;KE_S'/B;:[?]CO?F=F.Z4A^CL8XU M/26;KF@0S:F9Y72ZQ.F:W^QWNC+LQ9X^Z'@M.;-YIT/F.G[;LZQ'.&1FI]-V M3.OQ#YG@X/$.V6-7B8*M(8(;DLQ26EI.J.`('&[7$DN0%H173J$BM%)W7-:B M3'_;WQU12<`#QDK1DIL:4ZR:1=WJ>)U+`X3R\%HU>.]GMVW#RQTWJ$@#?!WD M`?[J=T#JW#?;P@."([3MY>DY;2%MPGNJ\YW.S4)JV1*6E:,4]]PP0]$DTNC' M62`9NQ>RIEQ["@9HU$"IF>"E\!=TQVW3-2GJIH@/7""@O;?L#<1I4?]18_Q+ M"_V)$Q@T*0E5#:=<&A9KJ*QNL^$BQFSB)*6.D3S\0@6=%&U@3U$49/`(-MR( M&\XGR&:FC).3](]"#)^P]T"T'&Q)G.*\*N!$Q.Y>(W?L3FNO*5'F'4NC4HEP MQ"7"(D`I(@?B$5H(F"Y(60$)9R_Z&LH9Z-.8W%!U>$G:WFEW4!N;`;=NH'[OF&V_ZU:N-KK1 M1"7$WO<:IUWT,+"(L?=^]N`>L=I.Q]_ZWN(BE048]-+=ON^6UW*D94?[Q2X9 M)>:JRC!LD16WJ9ZA?H^RJZ>G:QN=U.!-2L]1<7$$HI_I^W(NS8XP8ZOC#L>J M'#V1G*0@`UDD8M_0^:DQ-3C:RZ-J0Q60AN_^ MEB;K53D$JZ;N;._&IQ/*/O8O@C3T*&?<3N!]I"-@:G M/-M1'E[]I>=J3>HI5V$LN(A0`>3+(TX"-8T4'>`\N%'ZF52QEE=W057C2:JH M+QK]#CR*!F*+5=:.E8'@+>:H6^IG0)-1@CIG*:N(9F6FULP'CPN@P?T,#6EF M--R:G>T0)U2TO']O?N$=!2)?@S$;!&W7\MX(F]+JM`.[6V?(GKTJV93W-V3A MI:[KM@//D2_U;/C1#PYCQC9GS_C/0822HE$S( M0C2M"HLL;@JMTA5C7<%6U7_#&4*`T##W`!2]ZP$LAO&MQ:HYC:E.VJ]:0"&QJER1; M1NW"8V'L&D7GV2L-::?V=.BF5D.M:*>S\(.>!;RY"[M82;"\ER>JZ;,< MD=?*MM#@!%.7[6<,K^9+)>B$8S"BN2@5S8[V^/;;_OC'_!VA9QOE`X M=P.]5NNI@V%;M_E=Q8(@X+A2F5F[O,>3>1@OJ*J982=$(R8^XDH("A9?BMY, M4*OAG/=7S260($P,*Z/\'"J+9D0QU<_-B(+%J(S-[(50X%KYHP8OQJN3P!,: MW(IJ<#S'"?=G6J%\:9\MW]"^!MGKTYF]7-7]K*K.@3G#=$JT8U++N=" MJE$KK0AKLV/^117^$JQE:Q:A"1+&!*I1;ALBE[7\<>JJCB0,)A\J]:45.,:I MJF]0YG_9*53W(PB%?_N8<>_H9F)1$A)QK`KJ`CR[@ MTB(C]NR5*I,0#=5D"\S7BQ45&8E&)+<#&WN3,4;&)(I7>LOY>B5=]FDRH2%. MVOP610SA4:,Y`6R@B,K\AK)F8)7/Y]Q'+ROGM922[5-6U= MT;G(\V#G7RX:XHNF0E41SWI5E9_?VOX/^OTTNN.'5;%"&+$;M%U(\X20E]#] MHYHB@H"0()JB[2O&5(3N!N9H+,C!8%+E7:[K'D%=O-39-2T4"8)SH%6YC#XE MH+)P\2#I=?,B.W_YM?7/T<=/;P>]=T;OW=O?_OAK2TX/E;P8,2_@"?C;UC\Q MO/FHCVP+,R>81*8,V5HMH)ZZG@H@C:\):$.\ M^\!2KB8)RSUZK.49GD;HLDJZL,>^>1920`(1"]MXKY:I*(@3_4[X;*'3BGZ; MI0R<:<5TG$?4QJ&H2QC_4@03K-:EN#:X+5=XA.`XE6]*UM:P++>X7KGFL$0X MZ?$-TN$S4]$E4ZU3W""KN(:R*AP%W8V56U&;HP>J'`M=BYOPO-77\<_D>1.[ MB-<]=R)O$"N-D3(6+:]"U(P?YB%&'-XNE\E7/D@?J+[\ M'3RHI',V/EC2,1H8`*@WNDRF$?:1R:CA\@H\W8CT%8\F$VB/X?SF?Z.4V\9T M:.NP0(C@-Y^]TAE!R[>?DYM^)4E937;@M>0-"/1 M+4K2+R*&BSIT+VLQ:Q'18`Y?1:(.>0CE;9 M^YT1ACL3QE">7"V+A,ET+D6HP+Y*KT3_*J<7M+(SKE?84821"1*L[9,DB5+M864V,IOH`M=& MV:<*VK:RB*+1GH8A,29Q^4/3A8-=6"DA:%"1Q,;)'Q8_P`I6(?:I66S+N29#U=Y[@=PQ0U/`149HM4XMM M,$@GI`!U4A3[';ST7I9\9U[=5_\P/ M*"XB$654R?LM)7$2%S@-,]-$:>+/)E\,?A\X$X! M36'3AY6(0FQX>;'VB;9V-&:O4FSBP1!MNSJS=ML,>S)D<6A$NPS[*3HQ,H:* M6Q97RNU;WOHJ]+^HWE-*A]Y#(7+5XT>^0FE!1!_()]>-JK)6U'K@/R4+O!'? MA7F.BFJ13*,Y/1#NJD20CUA)T6(U3V[PBOL88>AAPIB)M.^MSP3V5G+O/EY\ M+D>-B!G_-TJ3U@>&!AF))[;>K^0\]-(3_N_HP_MJX`F?*B80X7M#GLU!JQ3F MGERFC(%0DGO.;+E.YM1`D[0R.)>1+$M=4`")GI<5NP%:&^5G*Q[ M;>FEPJNYTVOE2U&WT`YR:$P1KC6]<-GC]R)(5`AK559KE2>_7$.!B;ZCO9K) MJ1KP6B:=07'B>4/N:C$5)IT6G;/8AR1J\Z@9@>6"@V"QJB1I"80B-*X81Y81 MRH7FQ8-N35##^9H@C.BAN".J1OK?ZS3.IO%$ MS*<3-M^W2*Z4&@DIFBS6"19=J>I%)L]RO7=8XT"E^ZJHC%5%J6>$\;Q*Y(`S MHI%GE^!SU)M+'E.94V31$,TFH4J97#'.D/Y,>3$9HJX1;H]N7W MXD>C:;:51)6H)2V:1R(92<5H"-DM1C$*+DS@VS&;O&C>&?'24#,F>;Y.CJPO M9AK4KFEC&J&^,%&3\000<<\ZDNG613*E3?$ZK$X*O%-DLFR;B%N&`F&[GOI$ M]6"W0.;:INE6H'*G<`V1QE&7C[B86JLY61<;T=;*72JN71QCBL$T>9M5X1L^ M\-,(F^Z&!C@E2QT"C`>-@@C@Y<6Y#K$@]3>JOC][Q78./`&HQQ/+-LYKF6#` M":HBET2!6QJ$E8A!&?.$T2?@RUA#BIJ*O@YTC*C[CDG',219Z=+5R@7.&!IS MDL:7W`F**"ET)5=O9#W=LUP3>BOI?GGSDZX1?(NS;%WJS46&H;*@>HQ%^#U> MK!?B!CFCEH]%G.?,G'GX3>G?=S&;>!_7\Z+@M7?Q_Y6OYC.!V\"19$0YE'M67R&]@YM-?)ORS*1M-"@*V#H2-&"E=#J/HY1' ME^.51!$[E<[&K2D$O[#?T"K`%U($\3K$&#U)&F=1+5-D))&@*SFXC6F4M2!G MW/4UN8Z4U8Z-/O2]AIA-O:4\)>)LB,+O0B)+<2NR6$+@^!+SRRCD9S0?"]&! MZ$=&$YF`-2,GNVO%2&'Q,H2\D+550O:*[[-!+/'_2LNK*B+M".@O4',A%$ZP M&/5,I3'R\,ICRB^D98!2NKINBRFH,DD/'VVW)/2]5H`+B@,GSV3T0VG./=H9 M2_"(A)4@QWOQZZ294<6A%U&YLH)11T&!]6[8X_H9>TVUC\5,JS=L0,[C+]$W M_!*6)$S_#>>U,:@1;S=/)8YD\BR_7>.V:A)!)S43R.>%WRVL5WK>)N0D&G;"E)H2A>S?H-4]B MK^TRV"Z3/$\6>D)[VU<>Z_>G5[^45YL59ENKE_S'I?RUKE;?H9OII@\-PV.&$PR\LOWJ$):LH`/L;Z<@AJ,U*4/9N M5)PXO\EY^R;)C)CZKX'RQX4@(HUD3?-\\M;Z]O5F3IN.M^ M#$K_B."J6>]6(H/?">/HZR;HIJOJ!X.>OE,&\5KL1)2S==T%^. M\GHYE)[4=+/4='-MZG\F6'^+'6#/3DG?7\C_\AQDN^N4]7]^MO`+,81/9)[(/)'YLHS?CW'VI37&BBPUT^>C3'\^ M)Q7MG%L_MC7EG/OVB<#G36#GQ[:(G7/GWMKX!=G$8RSF^Z^]@Q7W,Y&:`15]H/:D2'^)&QYY44'W<.QQGCS*) MXGE6-WO=AQ4W^][=BYMWU$,_UN^?[-6GBD^L!BL+E.34)?[CCW497B*9%?_F M7A1:UN6^.WL0S7IH)OPK0AT=38MEB,D4](FT]8M8CNQW*3Y'C2^53_5^?ER6 M_>BQC[X8'A/F.^!.GIU1;IGMKMEMF\$+,5BM<_-9Q`"/)_7.3JG_C9L[GY]< M=^PV:-V7(=2']ZR?OW+?+>:R4OKY"?IKO^TX]PYFOWD>XGWH@_QCZ>QWZ,L] M1TEVW'80W#OJ_2QD&>R/>^0Z)>'M>>O^FQMU^Y`V;S?MH<_C)+EGE].&GWZ<7O/59H8!_%&+0# MRVU[WH&UXV,PZBG8`_=&]W1OW$4A.:"0ILGZ_XU-NCE^)+XU,='T MJ82G)%&(1,R6IP;?/K)QN7OHO(,8/RV_;5M!VP]L0D("/]%UV[;G5>;0BR4Q MB!)CF9:P.24.I08$&2\E@J7"88:GX"M[/W>MMFSY;7:7=M1P%+,YH7 MC7"3>;1H.8UV$^/*<4Q.>>7TZ]>]GY%(LVN]$5SI_>QV@[9E=]1;EX@$O/G2 M7:^$Y]2_M"$04#V"MMM!0%N.U:)-@=^T+3_`[ZR7Q4:>O=JVU3RQ-D_@XXC/ M)A&_:M"=D5-IBE!AC(=?`/A5@(D%:MPG'&LB7T2(N)4)3^5!Q"\TP=KU'YA@ M]>^>8'5_D"SG7*3+QG&&HRK^)PI3>OM],UUWL]SVS.6=LF]W\Y+N[P,]840+ M[B'_T'W1SRUT>>LV=Y[=-ENFV^X$SV*?&WW`N\]NY^U.V^\^BX;J!FVS]^RV M.3C%7D[1YV.JW;WW)G%$V3> MFH<;A#@Z303IDG6>Y2'/!*0@W1YQJ]N"=/\;I`A^.?27"OX5'ET&$W55&]^'<[S:P3A+QY\AE-< M,WWP`TXH@.?PQ``<.Y[?X,_+9&E$WZ/)&J.;Q3/?$!'PE")0+59(43$.U,FY M#SC0)P;"U'R^NBD=Y:^$.<[L:,O9'*WRT`X:>'$C9_3%S#,>G!2N@=24@H,\ M<42;BT1\B](\GN%$6S'3&>/4Z2I)0YYQ0(,0R[R$AT2@*6,D#`^\(%3%,>$A M-9O)NZQF)<@)T#C:D^=!T>3:)5"UCGA@`[.^][.%=8DXYC*_5A/)2J//RD,. M:&[+&4Z)PI<@DVA@2[MUN`'$'ITB0C3\,IS7+)X[F<+B4F MBA!Q:J0'+#Q9:,,'Y!0O6I@0N%1.@3BCN1GJPSQ7>QY]Q?.C9O=,>&@DKZ,T MU$?.^E-\36E`!1*-0VRS+)G$%/6^PC$[H30-L?DRFB??6G). MFYC*0I(D!F8(/25IS>`8(.W_'8)/W!_4OW"*^?^I=._4MZ M_]*\U(U3&$C%ARY48Y/VP;=TP(F(1TL>-)QYOX?IER@O%O%/-,X?D9?J0ZJM M_I26V3.<]WMX\TP;GX)'2#0):,_N@[_[_4R>DB1\5/FW]JF^T(D_>AJO!D!6BUP6)I5OR]"!SSBA9:0 MG3`Z3C[N4_NXZM\GC(Z*ZTEQNN)#)X".$T#'%A.G:X(Y_V*@QYZ',7\\D=_= MZ?TQFF.^`Y,5&RF>9R?IKX.VZ=T[*/,LNK]!OD]EHB\2C^:Q/-5G(>2'1C_] MT:J\?IQRR6,VJOXX7'MN1LD)T&"OW@"G[=U_JM&#=/Z=V/04S#G\Q+T?[8[X MD2J!CWE+_$A\>ZH`O5^NZE41*:K=5<61_6@9S>*\-4BRG+W/HK:W"&(]=95O MJ6PSP8+ORW7.%8-4VXUEN5.@8TE][N+OW.>>K5=12J65U,\^6R^G5)AZ&5V' M\QDZX5@LK@HY1:][Y2%<&]O&NKU%E,YOL!@WG./K@[_@(Z)P(80![LO@ MUZR5P<6:WK2Q(/F,*EO3B-KQ+V^PFI8><6YW_L)%E?^]GF_6^5%I;7`N/G/V MJO93KEI&MKYE+0@><5'F"F9=J')R/<^2]`8^^#5>7F58&'N5AHO6-X0E@!6+ MQZ9("M9X8@5KG'*E\"J\@8>LDI2>B'Q=;EE&&BW6RRB52`3P7:Q^7<'+OF(@ M9'/#L#XVIVR1J@R%%>K`&^3I(L*JT*]R"-KN(,)RC5+I)V%[Y<%,/J0L0UL:LPAA4,-GX_N0[3 M*V(C\H._2D8KU;;"#U-$7I@6R!VRJG>51M?P)ZP#%^`>)&9$]65$OX!]0-: MTXR6K.4D[7GK/>*4<-4Z4!6BGH!+!)ZR"+_@9[%.G!L%5DD.U,=X3%MJ>V5K MCJA[UJOV/R_A`RDHJE8_AC,(IR#-:D%)@!I1PXYG)9[2L:1^#CX_2'TH5=&. M+8)3$JZSB(_,MV0]!]6,"PE+`GD%_UGJU=EEC4;/%+2ODBRFOH6&'+A/A!$T M*.F*MZ0K&GNV=!4M"@'XH-B5@U)'%5YO@SK-&&?*1H!#DBOX)%"^RZN(98=D MXCJ9@SAE^A;+[IN-L]!*BJ,@KN<<+H8,2QU0Q.F0ZT]MTQF6*$>"RC:N<;Z> M`KM`1-E.(&4.'YVL%VN<7OTUXB?/6:K#Z;_764YWP0_;B586Y(\1YFY;O@+IT)-F6MX'Q/XM5<]AXI(IG-:':B+5KH MAL&O:.(-J%G4A17*:Q.`7;+)BGXY9Z,D^BXT M("LEN'5Q?\22U(+."Y*'OX*J1=-X?B.589E+9,:6A0K1Y^"?V2191>V68AG\ M;3Z_?Y%7]SG6>%FF^9<[5G7]Y2ZQ%@P>:_!@,HXWCV:E**)MVO;^#[+NOH3J M>]].<<]G-X5O!-+Q.GO#2BY9P$YB0P^+$> M>)X3V;6^*2^,F\#1ESJ-M$4?N2?Q.HF7\&?95U#6\S?PZ5JO$>,`K"(!PHBBC/REZQD:TO,_C:T?X8 M+X$:!F5A"MY@,&XD$$GT8(1T_WG[)S)U`_S.(HV+O')X!D;_G*YIV.:;(L0= M+A@2'+U4&:28-B2@0($]#$D+,>:(R>?SB_/6;[W>!XFB\YE$2.;1,HKQ@$Y` M821@&/#:0Z)Q&F>3>9*M&`L&OQZ4?,Q==91!XA?O@%9N(J72Q*P&7SS[%5-)X'5H9!;EU*X MK=4:U.9$Q&"T/0LBR(C*K**!1K2Z^OD&_`\;1,NS@W#2XGL*?\K+,?A M*!XD:>`DQ]OQQXOL34/V:23CA0I72!"$B/,4'8QBTJ1A:[:>X[[E:2)1]0F* M!S,^I#LQIHZI4DQ`HR9'UM`3U4$7:ACDXA3N>1'FS7A39+0#5NP8QKM_;7W< M]D&1D\O#+Q'GU\4M(NPCH3DY)PXR1FFBCMEZS7I77.4K-"FP6(#"H-,8/WTR MPT]RBA_[72JPO67ULYJ6L:'\]-!VD0LH/6#P*[<]JZP>WY&$:8;7.*7*2\%U M,A,P&8.FIDK[2=P^,-^6C##'%;S45H12#\N*9"&!`E+;<@6SJ:F2D`6XFUJ4 M,',%2TK)@-?2%(F7ZJHNE3W@XY1QBS9.4<9R&;<>YW&7TKI4?(:FG7\5SG^+EN5H%A(O>#BZ^*IQ$G MJ38"TX3SB``P"V85!AF^"Q[R.CZ/SG4V(4'+Y'::.,L#AL$LGL^!^\J:H!5$ MF)VJ/R.M!4BP-&A9)E$M@_2J>@W\7@P&-!\+-K2*PZ![4;P7A>>D1*N%:=-6 M##]DHGBK.-J41\L$CY0T[#F;CQ7317#+]/X*_[X MMU_6F7$5AJN_7A3.4>'*?X#'3D#P/D7?\_X\F7SY.WR_]3?YG2%HI*^D:3/Z MY(WZ')T:^.%C-/NOGZ)D_N>'4=F:M3'N_S^BZ16*14\%$)ZZL$(G MH[KZ0I+B@H[*@I^Z_D,_A&L$.IW>LG[4Z->P#:B_Q+`M\]0_I+Q=/X.)4O.L3>A.646-B#Q_`%&M!(JH-Y1\C+IGB MXE;Q(FT!#7&H;Y-+48BLC>13]E[>FH4QQBX(Q/R\=;&^S!@>F!"@A3V@Q7K: MM5)$X9/R^TC#3N4;Y/-QWZ\HRIER]2*9N>A(A2AITL`LOL*&6;'TQ0+\*'@R M+%Y84%RSIIMWF@A0!;DN"#NWOGWVJE151!%/M*BS]3Q'Z.#2TJ<1F,!$B)L=KT6S*S(&SE[):CE8#*)4 M%8O1;&JICK$H>!*OZ$!Q.)UU*^@\^))8M*2*C:V)4K.B?`MD6;YJDGQ%1S+\ M$N'ABS-9L9>R9\)U,;(#@=?+E&&$5$0;HTF8-48!_HM.>7C;!<>EN!CI9M6$ M62UFL-K>KR`$X64\1X\$"^>E4),K&Y;G36913KI`?J%->1!\9GQUS?#NEZ%` MBB=VZ5&VMTN,@5Y8JBL^19\)# MKED=:E-U$\RE!E1GHZHC:31`)8W$=87E/Q2L8NC_`D==BTN4"(XYFKT@4213 M0U1$LSQ2W&!:W`1\74V2C':&\G'H`X1I2E&-XBCP":];=+'(A@CW&-8TJ2C7 MME[_S7$".M2%)[F"/8I$9D-=C'=@>XGI(C$GV%X>[KO1-E1J%CI[5=\N)%.G M.%!`5K2G*HHCRMWUL`=?H;7"*KSH[)Y+09(2;3G*@>=R?3!@^-UHA=:\G94L M?*=ZE.D@UPGS+F/FSLMOB)"2-F%M6K:1T8F(J;4'[7J$1)BV6UP01322EA`# MK2/X4[E!`;.-R9>H4-M:H(9VA1C*K0G9=;RB(1/JCUO$!9>18R!!*FB^C),) MW)SM5B5*6MK`4%1!KY*8ZM`Q5"6FN>AJ*:LK=2H?P,D%1XH-V]:$[C$P(1&D_R\U=MGM#UV M_8DI[=NQ_(@STYB'&U$$$=6+*'@A)23O?15+EGQ\!Z[DO.4(,EG?%[Q%QA$U M&UZ%[G52RQ\U8(NK9D%S"HK@-"6^D2<%6\5'^+5M;K"F*>=LQ:=A+N8?%7.+ M1$6/HE+Q$5CI)[BAE0SQYJU7D6<1R!55U&A5&1$OC[1I6W1XC+D>0Q"]:` M_;J;3UJ?7V\Y_50TYQTLT.SX_-8&PYANN8IM'O.8%AVN-A9^A[EC?T MFQ5H%CQK2:8U+I8\7B\GHG:';6J9&)W4K_C)KQS*:%4]KCK15X@0*OG[&P[) M*D=!5,\@'C41_--[QB47BH>LTGB!!89@A"R3!951?8W39,F._7*S\XQCTA3Z M?5U-@\\*[BM^:ZGE-T*';'YJ(Q!$N_>Y?X&:K/=YB&94[VMYYGEU7/0F4!,1.3C!7P=V=8H5)>LS04YWY MJ&MA'D+(=1!-,Q7'Y:C@3;E-'#=!=G?3J997FI+\LU?%5XOC641.R0B!??P: MPM6-6YBKB@*M_$-_Z;E:DWK*%?E1R$5T0:B)%>--*KW$#X%[/Y]SB@!G3*(Y ME%=W0-RV6[OJBPF-\(CP!>ZKIN._`<^5+/ MAA_]0+UUB4$>>FGIE6>WS^C=?&F#]DS&:>DH**TKS6F).H4,H#M9:]UGMY`= MH]J+;QK/9A%5DZLSMJFJSUYM52DU>IV(@L$L^L(O5D,K*I*NXJPB,L#"[104%!!L_+6B]3(-R\]]'#H=R?I>EKI MTD+T&-M<9IIHU23^;Y4NB4!5M@'PQE@OYYC`I2I.KG2D=%^8@1:D*!8&:KZ# M"Z*'H(L26E$57K6&1+!'#]F29=0N/)9)F.FI"!'%)4KK3X=N6I4,H#>_X@-. M9^$'/0LA]35(N[B(,HI[>1(5Z(A:DAJD.(M6(:E2-#C!U&7[6>2!GT<]Z?NE M9DA3U+&._G)-6L4+X'@D&K1+"JIBE9J,':C0K1Z5H/J(HMNZ-Q')$V`KX]#5 MHH#M$?>[=SRO'!;\G$7O9Z,L1YT498\6ZQMX@>OT[8'1M]W`<`.[9P3C8=<8 M]GPPVZV@VQW:M\;Z%F%Z%2\-D.._DKZO'G\"`5U@JB\L8!6Q459(!=\H8*2M%P+\D-.EZ,?K=CGJ M"E4<4=ATE;2(#/477:'LQU+Q'*YMJP.MW5W[TR]>IX)":I$9=YM0]T=6M@XV M42/1IROJMT5I?K:^_#=U"B0"N%;G6(E?(N0IC-":4I)*)S,O1[8Q8[DDJ*(/:L8/KH)N"P7J=YB(>H(,7.%(K(PDZZ7-N&57\`%# M;KT=8V.W39IUGF[([>G5/]JK3U.%?[+\G1-U:>)?:PC6:L66>N!(F1/G<91Q M9;[2KHWHK:\,,;?KT3;AZ68XWX'P830QQ.3@$^$O@G`2]9=(^.]A^NB$/_^1 MM+OG'8Y$IT/K`V._]GY^L^E$'7B"W,/G\5D''DS;T<2D]JNEEJNKDV]3\3 MS&ACX]BS4]+W%_*_/`?9[CHG\IXQ>?>>1_\\R.L242!=_$,#&'J M9WM^MO`+,81/9)[(/)'YLHS?CXCN,,86NK<8H8^RO/51IC^?DXIVSJT?VYIR MSGW[1.#S)K#S8UO$SKES;VW\@FSB,4++_)/`:9.9+-A\KC%B\V58&2\I!?/6?4,4R_[P?C03#LV=V[-+R9A^QW*]\]BCLZA"'M M5P-;X%3KU%>Y?!J\*484:IUC\E>5#C+5@(T]X`4^O.QNX*ZR&)L>DC0W$!U1 M0+(3F--9T?HTU;\NEL%PNK*[3+682)3%:(K@S@SXKO5U"\AWQC#$J3??"7AJ M)F%V&5M0]'UHX,>7$DLG6?)`.US!3*`Q(R`&=9@):,!H%SI&L1>X>Q4IW-A+ M)5=E3;"U1K]:="__L7//JP*B%]EOU.97:_?U6OV2R5C6>^)CG;VZJL6'[;_\ M5#(:[][87?1R;UB?MRQ!?]7&=W^O0$&J=6"CE`2-/'LE\2!I"K3H$"2IC:GC MBCN!J-=/?%#'!CC#[L.OR?PKH?/27'L<2X?0TC0Q-"R&I^H8V+'L$[S+97$2 MSA](.`>(I;Y;-!7254;]M.&$NI99MNA:FN0U4C;G>0FH^Y)O8A@Q]BG-2L"( MOR#8AT3\2RZS!+XVP6;_DUB^:+%\*P!3]A%,T9^J7?@@9'1Q@W!&X8*&9H.^ M+(8]W%^V=.`#^Z#V5*9CW&X@W**A(JV4PJ3(;U:1P))GI-N39?%#GY+_LT[0 MW!46`VK7XNK?!GU->/74$Y(I7::R&!@;IG>0*/C2 M?W:()CUAXZG59\J'$1Y<*#KEPV)(>(JZ7TV^P103P=JB8U^5)`7<7I1JLJ'U"8>7H&9M&G\+OAT)DZ0T\;SQT M1X9G]Q`-WG4,?]#S#3,8>#V[U^T-.V:S$%F$M?@)@7?N%AY[HG&=R5!N#.:$AJ%A7CH9^WA@(3"=^U`VVJC&4GURQL=_PJ M^I<6V7-)>/HC1R.*H8(K1DNL6\#'HM^[X8-]_.G0W>E&'S43,M0Y[^`]]C M*$I](!#-=N?)0-^%>M-'<='6D!0H*'T<*P;LP<5N@R)64IQ#'S\L8S\=%KJP%-<8`4>D^ MGU^PL[=]X6;K_L:T?MH)?.ZG=FT9K:9)A44*$P=OB7@K"%=*1_H M6),95"0;\:J,EAE+X[U-FS5L$7TKSA+7ML"X^3S\"81V`B;>/",SN&+]=$VK MVQV.^T8WZ)F&"[\V`JOG&8$[Z`Z#WMBSO,&?@6EV_[2Z/_W=TC*F=R9KWS%` MOX7Q$@'G^A$"F7[BB_%8_!B;@0Y;[ MIX/6H.NZ@>?L@X.Z0="&A8O(S-$PXO]_N_R`\)KQ5-Z<(T:#["VG!./68[5S M1*8,!K9G^L"/\_-KK@*R`B6Q9/_W=<*R.XUO=TBFY M!WEE%I6P:?G8_1'E[V='%HZA.;:<[B@PND-T%;I>U^CY06!X_6%G/`C&@>\. M03AL'_C@^_!W4^/##AK*Q(JZ@TSY2,LK3%LT<<=M!W1"U_&]CET0NFW]92I_ M2^%$?"`8P@9N(>R@V_'AD4%!E[;B"BGB?+]?7H180O)!0*@BZF$^DMBI#=R^ M#LJI&?@:C7N14KG@<(3W1X:O_2U)IADBAC9O2T$Y68YG!ZYVA]6LO$P;::0_ MDJ5R>OC@"I751"I!YZF?+8M_PXVF5;J)?%MI@TUR=R?_F[N:9+5456U0R2(/(N'ZL!HH)2# MYK)\SW8]WOX`SNG/2W^\BGY$*9'5N+[6AM>20@>2&"% M6V6%03#0S>.`!5:(83F!V7&[FL%5L_CM%]=%E'[%W$TS[RX;S!'?ZMAV4']Y M::N_JY?UN1B_Q,DGC_$8J$W!2RD\9T=R1WZE>H=!`33PEMEGGE1R1)[=YO3T.](-, M3Z*84U;-DT@+N6AU.I;?V>7B;M)2IOY9F90!F%GP#:^K73-[6I.@D)[FZKB# M$>74G8O2PF^37!3R90Z'XB&#:PXFLK!]CA]T''^7P&HDE*GM3?^]%@?X4]*; M3F,.P7X(8SC;@W`5Y^&AV;%=NNDF58)'!PWZ-@=VZFW2C:L$1D9`NYQ56TIO`#W2).#)1;8 MV=W``JG9#'7=3E#5R&6&21T&=Z:8HY0OPG7L0I6#5@EDT`]L;V"/QFZ?P^.> M[5M.Q]<]\T>D>5];`C8(+U]X)_PF! M+E6NJ*=*L.J\T08J)]M%E[":!7L8F?L'+<&(G(=91O,`*:BGC%1TQ7OO!V_? M+X=@;GXEW9`U.6W:W3N0>4^B;[L3949:V*\-E#4+(X%VH&N26\FHN!5/7G*R M)ZENC0>V3V&)"OM2TAEM<#E,LWDBC]MI^6#N=?5PTE8*RH0.(ZQ$C?D`@!&P MP*C^_S9U.QVBU',L371W4%"Y!4&3P@?P_]"C^@I.)IJ_Y$57Y;^!M-N8:'=\ M^$:@N6O0^H9$GH"\8!/`TOV-8IN\;[L@;&;X% ME';'ICD>F\[0'(PXU(&I1S,(@MMB';7T@GA/HFA*B9,G+SW85Y_9)4OM5A(J M$65-S3^#&C<\E8[CE`+!.RC8OKOR&#>_KL;.;_:Y3&PS\+\7,14&8!GK1S4. M_;V:?HZANNB)>##H]/R1.?2,H#,8&*X[LHV@[P6&/1S9O:#7,4?]$5['F/`S M]>W?FYHMS7OBKWV>\-[`:PIKRJE0B`-J!4,H7UG3C?]&1^8S?"[-PWB) M5MNA&CI]S^O9#GQC8'?&!CA7MM$?>)[1]WL#;Q2,G=%H=!<$-,L_)`1:B7?8 M",7<8R1D;%[AT>W$0=%56.)B$_'14%`81@S_$6FG@'J,1?8">]^T0H\LSG+N MW"QZ<^*B-Y@;J_3I]*I=2>LTS1-LM:NR5/0FILA2T:T%1&*:48*;<>\6-N.E M4^[Y6XJQ]%J7T64XIQ:Q[#J*\NQ<;W$M=Y%.!/W4AEGE`+;(D0L38=MW?LVH M:;.BF:K\K#GL$'P8'G49+K^4WXJ-=M'W59)QVZ).INC9P@B0X.HTFH78_GIY M0W^AI[6ND[GJBZ*E(LQ1=RS3&7DR0#O@] M-I9BY^2R%><$_Y)D,7>PXMJPQ:]&MLYK'\TP#+.8GTS",!QS,UMB" MC!LA6EZYY4^*9K:S$^RQE%^A2S^BVGT_ZQ%S/R7]",L+WB_'<9KE0-P"3>IP MCFGVW^-EO%@O'O%F^7Q1NEG>_C&NN5O,;M_K#0S3ZKB&VQ\/C5['&X,%X=E. M?]B#ZV2,=POVA="D5F;2G:DJ&/+'>G$9I-EM3!B"-^"ZXXXQ\(..X7I>W^AY)ERUUJCC!8.N-^IW_K3) M-63R]Z=!$X1=/F0%Q^KX MQP9#,'=TKDHFD4:8%FPBE4)!7]EGGU_C5`'\V#(&A0O;D%]GU&6.NNLB6N41 M[E&!MN&8;6P5=>D[U#.*JCO,!`#5+K"IVQA`O;@5$N\*H'*76>V_MJIP*Z0& MPU46;>*D5'%4!#1)@"`G`EY$C$_6T%?V`%3Q!:)*'8A)%?BWP%79]I7'^OWI MU4=]]1[0^;=*\Q;D_,>"M-[]W8=/)>_NG$+^"=54L8;?24T5/X]06]&'T]8O M8F7UNJOB#1P:"/QIN?8'J/3F,>TD[#_9.[<-K]P\^>Z3%'W\66CLP MK;9OWWLHX7,EW$+*S780//6\K.-3#OMM>NW@_E/^[C-KJ5X+KK[O88$<@:=5 MW2G,0(K!21O067UO39/UY3RJVX:[:KO#OO&X]^R)@R<.GCAX?`[N#[-]Q[11 MD6QZMUZL+M8+T<_*-48L?IV,ZXTS/ZUL@VW$X'>.3VQD;7 MLX=]?^3T?:_#E5F!Z7G,HZ-Q0:OTP;:;][-_A?@2E*J8\][#,']`(5N%%[89 MN",G&!B.[8T,=^".#-^!QUACNS<8>B.GY_'*JGR?'?4LX*1 M88^&6`O==8V>Y7<-W^YT!YYC]7I#^PG2PMNKJI@[Y+@*_K2(0:0OFPB7_RZZ MXA%AK056B$1+*IN9102_3.CS#!F_$H0AHOY$]OIDA'NM,(P1:SR]XIH@X:IK MT/F,-)YJOOW9JSKO_GS?-<'7>558T35G:'BL1E)E'00NM4J3Z7HB"J`F#)9! M?^`%A%Q2C65$7R/.V,_CF9R#*5]P6RW./H="TP,T<@66>[%>(6?$21NNTP_W>J.#AR#>Z]]MX&ZFW38WZ6TC0!)AKI7['N:UP MH?,5\7[VC_@*KI!W,=SR.O[6AS6<]P@-_ M:'3AGR.KXW3[@S'?"A\<>;W=:\4%Q>)FSX9Q-IDG."_B`/7#O3&(;']LC+P> MF&)C!W:M"P_P?'LTLD?CKCNXO0;J:/7#DB-WN]F.4P<,^X>=(KDLNA6ES;VK M-"+[M-WZW+_@$LRI_,P[+,BBT1W?!&4MK.#,Y[),]9IK_>#C*RG0$NF_%5[! MHZ_0%LT3N%_@(7!_N.>=PKN"Y M&D:32@V$%>!D:#2KVSPZ)9E'/&P,KN`TIT%EHNQTL9[G\6K.3.R89AN=8,76 MLUKE4Y"?/I-#4O/:("++$P&T<&R7OP8A3E)!N![-$$D;87% M5)%9Z5DHB?@T+'U>A%]H``X]E(:V2@;12)&4P`YYXH<4N"45;_+N%V)3DA)- M+K\EZ[D89?P-Z;B,A(`W2CRP4)(LY_;I\W^PM)S8ETV2%5?Z7PQ: MK@^.JVG8G?/RJ<4GS-'NGM_@N/80%!P6?>+,JC,>135/4-$!'[,(9Q#G.%Y& MR#`/)*8Q;KPUBRC*Y=R:F)'F6(Y#>&(4T00M%/.IPLK06BY0ORKUC6OVK<[3 M[\0_DF\@FBD/`&*61M\G$<4M>#8CMB.0IT)%_6+AR&SXK^>B$(IQ9$!6P7<< M$Y,3PX2&B0C0C<^$V#1XCIS&Q,<<#K<$(F&WBM0!:X),OU6H42&_H!)N$FV^Z)(1;A\+T=;'PW/X!6V6C/4E#Q++Q=@I.M7:?-WR2"7N MWY#-&=K'RHH:_C]3XP+%F"[Z^ZTBF4;SIY>63R3[E[G2 M7>PM,[-5YTJ8%8.=RA\4*HLJOY6'&B([!3:Z<);;&CMX/!B?)?X4/(4G&K<+ M[Q;^LI`,IB.]<=J"EUNWR$R##R>(P0*?`#)!D)=D%N''X.HB414SN<'`NG+0=.$9F4:O8;'CBZFR8,EJI9 MO](Y$BK71(_B& M1NZ5/K[!B79+Q,)NQ,1&OJ,V.8.,$-/\9`L@FHNE]V?:`I1-MJNU[A85'TA6=SM@/@L`W_#YVZXX=R_"=@6F`$Q[T3&=H#[TF M=>L*UK2(-ZV17@C5,-V@EIK34OG>HXN,1I\F2V'?IUNJO-"F$.31"58,,[R8E<,[L=)O*((,,:CDXRBO&)L*+4Q9RQ^Z"(@J$\*FHO'7V&2XY!16!F9LMR%BM^/%_3SK"4GPL@0P\8B MY.!3L+QQXC&IQVYMG]U`U3Y#V_5>$ MCFLT[:%^OXI^0^L*80T&"&#>,PW? M]7VC/_!'5M>QK/'8Y$R">7[T+/&M3--[6\ENT0#0Z\L6Q.<.=?<,K+'5-7M# MPQR`=>H&X[$1],%+M'NNVS=[[F`$WW_BT=]TJVRMQ,5YIS'UG[._@:@EE+(Q_"K-DR6$.\--2,H!4&$8\@IQ;=FS!F!*:F[5Q M]#64">VU65`F!332"8#0UP)/1:C.^"ARX'5#1GB6T4_4-[M MM@N^O`%G:F(Z!CM^=MJ=KM6VS8`'_?[LMNV.V?:[;J6AFOJHQ:3JL[MT4[>U M">,8[J`L<.]GKVW[5MOI^%O?6[1ORP'9]-*S;3U]NU[+IOV.7/@N&27F\L7' M\!DK$5\K(C.#7TEG%K\8_EIKRZO![3*T7(#>JGT1L2.*PBR3/7>UF(Q<,WH^ MB[^+/GBQ;_^]UMLH!>^<%L?&LV#TK1Y"=]G@(HV>/>J-1YU&&"',H"(R1F$RXE&1T6V8[?%VV7H_R1.X$D!5F%[9A^/B ML%ET@?E':A>C$!&FPUI,*]TI.ZAM"_7/+JS^;$H/8#"(O4?IUDH/B5Q1]6Z9 M8XXCS!S.6I?S!!3'U7P-WB*J7=#1,8YF0F>8\+-R5,DA:."E$7V7(2U@S'H& M?P.3)*U["OK3+3SZ*P&5M,]^HJ9'9U@E%/"J7O!MP;D\%5J#Y]T@EX,-(*8S MAN3B>%>^[YNS:Y%BP1AE*1E"]Q$:'S(#1DHEX]@A?1!8!8+T1EV2(HQ?NB83 M-"$1IS#C/'4`ACT+86/$Q/'A&@1&1.*+B^B M?(L;`]97@BR?Q=^512:-MB+8O2'"9/'))W&Q#BPE%*HA#]ENDQ^6KT9S+E51 M=N5JE2@@TY3)1F]/Y%[EV<-<+:A0X."W,%,>W;E*?(CZTRTGB^*.+/NW"#MN M0%KEK=H.3'.H^E78F](?Y)%J$R6%;]$NZ)DEZQ2C:?&D,*%GVG/2PA@5"T'# M^A9#]H[V2AFZ]!V8Z!*K;AQ."`NO7"YOW=?`^3.PT3K]'G0]-Z@Q=UPK"*S. M&&OJP-RQ>H'A]YRQ,7*[WGC(?IXT>BZCY%OJ9M=4V5#?2[T+>5A\%==;#/*U;]M7TAD-_ M./2,3F<\!/.\-S9Z?7"^^O;8NJ&\O%7D_.@\.Q=Y/WY*G9.]XT'&M0>`: M@\$(CE?/AN.%H>H>"*3I=6R,4S-[2\?KT7FPF[URJ`,B1@_I^ATRX.SCGD[% MP!7X.;N3)7MJ9`>3)9:SG6FW4*:U9"E-IK@Y^@YV29).P;A*;ZA$844C7C#2 M%5X]_JFMJVOK7`K3 MW4FK8PO\:Q&CQH^3]%-R$6'2M[=0$;VY`4EU.P-7MQ"SPX6]&9D MNST;!MAT2#I;&%!/C4:^DHKWL]^E:R%GYW[&$,H`X4@O$S;CE`DK.W\^):(K MX`D8-/*''3_H!L:HZW8,=PCO\L>V;0RZ@3D"[L"=-^;[WSQWI(0\%KUZ=)+Z MG*1=U"PNWN$RVY.=[D]_U^&C'Y/ZZKBA:CI`/?QW*MDL?^!_[S^/![C7M1WG M.]+H^O>:2#0T36"6#[SK@2$0^*81]/KPH]?O./[8\[Q^\*=EFC;9`D'7LEUM MZM+=*6TLIRIR=G].T2WGJ-Z[1^*4/@-=^NWZW!PZ# MTS5QM=&Q.O5E&:WWR8A]2) MC55$%''_G$6S]1R#[0]AA.MXWP/;@5_5%$?9P=^@F)SW_*]Y`2K[M:S63R)X:_UPY,^)>/U M8:V`ZYN>T8/#;PS!VA]8IC4:^5UU$7ZP;-&F?=?5 M-_A\$%\>XWS8R"6G(A.'.QY4LO&6.D7C-=(=!;^Q9WN#/`-]NE6=\WYW(.S#I,8=I M'I5'[OX\NGW:)MAKQ=ST9T%^V08MK;\R8K'H6OZ4]*93,M7#.7I[;Y<#AI@A M*;JL2M''B%N,I%7++-4,_@<5>1^56WZ)6X=FR=/K*+""G4.RU/T!=-01>-1D M'74$\D%'&;[O=CVS^X.HJB,PK8&JBFM!#W,,'1,LT#L7O.[+3^M/J_/3WWW' M<6X]ACN(O`N3#J/0#\XE#RM)W-N5U2XJG_S:JW+IT8^G1=>>]9ROO6/PJ,'7 MWC'(_W%,\V-PJX'WW4%UE-WQNX=DJ4,Z*@B"9ZVECL"E)FNI(Y#_`VFI(W`+ MM)1A6X'9M9Y,5STT7PH\`^;99O=QTJ6^XXW=0<^.)'](DTD43;-Q MFBR*4HWD+N4H3[;/6+J*W9>.6TH'U=/SQ&0_XEYC":`J*;T;V3N=K$IC*N5" M?DOO=+TP3QRSXUCWZ"KMCMRA/>Z-C5&_US-2X?)H.)CFD,^X0=VB2 MZ&SRYM%%QSF,Z#SX5K58TWIX=(YWP73I5C4['<>TCFY(W(GD1[M:J\?8$A\BB;7RV2>7-U(@1#R<5>R'=.79'=-[WL0.&[W M7CK.'_>Z'6"AX73Z8\-%_"A_/+`,U^GWNOU@Y`8#2]E/GN=U-.=@*S4ZL,@< M.^H_A&E^\RD-P:\BK(Z+]00^G8VCYT"XA..0."2W4/1(Y4,*:*P'M\A"8)3% MV9=Q&D5Z$\_]&>B95N>[93F6W;%V=!&X-5V$EM/O^UUPP*V^X0Z#L=$;!O"C M9]MNW[''HV[_3Q?+WLUST^EH;L;!N7%`YLM!)O],$`>1&M".P?[-)HX]V4]= M+MU#,;^>&S7LWPBJ;+[P\BXOQ";:.Q32[>;Z_3BKVF,/3NK(WM]S&_+/FB\P&8#S_;W<&P:Y?=MXS(9[B?:!S,9'#89;+\I)D/#E7[0]7RG\_@ZWS[I_,?@_CU/@7U2 M^;PGVP12^+7S$X*3PM[GO3ODN#JS`#1Y?XW>DQG>\D\9_`/OO M>0XZ0N5W3BI_!]?OQ]F3SK^?:!],Z7>$TG\,87\,I=_#T6\?HUS,XGQ_.8^O M^/V321KA/\38H#NPN-MY8+AKT.GY(W/H&4%G@&#\(]L(^EY@V,.1W0MZ'4R` M_LG!P,!W]8S"WN3)9[5YH;9.SZ?%S*N2K3,QW+>WQCUY+&KG4H%_NY&;OW8_\][W^! M]>@]1F+P61N[.[E^/\Z>C-W[B?;!C%V+C5W+;(BQ.PI31&=&&%WYDGB"##PP?)S;,,;]-WQJ#,<]RR7K5^K`U9%0?L=R"GS8:`/?^/&-;`- MWL^.2_>^>X[-8UW?<71+=P<%95(ID?\A36;Q'4RY8Y$&E'5LTPXTPK3U;K=/ M:=#VG8S38U&$WJ@3=)UM!==RY67::(#A'\DR8;"WY17OZ)V=[J-1Z:/%W>UZ M@::)=A-1)OCM\FO$O8_\(6DE-I!4N+S`H^GJN:AMJZ_9U)ISBGI)GM4/24HW M7\[^*$ZQ^)1\`#5^%U?[:(K(*_7\/I"^"K/*0G.W-NBCR0(B$G7,+CBVFN5> ML_1']JR/ML$@ZI8%MMM=8P<%Y=QH@'.RUL"1`KR2+V+^',@%C89,4FWP`Y@L MY:?P9&S&@BX.7`.EPC9K[NKI1, M]PG1O7EDG^P69V0T[@]']M@PAW;/<'TK`&>DWS6\H`^N\\`>C=T^.R.NW3%] M/>WPJ"17K/AH"6=B#D_N31?Q,LYR/"%?&WRVT1#N^JYG:G;3+514?;0,;`@U M7;)Q%';A1#A=1T^\';]\MAE,9?2D>8N]CZQ'B1(ZH($'W8*[O`,77T;XJ4E[V.F')^Z8!#`P_R.89F^;[@C;V3X M%M#9'9OF>&PZ0W,P8K/#"4S+MYW;S(Y::GOS>3+!-N'Z`/SQR?8LV+B!TS4< M,*^`;-,W^B,+K*V!UPUZPX'CFWT150.=K5.]'REU;BKH(O'7/M@CC8R+VE;I M3&Y9]_&+.IA^=X/^1ZKIL&5-1Z<\(NA1:CH>.>VSR82#I7TL2OL8P!BK>7F? MG7QXA+P/3P\+`E<'B&I"XN.;G")JHV9F? M(\@"9GY<-^BZ>AG+L3(_1]A@C/BX@1W<%2>LP9F?(W#-K+N@GW_JYPCG*?CI M[W;7M)V.==S4SQ&$PJX3BL/E?@Y/$>9^3+_;";;@)C8K]_,0AV2?W`\[))UN MV79]/KF?(QQN@>1L>9TGR?T^3G"??5<,S]'4&2(HV4[7E?OMCM6YN<(Y,%9[W;@/9UCI7^. M0!-(L^OIR&?'2_\\@+J]TC]D>;B>U7'=6ZM.CIC^>0#9>Z5_*++6M4J5)$^8 M_3F"1KY+]@<'B5\G:8X=285G^'N8K]&AY`:9W\/O\6*]N#>E%3*L\=@?=\=] M8]P?FX9K]D=&8(Z'QGCH#CW7[PRLSH!W31MVON<:[T(56)''IXH&UN]-%"_Q MD$&AX_46$XZ$N6=\2!!#[[HW,?0H>!CP%5@J?H*?XRG^9A9':2N;7(-[]5\_ M7>?YZJ^__/+MV[?S+)J<7R5??QF\_7]AO:8)EGK0Q3NN^%KQJ"RZPFW[^]^^ M7Z;S:?S7Z/MJ'D_B_/=H<0F/G\8+-(*2Y7_]]`B>7O_FT\TJZGV/LY_^OO?C M>"5_^Z5V@7__VR^2`L&K7TK,^MN*Y%"C-P]3:HY#)`'7,#T#DXK%;]4'(UA/ M\;'`<$Q\]%3[T-]^T1[^MU_$CC]D^P^^X<^3.TX3N>/LQQWG@-S9V=C:2-W! M5_E%#HS`;[Y+A!_%&@%NE*)W-9[EUX<^^EB51H>6;F<_Z78.+]T2_ZIITOWD[-F%P-9(Z;[#W9VLTX->WK!_SGZVEW/@ M_:M%37WFV_=^&1UT[^CN;<#9J\N71_ MNH[3PPHWN'M[72R'\PIWC--KY.YM&;P''I_^EV(S+U91-/W^$C:Q?@9F0S?Q M1_+L]W%=Z6.'VGZSL8X]>>Q/[-B71H^A.CJ'E1V;9>>D.HZM M.O8Y'/8!#X?M.>5\H-<);-A_N^-WF[G_RF[C&FTL0TB6\&-6WM?>=!JC71#. M/X3Q].UR$*[B/)P?-L2_3Y3GD/FK;;L)OJ;SK'<3?K](EC0N\47NH`T:^7GO MX,&"TI^@Z>PW8^QC:>PW8^UL\VR)YK`'BH@L0IGZ50%=,=-M'!W$*QL M]R9:Q]S$4F2Z^5MZW^CC26@>76ADZ/-9"LU>X:V3T#Q$:$1!M!6<0BOW*-BV M_+T*MA$%YP";9_FBY+>!Y8+[FT('JX@RRV%#3OYTG:[?4$>NFOP!L?Z_49I\ M2.,)N&TB!23F^#ZN8,=+V"7XM![KDK\[](:\A&SGN-_SV*ZN;UK8S>Y;5D.-@H]1EH-%!OLP"#/,R>/_X=Y]#>>X;?6_ M+4RZ03+'74Q_C!M)[)=MN4%#K8:'[MBT]S/^S+/?CB>/I1R3YE/MR4/%TCGZ%IUG%S`9[!=3;IXCT#S"<3M/KO"V&P'VY4"WNMD#MUSBP1(U=&VZ&0. M-7%;3N90@_?F9`X]D^TZX8,V<4=.J)\-VY53YNA9[MG.;3",F[;XJ:#'G`5+KMG9K_[UOE8'M'VQK+MES`2OUFFD:%E$808__QU_^;=?Y$_\=?Q&Y;MQEKBVY?W9^SS<>(3X MVU_A;WL\*;L.TRC;>`C_^@XK^7RQ?27PM[O1]">P[\_*RJ;Q5]BI8A?P>W^L M%U$:YDFA:/?A`^]0_??IL<-HF2SBY;8'U_&F>.;FE__VB[;VO4C_5XAZ.6\@ M[6@,B-4=@@$@*8^Z]QN2U[R]O\C3>+5Y`,E9I#_M<71^C^<1.2VUCU%_W>-) M'\(;O.5KGR/^MN4I;#G`/_Y_4$L#!!0````(`$=[747;-L1GTA```&CO```4 M`!P`=6)I+3(P,30P.3,P7V-A;"YX;6Q55`D``U8_4516/U%4=7@+``$$)0X` M``0Y`0``[5U?;^,V$G\OT.^@2X'#'7".XV3;ZP:[+9QDLS"0Q*[C=-M[6=`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`68^_"\`_>U[SA!$ MPL3(SZ]=^LP'GD,8MOV&4&W7NROG5X3;+N4!PQ>( M$SZ@&>?1@:-K(\_NV#:NQ M#R;#B+K$)ICO$?,N#!Q:#`/O"?J%LM4=WDEY=VKWT*#75&-L8_*$IB[FAP1? MV/ZAA2",0\3L.5AQ5'!R\)F!<^R/81UGT6P\=3GX7.)3^X^(C[[MDR>P M0`XZE10T?V@1/'A@HE`@^!,[PNH"<*&FQB-XC,';QLZ$/L"XP2SQ3VVH;!S0Y$W"A@/H/LF]!*^ M(7[_D>%P7#?D)AV082/%W'?]GG&B!J8Q\V`$],P4>CZD99KTFPW(%4'89]RD MHI'FX'Q"++2?]PBFO(DF5[AD)14!M/RG6T0\'_YAYV(UF>-8H08>_`Z.Q&(X M$VIUA9^HC_F$KD/8ZW@COQ.#$`]GPZ78*]O5TZW5SIZ1 M_1*`Z8&9NUK_+:-Y$_SB7[A@Y9`'(!-S<[]@-UN9L^X2DWJ/?>L M8MNMD$#RA4Y)K'EHA40F.\=[&^)@S]*0.5_I`K7G85*'@3W+X@I/_8/AEC6V M9XR)E74PG&4-[AFK,*'`41#_B5W?)^3B0R)7;SZ6@YTF'8F94YZ079P!]%W_].9ZE.7B;8E*^#!@+@SI12RZ:8A>T MLYRXJY'O=`?Q#OMJW!<6T82!!>#$$S0E;A@#J`0@H=?$?;`(PA4._#2&0:>% M.L/O+@YC_Y[37U#FDS_#[T>,@M?CKT:NL`U@C,*\L5R4@FVF>LVRD>7BW%#. M0?_`T44OU2)0JD4+TG5(8X2(,_`NT9+XR`56%]0+X_DR<-4%M>"1;CO?4<\N M'YXJ1;5AXF5<+K;+^OXE6*HK\,1^16Z`)0#4RFI! MEKQNF6"PQ>?8\7['2/V`3%/Q*/%E+O)00FE#H%=X1D&;IPQ?L)> M4&'428A;P'?EF)/3Z^#^`[AU=(6335]ELZZZ7`.*+&]$+F758CJ$G<_;+)1K M08KE87G,2$O"8I9",X9B6AU@O\9IS66JT8Q MK1ZN)=&.CZS`.E4KU"H<\E6]M(@.#.#QAWD,B=6?"US-B$UD2!0*ZL"C;`64 MK?N9F'J?Y5E'S$XJA%^W`NKY4ZPQ19>+3%)16X?X>)&4GS&ZV(ID)(U161#! MH@Q8#D]2_W!R+T%=1)6"-VC6D@<&BXR/S428=$";V=_ED&7Y)REJ@XPM M-=2RS;$4LD$FEQIDA9VI%+U!9EAI"'W+1:[,ZDAE\._7)`/EW;\4_X^O"7_% MSD6*VLPUK1QUR99ZNI@;9)*K1(R5O+`X4I[Z80:-^;I":"Y5,Q57;HKHM%M> M:@9OX>95.D@,,H34\&ZG5:5@#3*!U,"JY*FF\`VR@=3@JVQ2I?`-"EU4P"]+ MX4OQ&C3U*VI[W?SS5!9?8OJU_6!-_B:$]K`[?%NS( M6-VFT\'M1^QAAEQA>CL+XA'NBRLAGG"\$RCAO:J4%B3"DP*?82;-=,E2Z$D6 M3E:\:UA,+ZDXE1Z`(9#>PW&!9Y3%TQK,:)C?$B]<\S*W\N1KB1;?6^S/J3,( M+\$+3\9*)'!(#O1)&/B.%?$"]%2N#S)J/9Q'XBT?=YM4NE+>HSZ.Y)?P)&59 M0JZ#=S`54N65,)RGT<(EF&G1@/0>(U;*M4).KR5E.&$E7-1$W&9]EW$A]W)Z MK=Q7ZDD1I;84[0K/:B2B:N`>^CXCT\`7.XL3&KDC,G0[UMHV28RQ'?MA=GS[ M_7^#:%H2:UA_>#D8>E>8D:?0CJDZ$KV/EK1)K.YT4U%(3_)SR=7E$ACE9;2D M/"-77$,;[I"$OI8\_;R05#?/:NRV@=/$053C.$NM->JF$"[)AM\VK!TC=QAK M0M[+$B#9H6SY;E.#DE,R(XS,PZL.W^6WJC:"94;F1W\)YC3L9F2B=$%L*)=C MN+F(&9GD7P&RK-LE1Y%:/L-IB*?E9LPB5]'(,T^:!5GB@!B9QUX89&1S/9TN51K4D29"O2`"5F]-&'E\LV6+(@<^:\T;F!RL"+5$) MR7'-ED]SDIBHS.-,0[U&WAE0$VTN]+K;!0*M2)ZK]_)U>_C>?MM:QZ6FF73_ M=>ID/!%(`O.E1=ISV>D(@_8*%XUAQ/$5COZ79:W5J4)/3EMZ7&/CE(8TNTU> M0@>":W"GR:,796';V7

DA8)M'2*6)WU]267MPIU>35,;9:9H.S!M'`U4 M!K19KAUHY$= MA5D!L_D3<<0KAP\<@TVQMIOB!X[%&?R",+0\17*72ELDARB4VK`<5"MMD1S6 M/GB303(9<+6'<=$6*!A;;,$940 MZ\W`^8*0P49BWTZ3N)'7*NU):,H6@)'[37L2FK+Y:.3E+LW8S!O7OU2NA::F MNC0L*OG")$ED:?EFT'Z526*(&'F%UAXD)36?);GP9NI23>=-Y8B`21N0S4NE M=+O#R$O/FY>1S`@W,G6Z>?&H[L5(3A!\=1-1O?TYR2&$KTYJY?OG1CXPTKR0 M*C8P)*E57YTNJ>TVFGGSXB&DI;:?),E8_$M^V_O`1K[5<`A)E>TQ&WG^Z)"3 M67G*R&X'*/0E]ET1;KN4!Z%)3KBP-S%0^U$_KB\='7@SRJ+NT)V*F')\+S2$ MK8:S>S``P]/9GA_W%O3SB+K$%@]&O`80N>>S--W=%+9_+;+IY]@)UP@\9&>]T?&9!RD4D![!B& M)[-E'\-2$_H0YE9AIWBOL,^@%Q]#]>2BI!V6 MN8#B2=TZS)DDN!:?4RUF_8[&R/K/B#E\0J,W7-9_%QLP=]3_70S!-9CBY79_ M[=4S0((I$2)Y<_+V["02R)1\/E1'#SSQ+LHU#=BFE/0P89SH)L#)UM$I35R8 M)[QGJE]TP(-!@OM$_#GQAAX6O&L47IX/K7;XWA>.Y"4I37ULI'/TZCHE,V,9 M&=5[K1T2K;]&)K^]TBZ)K,G=;N@UQR4;@\08L1.I&>H;9U`(+SG2M?9YR;&F MCA#SLYF*;=^COJ",T6?Q\N1UX,/G6P0_P\2'S*VB8;92DCC_`.V']Q@A;\63 MTQCWV(;"S@U%WBA@XC"+/Z&7\`WQ^X\P#8:)K;N;LOGE,HUQ@GV2,%;)11Z]@*`'7"PUG4+=?(%ADN*Q`5C+=AX',?>0XH@B0FH596 M"ZKJHZH['$\M5(-L?0//=@,GO-&NCF[4KD*W:-.9(7L<:\2(9Y,E04K4!FU5N>SEIF2.)+U MEV0C[\_](MDHBL&@<\%%-E\VH4%13$;>%2W%7C4#&'EXH@RMQ!TTZ[S##NY$ M3N-W7M;,"N8?7FS&AMFUBBV3R/Y7U MEP`Q&,CN:OVWC-9,H/D+6`+_:"__\5T":9Y&>UDM32LQ0-1J_"=?F(YCDCFM MVD84L@2?=*8U0*6$P604P\DB:Q33Q3UU%^RR(A#@7``!R8`$`%``<`'5B:2TR,#$T,#DS,%]D968N>&UL550) M``-6/U%45C]15'5X"P`!!"4.```$.0$``.U=6V_C.)9^'V#^@S<#+':!39Q+ MU>Q4T#4#Y]9M((D]CM/=,R\-1J)C3'_]'E*29<643-F42#EYJ%1B M\_*=P]OAN?&'O[W-_,X+ILPCP?>#DZ/C@PX.'.)ZP?/W@\>'P][#9;]_\+>_ M_O$//_S'X6%G-.I;?[^OIZ1*F;MGCDD%FWCTY.CLY5O1B0*W//.ZD>7%"/1L0N(SCNGQR=?#D^.#T__,C[Y=G[V M]?S+EW^NEB;S!?6>IV'GOYS_AL+'7P^AQEEG=#0Z6B'Q/SL/)&!0>C9'P:+3 M\_W.B-=BG1%FF+Y@]RAIU$_([0!#`_;]8(7"MR?J'Q'ZW(5NSKIIP8,__J$3 M%SY_8UZNPNM96ORD^^O=[8,SQ3-TZ`4L1(&3J\@;DU4]^?;M6U=\NUH:<+CA MLO@JK*_=^,NX-//.F>CSECB"IPKD=`I+\+\.TV*'_*/#D]/#LY.C-^8>_)5W M^`,E/A[A24<@/@\7<_S]@'FSN8\/DL^F%$^^'T1/'A^F+\??SHYY]3]=$2>: MX0#XXEX'H1#QZ8[\)X\P'#!"F9AV83*%N[Q2 MM[3=[HZ@1U#QMX<0IBGO8C"Y\0(85P_Y0\+$VKGT$6/>Q,/N+C0H]M`@-4-$ M\4[#4J&;<(I#ST&^=OKZL#W.L"8JDL9T8WR8`@NFQ'N1[$3:J)JO=U=D5]YS/$)BRB^0,QC M@\F0PE$"6PV?Q#W7%9,9^;HVLNJ]Z2/P(9K-$%W`W/">`UB:#@K"GN/`V1V" M?#$DON=XF-5(\RX`FF9#/WB!<2%T<8]WFKP[]=LTT$WHO(($T MNI5(NF^:!8\!B"@$"OP?=KG4!<2)F9JLX!'V0;!QQ^01]GP&OPF9[8)?SU=+ M]R@,X[.8[(S7=$2="ZB>MMTD7QNCR<"V'U+/22$;6,(%"`PR@J^AWBNB+C.Q MA,N!Z&-+,F?AGAHNQC`O&7+$/EJC)%RM2XUW'$(I>04>LYLHA+_O$/R$'KG< M&6*88SI[P`Y4=F\)"H8191$,WYA MV'NF6*QK3=>D!@&WDLUY[4K;>*Y7-R0CH+T(\F`SFW,:SZZ6K4C\U4_;W"$Y!3/W%\KN5F3?&;^&% M#Z=_/=0J]ETS!Q)=8"8!U4/L>CEV`(I! M=/,HFD*FZ-;3`HQY78PM@!,'%5O@5'.K$0`!(APS.5P^=^0C5+J4Q0*<(/8D M5F'$#I\1FG>Y-V07^R%+/Q'^D8?')XGGWI^2CW\#D3::14*H*X)UE^Q3<><^ M>L(^G.Z5ZW=-4+?43@V1Y_:#2S3W0N274U1:QPP5_XI8**24,2F`)R;:TWN[ MV0C#G(.%BQ\P??$,%?D9^A`L947.W)G@),&L6X)8P5X\V5,H!SA6,E\C6C` MC0FET[B@L`GHZ/$XIB5?LY MMRMA]_M!2(4&)OF0!"%^"Z]]T<+W`X:?8^=(*]>W*D/6A>5LD.T]CA2I6[_6 M9L39>_ZH$?=.(Y(19N^94V%.5A,?,^)-'3PU$U]Z-\JH_[J?U)?>E#+J_[R? MU)=K`C+R_[?EY-=O2LEX]1&KMR`M5+">H25[9;2!?$032;YJ8,?:0JG< M1&-7:<7]1YQ"I9O#/EZK*S*G^D0Q?NW>+)PHG`@Y]6BVOQE7'"EJ!M>VY#5Z MUG2=%E!4HOM3)<@*[9["54*RYZ]2].[@KZKM,2]K[I)7R83[FR\:+\H-D622 M*')B4ZMLQ*V/)R@80R\EXEF^C`F45WB"*<5PTWW!0:&OX/M2%B!=_I>E/5&! MOE[-$"W_OR0LO"?A/WC^IPV3H+[^C'(OT^667F&* MRVNXSJ3Y>NX0_1WS`^8AFL\)#9-D$)+;RZ8:&D#QN`8_RP4V)B/LS9XBRO`0 M#HL@O,%8=J]2JJ8%'F7A-O`4JIF8D#>$8I`U+B/8:`-G-7+T1Q#&N''I`H., M@+]'F%BP7U\C9QJ?OS\)?PD)O@J5-4*]\WR81"3`Z:JXPCZ_=*X+ M5&J5-$!+Q%/TC*$G%$03.`Z$1;//[]':G_:1)^XET MT8GF!I/>C"N+>`9.;CD?!$+PY#L2]Q=!_@/R<7*:2I9?]3::!1Z?0;L!3]HP M$Q\FRP*]DD%5W/%ARQL3V`BY9H\G`.9>M^QBL4$=I:?MEG$EIR]$-"A4(NCM MHV5V>B^MC MBKB?HN,6/GV$HEGZB)T7DZNRB53RZ01X5KI\K M+RJD?M/2C:;^#EO%O[RK.7?SB-4'NME6V$\;N;42;M+G!KN`>4Y9*I?Z^K.2 M>ZQTMQ'WD,#EFH9[-"L7SVKIZI-GE;O2Y%DY)33D6;@SG7A>K6K"D^;S! M-3-!):`U8\)>"IM;./EG'-E+L7.+>(V,(_LGA19&]F9$[Y_PJ1(&F=&_?P)H ME5C!)1].]T_B5(DKS^C?/V&S@D--QH;]DR!54G)D].^EQ%@E`#MCQ?[)C0WX MOF?LVS^)LY;PBHQA^R>0UAQHK]$V7KSPZ6<6__!.'Z M@T\R5XF]%)_E<:09T7LI,RM'KV9\V#^A64-:QHP]AF1JI=S+6\1'Y`ZIO(.X M<8?%)FA>3T%]NM_TZO&337AU9OOK(57S)G-OGR`D=,$MNZU"OBP5.V7P\6?M MHD`^-1/1N&6TP)V:BZ:A1^.W:Y:VG?;1D>H&^#X@?OL1]HJ0Q<]0:7C11C1W M!7>C&V\23@LCSZ3%-,3`9>V2B"KUOUI.)X!!4)`-3%Y(9]>E2A_]5B)@*QX_<4L]?*>$_\\"].NE56PR(*2F/"R^OL!16&DC`].%/L M1CZ&77CK8`EIN+/V]JU,>_"9UF4S_];>0EPGYTF-G-CLQ'WB2Q,)U=/A'LR_ MF)R?B0_-^'!9&L%.U,Q$E/;<>HZ.//;[#<6X'X288A8VQ4]IOZWBYIJ:3!>[ MLH9;Q8]$-YY<;!*=Z"_8>YYR"P1N-)^N[D,Q)> MKR"QKZK'-@B6QE6B:L'P.HEN2^BZTI4@-8O(=0Y6A_#L1.:*:L'J2)V=B,PK M,:R.RMF)SIRNQ.HHF]V69DX?9SR01OUE=MUW>H6MVA*#W7JN`^V2:LX70A^G M]S%)0KV\;\+MT,8<"_5S=8T+%GIDM&ENR?4N5J=MJ)^]-:D%K4X"T9Y)*U=M M69UMPD[F;JO9J9K0HBWV_)548CTG]%Z`IG8Y)#P&=.GP*_&@'F&?>UF/R6/B M/[Q9,ESN8.1B-73?@%:M'6^*?[[NW,;7G3_MU1;;'SZJ/<;N9PMT.#@U=5SU M@W]@1+G*3.(^90!$ZU@W!B2R1P-,H&@?\UZ)>=8!AA8Q[A/K;9F=)=L0AHN%JZEG6YA-2GB?!DC*/./ MIN"&GO#;LW8HNH:X`XGLTM">9\\?_RM-_-X-L.BV-^RTB96SMHK MD>]63?:],72EJWJUA!&$*ZN@U*0C*=@RO(:"B@L.^$U&QHW5+**%Y7?3LN6H MWH"&K:V@MX?(`:F$W4@M3)OKZ'@YFS]>`A)2+"N)%&!"1&+%SU!OK&+6`4%M M8-6<#:JTI6,PYAB[;X4G7NYK$TP>8V<:$)\\+]0$\.+RG^\Y:U,];/GZL<71 M3UN^4&UQH%.QK+!\5C"W]-L0B[>9IE)YWGC<5J$=455,DEL)*QT_>VP1W(:+ M)0J>-MCE*I&L)'NUP4BVS4"7"!)M,%95'6@%Z;\-EJ.J9%=2Z[7!RJ.%`06J M0JM?2M5)?Z'^T7R6!;7,(=55#_D\N^MBD_EKAMJ]23/A5F00V<+);@L-0Q$C M-K'Q([)G^\3;YFVH%X12\@JB'+N)0O@[>1I>))".(S9!WA-9L].7HA^A?YKL M@>R6!,\\8!;V2*CLWA(4#"/*(L2?^;N$3[RP]TRQN`#88C9ND&28./!SBD// M@3&WCGX-AG*I6K`73A?4BV;ON%&H)RPO;T)Q>.DCQ@:37Q!WB`D'=,3C;'/) M'99?LN3;(KW]5DU90W/Z1IF8[6*17"+?QR`6[4)^A5:-<$+,PQODB"P+)389 M24'S>$MM>]*B+<1LR")YA9]"_GPIC?@&!9!P_*9M`?+"XN:QKR9D$%F8W.QU M4B5J2ALP3]_:':^4F%NCMN$\EC)+GZRD!8A!'%(#S`N:P,O'=S!YMUV+I;CR MC%BA5YY*75NHNGZ;>_$SNCP12%%^:Y6:ME`4/XZ\#47O:VJP>,N[R7;"*_&> M\U6LCDF?)%L3>+=IQ9;A2*R9RUO$)9K#-^&:/]XV3=0T0/.U,4*[7%,#BLWB+%FR9.2/,)3<8[UWF3DDC-0U.<8\/T=._,']@[)($\4UZ M$*@.6-56+2!.'AROHU5SQ/&(,S8EOINXG21F/:WC6-*'=81K'>.2/FS9DQZ# MB,=`)*.YJ&&^\#VW?GH9A3\[01!"=W'D^%EXK[W26/F`FL52WU*OQ M<,`A\MPQN>6:12H[#K4VKX/<>`8-*9['"`:3(D%\E&P_M3`Y@HZ@A66TT__;-'7MF9"8#8HWY MJJ54KO,U;C)6JR,EZ^--%;<6JT,OFV)1[*UA/)S1COUHH^T^XY.%\GP]?*JF M:\\89*'H7P^#ME$V9FRR\(I0-YLV*H\S[EAX86B(.T7Z_XPW%EX7FMNI)4X\ M&6C6Q(";1[D*'<&<:\5,1]7^AF[JS"T-UX` M^LLSFN_2Y"60A>?$[<:DY94:,9VRNARL:K)JE59:ZO1KN<>'JLMO MZ6%KWNM/-0'>KD=5/AW:+IN>^5FAF#K/%I:UQ7M>QUF8ZAX*)?(VN%;K9,3Z MK=.X?W5)&NYMQ("BI-Q*!^P>!R7LSLW-ERWC;MM;):NL('KMO@=;XKS:)*-* MO'>M3^QY3T+,QF1Y?@@72&&$O.=9+H$M`V"D4'(RLUK.8J1_CQ"%+=]?++]; M4`L``00E#@``!#D!``#476UOXSB2_K[`_@=>]K#7#=B));]G9V:13J?G M`F0Z09+>F[W&H2%+M*T=6?)2/;EJ7_U='U[>_;WG_[\IQ_^H]\' MCX_@8^#[T//@&_C5AAY$5@3!L_4:^,'F#=Q9"^B%X,[U?UM8(>P!\G\'!#[X M]'2P,':7`)S8(SZQJ!OSIZ-^>5P?#D:_F^^=+!]0^YJ'8%W M]GM<>##NXQI#\'C^>)Z#]U?P%/@A+KW96OX;N/(\\$AJA>`1AA"]0.<\%NK% M<`$VIA_^>)9#^+I`WGF`5A>XF>%%4O#LSW\"K/#E:^@6*GP?)L6-BU]_N7NR MUW!C]5T_C"S?+E0DPJJJ&O/Y_(+^RDJ'[F5(I=P%-K62A(*`6X+\U4^*]&/9Z&[V7KP+/YNC>"R6@L/H0M2 M_\*'*_PL'=+"G+1@3$@+?XF_IGYV!DC)+X^W7$#S@BQ6Z8(IZ9$_B)\6U(2O M$?0=Z"2*DNH"AEI\\Q:DTL;#54CX@7[_R],9<)T?SUSGVV0\&,_, MZ;>Y.9M/9]^,;\;93YDLD`@#7Q-Q__<#TZ-=:!&.2_#N]/C,P_!=H:+_6:;=0O/,8E"C92OI2T'TC;Y$(?>\('Z\U:>/!ZAQ#T:YA3 M+JR>-24-)#UJ.)Q.QP7&A"`6U`.Q**UD.0:668"U98(Z0`V.9U70H@J]3DH\ M0ANZ+T2CGU$0AG+4X%320)%J361]:C8P!*K(CI&D!:)$\*!78!?Z( MW;"*1P*#=(-/GV'4E$VY*EJYE.DA[6#3P4#`)"RP[S9[(%$`?R(J]&B15(MVR5XU!=@E*XZ( M&>]@&`(K9TLGIX#F6-$JV4JAI3U[:XY$]]$:(K)2@.`:!WCW!=[Z=K"!=_@U M!(\M[I?/UFN]VTE)T1-79%23=?R1:0[WPP=M`12:`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`!/Z+? M=&4=M(G?K,/?3086G56.?3GK:&,>=P*6_:B:1=(SCC-CEN?*B>9.:P^^:*XS M/>*"GE\!+*[F2OVY>L8S0Z;/-^LRXHJ%E/MJXU/V1N/\A$@'TL4.A\'"]-/3 MS?.3?@<6YE/M8]3GT#4)%84RRMVY82+`U"AZ\XF3'>1"\2$8H7J-)UH_8;8:0<>- MKE8(TFF=ZNWFM>55I^V(E)%TD\ET-!_$V3NQ.&!3>2! M5*"N/?2M0C0/AZ@DNT>&7FF63ZU5M'2+WRWD/.-6KEY=[O1JH8S*#C#?L/36 MOL$PV3Y)J@-2'_=V6(*NGNY@%*8T"F6=6Y6[%'JT/;`ZO/J#%;KA_3*[5X/S M:/;+*?3NO<9E?6,\&L6[>Z@(DN>8NPGEJ_8EMN.`F05@#UC#9(R@T_&Y'I5W M_FK@+8SC8L%Y8]RY/KR-X&8O:-<55SR*$^DB.Q8PIS.##>*87]P7_0)\)1(! M%7D:E^<-YEH#9V@$)QS+M8;0/!RABJ&<#,.2D5RM34[#^&>RD4_N$;&B^IE. M]9#,Y1^,9J/13$AS*DX[PP\`):+W"4$U9?8!R$2TYB/3Q.@"@P1LSNR@8_!* MSLNX\AWR#SG$^\7RR/D:-?.5-944#FO%FD@?GS<8QRM8]%@;<@(^_9`3J7T* MLT6D9HKTJCE256-@.-@N.O!/KJY^OA45DL[Z,F?# M&MKU@!6!1#B@TO7MBVH?_*@`GA[Z!'-,Q-@A_AZ_F3+]=.Z?:A_\6`2>8%_` ME>O3G5:GM<"AL?<([*;PP7T&X0Y#,8]%IK$8N M4%5?>S2N4$H^S[Q^()2)[\#LWVDL0-GY"/'`P;7)V6-$?/>E[R3-0= M;K+S3&]]&T$KA!\A^[>1'W!$:&=HM5[2'<@DNZTE* M.IDA:,(2.:+4B6L#>IO`'Z9G%;MY/9$%)NP0E^E^GL/ZV')=_>PM*B3=LTR2 MB_I$M.W8!K;V+9"-?/]J;;9_V[-!!QE:[;P2U*PP4PNS]=>>%8;IT2TWKUL7 MLRHN=_(..18@E@@<+%)MLE5[X(P, M7'98$L@D`B)2_21^>P!I$(CEA/BI062[N.2 MM@!M+%XS#.GQ]GB@Z$:Q;=PPW)&9_BZ<@=H2IVIC2D.3M_+JX/JN;7G/R+6\ M^(2INI=SV6K*7R7J=9()MK$9!6Q4;G)* M7)A..NB;;3@)9E.`6=^KA3P!LU<,2"U# M?SR60'=X-=A*S?#@3D?2M"M@^M7IS%% M)3-K(T\'F"FSEM7,9+IX&_CTCCSA9?;[Y12SL-"XM(=-1CFR!3Y@EP'JO:;^ M.#24+_?(<7T+O;&K'#4/].H\JR:'?_!0O?H*2(7*=+,R@>(J%WKGQ^W MIAYR\-21=3!CFFQ0SM,%=T46(A.M3#)+'2=94 MFKP&5M6Y*8=G0O-H9AX+7U>[:!T@<@UK_JZ&':64UY$/X=%+%L#B.9P*U ML^HHA!5L"AE"2XA0`ZMX+LAA4Z59.L&BVS#8M([0Y@!H?,JX7&3:Z%+T-2%5S42LR8GL"'4.!.8#@8]`;LOYA$?XM[(3H[ER,4 M,*;CWL08].;36=I?^8`LAH)WQ(GT%LW`LL344Y"?5,&P+N[(`S?]P#91!@L`1;<`U=1A-S%+B)G\X`H M().)VLYS;\L"DWT+>!BY;L+5>&699")+=(18C//RO9Y4=;V4J]1)/A%X..+S MKYL]7NOXS>QBA2HK=(R%0A>NH23?5JTD*&(X?H3B^^O9^=:/;OC;E>_<1VN( MR&>R'6V+L6 M:9O^R3(C=OGF5:=@)Z1D9^B%5QJ/:RHR%!%:4C(+X>TO>'S:;I M+'9.6A>'.RV!I?1]0*YONUL/TCUR!=EZQSCUSE@Z(3'Y<2QL+U-7T?K/AV#"E^*7_ M&.1V,9MYS'\PL@G/0I8SDV;RR?5<&KNK1B%\-JGDT.FZI09<:0R$0XR.,$&B MK^E`!Y/03OAXTD+*/3QI6=HOQMGL!O.+)T%\5.7>!Z$H>'=WHGS98?9=NX!6 MBV?3.8AXN^Z;X!Z_BH(J/7RO=>FK7D=F)A0= MB\^%G`4.9T,([?-5\'+A0)<1`7\H^S_^ZMLUNS7ZDQO:EO=/:*$;WZDX+=Z(/\!8UL4[DB;T7O&Z M;1N8"A1F/A[+`G>U+:TKCJV9(N90J0ZQC)?82+*+L#HV;: MEU-8X6BN6@/I@]?3+=)$3N$&%\W3N2W@,IOC4C6J$SM9?EPGL(-^=M2MVO-* M:^-'\PR]^6C`(8CVY?DVH+&+4P.$@N\D\G:'$\(U>!%R7:RX]3$UZ6@,OX3! MJPVY>UWPX"J+*^9%E0[2F['&TW&.&)FH'GE_AH!)TT>,H['ETG(M6ALL7=_" M7JQUJ:/.T\HLX9I!/TUN??P@81@]XCR&U#J*;*2VOA!FY=V("/9'?EDKZ&S\^@E-G>!O^ICW]V`DEN%^)6(B.\$ M6YH#-=L!JH<[!0?D\R:S2@_Z$$5RJEV^GSCTE?MSN;S MO,_',NB1#>TZ_)RA\.&*C)5K7?YP,"."YA-]V2=GPMBZ#Y_@.M">P^]AUN/O M2X@0=![A"_2Y9RJ52RGU]4+3TK-"."`FGLX$@%B"KL!^.`QV^5;@]_%SW_D. M/;R**?>HDL+Z?#[60-IG1CS7[X%85"7W$R)20OI!EF-P%N\^-3%HG MZ'$@N*XS9-_1!"0IV:`#/$G_L8.5+S@VO+::/M;LZ2)[N,-@..1V+/$'D$GM M!(F.PUK));#;]K&'^U$R!L,_B#!KXAG7405TJ[:6)M:Y/J37UM`#W,CN??S` MXK,&T2]69*_QZU[A=[8>P_>+0P6J9>J!6LI.$TWG@W2QDK8%\L(`::T'DO9` MTF"A4"]9P"3SKLGIC^%_@9]1$(;@P7K3QGP5MLN?>8E">H];:KTH`/1P6@LY MP(G-6R@0[K806;Z_8Z?BD+>Y$.`/"[BVO"6QI^5Y`"8VU1Q.CF1@*=`<\W#T MA*`M#NPN?5)7OG.U"5#D_EZ9O"U10VD0X:HA/;4V'L^2*)$)ZP'\EP>IZY(C M!?*2Z?!YBP)G9_/.B%$1`MI!;I:14[A63IQ>9M8Z9I%Z8J/HX19R7[`*+[(W M-`HJ*&463POI^YY&XS2#(975O;.D6@)J%H$65F4)H_X;.BLRNKC",>/%U7;N MF[13%FDE-)$65J5)MO=+WD'6]#J'A15"YX&]O81UFR:.$ZJ2G4=I*G_'E)$L M&V?IY?2(-/Y9\+35/FT6).WJW[.ASEQFR5SW(G.!K%%98RF+$*T0K!!%CG\( M+6R5_!CO3,3#@QL_7*J'<*L$8'P`IW7K:.V#P>L8KMF4T8FNS5E+;5Z0\=2%1AF[T? M:%K2)_Q=.;M&7%;1L0-3WYQOS$I7B#?I,&*#2U)\[T`XP\Q!@*@X>J'6R MY.0!L1U4LX'LI9;C0E92"Q/2YF7=Q9A/1]4\H)OX.\&"PT!5[2WH\*I(EO/B1VZ>](EG-?H+V#FE?M9;T6!$)N[)^ M?;-<0CNZ7]Z\VFO\H"`Y:^/>O[;"-8X0Y)^;?^_<%\LC2V`\3V@B0B4M&^@E MG:(\2TX[8])I.F8LGQXX0S(+B6SJN_1#KA5-3#V5'_E:Q=M M/JD:`DA6*SW(,C^V*'AQ0\TIE](.6J">E(E:2-_@-\3?U2=;37'ZAHQ.LOW" M9#"-TS=J/$OMD=BM0RR$BC27*B=7W\[&4\#M;*QHR,0D34/:0#I[YOC"HN2= MG62F9LX45`F_XW5CW+L__+^_;FN/&D73_ M"AY.[+HCY)TJUGWV29:M'L7*EL:29V*/'TY059#$[2JREF3)TOSZ@RLOQ1M( M@DB4>B-VK);(1&8ROP^W1,(.#S,F^N&GQS_1.NLQ_$I_)E,0P"5XJ[4 M(\.GB/#DW`O"^*&[O?(W^/6_\%M)ZD/Y'*UD(.8($0D MF4\DZ6^0T]8@$\DEM<$DLTRJ;3<6[<%N%_@,<:R?BVX.,3LZ[_E/U1^K[B6S M.*C11#V9>NKD0<&$O2V^+P M@DPXGH*PNA?)/V44.[FFU0E77F4JXH=)05(,%#2ZV^*TLL5&3S[4BT:; MBNWO^,FC"2)^_,W=E:73ECYF-+KS;:N'Q"0_0$K%("H'*KY[6..TL\9N1ERI1-T[%Z^[O$ZQINO;O@'CLEPZ>ZPWP=A+`Z[EVTI-;QA M>L^R7AW%6V')_\W'$[%?*22BG11)*X=1F;+FH.$M2YT6CG,6)B*1D"EK/@#L M5.JTLG@A'N$_W.T!WSR*.P'H`D=2=8AG M.E90O=J[!GM4)864DUM7$[$J3<4B)I?&9"(Y6YW)OA1?_;YP%'T!V4.W"N=L MCZWN+@T].&UA>_.P]9Y8%WD??,?>[N%`ON@MF27Z\27&A7Q=U=<,]^4J.JEV M!*,1O=-M(N\GV:(@D4OW@D,IF7`_%8T>B6RS_;I^:\>IM:E<=!^@1#+BHM%E M17W38?MX_18S&KEI_K+D9V^#'M[0M?>([]8NRT(.L?M(](7J]-L`5_;\RA[4 M1"R,NBZ"%TQ^C,MWCVN>!*"/$C44(VKDC*>K>.\)5(4 MU`ZX+K.<"K-N"0H.]`?"`?2(P46(-UZ,SI]"C/E5GI!;X\UXRD*\RDE:4!U& M<9?A@L)KQO'>K)-R;*U&TY4$/Q%KXW!!M[7CU%I+APNZ+79:?=_"H`&..=0Q MF]*(HO-`%@KX*2]^$F/]=A^Z?N2RTN6_NYY/SWY^PO0DV+W[6C4C;2'!Y**! MNEJJT^7)2-;Q$L*1E(XRXA&5CS[0%GX[0P^L$41:`5HO&,@-3M8-:^F&...& M#[14!HY^^\L3:0AV]:!]C.?6$%JZT$X8T_QL=UMSY*"5"*N`G.JE?(?>9#9J MB^2T%:@;8H?SQ%0>]D_."V^\QT=,FP&ML-$EK-M!]\AC=F$W.O4/$A!"E( M?KKQ[]PMOGF\#8,]#N,W>EM43/,0]F5)`>U>-@AW-8V41Z"SJ=@_S_30M*#% M9R_:!Y''.N_@$K`A_`"Z[I9C1YZD9KWBC?()>/N.")=.'4& M[,&Q=F&S=1LV3@VC]XA( ML70-+!E@E'01! M$\QI+?)+[S%^KMS;+GW,-`F4Z*"Z\;$8D:F6@#T[`[!A-=FH(,.`[VW$.#6" MRD%,$.!V=G^+!(:?/HZGX-O3=7A(T%EEL58\DJ^D!,CL31(D26X*$`R&.+0792PB"*;L/@T:O4MNLDK&?W1+CK\- M4[^RJ_JLXN1%X,>A]W!@.ZDTN&A-X\.:<[=1>^>OM@19(NB)]A__D/6PQ M_P-?;U7+^AFB)8-@&T!]]4*.,Y%-D"J!@A!)-6@F`57D(],$\1;/4*(,2K5) M_FA;$A&T>YUC]Y:X%))*!L1IEI*&^@P@U.:O@QVF*1J7Q)6TP_#\`]'Z9H]# MGDO%TZ+Y<_?N*XZ^>GX0>O$;,0R3,(_/_4U>"B^P\A7'SP'Y"RWPRXYI5P6U M00U,4J$YLY2SA*<3WC#)-,P*EHI@!9^C+ M:QRZ04CBW@W?T%6,=Q&KQ;ZF(Y%@NQ5$R\R#&5#9^EWF,GF;W4TJ_!Z7'S@Q MQJ?FR2''LX8_%1S_WL5D&D<5:;@DM>IIX[Q64$&YB-A2GMD0Q)%(`K_O5(=E M3@?+S**Y,M2*R"MWA04HN:8M$?R?OWKUHXKR-^#0DE5#.:Y&XUD%8J0X$F!$ MH!VPZ6QB.7043`3"3UD0UF"HX!>+<%1;BK/^'7@LM2IB.1FO1N-&-('6Z-1G M9A.B+"C:J120"JCJ7,13)Z[("%0D77_"/JY>":]ZVCB6"BJH7U+KK'(HHIFQ M0A3Z((259LEVMTK]@(X6XZ89Z\@TC,S(F)"_?!`78<'D`*O%6Q$PY53MY*V)VEIE`KA8E%"[,A=B/\&?-_K_SS M]9J6WHUNW3>7KB;[&_*;\)"[9+/ZVW819A9C'314CFR,21:X^??>'O9RV?!H#FTM0'JJC_K*^6RJANM4-N"H5+/=TQQFPUH+X1%:#%0U/!YY MQP[T?<:/.`SQYCM^P?Y!'7K'[X'B[D@9U>!;CN79L0K02;E("+:ET^QCKTC7 M%8:%U8;!`:TB)NM15N83.R!6?9.\\@>O$0$*O&J]E.L83);+6@PFM]F*-FP< MQ&IR0_[V7DROO-I67SD.A\_F@*Z':H.[[$`MW5/W26MM8)I]!Q27&4641V*+ MS'YV&1`S,NT9>78V5*R*\K=!*XLIA5X]H(Z]8`>"1':+_W3A[KW8W3:GA*@* M`,56E5;*":A)M;`*H"4-(-&"#0DE0SB!]7<7O,`GL5O4":-+-=NT2_BK7=AL M"NIZH-:ZS0[4WH:85C>7PVFQV7+N;V[HQ2@\\U%Z+ M;-%8LL%(0YVU4Y-R#M.OZG<+ZW"E`^02+/-`P#S@PB?=]\)"/?"5_0E#`K=A ML,91]!U'F#CLF>CUF4RCMP$K:EA[.Y_:NT8AKJ"0:C>U6BR303$22>9FN*=7;8A=FN,O MV/"TX:/B-:HH'DUVIN/E7-0VDM(R["]N56$2S1X@UV;:.&?:>=*U4X%R-]9X M!Z_50%[;EU*@N#N7=&I$,EVH(I,5K_RK0AT\5\":/'_>Y"&8/IGK5%_`]_@I MH_ULKFGE/8B5,SF"RB#E>-L,?GL8,LU9@JLM,=<1EL9-OLLK&@P3XF+U[9(6 M^WW&&U;BL_(KE3YL-.#+-%#.Q5RLDKU&(><,24F\1.L98B4"H(:*O:V3]R]R MDY[H^[!(J`NO/"`J;0?%Q3=00"`Z1=9:)%R"?O`\=Y6PN M/2+L#V5#\\G?CC;,BU_A#-W3YJP`:B;>2^$IS04%I6JV=\7C$&#M6"EC.9O. M"\"U;XE#@Y&.19N!]6%6B@M[,KV%0M_=7U_)L#OTW&WC>"[W+`0ZL@HHL^G$ M&16@002A1)(=@[G.MC%$4(-V\G4K4%$66*60*!@.BH=_!N$?R4)CTS?+/PR! MB)P&ZLF%H^($ATKB&U],EAV@Z&X>0X6T:1\&3T11.X!1&F&ER"A:#P4-7K&$ MGU>2:Q(UWZ[T<AMG),89T-=P;JP MRN*ATFP8+,3D.]T\7H1XX\7E);7K'C6*A6+[RN$RD>5QN!1:E)++@2I&K$ MJ7C9P^9O5/X:3+27ZJ)^7&&Q+$"`Y5AP.>!HZ&]=.43X-:09R?^.<*7%`-BI M#0'$\L1Q_XT8Q!#.8#MJOS3U?75_=77^[0 M^;?/Z.[^YN*__G9S_?G+][M_1U_^_N/J_K]MAF+=R8Q67@.&YL4A##.7TE=_ M?_D@#-Q$Z\I+1HXL7YB1<8:$%/!.K8LUF6YLS5^W<,1W%$T5H,B:;T?XJ_=% MQR^`PJ$M_:X6RT4U+&SJ;?H8R$\1%#$">M:O.>;JP6)3GT$O*E#M-C+/PD`E M54!Y8NTXLQ*4I(+`^X^.-F6Z$#_P/]K;C10#K`(<1XZP!A?J_4G).]`X:4FZ MD[&S&M7BQ::.I:>9K&_Y5@X>6_J7ZC!L1)$%O*(HJ ME%!FYT6R4XWC=3'F6DV[&[+PMCN+`Q_1@'G@9HL:XRT.G MSB4PL/&QW""Z=-<4UV_G[!3=S2&.8A)-GO]4^8%5WC4*)P6%E)>`E_.IA!:) MM72#4$H^0UPVR@B'0IINNQGJ[C`A=[Q!I/T=V@:N?X8VH?O+%\X\?WZ?7+H];A,#Q MF\"L%$_2_4X:^DQXS'_ZC!_=PS:^Q:$7;(Z_ M;4A$$QVK"VR+B,-8;VK#6SU5D& M=T?*1C<%-DJR\A%M"O&VD&@,\=8,$Y0)E\@*X*E!RG( MTB]=G6G+B.*K^^KM#KM/01@&OWA=2?*7F@2Y%B*`QQA5>BG/.4=.TQA?-(&2 M-I!LQ)YQAQ8W5"TS5"\P0`X]FH*Z:0Q2Z[*!!B/?`O\[?B3\2*M&T0)2BLQ= M?,^"`4=!J18=R'Q6/\2@^YIA(IR5"(,?4O0TN'80062C5#@K!V?'H*>;IZHHJ#W.R79P?+GLADA98"/(X:JYFJR`.M..O( MJ[;,6;YC>L4U&9?UF;74"`&>MU1KICQDGTQ7#3.7I!&KYRZ:7%$U>R&AWK!- M"CF+:0[SIGE,@_L&&HU4MWIW>/@?O([O@XO`)R^0_O_&5QVAM)5JP:BEIBYG6C^2"1-T/R3H7HNV4<0;1W&`UK)Y%/@6#'`&=5CMH*>.#I%H'-T'*&D> MD?;M&`L-ZC2^\<2S9]P7U]NR$1*)G`?&SYZ/)"&W<-[!BW1IYJ&Z$ MU,77%K#L_:]@@&"B4D^,98G*+>)_TK#9U9YEXU_!:;%L:X=I9EG2_NFQ;&NG M_5E8-L-#NEA6^AJ.9>^)R(@>_OU*'MP==B)16.O(MJ:-TV#@:@/:C$?F>O@X MELJ@'==&WF)],J-@7>[4PM:),DAH(T\SG-0869=+&9?__>"&1,DM"3M^?(`M M*HHH.S7Z;B:XGF3>X'KKJ%WK<+JFC9.F]I:#($T+&M74?BI#;UWN')C:3VE@ MKLNEC-K_07.XT-_O+M%^>XC(W,Y].FQYOO'.]0\D8F.>YO>^V%[?T+WA:]BR MR?3#/T1X([6_"'8[C]7WO<2X>G>]MSS@K2.5V]QV\SKU`VA*C"Z`-.U4J3L5A!\"_XD>>OJ,'RKK/60?,8GB M3+O*Q[5'\EX>^O9'MB'ZN>+L9'^,-9X3[6I!MER6&X9OM--]<;?EI^B-(:4D M5'+!?VPM=#PW5(1(HNEM65)LOG-(@3VMA?>6'%PBML1_7:FX"MMUS/4SHJ_\]?9`#T^WNSB[M0C3,_66^K6XIGDA][QR MI^KI;1R\E:I;FF'NWA[6$0E[H'O)'BAI)3W;9>*F[L;.='!G9'I;N;0"6M6E M!]*3"6P7AT'WUVFO]1W+#W#S>!L2A'I[=WO^2-3_;^R&E]Y+Y?2TJSB@GK^- MCJH]Z&0TG90/#]+6:):D;(].RI(6D4N;1+1-1!N%'S\,YB)>\('@`#.;;1E: M=$%!U?BCM>\LIX`K7Q_^,[+L!'^JH')&\'A>,3%00;[GGQ#L.SJ'89[$X?)$ MT%X,^(Y0/_+7:>"<1)BV2*&RK,8Y:5YYCCQ)[CWI@W/2XJG@O*US),X7IX7S M3,#WP[GTUTG@G&Z;:>O0N3";D4:"?+9:8'\*+>DK['GR><.ODN6M,UJPGA+Z M.TW2P_1$Z*$6*1VIHMJ+T+31?.=.^<-`$&]_0\UDFEQ0?03<+Z]R5\W&S?F. MECKY?=1(U!^@I0<&L>D%AP_!X%:-G:JTF[/C7X.49->^RA$0_?=7-_P#QS0Y@)6781W6W_!V M(-O,Q#CXF5PUD M_\C;0C_%O_?X-4:?R.?^`^@6LH']Q.L8/9.>]2/+2+KR7W`4\TG.AV-'_0;9 M]7;'1;9;[NA.#5TV;YD,;>X.>SJ2$6SS^1!6]9Q-;QCNR!O44*0FU=YX64F*5[,5E M)1O?!)_*81P9;UY@^55:07JMXXW2F3_=?I1?E!9^/ M*%%!#MXBQ)1`.2TRW'H?H$_T8>)%\J/0!8)=H3SI9,/1DCM[!Z*NE(TU.QMF M[8D9\17O'G#5_G'^&:,K1IF&51'WQ8X_>LO/V':]QR3F%%F_"#!J:U%*,E?EB.9GG MAP,^DYR9FT<(,^%D@D[+(#'Q('V\5IMS(.>2:>>==-E<."+2D1`/UB-KM=MI M_:T1Q3&Z\VCG`]T7J^+XJ)M5\J`.MN'G4N7:,-\:NGG\F_?TO'V[]O[WX&TR M*^:W)%B>W:B4?+H),LU%G;14'!N.QTMGOA3<),[[)ELP8M.0!.XS:PQM66O( MR^Q'[$5[AKG*@$_&69_(EL2^,"4QWACBK>7V:&1[`%QFP"].[U@!H[=>Q)&P M77AWX8RD3-[+%O,W>E&^'7@UG20:J_#=-Y*NBEO\BVGJWF^R]XG\MDP,RU@ MD*PZQO(Z))".>@#[/[GD*ZQKI@Y5+\"P3(4VBEW2 M:C2='M'*(2,0K8E$],!%@I"(#O-RK)$5B*A$)$2"<80.$YWZ+QAB,D(-,=C5 MNVI0.R*#.K_H@'_@QV3P?N5'L;O=LGW:AB3NIC=,$T"].JJ]RHP,2A>"`KA$ M,G]+1(*F>6NU<)RU,",2//M;JY5.Y7>T*AE<$7P)(RBX"&*>_8VN!^";QQOB M70;30B)%]8,&9]S%UE4WO&;SB;A2FLN@LXI4"OH)GI7=TS0&EYOPR?6]?R69 MD_$SIL7*]ZX/!F\^O?V(\.;*O_1\TF][ M_M/Y.O9>6$+W^0/IV-UUU6'(#H),HJFU=JHA.9V/Q!XY:8,/3F4KZ.$-?:`- M$5+_#25MH;0Q]%,V!P7%8?W"H,I\\K@-?D5\[^PQ<82;2/\K*&@[8R`'ZFZN MM!OT%Z03]_P#^5US=]E/J)5D4*:IZL+Q8CE?="8&>O.&;#K3>L$QA*Z_%(ZEO`21]@]EE#`@`(!-+G2;M#W'TNH"K62#/KTCHX"'SC%F8IPTK%Q"> MRW,Y-`KY^^@#E?`;.H_CT'LX\.I,<8!NW;#B*+Z1CKNC<!".4CLK/ MFY0W2`'%R#]"])&-,`#]=;Y>TZQ`0AB$77SRXQKSU'M6:Z&A'DM7,49AWDXW MY1.L,R?IOW^AM`F4;\.^\FN#.H2Q!SVQYL?5/H$%9K>(SV.W@P=!X$U4DT,$ MSC9?7O?8+Q[G:WS>)&"KE%#O">2EQEE126_>R_8OP^^N.OGFSV=@?XMV&Z*QR?; MO6PX)UQ=,]72!I/Y61MFL\4' MLGV'M@RR;RE_S22 M4*%&U6>\)2V'N.P4BL)+0*13K9%JL8'%:"%/N:815U([;R,%PS",+D./J*6D MO%TB&(Y.=!GKJ']5:.YHQN,Q9S0X"6)JD*RR7P113*N2BI%4U8IV]?,&IP*5 M2BAG:TQEEYUN0#%9K."LE`8SB=9C7'82G9BX9B;^F[O;_R?"-4::&OPW!E]V MT%_O%ZNPTS"M;G[/!BRUG64NDYLYZS`%/JO6:V]F5GV",*N;8ZOY"11VC=NO M94]"0*O]AM]T.9L?@RFW(0O<-W6T:,XOQ(ORV5`5R1W&X5&_J5EE.P@$,F=1 M+XC[@JVWX46*_-FF^46SHG&4M@[?&QKW7>$L]4"^,\8>.J&8XQMMGP:$H>B8 MZ#R*XHM*[:GZU6TZD@`C;\XT+.Y/6U0'#N9TYF-"LO<769 M,%"`5492#BWEE@.'?N.%SN7/P@"@_77`B]FJ%`.I)'`8=#0J@X3LE<96H:'^ M0N-J'X!A@E9+"?$SF45Z+S@=17_#M&R?^WK+[XO.9IK>!SS/M.X[]Y!J&F?= M556>92TFJRPBKTF?9;N^G,^>7,__RX=M MU9S;*.[[`ZC`$#W=>X)48^+DP@!LK:8<2SAGR MN?=B]Q7TD*!FQ&DD(3OFN17Z?\?K+1DQ>H_>FD_<-_]SX+7_+XE[SV\NKF[\ MSSCT7LA?7W!B;H?P[-J2)23547WE#='QR%$FK&-=4*H,7[2FZM`;D3,*96E. M+W>MN&-]_.3&>-.5O8SX=RI.1^2]1RN)9H90*,3NUOL7/]I(V0T^MWM`!*L2 M79_O`T9ZUY[[X&W9NPT]-@HPA7"M<"8)N=!8:_MN>?&EXRC;O>9X6FH^4BBSF`\U!*>--C:(HU M<"2U.@REX`(-*=(WOWSR+9Z]_=TSF19$?\/;S:>W2R^,XL]>B-=$R)4O:C67 MY+"V>=MPTG0+U50KP"_GB\6*9T\GTE'$Q*-G(I\6Z'BD+:"-:(*.U=:\$;.9 MU(-9/\Y;S\4C*A]]>D.L!22;(%Q25^=[0!89T@-.]??W$GO1KV=O_8R>W0C1 M%&PRP2'6)6$!=BU`![3+3.RV_AR*F[[C+9W0W;IA_-::FLI?MH&92C53[.<6 M2]+3-?`2K;D?\C;0GC9"@Y7^TAYZZN^">G(2\A%KP#YNZF\^8Z;/>!UB-\*L M`E)5--1%@E7<5(OV6FJJ=N=0S'2'B86;SL.FJM=M8*<*W12C<[F:C<8-_!2Q M%BP=..DPOYZ;>`L6CYQTN.#=C9P:$%_+3W4.UHTZQZ>4X/:N=2CW%L^S&U:`T&&<4HRRZ2UGH`$B+WP?F:W0E[ M&](%W/CMEGP*BNLOY+?[775F9@L!`#!JUDHU]N:S\?0(6'&`A'0DQ9\AUL`9 M/PDKVX#&FVXO,`3>$H7)J!='_+9Y:?^>BF;FXSKS38-3/;[+X*KH0!WC8!S2 MJI/N$[YY_.KZAT=W'1]"MIOBQ9Z[%1J5#5(4WS0]&E932W7X-'*FRZ48$">2 M6?V0K&PR/V/"92T1PV/D(4P>'YE,Z\/D3!;"9:T8@%'R$&8[+;\TV-BY'6Z3 MX7,+G^EFE^,2-3_\#Z#:TR?*HR@M;",60OQ9P6=ZB"J4L+M[6S- ME'P;XIUWV-WX%]L@8D6YO37Y-2L]V!`XM:\"$FJ=7JKUXJ936I.]A"_W7#C- MT5YS\>171#[]&RM("4>%^NPN83HA'-WX2(A'3#[]&VL!EL3TV5["4":ITWS M2[4JJN$UF2ZG(C7N]O(K"9M$'-IR>8:I0Y=)G"T>=R@C#@EYZ">7"+&#HLL^ M1WZRMO8907XSHA*P-S@$9"V8R,)AB#>,9F[=\"9D=68V_W"W!TSHB>T'5ZTU MJKUL<@U822/5E4]G)@OT)G)Y7WM&$[10$/*"11O$I",BGN=,P.2C#V"[D[<] MXK;OB>TO5";H(F^KP,TM\*K["1Z1/!WC_!`_!R$]6:?T[0LO@2'P6!/5$TBK MF4R5+"!/9"6E,FU`6R\[RU$F4H_<6CMAT%85E-4H*_6/+>BZBJ)#*V2)%X!1 MQ;50YO/59%J/*"[/'C1UL*\625ZE?9`HR@=?$X(R/K$%/3>'.(I=?T-FK"T^ M;O8M8!QE5%&E[?EXZM2#*2/4'D1UM;065D&]I9#8*@G-)H`=NP@>96Q4JO21 M^9-@:&+-*Z=UC6:S"@0Q.6<6=4?M#2L'S(^[_S/ZC]$XG3_]1V84B\9GH]&( M_K\`UG^*#HOEU61`AGQO2W/1Z=H>^D!#Z*_T5Z#URVHBMAIPJ5N!0$;W4,51 MY?HJMN7/F@5:40'EDI>+T2*!&MLW%G*`R]GV-\I)C`+;FI=,/[`D.8/#XR66XG,MGR:%=&.L!VP1!F.RV_]!G:)SMR8#L*[3"<["ZT M\-\03',;>D%X'W3BFLIWH=FF2K$V4;BHY)L]E4ZSN*RC'#UV5Y$.DT[SKZSD M'3VV5S%/S3>WDGR:8%U)/[5NU$I`=X>'_\'K^#[X\AJ';A"261)IYSM>8V\? M1VF*1>W'5Q8"1DFJ&K:(T^FTP$T1;X5=Z)MM!X6BH4R00I'4,)XX9BO1"KO: M.><)V1"ZK86K*=H:QAOE:5C2-VGF,4W$HZ4^UV[T3(\$K3'>1#Q87N!N<>U. M#D4^:^5?F*4,[G5:3C3-9`V*&?N-SQM=TJA00KTN[3A90111QRKXYH1!K6SH ML,T1)7<9D)`+>MI%-=+R"QUU7H`&"EU>=GV:8'D=^$_W.-Q]Q@_5"X"-+P)! MIUP;]7NA5I,R#$FIE/6IW(\DY'>(2H8'E`:+G:+%)#;#X)?G/P$O(JH&:!70 M:KP#C3BVZ'^S9S>"?GDEW:87U61=-+T'A+=2992#;[Y:EL&-"45"*DK$PF.M MO[4E4&.[82@0UN(Z:R%P5QNF5;"K=A00ZLI/K/\>5E^GW/"26;S5:*(\AEJF M.\RY0@WY.@UGB$D%PYHN2YV\I;:59%"*R"-T-;G&*FA]PS6#Q^I7;(`5T4,Q MU*:CY7RL!"HB$^82=8!:F&4H!M7[D,ZPBEQA$+U)7!0UI75Z^(OJ\#Z(\*/A^VU]UB= MJ]C\I@T03=51#LKI?*J$3BX:4=F6P;&CT3DDEG:1!V[RML)D<$P6PU8)CD?^ M@D#BWP]N2#[X]DU4%72W5_YC$.[81J+RG5UMI1A$:$O5E`-W-1?SPJ0!E+2` M,DW8=+?7D+YPM/K"%*([AG\6W5V<:AW2FX;'BB_;@NO6(\+YTBV.WH M/IJ[O7.W^*O[ZNT.NY(\N/8R#"=PME90M3C2:+I[\7"=M(4BTAC:\=;,YG`.[(P,)=P\(MY*MN3GC2^N?TS;0K0Q)%HSG\8Y ML$,8Q8@WVP0'"24_\#\^;0_K(,(TKW-S6(,56N[,$S*9LYN7S3*&@DYK&D,N-\NI M=P`,9M);8ODTL?+C%1XTBI'CUI5+=XUER>O\]NWY^"K&N\H5V*;7@)!1IHLJM2Y6TTD93C(RT4\J%3&Q M%N"FM[4E*&IC+02JZH*T"F.5?K((<5%#)D'C:_"(BUKOCR_FHP;$1>"Y`5J- MK0="N$J`+>(O#M_2K%/KUE_U*WVZ@NP`(,%K52GEK,92&SHW$5Y+[E M,%:6C1[A-SA;!ZH*_BH\91,2TUR@YN4*=0D68+%$+>4=S,5LW-@U9K/&+%C; M&,8)#5VFC8BM"6@5R%9Y3,>&27F3=X?U&D?1)2XKXM/\CND-D2:%5$NQC);3 MZ5CL@(@`V[,`BS.3H(B+18_8<$$>S68VS&R%6$3D`FQCZ#654<9=^MW`=AY4 MT9;L-"CY`:;OEE5@E2IZ5#YNM%JR;YLRC MUME1J:,IW/+=:(TG8+`286+K\[F_^8Q?\#9@9UK.PY#N(](?+P*?S8GO@UL< MTKS;RR"\B9\)0WYZNR?:U4Y&=<@VBD(-"BM/[IQ)LH3+FV7GI3(-HTS+9TBV M37>U1>N(_`_B[9\AVC[P_->T]QQCWC/')1KAF"<>71_GQ%CJ(MC1ZNIL?/[% M#?W*.D-ZVS@-UBHJKMHES^>3I4[VRFJ"N"HGQV(]O5EDLTW&F['[BCR?UI?T M7C#]*=B!'J,=!)*:&*OB0YP87ZB5ND6@6$?`<A42;X-?%R-I)P2#& MO>#P(3!EWKA^TH.Y2.#E706T-=-'UCO6D0;/;^_RM<6;MA`(5T?YRO7E8JY& M(S8>S]#KAMK>W5K\Y0-7&849_VA)5*AI*KJG)T@JDX7:OFX\?4%=-\5P6TZ6 MRZE,9&C@?=-)#`,9FZ>8\W**B1!K`3([:D@?U,\>OD!V]!TAG"9"M'094/=>?-#K$16.6_K<^:Z"K0(C!6:ZE>TVXT5H#,LVJ"_P<&GPPM-:^S=15K/#:U6I,F<5:[&UZ``>K/. MC!><[EZPFPUJ5^C[^=9&1F!'?:\;#[.W$F(1ZO.:*>\\K<;+%J,`)MN*D^^# M.4-]%*#F#%LXH#S\VZ"^Q*EZ5O=$JW?/;HAOR<_E)X]*'C._6E?00?$TRF@V MGSCILIP,KHC*H1?5KXT?*.IKRC%I,#F("0)95NMISC'LV9=A9SQH13-Z]HO= MI4CO:M_MM\$;!EU,JT1,9M&LW"%Z$4M]?QPV2A,A:,]DPZ&?WTF%RB!F2QDHXQPQ*6#\H0^L_G5 M/.Q%4>Z0?6;B@#?LAHQ#,)DJQ]0)Y;1B`9.H(+F$7!J]"#,3B,F,#&]H;C(] MO7:^)O@_L..4G_&CM_:JCRHVOFATQ-^DC>K`=C9-TJT&,UQFK=MP(;"C=-70S(_,E1QC`]8:5MA*'P;$5,OUH,EX4H4CZ(34WG85 MX")"RY)TT[HPJ\,*^*K4"_8/^#M>!T^^1SM'=H40Z2LKOV3E"T9Q4J6%:DS- M5HL$*TP6R@@[0U*<31E?6DQ.KXFBUMEPD*PI`//HJ76"'0CZZFV)0H&/O^+X M.=CD'_A7S0G4UH)`$=>DG7)YA]EB48/$I!G$VSE#1X_]"^ZLZ*`N<;(N";,N MV24NV0F7A/G'*EP"AVE52-1C7@G4:KQ<+>6B;Z%+ MH>N]Y:G8HF,QO?IKSB55/(4J$[;EPY+'@!.VS;GJ1"I4:*.4=#VYMX\!!R7- MU=J/'C,_Y&A=H)STM?G)NPVUUWN8DATT6#!0:*B>7F*HAF$`O90J(H"Z]@B' M1&S#AC=TRTOFE9!?XRN&N_(F?53I=KQ:+,4.+1/)N'8KA/42-K/)D)1`FPAUGS7JM=01_5K@N5MJ`)0=HM*_H'H^)AB0IG?@V`3?<-5 MG5_IHP8[P++V51>))G-YSRT/*R'F##%!9XB(@ND*>QN5FT/3`)7W,H)6`J@+ MJVP'66D^-!;48`"(@!9Q0G_*C0`'C/<@=K>J\=[6A#DUX9ZV(#L"6T)<(;IM M">P['+Z03DB1Y[-/`P5Z1@7EE!$G/UI*PE[*LH3PNYI6Y/Q(2+(%$"515@6, M8R>``&3]C#>'+;T->+VFUP%'WX(81]>!Z]-1VZ7GN_Z:C=KD/:=-NQ5]))H$ M6G31E':*OK)*SZ`;X"8J&IQ M6PY/!?_`@E+M9DRF=F,PM)$%`M<6"JK.))VY4S(NK[Z1\0P]O!W]F:,:',I# M.<<9RCGFF:`#6,IIH:VOH3FB_AB\*CNH2`'B!075E&LF+.61F'S0JU11LH4) M=+NCA`/ZN0,"^RU`4(5Z5;_"XIT=D/_D1D3/S+TVF7+TA*?29\3>Z_DO-]RH M,4%?^2`V0>%#H@I80NWF'1C@76& M=:-Y3M($U'*VTO&E+."QAV,+CL[J$QH^^LT/WXNC_'$&$Q]D6*`)N'8 M3JL=JFL!9-(P4B?`L^Q(@E?7H$.)PB^98DAJ9N%""K##CXO]<*\Q-*=NLXCT M!D%U#0_J_S(64&.!W$M-H#'0APU[MV+1<*^EZLH0G*Q*IHPM.$_0&QNAV$YR M1IU:X#5>;>@JB@ZP!U8'@F*;H5P7O]O(6DS[FSU;0--*5`J"+>*F9FV53Y4N MIZWHB'.0:/KL]`A(L^?XM#/C$QL'4#U0U(9C%%UK"ZUD9[%9U?_A;@]\^DLZ MCMV^2W:*ED:`Z::[YNJKQ:N&Y:_<Q)-4$85JXG(D$]E4DSB$W93,J>G MWT.756^V/A#9_'MR2L[I)! M6*JSNLJUK$;S$FK*-IM?4Z8-T[QE5Q=T9IIL_!9YK:9/R1LIT,M+&@5Q'E%$2,2U13-1, MUW'$DH0'=#&&S5^"4>BW`ZWA32>@_/X,X3'@R8YA+M!"IET^U7LFVG]B[^F9 MSAE?<.@^8?;'SV1*?NEZ(5T1JTSOM$:_=TC5C48KUWZ;3?2-9SMR^1F2YB!A M#W\$48L0-8DMXYN^-.VD/RGK%!*WNL*M'EW1YY?I_:DZ"&4.@^A!U#[\^^IB MDI5(/FXQ#KWC]M]%%W%DE/)J?)K=8:P+2%0E/S)E!^%V?FW@%W\#P^]]OL>T M?%!/;*%+19]<(F*@6T2YT^YB-XQ/SVVS[S=X[O0[O0I6-=.IE7VV M=]IIV3O=6;-W_VQ] MKF5SS)8?7D?U_,%L^8ZWF+Q4M?5CM&W3]?Q-&:982GXT7HVG\F*`3*['.MM1 MNOF.,BKFA""7;7UCWD]ZF7XR2/O)0&P+AUQ3NF`(<1&\I9\@':N@^DPX]$F, M5<1S^?/KE4.5^\Q0!0E-R6.#[+^M^!?P\1/-]2OM*2W^$!5S=>DS\JLP/7#& M_PIVP8)ICDYN:C#Z[4ZI-VL]F;1+N??:'VH:+X_'T]ED-`/N,-&OXZ$Z2[5" M&SJ]?*33RQ=JTCOM5S5_2MB.U\Z]TA/^G`H[I7_JGKS=O-8JS4YO#3I1/7/$ M[,LK#M=>A&]I,.I>0&IN\!36BQNM:%&<<*EM%3AEX^SATS,D-4-,M1/+:M'K M:D:^B3_V5?ZP?IE0&;=:%O_4O@$8\3TTF_2@9A(_P'>/PUWMV95A&C1-?(-8 MH;I[/I\L3!"?.)%)50/D/7A/"]X3[KCV'C'Z\(;=,/H-G/X&16^!_H;[%.]@ MW,=-^D>P)6*V9&C\G0QNS?3GI2V?[DBPS)P6A]4;3NSJ9,941T25?!>#P][> M9VR9O@].D680/N!0L?*+G#QI?O>B/RY#C*]\$N4XBDU19FF[ITJ89<8H5SP; M+Q:#TR55$%$-D53QO;!E;]?S`I?J_CE)XJQ#^6"T6?EI3HHTKST?7\5X%^F. MYE3P*=!>HJWRM&VZTC5!1C]IZX@U#U7LR:S?'#-^LY[+"N#30E;Y;W)2;'23 M6[RD]:B&.1!6VR]D[PQ6IZ:FI9/BLH+ZRJB;C_6MQV78+%%HJ"(S M"DFNMGAW>ERQ/)(4GTUPO7;WT8G6#VC&JUZ"*_\>ITAQ^=H%OX=!I'TF6=/2 M"5%=%%?U/4Z?XHP? M]G['5:Z&+7RTG,P&F.?^2:I5&?@TC',S6SJ$:'FK[X=?S1X"_K.4DQ)VWASB M*';9H?TK/PX]/_+60S)P=7LGQ+651JCFZ:X6HP%8-:/6&4H4.V7FU.-H?BW/ MTU/(5@E(KR,]PPYHL4MZW.TV668,TD9/F40;D:V3+NL_U(D3XZ#;)\5V3I,( MVRWS+\?.T`1XLC7PM/BV;+4Q([%D7OX.*O=H\=RLM>?>1U6>)MX;J+LX\=VI MC"5'DX1!CQBV;/TTNY0ZDY0O1%G0C9=!.YK"TH6!LXBF>R!MGZ*L7RH<%,>Y MPXOOM&O2YM*R#JO1I>^USU(AX8%ZLL8/:F7_%M5>@'1/]#OW-[NVL$>S9E4\_507_ED>=L*8J@B!(F(CF32[$UH75HASBM'&(-6_6`5"MJ MZNK^T^*A?$(;KEJ3US+9N[\64^4LPLY>C"LW4Z-T^+M5K:U2,,?AKE+,H+? M+W2'06;:X:469 MKQ7R]-X%50_T03JQ]"GD1^MG#JT,W?)SVD/.7/]S?W-%OI$?>R^8+M]$M\'6 M6[^U"OYZ2>!D6:N>\DW=JZ;KI225(=??H*0IQ-I"O#'T4_Q[CU]C](E\\C^L M6F[5YZF4C4H\91_=*&&AF3::_0<&_\:A$\S(IE4_MYQ-LR4\P$TH).++L%6O=EZMH\/D MKVY\"+WXC0^-O[JOWNZP._XH;5XU?E>-FEZJUTTYB]%D)&^2(:(1Z69V9,(K MA:.=D"YO?=EQ^::O=1G"ZG%J-96-4N%(2I<7I`CY$#>@#&&YDUC^\>A[1\]GDI$9)(^5K8T9+"=!4+DH%(RD9_81?)=-O.0?H8;=S MPS=ZKJ?!":#SB59AG)MDJ/M-QV!@C_'F]2LN.SAY_&?3G7JF;<4P64VF"PUWKRBG_Q]TZCMH[Z3.KQ6?2,=8TE`)YW?L8$@'1P)>+8Y MQO.EZ1)XX-,QQOFK5UE-K/8=D]U9G2+*6ZZSE9/+H4_%H)]4$%2/I#+]4:-/@'%T'530??B@Q!HN6Y=.'RVD+V"E&%#X?1^]CCM[#&.B4(P ME0+A&K[@N%3EYO'"C9XOM\&OZ/PABD-W'3=]N;)7(!!1HH?J5(!0[/P8&V0R M0.4A)I#PK!`)C9.^5CK=K32.GII@+,51E6^`$77I^:Z_]MSM;1!Y+"-!&5G5 MK\(@K%(?]7K(JTD)TA*Y2`JV"7%ZK"XBK[75``AL#-X*)-;[#!B1+!/J.=AN M2!#P4:@Z)&O>A<%DM4+*0RDG60/,AF=6\+\C,?>P")::#"_BLH/A`,AL#N(* M:#;X#12;]_36BJ9/SQ^"0!MK63FZ%HMQ8<;%)$!CI[T9QQ.M:C.,(R$7,J4A MGYH+$]O'<*O\/(4'C<;X<>NJ\XKI?.G(."\ASO,X#KV'0TP_`HH#=.N&Y)L` M)M'U,[0DBPXT>ZZ?->7I<\/04Q"[VP%-F5-3[FDC*,K%(6:R8+FJB@+R?%5J MOQV-<"P>W1*6K*#K@ MS>=#2+?>.;6SU-_OF&CGT>O#V6/L*%OM+4#=A)D&86L-E0/5&64!BGA#B+>4 M'%656?MI?MA=D#0^4::<:VZ/Y7-<5 M\O45YFQDA=Z.XPE%L@`%+6G/N%3>A-*2)[J[H\4UK@-'DMHMK7;4P>O,'>IL M6>E0B\B2W3.C:0K5(`N>,NL55%XK&TTFS8,GUM8IS9\T.HKKJF-D'208YZ]6ZJE6Q)B/%J.)Y"]^X/ZF\<#]\$?4JNEK0"^,;?-"`WT- MZ`I'LRO,4%M)*P62<_CL3.:C*;MR6K`[.Y^/-7! M^-8?2E;'3OAD\XOHM#;Q]=!B%?;R>-W1WV M^R",Q?9LR>=6?-$P!ZEII=HU3J?+F:`?+AA%3#)Z#$*TD[)1Q(6C/9=N=GXW MA,7CC,5<,EU>1HEL)(3+W7OS9#.$U4[Q.Y.IV@-&4;#=L$\N/C!=FZK\^E"T MTP[(DG%:^!%BH?D>KY_]8!L\O=WA\,5;TU3"%^P?JLZF53]O<.&X4@GUU="5 M6"!.12$I"PEA,"O`>FQC2+L(_.BP91!Z!%[+;0RS[)IMO0M@4")JQS6<#BD^ M9Q051XTKYTXZ(T>B058^!#_JT<\:IY4UYE!0$4;YZ"\SO'O41WC]'T_!RU\V MV.,!3WXXCG/RJ_]W'[KTK-_=V^XA./XHQ;\;B.M"HZIG`\8K.N9@$\I2F4]\$/ M5H@7;YHOTZ)OKMD[G\CK4O:5_]_8#2_)-R\9``,H87@J9]Y"Q>D"@33 MPJR2:)W-><9<311R/>E4XB`TY4FLB"?SY%YRLS<$8J&NF(5D&O)\]$9T)G.2 M0VAVMFG[1QD7/DHN$5VHB82>=%=2:LHSK-"GAFL;I;KTU4]44-+0E8^HSH@J M;7Y";/N'83T&H=(%U/P8CK7E7!OH$YU MIVI!IQ=3K=]SK]?ALUC0[3&MWWN_U^'3R(YO_N?H^'+D#=/SI1_I]+J^7P%\ MC!,=WG>W]RM0W8">3L<3QXI.[U?PKKN\MI_$A@[O5_#NN[NVGT5V=K,_26>7 MTC505R<^T`EU=/_TXF?/O_$QU1\PPO-ZO-,.+V>D/ M7Z+8VQ&KJBI>'#UD,/DBW[)RKL)2'E3]P0]D)A+.>+;M&_HI_@6_E+*'A4Z9 MA9")&.7!E,W"*+%6PQ#PGZQ_CJ//7K3>!M$AQ)77LC8\;7@X5:.*ZOR%'D$6 M%T-+:6B3B#,[!-%FSCAG3BH.\A)9G?8Y6?N@>EL%U,@^L:,+W?XNCFD9?".;H,OOHKU;T,B_8:S5133&;+D3S3 MG`04F:7NI-BT<"#:<44!S!=$T^4\C\URZ7LB*T:0CEIKO6_8T$+>4J*(X)YS/QZ/CB<`CD89> M6`U"Z#E!7\/RE$&EB>**J3PX@NAK'".$R_1C>?YZ>]CP;=1MX#\AHL4.;?`# M+<\2AF\T>YT]:;R6KLXOR@KF7N,H%Z>$]W[)KTP7XL)-NK"^#5P?F@5KF.68 M]JH&2K];TAF&^:U!'-9`FF8E\_/P?K\OP[`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`[[?7)3HCZ-`KJ$O?`IP+#\8DQBMI"2?%F^IYW>2\=] MWY#H"73\[1$6/J*?&,^O@PAF*O#"!QP']`L7H1?'P3Q`LR8\*'ZA0VX>/((: M38O&9Y)GE`2^%QKG[P:.O"4RQ$4^F&D:'Y\!@F<,!A MX`7F)7E"(5_3LN7I=`9O=PE%!2>F<4VMK"< M$'.PY&L6]-1D/85U&7L^.T=;E(3U/FE0Q\&$X!^`<7R=)O#O.P_^"U^D" M8,TE&RWQP5NSW?D]FF4JHQ>MXUL<+::(+!^1#YUGM]B+'E(2IS!]4WP!OPF2 MT8(@MJ\-J4D=$GR4,)>M*\>&N5G;$(^%-E7XBH^88^=7CS!1KD5FY)\P>=AN M#G5JRRG_Z\X+H@3^AV;GZ^DSRA?4300_@TR[',_ILKI$*VIB-*1SF"/'B`GM M'B@%(M/& MID=#%+2,AD@/*"ZHEK>)#@$M8W&)GI+.^!9]K&4>-U)69WS*/M@RKU2$`D6! M_A]]@'SQ0M0EY^J?SW%8[3S%4?^7$B#0&(&2,]M`0C]NVI&!D0&$`%&E;X?4 M[0.3\FSDGV:^'3'RWRWPR_L9"MY31QCZ`_.(>?OA8^[9\2_PJ]]&\.D9_?QU MZ"TVPX7>$PI_>7/X]_>MTW.1$JK^7<.<>.$_D$>NHMDES!^'-&%3/2H/UC#\ MXK?-I(PXDS)Z`HW`H^_7)9*4N[4/XH:,#)H'1`(\NX;?Q1P4Q6V[II-.H1J5 M1J*\NL@1.0"5M8"$S&NY59=T39!BX`><5%R M[RUY:Y';K'WJ0(:E<_2X7C[AD$-6^>];>G;O_A$IT^81?S,0_'AP\9>]*_,6 M[U?,L/G6?P["K8!) M)J,40/TT`"47.@NH_C)`=7@C%?#\ZP"/4)PH4/J_`TIB4;N`Z=\&F*0&A0*I M+P-2(@UC"Q+(E`-(:@ID@5G;@OC/[_>M M,AT/A4F\^>$]!R!R$*AD0M+=$?;I,V?/7)8)-!&N:+F?X.43L5(AFHR4F2?`G M^_T#P2M$DO5#Z&6GR!]IL%I*F34SO&5L1#%CMSB.8?V-YU/OM1H"I5&L<+KU M=WKP@ME-=.&M@L0+=PY]$7/5':WP(PR/N,>1+]^>*EVM\;3_4K#W1WMTB9Z( M^(WLT5EQ-I?:6*=2"=3]MO:H5MM;_=A'!1%*('.:VZ"=_YP_2BX\0M8@B?_- M"]/]=PB]OE:X@MLB2)B_`B40,U\D%&7.8'Q>)#UL<9#?=](IV&]FX-T^W_Y, MS_=(1!VQJ3C!>:H7M;0!V&6N($[0"XK2"H5%T+@'=%>>>.+V-JB_6JY"O$:; MP!MEE:6ZGX&%+/Z(&&75;C;`+L?.G9TEO)Y M5)/-[]9'7BHD$>7NEGF3GR4]L7LV03F7)[#\/_$#$B4)'&_S(7OHJ MKBNEKG9X4I2=>R(M:\O'*A)QE^_M4OLX?5VOL/EN']4_.^;^HPD,3U(LL'', MYT<3FUTDZOCTX,0+CP$)@8ZV"XBB;;QP57',VU<7K[)]JH#%,=]>75CD+BD% M3([Y]>K")-`9"GP<<^S5Q8>G:Q?@N'RAJ^PQ$2YU+O-CN<+$!J_ROI)KM5NL M/KF\AM2P,N>[5J"JLP*_9*A&:,%>GIS!56Z1*+!R6>!40TI@H2QDU M`CC'8JT-`"=K7>#FICG&T,X4^+X4Z-6QVAS5=M4PW>Q'03F;)J(N2J)X)6<3 M1M0"2N2CZFR^B%HH*?B4.ILWHA9@HHTUR77V1Q4M2`ZC&!T-OM4+7Q4,B0XFXBJ%F(J M/L'.)J320TP6QNML.JIZVU`W)4MWF:F.`3ZI#?EC'25:1RCM?^ZN<+`IBJI& M?:F`J67*Q5G?E;K8#Z?3W!2*G>WSI;@U*CKUA0_I!I%TZ`O]U=NDJI?306M' M9#%1/3U7ZB[%)W#:GHNOOQR8QXV<9=O0=N2YP2DJ#LQ4)S($G M.]YO? M,)ZQ1T!$7@(?Q8\X%%LDA!WZ17^%DJ+0T3(_:I-@&?D-<%)"MXWL)-E\2NB% M`LL"CJIZ6>&$A@$_$#P7IE3:;6$G[^GF%>X:1*(9*Y<)ZC.2;Y50JW*(KO@HB)+3<1"#,HIC&GY5&RMZH[!)+YC.:M MB+,P'`$"75)@#^&M.%6Q+T6M[5$.B.=;Z!QVF'@EBUK;H3Q;&/(38[^5K;S# MV>K,\-O0)"19T-P&[2!8%]M.0'"YC14J0:G)CI)HD9$B7Q7B]KVBON(YG M)4?HAB0F`-)D!1E1HM4C;M\KZBOFHKJ?56XJ]S"OI;4,LQ4^1`\T@PB.1DE" M@JM472D'S:RX,'@ABG-*F*U,G`.9V]0VS6KD]H'2C8%/C>+=UC:?7]1MQ^7' MEST+K>M))YK`5)B'FR67L51CMRI$S M^S=V,Q]]I\!1V;6NYWC6@*OT7M`LR7/_SR<-7!0L+Z[G>JZ#UJYEIUFN9Z=6 MDX)-U?7DSQIH=?I"Z'IR:6W<.:]O]3*+'E/Z8YV]7'Z#:I8ZU*GUHRS^-\LB MZM199\RN[GJ"4>5GR?T:)ORW;M<=D6O"M>?$4,_Q^)@._EHX<1P0ZV6JU[-7U`)-"2\W\V\K.SR4[6'2=SC72Z+4PJS2X[5>R1/'49-X$[E>]L2P M`XBJ#%S;@Z)>,.@Q7(Z@;B> MH4$7F9(#A^MI&'3!V0.ESBO@$28V8T:Y)4@1*N=(VL<.%QL!+)YB`7ELH3UY,9K1&0#XV0J?(%AS<9!LCJ8' M$-OP#`0\O(C8*'EB60$0+7_6M'0&3T6CM5 M@)`L(=-E2N!TRR2B[-#;/-R792@92YHC]8]C^L]C)Y7)!<;"-7NI[V7AF;"J7<=<=Z99Q$"HKK MKO3J"TG==M7,S;[_F"FI+27'03[(A8'63><0L6*D7).CSF/'*I-9$H\D3N`C MRY=9X]1V#!Z1N[+KR:6K]Y2>P'@RR:7K`"?5I%SW!3"PY`0ZVA"I><)+B)\K7(#T(95VLN/0`SJ-H1O^/GE,O7LB.J.3"(V0-E,E\G-3Z M.LF5I:=0/FV9K`N[AR`0BR]1]O]:[`F&L%,M`.(#[S('TUG"!L\7F."@D64E?GVUU/B@2+F4\B_ M>4%$S_#O$:RA4%+\4VL(*[4)FPAK=1+Y/4A"Z`N\I"-E5*^"SYF#]XAND$`3;2>QH MI-2U'SQ=YO)R'CJ@S-!^OWYP<[5"%IYP6RS339Q\7E$RBB.D:R`2YW!++F?\U2O MK::BK.75&*C?_/+R>C7FG3MHCW#($M(8F'?90/WFM_F\JP[:(QSTK3HU!NHW MO\WG7770(%!JDQ@!7^"/81 MFK%LE9OD4N/Y+8X64T26-.64B*_JCK;YT7'"KNYG)T!OM=T,"G,B;&XM[$W9 MY;]/;OV';SKJ\5>'76R^WK7Y'E1.32>Q]KJ>!J(KD*N=CMQTKNP*7U5#L?LY MGKI"7._YH9Y'YX#[(>[R)V_7_3_UC9Y[ZE//2>^4452S M:]<+P#QE7`_>X5R/S30-H.SIS_4PSK:.2OD#O^N!GLU0;6HZ;E9_J?^Y,.L_ M'>ZBK&)6;%:IJ?_KU`R28A-@O=I-QW29FU^+5<&"MU8$B!< M!K$?XCC-RB['U&EF9S:WJ7]NHCDFR\Q?23Q^^?/Z0>>D]!;]Q M/G4K2O)>U5S/PU"5'&ZVKDQ41V6AC8@H_I?![X M`4P+WP`PQ==I-!-'@-09PLH%IGCZL%+%I'+5 M=9GOR5+I39/7D`34$TF\=G!_'>R]@[3E+B-1OBMWL=@3TKJ+I>B'5O&8+I<> M68_GC\$B8N68HR3W@J(I66$7^E3K:JYH&,HE=DA:118U<062LZ7/F1XV:-A^W\L3Z\X5U1E-TN\ MT!(C]*&%5Z@FZ= M>\SLA6C&=@GH#8D7[OZ=^@'=X^0?**E@!M,CU@?0 M[CSR.Z*7RF.Z6F&2Y$^X'*VWJHB9,ZY"ETZV=*OW,$,A*:>J^"):HS@H$)N$V7*Q#S\A67>6EQ M`.A=PRAX2(G_S$F[ M6G\@%RW[?*!!G@$D;J(8[NJ0;=**+5W5PP!1FQ6V4XSP&RPL.*^O//\YNW__ MRK+C<^C3Z&R0U+L@A$6$([39%9XCD"]6>ME/%7.`0J,:$?DN8ETC8WA+U?"^\[S&:I^%M,!T?LXX8H(G/9%H\(H7TE05^6W*V7[Z8W1+>'8' M-2,\'\-.>J88>7#/PR:Z1"\HQ&P;C0BAU-,?F8X/1]X4PT%(+9,@6[.`[/A\ M76&.,C/VD:%2LA=Z)!(:$CHM+[5YK>919$O=*OVM#/[NP9A9AO;R+5W*'G& M,U5#P%A@4JC.$Z7Y6!E[D'3_@>/"K]R?#=UJ,C49-.P";]S MC&CME$F\H0]341SXL@)+[7VOE^C%TM.&R=O1C&K4]]Y2+IRU\BD3/I3/F"0T MNT1AQ2S;.L5JIG+73L@4*I7*78UXI*HXKMQ*W-9U1^B,:)%SNTYO`\1./;)` MR2,<':L8U!?U-T_%C@9(_"]$,+L_9YMGW_SPXVLQ"CVL9J>L=&XJW(XUUI'K M#GY78_T:0JIN97"VNDD7(&XL2LZ6,&D(HHZO3[VR)">#H3B1NU8Y$??QTG'L M=;942',,5=PYZZ7+!6QP&E7JV:DX&T.E2T M7E&:DP'0L#NEL_5KS*"M%3[G;/V:YN*/6EBELZ5J3`"H$C;;K!J-TP#6"$-P MMB)-IV@>&'6TZM.>1L60HSB*LFGG2V,H49&%O,Y===/8NC1+[%\+O"\VU0R_:M4MPH M_`*P01<3`R;/&U!@."AC_%?-VDEC"VA/55<35EW8BY5RNO)"0Z@X!2K:D6L&#J%,_^*"5E36YV.EBJT36#R_R$>B)ESA] M2N9I>$AD!5-:8QS/F5BU3@=I9/_-2V,E#4**?*GM'B7-1!57KV.^+2Q_6QTN M9F/IJN5E$N5]CF<'5O#>Z*R'Q?^$W33TC>*8/JPG`6'FYR+"8]B`=>@7H2DB M7]C^J*G_[5._Z(=50E#)<4>/GX/^QW,L2N:TT9&X8@_SCXE'$J?D./4E-`C` M2L#!6=!,_LU6VE4T<_3ZW3@@TX=>]M,W`DWC&_@+D'-2ES`W:S&#X])+T'4P M3YZ%J8JYS8Q^'J=$Z?N[[4P2,(X$!;_XC4Q^^A'Y.)I5?[W4SB0!T^>`*'Q_ MMYF=1SXX$A#O1(PZD)03D?:S43_"?T2P-$9R^M9-% M3Y`I- M[LS_*PH6SS3>X<=3_L<49.4#0S3?@ MHUC3?/N?Z^$A+4Y-2Z9M9RO"',]FX9MVG2T]T\^)J6L5[:ZZS3%YT.P40!SY M2?`"?-EPFBG(9JD=M^MA@D*:1XPFL8H/3LXJQYJ&@Q[C6P'<&4&6Q':[-5IZ M#^!]Z1@1*Y\C+,*IDQ>4[$O'B-A.9$;Y&/O4F_5 M54;SZP.R+7V]KZM6:/8K)XE%(HG4",1FB3A2G`_$#CM(ZY%QE%A+5:Q.8-:@ MP`K"5'G*(@TN60V.C$[&TJYFM=V80F%K;Z82),*\#-;//:H9/#5&AJ MFHUL\L,=W8UH[[J/9P^G1].:X+J3:2]G2-,.X;J3Z]'>0B4QH8Y[K=,9%KY' M9%LVB%/#*9_=*?Z>5R&JWEA;MQ9\CG9*$IU4I@9#])?K:_!)+K6Q066+5:RX M'+?W/:OH%1H_/X]#9?LAD8!L_%X:Z(=`6<4Y+$ZY:$8K-]U[2R3-N='*IPQD M;.GJNKV)_H$\0N-G]@&R0\3103<%2@Y.)4M4'!]X/[!]Z("&(P+NUR!Y#J)Q MA"CM%L$KTS$$T3NHR7/5"C/&$]D][3JLK<88GDRIQ2%@LS=38#8LQ-Y=.L1Q M]G6B=J1%UQU(CGZ2,GUH"!OM]S1E&O\02EHG8K%%0W:S$%*="C<]G9`&ECWN M%!U:RX?P3T$1H80$_N9L0W"]XVQ';% M6(YY3]1<1ZYK0YTA7;5RN]-HCO1"V@(6#YD)>G`OU96IK_Y(8>IN(J`]96R, MDV<$^J(7<7U133]IZW[>96P[SQUMG#ZW9F>K++:3&4#[^P.Z+7Z_KY'MS?GK MW[&B0=HP)[V;$^V=PO7,:(\3D-(0=!))+)U^^YB`TEZ3_2+.,:VUNWMWB,37 MG*)N3Z]ZAH@A6+D;;=CU%]5CFIM#B;[94^H08&Y5`#:0'&"XERP*B]T]Z1[] MS/7.D#=D%>C1Y&FIYLVR#1QIL'0^:P]PVJ^G@$H,:_!,EU*(UO+;:Q0&4355);: M&+#.C']$L%"?@U7V8T&\F.$*WP3(`5/@KL:*UC9TSH5>4)$M! M\7=KU$EW]6X+*Q3N[`)I7#.GH6UZ=Z[+`_=:"?7<;CWBI26^Y@9@5_HZX&\''%A%XL]+<'UO&]5:)0U.]?K&(L%M:T!M71:N9ZYL1H/J6+C>DEG M53EY=T=)+#VN^^YKP:4DIKD>5EQG@4GD%=/_\AV^3_)+.+[%T6**R!(NZ92BA+WH(25QZD7)%%_`;X)D MM""(^;[H^5QP[JF'SW@HJ6ML`D>[0\3Q;3M>>'X2PKV"*TRC9*2`A]*)1Z6N%JWSO MT%D7$;_;Q#:-%RDAG(R,NA;FI8VUC*@=578(]0VJ9BIL MYO+IRJJ2:@/U_$`=6U7B-P?7_1[KW8F[N-21]YW863+;>0'/(,SS+2(%0C6D M]1=$GO#P!BM\@WU@$_B,DL`'$$[W/?1D[&#*MWSKYJV^[34#>2'X/@K)\YH$ MZ7)OYPF#W^3M;=BJ+T(OCK>BSIA,:,:1JU=$_"!&H-_Z:/O'./^K*!BUUE"] MX3G+(3:>LY.5'<@77ABBV?FZ"?L:HUI!HJP[B0.-.0WMTRL-O>@\M1*_-&@/8Y^^V(H^#J+5] MRF4![+R6/:`8A&\U@FG#P8&N3:ZN7E@F`AFA%D?[ M/4VXXW$_4YR$676E2S3WTC`1YEZO,TI?IB./EM_J$1?>"OZ2'"2@JC-$2Q-T M3U,:SM-H1L]+^G*@."6'_;HB4'P7UQBA+RLGIB$C_C<):G1,G#R(W.H^0;O6/< MZ!Q+OM&7,^E[E-)DM3GE%WBY#!*FJR%4J0_5'\_`M.=W:"Z(SN^"$+'L)'L6 M\A!HQIE4M[6LT:+;#UXPF^);:ELDO.O0Z/`FV,U6T`/9>)KL.IKD1%+M@AK_ M>>SH=#='+BV>'%S^=>Z$4^[VBIZ&`B.^=V^9E?+>;&-LPH3/@R2)?C MZ"+$-+E*;G%E=3LK^)!V-4'F=BWF7V+^4EFP_RC*K?J$E]=5M6<;1#[05XXI MKD6FL*]10K>WS]5K0CQ,0#N';TR0CX)5(A>L:PQB\"DN?Q6@`KQ0<12WM?D, M)[:8[[YW\^W4KN<1D%GGMQXV\A>S+42?W$S`INXRP364NKZ"*NS:5IFZZ^S5`#&90>P48C:JH#-ED#N%\(WVL)29R$XA MJ*.#5;H7*.AF.C?)*[=833B1O%B*V`B78Y=YFSI&R.S#13MGX=[^=4Q-:V$& M=!P8G,U.WQZN.JY>SJ:[[PK>S/O)V7"H[L[?2C^:9J%5)X>QWIN9LX%9[8!; MY\&A4637*4-<^?A4(.N8AM\1LJ*WQP)7Q_3[[FXUCO-A@:ICFKY%5/GG[*") M-=#$%'VC"K0'_4SE[#7GAU,\#`^JFXH\;-1EK@!_4/C4E1&A1UP!YZ#;*9[9 MC4-V"\P'E:\)YI6AX070@^*G>47*/3@+8`>]3P%8B:MA@>2@Z=4R`^\&@Q=@ MMJW@]2.IR&9=M952I'SJEE^(.%ZRTN9#<@V;R358%J?;P'NBFQ"(4TX"H=#1 MO"\VNHGNTC`)5J`I`*2L*%\NR%8[9\LZV_0U4)^"=H1-1]U.-6&M/-5<]S;5 MQTMG=J/&WA2TJK+_[H#02>!_]%].7U&>=J\FPA^OH9+.GL$O$0KD*]A MH]JX'H'(4<1HO?HC#5Z\D)IC*BZ$BDX&+@-F"H*UX(7"W&4'3>PG@!H25BE, M[740>9$?>.$%?D'PHS@[G:BEE0!FE"3TNLU0X9,L:VJ#YO)1=+AA!?17=NLC M+X(C2;PA&PQX//Q+UVFC(?N(`7/(O:U(/J8YB`T^=XO.RHF5Y2O3'<5JI*:2 M%"(J-JZ$D>NABD,@<(-`8.DE[WHD7?.KM5SHNLE%Y?I*-'&-;W1RH2#MNKG' M)(B'BJ;KQI]Z4I3.%G<_@K:FA-;\G#R1F#P#^,IB&9V]7CI8E_O'0Y?ACS;M MO?`'J,J(*^E@ M0^GEH,BGF]/0YI:KQGUW=_&X/(TR*.+]\Y^I1X"-<+W]VXX'PQ0^?QY2AR,+ M:U)*F?+SN>XH-G:?XAS48+#H;'.7UIS)W:VK"M&I;^=S+P[B\;PX%X?;4)_^ M0Q#Y9!^V.YZ[D,/CJ>^=QV`1!?/`]Z+D$$NK5^&Q;RA%9`5/*6J=CV?KJ:(Q M[$<5G#:_&/9E#?KC&"43E`2$(3Y^"H-%IA@Q\D3E*2J[67&NX1I,,H*JCABU MOB8\JZ`!+<`Z);#2KUY7L"M0%8VJW:R`OHV-C2E^F"UM%-&%K8B\^@"6^*-@ ML\4]0?2M`FB,E9>58F];G!'T#.3!(7T3P;F,,K+465/J;L0=,:)1420OQ)[9 MEB=!_/NF.#+]F2Z?[]".4(?/I'K]&1O7SN3!;1H&,T:YZH1)NMBII$?@H$U@ M^2CN)DD'&_1?>81&4='\"\P%6XV)JEXV.-F6AQ[/=ZPKF_`NN2B@UM<*5Y@@ M$"`O6'5Y@)AXX*+54S5W\\`T?@-XQG]#./B+P$/DB_WFOU M^:;0R<;$W"Q7L&B8X$@N@WB%04,8SVDM^UO8VS,F7,9PI80IS:5]`^I'M`B> M0I3]0>>2:N-+5A!C]VOUG%&B MUM<.5R]``":J"U'4W(XSO1# ME[>_ERZI&@,9J5D6LS1CV3E,C^1TM0K7VRPKU6>Y[@A6'I'1CQW[!L$1_.BC M'3E`;=%I#V.BBA+H9E$"L-X"O*!HP^:M58*:PT MW>YV`A%\!(H`;&%%R4W2P5(@!>LO4;'\P(FMU^Y[D&OA]7^2G#= M0UYS):F]^K@>1:0'6AUMRO6@`D4$S3U'N%Z;2V])REX#7*^UI8>4V/3D>ATM M/9QD:J*S%8MJ(:5N+'"V(E'-%::@R#M;9:CFX25ZR7"VC%`MG*H=LYPM"50+ M+\4G;&=+_=3;C&T\Q#I;ZD=;3U!YLW>V?$_-"[72#NML71[MY:7]INAL\9V: MDHB27X*S%74,;=#BHAP@2.AY+DJ M2TDG=QO4Z&XW<7>.8\R6SBWVF*:8+Z!H43P,5V:>:#"B902$[T?R>:X_D%U^ MMTX1F9D@T>2RHKM=WIC0\;0O^1:9(EE%2%B.>[_Y'@6@Z/L@$\/)KHE'"Y_L M`88'V@.7_!\>F36!K?%7^H@4HSQ3MAJMJ3H#]P6/O%HVF[I=LNF[8SA?8]@`C"U=<.J/?#S"O_I--CC'\W&K M(?,-GO3%BY6.:C`XTPN6H++0/3C3\Q$T<]D.GO55Z.J*=H,'/A_1!D+/X*RO MLTBU-;7!PU\"KV%C0G=1`?VT0^=O:0\>24KN*45FL8T.VQEX8I5ADZ,GN4"OUO)\Z6-ZI/\G>U>\B]?['59A;`Q?+^_3G]Y1XJHG"/_X_ M4$L#!!0````(`$=[747S9*!*1A```$>D```0`!P`=6)I+3(P,30P.3,P+GAS M9%54"0`#5C]15%8_451U>`L``00E#@``!#D!``#M'5USVS;RO3/]#S@]7-.9 MRK+B)&T\<3N*/UK-V)%/4MI>7SH0"4FXD(`*@K;57W^[("E2)$61DFS3=WRQ M)6(_L4M@L0!6'WYZ+.4Q1SOC[IMV][C]^H=Q]_WIR=O3-R=_)*'E8JGX;*[)*^M; M`#Y^VP:,$S(\&AXEM/HG&4GA`;2[H&))>HY#AHCED2'SF+IC]E%(U#/*$NA! MX9VU$OK=GQQ)->L`BV[G]YOKH%-:7W]%`MC3AXER^!H&/HEP3CI<>)H*BR50 M'"Z^%&!@,_9YDDD&)12K^_[]^XYI34#[7GM&Z6(%/Z7>Q$"'#1WLJO9QMWW2 M7Y=@"H#5!,<2N)NATO@X,PMEZA)7O];2=H3$!;X*-:+=?!/68=S>1=)VS, M[Q'+5PI>O$VH82OBOL[@VHSGHT%#/C?V8,WS4;`E'X>+.^;I?*R@+1_/TPN5 MCX4MB---X&BJ9DQ_HB[S%M1BU;T$AB27"7TEE7O!IM1W0.2_?.KP*6=VBU"M M%9_XFJT!^"(&^1&I?*!"2&T&%_,=GRP67$QE^!4>X!MTJJ3#QN`Z!#]\'O9+ M":S#X;*#2)T+:?DH,A7VI=!<+_O`1KF&>8MP^ZQ5"+$2*!+)9E,NN!&]>]PE M;1*A)S\"*1+0(@EB'SII"FGB/HSK`_&C^6Q1Q_(=@W@-WT/D$*((<:%@)!5Z M!\Q8LLUXX=/(,H>'31^K@U$%&<\:TUQCT<`:]I3`&ZSG3'/JI MLG4-]A83O]G%Q.35FF#?-B:O:/(^Q+LNRS=HV%9LMK?ES+8"\8BXLL7(U$L2.\V\D1YE3, MF$>X@`9I?0EE^88$TIB9NG&6`SC+.?7F5XZ\]_K"YHI9.M\ALF#%1O]^)Z,# M$V*X-&8L8\9/4C-O+%?S:]R;GZCV%1M,!PM,18"47L*LE="*S?P#1L_ITUJ M".![?)OHV,:6^]ERQ&<"5C\6%3JVS"W,CA8'C$HO@5.\7KM%.$I(FA M39+$&R?8SPDNV$3O:O!-N,7&/0]O=F/,/8WY&U7P:NB=W^`B_&*C MODD;-2+5F'0_D^*RM"=L_(?9ASOJL#T,7)Y:L;G?9@=H3RMNF04V$&^L_A11 M6O3@@-':BF2Q_=_M'K615]&G)B_^)%XRIA/GH#X2$BSVD._W\9"`0^,?Y3:K M5[T;1OYUI(LX19V=;QBDV?R<;D+>'@>$T_N=)-7%TQ3WFR7535[ M^&8-IH6O;RE/V(=4L7-D$G85QH/&8Y[%8_KB#K25:OF)Z=T<98U"H7^\SF3_ M*OG'BM%W!%@U?O&H?K&"&C*+P1HB#B\.0JG83_;(%ZX#)U@V_O*H_H*'=*FR M<.%YP>Z8(Q<8;%X^+'`;=D?/V4*SV([A@5Y1`J]IU,.K9:4(3\(H^).#;.\JC.\EDH9DD`^)O9>$0)"!O5PQ@B MW.\SS9G(CWB%*PG=PSV669"[0TS+X'P$](CV;A[X9-(5N_4^6>8V M22I!DG)%@=IJ5UE+$FE"C"IMH\LZ4E(;$JF#J!,DM&+4O#:/O)0(MYF,G?:: MKS?0*G;)?=+::[MD`<]F9GYBK\&IKG=/E>WM-T<7DRSVH4R>?&RW-XPG5OII@) M(S+;<$_(NM`#3[)'<5>BP9=`.A*+]QV)!#0Y,2,BB60D/@H9G[$69[80U+VKFYX-:-CI76LJNQ<#%5LUD]R-BC4T/'WE'2QH\.[K^[89R M4)$+9G]2[O^#I^,?+!4V9%-BJH"=8NFKLY;'W87#6N$SJBS$+ZX?UEDHN6`* M#=:)R$8$,MCK!E9RY_P=E3@Z4]`.'IPG0A"E^LJ+P0M1TZ84XYC0$T1^-K)/!"E$V_X]MU M!HP.,^>H_J&3K$P&W]8KEWT`S:721.265-M0=Y`$I0VOI64(%:#@MW:$ MU\9'[>[K]DGWZ,&S0Q&K2!!W=#4)(KRJ$N36\RO+.T)`IF]+L2LLC[B)K6&9 M6X^QPQSMK6BU8UK5>S]3`K%4)Z2QL"?>8_=WW^TC0J)Z8T4QI/BTFR1%]2[W M,`P^J6J7;44C"\7)PXN^["=(3@G*2(EV[LY0,*R3SJ1VC)_F'!3R-`&>MG@O" MA%5V!M,P*Q(L=6#N_'-#2WML4(,934=-DZ#BWEG+,LN(%A'<VM*%17Z>HH&463UM7X6Y MK`-HE'.S"^(5AO)XL4+%4$G+80Y#S.JDCKDJ6*A*"/'$:MCZ=`Z8RO(GIB/S M%3+%*%=OR>7#@@=L+F#M&RM5#)54#$N<57JK#FJ>0(Q^5@[!IR[TN4 MF$.R9W^0F\-3!%QOY"PP8P^1L0N5M@'MK&]LSI:[-)@?2%LL6./%=F;$<,NY.?.6Q M6["CT%>,)=[7,?B8"3XW`M1ILKGBRM,5 M;%0&NCXV^EE*&Z>V$5-WW&+>F#YLG"?+P-9M$C27AC"VO.)3/4\[8'YKG;PO MEE#ZJDB!M>9::C`0;*/XB;9:RCYBEA3V1O'7FVNIP7C.U68%UEKK)']Z,QG' M3YCBUQ?*A4`O(>K!#$6T\+BB%L9NRTBI(9CGPL=@-/P]F5LC6ZS]3LC[S4`' M-7&>_!"V#MG4%S;27I]A2X*_A/"OE"JW@7WHC%7L@R1BSNCFV< MTP6TZ>7(G_P'XORQQ%+W9C,:IHKBCJA,[*6.$%44'=_+P_6:(?8_W&OC.8R= M^$,9-P#H^NZ0P?+$9X?PO"+2CS=DU;9+#^&61:1?1I>&9^&P!'%?6(Z//X]9 M*O"ICODBWEK?78Q\-\SD9,*=W-:UC8/09L\WQVU(2EVL>$3*;`6LFUX>^%:T M_L=4`(CM+./[*IM2!Y41ZY9'N*$/.+;T7#SK,)C><`?>,'A_4H=;D8\,V*YT MPS(!MY3;8WG-$,I+=LLAJ;Z$D#?4^)./2\W!-%(T2,K?T&50R8QENF@[0E)[ M#D/@C*EG=)=@*@I/'"^#46HP_87/YL[RFO_E<[MO3DD896Y]9,$MQ5S)^RM@/5RVFBD.9,O,YEG+0=8NLXS0EC"U4^%/@;3+6?;Q\ M0IW,SG]IA!K9,2GR898.!R19H^1P4BL(`%WNNP-Q[D@/RQ5!G`2/S>R:WP_% MRAZE[+A4.26BT:^YR/,B2VILK!*K3%ET%28E8\QU07T*VIH):P8)VIQZ)4%]$C^37 M1AOYEL4\[XHEWH82H"]B>Z*X/+VYD9`3C%;#JEM0FJJG:0*)-=UR6@^7LSFL M`AC]@/_AUE#T%.BDLS2E$>J5K0DW^\*BM8B8[W@AW,:UT[YTZN;`.+!ZJZ6@ ML:01W,LLI[9#UFB*WEJ<&9;U*Y!0`5-3%'\A4IL4Q%DY_`' M?QD@]3,OQA.RK%-J\,G4_HWQV1R&G1Y$PQ`1QB=:*5>_4L=GSV"*$C*MO12& MZW/:2BJ-6R+QGM#ZSE$F7BV/4:_A?KOB4Q6=V]GU9.]M2% MYDI(3ZQLN3O.8ZIF3(]`G`7^,,[66VIEX>NT=X=0`[Y^F-DF+_`@P3 M51N.*W3F9&`*@>J67HF$O7S`/+:'U-)Y@P*0>L6O*4%A$7SC.YHO'.9!I&;2 M$)E5516<.F4U(KE7"_G8V[+*Y0(]VNMVP(S]'TQ)DY2VH\(089HCO9S<"OB, M*\P/G:#F%WS\+U!+`0(>`Q0````(`$=[745`#%T!-_D``)YK"``0`!@````` M``$```"D@0````!U8FDM,C`Q-#`Y,S`N>&UL550%``-6/U%4=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`1WM=1=LVQ&?2$```:.\``!0`&````````0`` M`*2!@?D``'5B:2TR,#$T,#DS,%]C86PN>&UL550%``-6/U%4=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`1WM=1?LLB(0X%P``&UL550%``-6/U%4=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`1WM=19&KVANA7P``=SX%`!0`&````````0`` M`*2!)R(!`'5B:2TR,#$T,#DS,%]L86(N>&UL550%``-6/U%4=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`1WM=18&*KH'Z+```QE$#`!0`&````````0`` M`*2!%H(!`'5B:2TR,#$T,#DS,%]P&UL550%``-6/U%4=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`1WM=1?-DH$I&$```1Z0``!``&````````0`` M`*2!7J\!`'5B:2TR,#$T,#DS,"YX`L``00E#@``!#D! 8``!02P4&``````8`!@`4`@``[K\!```` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized (Detail) (Employee Stock Option [Member], AUD)
Sep. 30, 2014
Employee Stock Option [Member]
 
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
2014 69,817
2015 104,597
2016 25,869
2017 906
Total 201,189

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation
9 Months Ended
Sep. 30, 2014
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

All amounts within these consolidated financial statements are expressed in Australian dollars (“AUD” or “A$”) unless otherwise stated.

 

The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. We rely largely on our existing cash and cash equivalents balance and operating cash flow to provide for the working capital needs of our operations. We believe we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. However, in the event, our financing needs for the foreseeable future are not able to be met by our existing cash and cash equivalents balance and operating cash flow, we would seek to raise funds through public or private equity offerings, debt financings, and through other means to meet the financing requirements. There is no assurance that funding would be available at acceptable terms, if at all.

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V-64S-V$T-U]C-C8U7S0T-V9?8C5C95\W,F5A M,3'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]#;VYD96YS961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=OF%T:6]N7V]F7W1H95]#;VUP M86YY/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D)A#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E M;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-#PO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-SPO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I M8V%N=%]!8V-O=6YT,3`\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O5]4#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)O M#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E=A#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E)E#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O6QE#I!8W1I M=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0 M&UL/CPA M6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G M92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S8U93,W830W7V,V-C5?-#0W9E]B-6-E7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)U5.259% M4E-!3"!"24]314Y33U)3($E.0SQS<&%N/CPO2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#$R-SDV.34\ M2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)U-M86QL97(@ M4F5P;W)T:6YG($-O;7!A;GD\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XX-S`L-3'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPOF5D(#,P,"PP,#`L,#`P('-H87)E3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'!E;G-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&ES'0^)SQS<&%N/CPO65E'0^)SQS<&%N/CPO'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-CDL,3(U/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO&5R8VES92!O9B!S=&]C:R!O<'1I M;VYS(&ES&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&ES M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@R,3DL,#8Q*3QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@ M;V8@8F]R2\H M=7-E9"!I;BD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\ M=&0@8VQA&-H86YG92!R871E(&9L=6-T=6%T:6]N3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\V-64S-V$T-U]C-C8U7S0T-V9?8C5C95\W,F5A,3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R3QB'0^)SQS<&%N/CPOF%T:6]N(&]F('1H92!#;VUP86YY/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M3I4:6UE3PO8CX\+W`^#0H@/'`@6QE/3-$)VUA'0M:6YD96YT.C0E.R!F M;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX- M"B!792!W97)E(&EN8V]R<&]R871E9"!I;B!T:&4@4W1A=&4@;V8@1&5L87=A M0T*($EN=&5R97-T#(P,40[*2!S:6YC92!$96-E;6)E$$P.S$S+`T*(#(P,#8N($]U$$P.S(Q+"`R,#`Q+B!50E,@8V]N9'5C=',@;W5R(')E6QE/3-$)VUA M'0M:6YD96YT M.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B!792!H879E(')I9VAT'1E;G-I=F4@<&%T96YT M('!O2!5 M0E,@86YD(&$@;G5M8F5R(&QI8V5N2!,:69E4V-A;BP@ M26YC+@T*("@F(W@R,#%#.TQI9F538V%N)B-X,C`Q1#LI(&%N9"!O=&AE2!L:6-E;G-E97,N(%5N;&5S2!O M6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!792!A$$P.SPO=&0^#0H@ M/'1D('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#XF(W@R M,#(R.SPO=&0^#0H@/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$=&]P/B8C>$$P M.SPO=&0^#0H@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^0V]A9W5L M871I;VX@=&5S=&EN9R!M87)K970@)B-X,C`Q,SL@=V4-"B!A#(P,40[*2!T97-T('1A6QE/3-$9F]N="US:7IE.C9P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM M8F]T=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN M9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@ M/'1D('=I9'1H/3-$-"4^)B-X03`[/"]T9#X-"B`\=&0@=VED=&@],T0S)2!V M86QI9VX],T1T;W`@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@ M=VED=&@],T0Q)2!V86QI9VX],T1T;W`^)B-X03`[/"]T9#X-"B`\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1'1O<#Y";&]O9"!G;'5C;W-E("8C>#(P,3,[ M('=E('!R;W9I9&4-"B!S97)V:6-E#(P,40[*2!A;F0@ M82!D979E;&]P;65N="!A;F0@#(P M,4,[1&5V96QO<&UE;G0@86YD(%)E#(P,40[ M*2!W:71H#0H@3&EF95-C86XN/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@ M/'`@F4Z-G!T.VUA$$P.SPO<#X-"B`\=&%B;&4@3I4:6UE2!S965K('1O(&5N=&5R#0H@:6YT;R!C M;VQL86)O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E#(P,40[*2!A;F0@=VET:"!T:&4@:6YS=')U M8W1I;VYS('1O($9O2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE M(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T97,@2!5+E,N M($=!05`@9F]R(&-O;7!L971E(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!);B!T M:&4@;W!I;FEO;B!O9@T*(&UA;F%G96UE;G0L(&%L;"!A9&IU$$P.S,Q+`T*(#(P,30N($9O65A7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQD:78^#0H@/'`@'0M:6YD96YT.C0E.R!F;VYT M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!! M;&P@86UO=6YT#(P,4,[055$)B-X,C`Q1#L@;W(-"B`F(W@R,#%#.T$D)B-X M,C`Q1#LI('5N;&5S$$P.SPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P M.C!P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4 M:&4@0V]M<&%N>28C>#(P,3D[2!L87)G96QY(&]N(&]U&ES=&EN9R!C87-H(&%N9"!C87-H(&5Q M=6EV86QE;G1S(&)A;&%N8V4@86YD#0H@;W!E3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\V-64S-V$T-U]C-C8U7S0T-V9?8C5C95\W M,F5A,3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!O9B!3 M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#0E.R!-05)'24XM5$]0.B`Q M.'!T)SX-"B`\8CY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@ M4&]L:6-I97,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0G/@T*(#QB/CQI/E!R:6YC:7!L97,@ M;V8@0V]N6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$ M14Y4.B`T)2<^#0H@5&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE('!R97!A'!E;G-E6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y# M87-H)B-X03`[)F%M<#L@0V%S:"!%<75I=F%L96YT6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@8V]N2!O9B!T:')E92!M;VYT:',@;W(@ M;&5S&EM M871E2!O M9B!T:&]S92!I;G-T2!L:7%U:60@:6YV M97-T;65N=',-"B!W:71H('1E6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y#;VYC M96YT28C>#(P,3D[#(P,3D[6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@=7-E M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q.'!T.R!- M05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B`\:3Y# M87-H(&9L;W<@:&5D9V5S/"]I/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*($5X<&]S=7)E('1O(&9O0T*('1O('5S92!F;W)W87)D(&5X8VAA;F=E(&-O;G1R86-T6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4 M+4E.1$5.5#H@-"4G/@T*(%=H97)E(&$@9&5R:79A=&EV92!F:6YA;F-I86P@ M:6YS=')U;65N="!IF5D(&1I2X@5VAE;B!T:&4@9F]R96-A2!A;F0@:6YC;'5D960@:6X@=&AE(&EN:71I M86P@8V]S="!O6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4 M15A4+4E.1$5.5#H@-"4G/@T*($9OF5D(&EN('1H M92!C;VYS;VQI9&%T960@2!A;F0@:7,@2!W:&5N#0H@=&AE('1R86YS86-T:6]N(&]C8W5R'!E M8W1E9"!T;R!T86ME('!L86-E+"!T:&5N('1H92!C=6UU;&%T:79E('5N2!I;B!T:&4@8V]N$$P.S,P+"`R,#$T(&%N9`T*('EE M87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@=V4@9&ED(&YO="!H M879E(&%N>2!AF4@ M3&5V96P@,R!I;G!U=',N(%1H92!V86QU871I;VX@;V8@;W5R#0H@9F]R96EG M;B!E>&-H86YG92!D97)I=F%T:79EF5D(&%S($QE=F5L(#(N(%1H92!F86ER('9A;'5E#0H@ M;65T:&]D;VQO9VEE2!C;W5R2!T;R!D:7-P;W-E+B!);G9E;G1O2!D971E'!E;F1I='5R92P@=&AE(&QA='1E2X@0V]S="!A;'-O(&EN8VQU9&5S('1H92!T2!O9@T*(&%N>2!G86EN6EN9R!C87-H(&9L M;W<@:&5D9V5S(')E;&%T:6YG('1O#0H@<'5R8VAA2!A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\ M=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X M03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,C`W/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y296-E M:79A8FQE6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^ M#0H@5')A9&4@86-C;W5N=',@$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8V]U;G1S(')E8V5I M=F%B;&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`Q,BPV M.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L M,#$R+#8X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,38W+#@V M-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@ M/&(^/&D^4')O<&5R='DL(%!L86YT+"!A;F0@17%U:7!M96YT/"]I/CPO8CX\ M+W`^#0H@/'`@2P@<&QA M;G0L(&%N9"!E<75I<&UE;G0@87)E(')E8V]R9&5D(&%T(&%C<75I6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($1E<')E8VEA=&EO;B!O;B!P M;&%N="!A;F0@97%U:7!M96YT(&ES(&-A;&-U;&%T960@=7-I;F<@=&AE#0H@ M2!R96-E:79E6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4 M.B`T)2<^#0H@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N#(P,3D[65E M(&)E;F5F:71S+"!C;W-T'!E;G-E9"!A$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X M03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#DP,"PY.3D\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/ M4#H@,3AP="<^#0H@/&(^/&D^26YC;VUE(%1A>&5S/"]I/CPO8CX\+W`^#0H@ M/'`@2!A<'!L:65S M($%30R`W-#`@+2!);F-O;64@5&%X97,@=VAI8V@@97-T86)L:7-H97,-"B!F M:6YA;F-I86P@86-C;W5N=&EN9R!A;F0@F5D(&9O"!C;VYS97%U96YC97,-"B!A='1R:6)U=&%B;&4@=&\@ M9&EF9F5R96YC97,@8F5T=V5E;B!T:&4@9FEN86YC:6%L('-T871E;65N=`T* M(&-A"!B87-E"!C'!E8W1E9"!T M;R!B92!R96-O=F5R960-"B!O"!A"!AF5D+CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U) M3D1%3E0Z(#0E)SX-"B!792!A"!R971U65A65A M#(P,4,[05)/)B-X,C`Q1#LI(&%R92!L96=A;`T*(&]B;&EG M871I;VYS(&%S0T*(&-A<&ET86QI>F5S('1H92!C;W-T(&)Y(&EN8W)E87-I;F<@=&AE(&-A M2P@<&QA M;G0@86YD(&5Q=6EP;65N="X@3W9E2!D97)E8V]G;FEZ97,@05)/(&QI86)I;&ET:65S('=H96X@=&AE(')E;&%T M960@;V)L:6=A=&EO;G,-"B!A6QE/3-$)T9/ M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#M-;VYT:',F(WA!,#M% M;F1E9#QB$$P.S,P+#PO8CX\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L6QE/3-$)T9/ M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T M$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(L,S4Q+#0V-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XU,"PP-S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($5N9&EN9R!B86QA;F-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#8P M,"PP,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#4T.2PY,C@\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/CQI/D9A:7(@ M5F%L=64@;V8@1FEN86YC:6%L($EN&ET>2!O9B!T:&4@ M87-S971S(&]R('1H90T*(&QI86)I;&ET>2P@8GD@=7-I;F<@;VYE(&]R(&%L M;"!O9B!T:&4@9F]L;&]W:6YG(&%P<')O86-H97,Z/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0[($U!4D=) M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1'1O<"!W:61T:#TS1#(E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^36%R:V5T(&%P<')O86-H("8C M>#(P,3,[(&)A$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX] M,T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H M/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$ M;&5F=#Y);F-O;64@87!P6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L M92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E(&%L:6=N/3-$;&5F=#XF(W@R M,#(R.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^475O=&5D M('!R:6-E$$P M.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@ M/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P M('=I9'1H/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y5;F]B6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX- M"B`\8CX\:3Y);7!A:7)M96YT(&]F($QO;F2!R979I97=S(&ET6EN9R!A;6]U;G0@;V8@=&AE(&%S"`H1U-4*3PO:3X\ M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4F5V96YU97,L M(&5X<&5N6%B;&5S(&%R92!S=&%T960@:6YC;'5S:79E(&]F('1H92!A;6]U M;G0@;V8@1U-4#0H@6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$ M14Y4.B`T)2<^#0H@5V4@#(P,3D[$$P M.S$P-"!A;F0@05-##0H@-C`U(%)E=F5N=64@4F5C;V=N:71I;VXN/"]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY)B-X,C`Q M.3MS(')E=F5N=64@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%=E(')E8V]G;FEZ M92!R979E;G5E(&9R;VT@65R(&%N9"!T:&4@ M8G5Y97(@87-S=6UE2!I6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)' M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5. M5#H@-"4G/@T*(%=H97)E(&]U2!E M:71H97(@=F5N9&]R('-P96-I9FEC(&]B:F5C=&EV92!E=FED96YC92!O<@T* M('1H:7)D('!A28C>#(P,3D[6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%5N9&5R($%3 M0R`V,#4M,C4L('1H92!D96QI=F5R960@:71E;2AS*2!A2!O7!I8V%L;'D@9V5N M97)A=&4@;6EL97-T;VYE('!A>6UE;G1S(&9R;VT@;W5R(&-U6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G M/DYO;BUR969U;F1A8FQE/"]F;VYT/B!M:6QE2!H=7)D;&4@:6X@=&AE(')E6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/FYO;BUR969U;F1A M8FQE/"]F;VYT/B!M:6QEF5D(&%S(')E=F5N=64@96ET:&5R(&]V97(@=&AE(&5S=&EM M871E9`T*('!E0T*(&%R92!E>'!E8W1E9"!T;R!B92!R M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@86-T:79I=&EE2!W:6QL#0H@;6%N=69A8W1U6UE;G1S(&EN9&EC871I=F4@ M;V8@:71S(&-O2P@86YD(&%S('-U8V@@ M:&%V92!A8V-O=6YT960-"B!F;W(@=&AI#(P,40[+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&D^36%S=&5R(%-E M2!W;W5L9`T*('!R;W9I9&4@8V5R=&%I;B!S97)V:6-E6UE;G0I+"`R*0T*(&-O M;G1R86-T(&UA;G5F86-T=7)I;F<@;V8@=&AE(&)L;V]D(&=L=6-O2!C;VYC;'5D960@=&AE('5N9&5L:79E&5D(&%N9`T*(&1E=&5R;6EN86)L92X@5&AE(&UI;&5S M=&]N92!P87EM96YT('=AF5D(&%S#0H@2P@=VAE;B!T:&4@9F]U6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q.'!T.R!-05)'24XM5$]0 M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B`\:3Y#;VQL86)O6UE;G1S(&9R;VT@4VEE;65N2!S M=6)M:7-S:6]N28C>#(P M,3D[F5D(&%S('1H92!C;VYT:6YG96YC:65S(&%R92!M970@86YD('1H M92!C;VYS:61E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0[ M($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1'1O<"!W:61T:#TS1#(E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO M=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^26X@2G5N92`R,#$R M+"!T:&4@0V]M<&%N>2!D96QI=F5R960-"B!O;B!I=',@9FER6UE M;G0@;V8@020Q+#4R,BPU,S0-"B`H97%U:79A;&5N="!T;R!54R0Q+C4@;6EL M;&EO;BD@87,@8V]N$$P.SPO<#X-"B`\=&%B;&4@0T*(&]F(&%N;W1H97(@;F5W('1E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H97)E('=E$$P.S,P+"`R,#$T(&%N9"!3 M97!T96UB97(F(WA!,#LS,"P@,C`Q,R!R96QA=&EN9PT*('1O('1H92!D96QI M=F5R>2!O9B!T:&4@;6EL97-T;VYE65A M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q.'!T)SX-"B`\:3Y);G1E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26YT97)E6EE;&0@;VX@=&AE(&-A6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\:3Y297-E87)C:"!A M;F0@9&5V96QO<&UE;G0@=&%X(&EN8V5N=&EV92!I;F-O;64\+VD^/"]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4F5S96%R8V@@86YD(&1E=F5L M;W!M96YT('1A>"!I;F-E;G1I=F4@:6YC;VUE(&ES(')E8V]G;FEZ960@=VAE M;@T*('1H97)E(&ES(')E87-O;F%B;&4@87-S=7)A;F-E('1H870@=&AE(&EN M8V]M92!W:6QL(&)E(')E8V5I=F5D+"!T:&4-"B!R96QE=F%N="!E>'!E;F1I M='5R92!H87,@8F5E;B!I;F-U2!H87,@"!I;F-E;G1I=F4-"B!I;F-O;64@ M;V8@020S+#4V,2PR,#D@86YD($$D-"PR-3`L.#8T(&9O2!A;F0-"B!!)#$$P.S,P+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E M;'DN(%1H92!R97-E87)C:"!A;F0-"B!D979E;&]P;65N="!T87@@:6YC96YT M:79E(&EN8V]M92!I#(P,4,[3W1H97(F(W@R,#%$.R!I;B!T:&4@8V]N65A6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4 M.B`T)2<^#0H@271E;7,@:6YC;'5D960@:6X@=&AE(&9I;F%N8VEA;"!S=&%T M96UE;G1S(&]F(&5A8V@@;V8@=&AE#0H@1W)O=7`F(W@R,#$Y.W,@96YT:71I M97,@87)E(&UE87-U2!O9B!T:&4-"B!P M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&-O;G-O;&ED M871E9"!F:6YA;F-I86P@&-H86YG92!G86EN65A$$P M.S,P+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!R97-U;'1S(&%N9"!F:6YA;F-I M86P@<&]S:71I;VX@;V8@86QL('1H92!'0T*(&%R92!T2!A$$P.SPO<#X-"B`\=&%B;&4@#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#YA M6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A;&EG M;CTS1'1O<"!W:61T:#TS1#,E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^:6YC;VUE(&%N9"!E>'!E M;G-E'!E;G-E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L M92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M2!N970@:6YV97-T;65N="!I;B!F;W)E:6=N(&5N=&ET:65S(&%R92!T86ME M;B!T;R!T:&4-"B!!8V-U;75L871E9"!/=&AE6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#,E(&%L:6=N/3-$;&5F=#XF(W@R M,#(R.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^=V4@:&%V M92!A('!O=&5N=&EA;"!O8FQI9V%T:6]N('1O('!A>0T*(#4P)2!O9B!T:&4@ M<&%T96YT(&9E97,@<&%I9"!B>2!,:69E4V-A;B!I;B!R97-P96-T(&]F('1H M92!P871E;G1S#0H@=V4@;&EC96YS92!F2!L:6-E;G-E9`T*(&9R;VT@3&EF95-C86X@86YD(#4P)2!O9B!T:&4@ M<&%T96YT(&9E97,@:6YC=7)R960@8GD@3&EF95-C86X@:6X-"B!R97-P96-T M(&]F('-U8V@@<&%T96YT6UE;G0@96ET M:&5R(&%S(&$@;'5M<"!S=6T@=VET:&EN(#0U(&1A>7,@;V8@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/ M3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A M;&EG;CTS1'1O<"!W:61T:#TS1#,E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO M=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^9'5R:6YG(#(P,#DL M($QI9F538V%N(&-H;W-E(&YO="!T;PT*('!R;V-E960@=VET:"!T:&4@2!,:69E4V-A M;B!A(&UA6UE;G0@:6X@96%C:`T*(&]F('1H M92!T=V\@>65A2!,:69E4V-A;B!E<75A M;"!T;R`T,"4@;V8@=&AE('1O=&%L(&UA;G5F86-T=7)I;F<-"B!I;FET:6%T M:6]N('!A>6UE;G1S(&UA9&4N(%1H92!T;W1A;"!A;6]U;G0@;V8@;6%R:V5T M:6YG('-U<'!O'!E8W1E9"!T;R!B92!P86ED('1O M($QI9F538V%N(&ES(&%P<')O>&EM871E;'D@55,D,@T*(&UI;&QI;VXN($)A M2!, M:69E4V-A;B!A;F0-"B!T:&%T('=E(&AA=F4@;F\@=FES:6)I;&ET>2!O9B!F M=71U$$P.SPO<#X-"B`\=&%B M;&4@#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P M('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L M:6=N/3-$;&5F=#YW92!H879E(&5N9V%G960@4&QA;F5T($EN;F]V871I;VX@ M4'1Y#0H@3'1D("@F(W@R,#%#.U!L86YE="!);FYO=F%T:6]N)B-X,C`Q1#LI M('1O(&%SF5R7IE7IE7IE6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`P<'0G/@T*(#QB/CQI/E!A=&5N="!A;F0@3&EC96YS92!#;W-T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3&5G86P@ M86YD(&UA:6YT96YA;F-E(&9E97,@:6YC=7)R960@9F]R('!A=&5N="!A<'!L M:6-A=&EO;B!C;W-T'!E;G-E M2!R96-O'!E;G-E6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\ M8CX\:3Y,96%S960@07-S971S/"]I/CPO8CX\+W`^#0H@/'`@F4@ M=&AE(&-O'!E;G-E(&]N(&$@#(P,4,[6D503W,F(W@R,#%$.RDN(%)357,@87)E M('-T;V-K(&%W87)D65E&5D M(&]N('1H92!G&5R8VES92!P"!A"!R971U2!T87@@"!A"!D961U8W1I M;VX@&-E"!D961U8W1I;VX@97AC965D'1E;G0@=&AA="!P M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M.'!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ M6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@ M26X@,C`P-"P@=&AE($-O;7!A;GD@861O<'1E9"!A;B!E;7!L;WEE92!O<'1I M;VX@<&QA;@T*("@F(W@R,#%#.U!L86XF(W@R,#%$.RDN($]P=&EO;G,@;6%Y M(&)E(&=R86YT960@<'5R65D(&)Y M('1H92!'&EM=6T@86UO=6YT M#0H@<&5R;6ET=&5D(&)Y(&QA=R!A;F0@=&AE($QI2!E>&5R8VES M92!C;VYD:71I;VYS(&%R92!D971E&5R8VES92X- M"B!4:&4@;W!T:6]N2!T:&4@8F]A65A2!V97-T(&EN(&5Q=6%L#0H@=')A;F-H97,@;W9E2!C;VYS;VQI9&%T:6]N+"!S M=6)D:79I2P@=&AE#0H@=&]T86P@ M;G5M8F5R(&]F(&]P=&EO;G,@86YD('1H92!E>&5R8VES92!P6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\ M=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO&5R M8VES92!0$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#Y.:6P\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-H87)E M(%!R:6-E(&%T($=R86YT($1A=&4@*$$D*3PO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C`N,3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C0Y/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-S$\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$3PO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XV,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C8T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)28C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D($QI9F4@*'EE87)S M*3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C$S M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C@R/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XS+C@R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C4T M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C,W/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,3`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E=E:6=H=&5D M)B-X03`[879E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C$P/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO&5R8VES960\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH."PS,S,\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C`N,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($QA<'-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@X,S0L.3DT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C`R/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4 M:&4@;G5M8F5R(&]F(&]P=&EO;G,@97AE'!E;G-E(')E8V]G M;FEZ960@:6X@:6YC;VUE('-T871E;65N=`T*('=A2!A;F0@*$$D,C$Y+#`V,2D@86YD#0H@020T-CDL,3(U(&9O$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E M$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8Y+#@Q-SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$P-"PU.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(#(P,38\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR-2PX-CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(#(P,3<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,#8\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G M/@T*(%1H92!A9V=R96=A=&4@:6YT$$P.S,P+"`R M,#$T(&%N9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!W87,@>F5R;RX\+W`^ M#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G M/@T*(#QI/BAB*2!297-T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3W5R($5M<&QO>65E(%-H87)E(%!L M86X@=V%S(&%D;W!T960@8GD@=&AE($)O87)D(&]F($1I65E&5C=71I=F4@9&ER96-T;W)S*2X@5&AE#0H@;G5M8F5R(&]F('-H87)E M65E(%-H87)E(%!L86XN(%1H M92!#;VUP86YY(&-U2!P2!T:&%N(&%N;G5A;&QY+B!4:&4-"B!R97-T&ES=&EN9PT*('-H87)E2!O$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.U-H87)E M$$P.RA!)"D\+V(^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*($UA>2P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CDQ-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`P M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-#(L.#`P/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8Y+#DW,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,#0P/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#`P/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX- M"B!297-T2!D=7)I;F<@=&AE M(&-U$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/E=E:6=H=&5D)B-X03`[879E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XP+C6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($)A;&%N8V4@870@4V5P=&5M8F5R)B-X03`[,S`L(#(P M,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U,RPW-C0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XP+C6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q.'!T)SX-"B`\8CX\:3Y%;7!L;WEE92!"96YE9FET($-O2!C;VYT#(P,3D[2!L87<@=&\@.2XR-24@9G)O;2!*=6QY)B-X M03`[,2P@,C`Q,R!A;F0@.2XU)2!F28C>$$P.S$L(#(P,30@ M;V8@96%C:"!S=6-H(&5M<&QO>65E)B-X,C`Q.3MS('-A;&%R>2X-"B!3=7!E M2!A('!O7!I8V%L;'D-"B!N;W0@86)L92!T;R!A8V-E2!A65E2!B96-O;64@<&%Y86)L92X\+W`^ M#0H@/'`@2!D:6QU=&EV92!O<'1I;VYS(&ES6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y4;W1A;"!# M;VUP6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GD@9F]L;&]W#(P,3,[($-O;7!R96AE;G-I=F4@26YC;VUE+@T*($-O;7!R96AE;G-I=F4@ M:6YC;VUE(&ES(&1E9FEN960@87,@=&AE('1O=&%L(&-H86YG92!I;@T*('-H M87)E:&]L9&5R#(P,3D[(&5Q=6ET>2!D=7)I;F<@=&AE('!E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G M/@T*(#QB/CQI/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]I M/CPO8CX\+W`^#0H@/'`@2US<&5C:69I8PT*(&=U:61A M;F-E+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@8V]R M92!P0T*(')E8V]G;FEZ97,@2!E>'!E8W1S('1O M(&)E(&5N=&ET;&5D(&EN(&5X8VAA;F=E(&9O#(P,40[($EN(&%P<&QY:6YG('1H92!R979E;G5E(&UO M9&5L('1O#0H@8V]N=')A8W1S('=I=&AI;B!I=',@2!W:6QL.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[ M($9/3E0M4TE:13H@-G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO M<#X-"B`\=&%B;&4@$$P.SPO<#X-"B`\=&%B;&4@$$P.SPO<#X-"B`\=&%B;&4@$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$."4^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX] M,T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H M/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$ M;&5F=#Y296-O9VYI>F4@#(P,3D[2!T;R!T2!A8W1I M=FET:65S("AE+F2P@<&QA M;G0L(&%N9`T*(&5Q=6EP;65N=#L@*#(I)B-X03`[$$P.VEN=&%N9VEB;&4@87-S971S*2X-"B!%>&ES=&EN9R!A8V-O M=6YT:6YG(&=U:61A;F-E(&%P<&QI8V%B;&4@=&\@=&AE2!E>'!A;F1E9"!D:7-C;&]S=7)E$$P.S$U+"`R,#$V+"!F;W(@<'5B;&EC(&5N M=&ET:65S+B!%87)L>2!A<'!L:6-A=&EO;B!I6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4 M15A4+4E.1$5.5#H@-"4G/@T*($5N=&ET:65S(&AA=F4@=&AE(&]P=&EO;B!O M9B!U$$P.SPO<#X- M"B`\=&%B;&4@#(P,30[(%)E M=')O6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$."4^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T/B8C M>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y-;V1I M9FEE9"!R971R;W-P96-T:79E(&%P<&QI8V%T:6]N#0H@)B-X,C`Q-#L@56YD M97(@=&AE(&UO9&EF:65D(&%P<')O86-H+"!A;B!E;G1I='D@#(P,4,[=&AE(&-U;75L871I=F4@969F96-T(&]F(&EN:71I86QL M>2!A<'!L>6EN9R!T:&4@05-5(&%S(&%N#0H@861J=7-T;65N="!T;R!T:&4@ M;W!E;FEN9R!B86QA;F-E(&]F(')E=&%I;F5D(&5A2!A<'!L:65S('1H90T*(&=U:61A;F-E M(&EN('1H92!!4U4@=&\@97AI2!T:&4@28C>#(P,3D[7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAAF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y296QA=&5D(%!A6QE/3-$)VUA3I4:6UE2!T'!E;G-E(&%L;&]W86YC97,L#0H@ M86YD(&]T:&5R('-I;6EL87(@:71E;7,@:6X@=&AE(&]R9&EN87)Y(&-O=7)S M92!O9B!B=7-I;F5S3I4 M:6UE2!-3D%Z>6UE#0H@=&5C:&YO;&]G M>2!I;B!T:&4@9FEE;&0@;V8@;6]L96-U;&%R(&1I86=N;W-T:6-S+B!5;F1E M`T*(&EF(&-E2!P87EM M96YT"!T96-H;F]L;V=Y(&]R('!R;V1U8W1S(&EN8V]R<&]R M871I;F<-"B!3<&5E1'@@=&5C:&YO;&]G>2X\+W`^#0H@/'`@F4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P M=#X-"B`F(WA!,#L\+W`^#0H@/'`@6%B;&4@ M8GD-"B!3<&5E1'@@9'5R:6YG('1H92!F;W5R=&@@<75A"X@56YT:6P@4V5P=&5M8F5R)B-X03`[,C"X@365S M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)VUA3I4:6UE'0M:6YD96YT.C0E.R!F;VYT+7-I M>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!&=71U M6UE;G1S('5N M9&5R('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@;&]N9R!T97)M('-E8W5R960@ M;&]A;B!P=7)S=6%N="!T;R!T:&4@8W)E9&ET#0H@86=R965M96YT("AD97-C M$$P.S,P+"`R,#$T(&%N M9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@87)E(&%S(&9O;&QO=W,Z/"]P M/@T*(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[ M;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!C96QL M3I4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG M;CTS1&-E;G1E$$P.S,Q+"`R,#$S/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,B!A;&EG;CTS1&-E;G1E6QE/3-$9F]N="US:7IE M.C%P=#X-"B`\=&0^/"]T9#X-"B`\=&0@8V]L6QE/3-$)VUA$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$L,#@S+#$R-3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3I4:6UE6QE/3-$)VUA$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L M-S0Y+#$V-SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)VUA$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$L-S,R+#4P,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3I4:6UE M6QE/3-$)VUA$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$L-S,R+#4P,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3I4:6UE6QE/3-$)VUA$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+#$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$V+#$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&5R96%F=&5R/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/"]TF4Z,7!X.SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@'0M:6YD96YT.BTQ+C`P96T[(&9O M;G0M3I4:6UE6QE/3-$9F]N="US:7IE.CAP=#XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(S+#`R.2PW.3(\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1&9O;G0M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!,97-S(&%M;W5N="!R97!R97-E;G1I M;F<@:6YT97)E6QE/3-$9F]N="US:7IE.CAP=#XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@X+#`R.2PW.3(\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4Z.'!T/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4Z M.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0MF4Z,7!X.SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M M3I4:6UE6QE/3-$9F]N="US:7IE.CAP M=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$U+#`P,"PP,#`\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!,97-S(&9A:7(@=F%L=64@ M;V8@=V%R$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UEF%T:6]N(&]F('=A$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4Z M.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0MF4Z,7!X.SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[ M('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$9F]N="US:7IE.CAP=#XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$T+#$X.2PW,#@\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1&9O;G0M6QE/3-$9F]N="US:7IE M.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P M>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P M>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)V)O6QE M/3-$)V)OF4Z,3!P="<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[ M('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`\+W1D/@T*(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M6QE/3-$ M9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)V)O$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)V)O$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M M3I4:6UE$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T+#$X M.2PW,#@\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1&9O;G0M6QE/3-$9F]N="US:7IE.C%P>#L^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@"!S;VQI9"`C M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N M,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/"]T6QE M/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O M;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.C$P<'0G(&)O6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE#(P,4,[0VQO2!O=VYE9"!S=6)S:61I87)Y+"!5 M0E,@*'1O9V5T:&5R(%5"22!A;F0@54)3+"!T:&4-"B`F(W@R,#%#.U1R86YS M86-T:6]N(%!A7)I=6T@3W!P;W)T=6YI=&EE$$P.TQ0("@F(W@R,#%#.T%T:'ER:75M#0H@028C>#(P,40[*2P@ M87,@861M:6YI7)I=6T@3W!P;W)T=6YI=&EE#(P,4,[071H>7)I=6T@0B8C>#(P,40[*2!A7)I M=6T@02!A;F0-"B!!=&AY$$P.SPO=&0^#0H@/'1D('=I9'1H/3-$,R4@=F%L:6=N M/3-$=&]P(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^#0H@/'1D('=I9'1H M/3-$,24@=F%L:6=N/3-$=&]P/B8C>$$P.SPO=&0^#0H@/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1T;W`^55,D-2!M:6QL:6]N(&%V86EL86)L92!W:71H M:6X@,S`@9&%Y28C>$$P.S,P+"`R,#$U+`T*(&-O;F1I=&EO;F%L('5P;VX@ M54)3('-A=&ES9GEI;F<@8V5R=&%I;B!C;VYD:71I;VYS('!R96-E9&5N=`T* M(&EN8VQU9&EN9R!T:&%T(&EN('1H92!I;6UE9&EA=&5L>2!P6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M#(P,4,[5F5R:6\@45-&#(P,40[*2!P M;'5S(&-O86=U;&%T:6]N#0H@;6%N=69A8W1U6QE/3-$9F]N M="US:7IE.C9P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#X- M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z,3!P="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P M86-I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$ M-"4^)B-X03`[/"]T9#X-"B`\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`@ M86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=VED=&@],T0Q)2!V M86QI9VX],T1T;W`^)B-X03`[/"]T9#X-"B`\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1'1O<#Y54R0U(&UI;&QI;VX@879A:6QA8FQE('=I=&AI;B`S,"!D M87ES#0H@869T97(@=&AE(&5N9"!O9B!A;GD@<75A6EN9R!C97)T86EN(&-O;F1I=&EO;G,@<')E8V5D96YT#0H@:6YC;'5D M:6YG('1H870@:6X@=&AE(&EM;65D:6%T96QY('!R96-E9&EN9R!Q=6%R=&5R M+"!50E,@86-H:65V97,-"B!697)I;R!14T9S('!L=7,@8V]A9W5L871I;VX@ M;6%N=69A8W1UF4Z,3)P=#MM87)G:6XM=&]P M.C!P=#MM87)G:6XM8F]T=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'`@2!D M871E(&]F($1E8V5M8F5R)B-X03`[,3DL(#(P,3@-"B`H)B-X,C`Q0SM-871U M2!$871E)B-X,C`Q1#LI(&%N9"!B96%R$$P.W!E<@T*(&%N;G5M('!A>6%B;&4@:6X@8V%S:"!Q=6%R=&5R;'D@ M:6X@87)R96%RF5D(&)E;&]W+"!50E,@:7,@;F]T(')E<75I2P- M"B!$96-E;6)E$$P.S$Y+"`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`P('1O('1H92!,96YD97)S(&]N('1H90T*($-L;W-I;F<@1&%T M92`H8F5I;F<@,BXU)2!O9B!T:&4@86=G2D@86YD(&$@,B4-"B!C;VUM:71M96YT(&9E92!B87-E9"!O;B!A;GD@879A M:6QA8FQE('5N=7-E9"!B;W)R;W=I;F<@8V]M;6ET;65N=`T*('5N9&5R('1H M92!#&5S+B!50E,@ M:&%S(&%L$$P.W)E M;&%T:6YG('1O('1H92!D96QI=F5R>2!O9@T*(&9I;F%N8VEA;"!A;F0@;W1H M97(@:6YF;W)M871I;VX@86YD(&-E6UE;G0@;V8@=&%X97,-"B!A;F0@;W1H97(@;V)L:6=A=&EO;G,[ M(&UA:6YT96YA;F-E(&]F(&EN$$P.W=H:6-H#0H@ M;&EM:70@;W(@6UE;G0-"B!O9B!O=&AE6QE/3-$)VUA M'0M:6YD96YT M.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B!!#(P,4,[17AE#(P,3D[$$P.S$Y+"`R,#$S+B!4:&4@=V%R$$P.SPO<#X- M"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#L@;6%R9VEN+6)O='1O;3HP M<'0[(&9O;G0M3I4:6UE'0M:6YD96YT.C0E.R!F M;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX- M"B!);B!*86YU87)Y(#(P,30L(%5"4R!E;G1E&5D(')A=&4@;V8@ M,BXX."4F(WA!,#MP97(@86YN=6T@86YD('1H92!S:&]R="UT97)M#0H@8F]R M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-64S M-V$T-U]C-C8U7S0T-V9?8C5C95\W,F5A,3'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!0=7)S=6%N="!T;R!T:&4@0W)E M9&ET($%G$$P.VUI;&QI;VX@#(P,3D[&5R8VES92!03I4:6UE M2!T:6UE('5N=&EL($1E8V5M8F5R)B-X03`[,3DL#0H@,C`R,"P@ M:6X@=VAO;&4@;W(@:6X@<&%R="!I;B!M:6YI;75M(&UU;'1I<&QE2!T:&4@17AE6QE/3-$)VUA'0M:6YD96YT.C0E M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B!4:&4@=V%R3I4:6UE3I4 M:6UE&-E<'1I M;VX@:6X@86-C;W)D86YC92!W:71H($%30R`X,34M,3`M,34M-S0-"B!A<'!L M:65S('1O('=A#(P,3D[#0H@97%U:71Y+"!A;F0@3I4 M:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\V-64S-V$T-U]C-C8U7S0T-V9?8C5C95\W,F5A,3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO MF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B`\8CX\:3Y297-T'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!297-T2!T:&4@0V]M<&%N>2!I;B!T:&4@9F]R;2!O9B!T97)M#0H@9&5P M;W-I=',@:7,@87,@9F]L;&]WF4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#X-"B`F M(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$,"!S='EL93TS1"="3U)$15(M M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.C$P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.T5N9&5D/&)R("\^#0H@1&5C M96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/"]TF4Z.'!T)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N M="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/D$D/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/D$D/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P=#X- M"B`\=&0^/"]T9#X-"B`\=&0@8V]L6QE/3-$ M)VUA$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-C`P M+#`P,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT3I4:6UE6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP/"]T9#X-"B`\=&0@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T MF4Z,3!P="<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[ M('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,C`L,#`P M/"]T9#X-"B`\=&0@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@"!S;VQI M9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V M86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.3(P+#`P,#PO=&0^#0H@ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C,L-#DU+#`P,#PO=&0^#0H@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1&9O;G0M$$P M.SPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#L@;6%R9VEN+6)O M='1O;3HP<'0[(&9O;G0M3I4:6UE'1087)T7S8U93,W830W7V,V-C5?-#0W9E]B-6-E7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2!A;F0@:71S('=H;VQL>2!O=VYE9"!S=6)S:61I87)Y+"!50E,N($%L M;`T*(&EN=&5R8V]M<&%N>2!B86QA;F-EF4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y5'!E;G-E2P@<&QA;G0@86YD(&5Q M=6EP;65N="P@9&5F97)R960-"B!I;F-O;64@=&%X97,L(&%SF4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y#87-H)B-X03`[)F%M M<#L@0V%S:"!%<75I=F%L96YT6QE/3-$ M)VUA3I4:6UE2D\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y3:&]R="U497)M($EN=F5S=&UE M;G1S("A(96QD+71O+6UA='5R:71Y*3PO:3X\+V(^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1% M6%0M24Y$14Y4.B`T)2<^#0H@4VAOF4Z,3!P M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y#;VYC M96YT2!I M'!O'1E;G0@;V8@=&AE(&%M;W5N="!R96-O M2!H87,@;F]T(&ED96YT:69I960@86YY#0H@8V]L;&5C=&%B M:6QI='D@:7-S=65S('=I=&@@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y$97)I=F%T:79E($EN2!U2!D;V5S(&YO="!H;VQD(&]R(&ES2!F;W(@:&5D9V4@86-C;W5N=&EN9R!A6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E. M1$5.5#H@-"4G/@T*($1EF5D(&EN:71I86QL>2!A="!F86ER#0H@=F%L=64N(%-U M8G-E<75E;G0@=&\@:6YI=&EA;"!R96-O9VYI=&EO;BP@9&5R:79A=&EV92!F M:6YA;F-I86P-"B!I;G-T2!I;B!T:&4@:6YC M;VUE#0H@2!R97-U;'1A;G0@9V%I;B!O6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QI/D-A M6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T M)2<^#0H@17AP;W-U&-H86YG92!R:7-K28C>#(P M,3D[2!I;B!C87-H(&9L;W=S(&]F(&$@2!U M;G)E86QI>F5D(&=A:6X@;W(@;&]S2P@ M=&AE(&%S2X\+W`^#0H@/'`@2!T:&4@<')E8V5D:6YG#0H@6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5. M5#H@-"4G/@T*(%=H96X@82!H961G:6YG(&EN2!R979O:V5S(&1EF5D(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@ M86)O=F4@<&]L:6-Y('=H96X-"B!T:&4@=')A;G-A8W1I;VX@;V-C=7)S+B!) M9B!T:&4@:&5D9V5D('1R86YS86-T:6]N(&ES(&YO(&QO;F=E<@T*(&5X<&5C M=&5D('1O('1A:V4@<&QA8V4L('1H96X@=&AE(&-U;75L871I=F4@=6YR96%L M:7IE9"!G86EN(&]R(&QOF5D(&EN(&5Q=6ET>2!IF5D(&EM;65D:6%T96QY(&EN('1H92!C;VYS;VQI9&%T960-"B!S M=&%T96UE;G1S(&]F(&-O;7!R96AE;G-I=F4@:6YC;VUE+CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP M="<^#0H@/&D^1&5R:79A=&EV92!);G-TF4@=F%L=6%T M:6]N('1E8VAN:7%U97,@=&AA=`T*(&UA>&EM:7IE('1H92!U'1E;G0@<&]S2!C65A M$$P.S,Q+"`R,#$S+"!W92!D:60@;F]T(&AA M=F4@86YY(&%S2!W:&5N#0H@=&AE(&1E2!C;W5R2!T;R!D:7-P;W-E+B!);G9E;G1O M2!D971E'!E;F1I='5R92P@=&AE(&QA='1E2X@0V]S="!A;'-O(&EN8VQU9&5S('1H92!T2!O9@T*(&%N>2!G86EN6EN9R!C87-H(&9L;W<@:&5D9V5S(')E;&%T:6YG('1O#0H@<'5R8VAA2!A6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C M>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0H@ M4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L M,C`W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y296-E:79A8FQE6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5')A9&4@86-C;W5N=',@ M0T* M(&9O8W5S:6YG(&]N('1H;W-E(&%C8V]U;G1S('1H870@87)E('!A$$P.S,Q+#PO8CX\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($%C8V]U;G1S(')E8V5I=F%B;&4\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XR+#`Q,BPV.#(\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,#$R+#8X,CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(L,38W+#@V-SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0^)SQD M:78^#0H@/'`@65A6QE M/3-$)VUA'0M M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)SX-"B!4:&4@0V]M<&%N>2!R96-E:79E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M.'!T)SX-"B`\8CX\:3Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0\+VD^/"]B M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%)E'!E;G-E2!C;W-T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4F5S96%R8V@@86YD(&1E=F5L M;W!M96YT(&5X<&5N6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C M>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#PO8CX\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.TUO;G1H M$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C,L.3`Q+#@R,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ,RPY,#`L.3DY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$Q+#@P-RPY-30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M.'!T)SX-"B`\8CX\:3Y);F-O;64@5&%X97,\+VD^/"]B/CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T M.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(&%P<&QI97,@05-# M(#65A"!A&ES=&EN9R!A0T*(&9O"!R871E'!E8W1E9"!T;R!A<'!L M>2!T;R!T87AA8FQE(&EN8V]M92!I;B!T:&4@>65A2!T:&%N(&YO="!T:&%T('-O;64@<&]R=&EO;B!O"!A2!A M('9A;'5A=&EO;B!A;&QO=V%N8V4N(%1H92!V86QU871I;VX@86QL;W=A;F-E M(&ES#0H@"!A M6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`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`\=&%B;&4@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z.'!T)R!A;&EG;CTS1&-E M;G1EF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P M.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E6QE M/3-$)V)O$$P.SPO=&0^ M#0H@/"]TF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[ M(&9O;G0M3I4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(L-30Y+#DR.#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XR+#,U,2PT-C0\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O M;G0M3I4:6UE'!E;G-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)V)O$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L M;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B!%;F1I;F<@8F%L86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4Z.'!T/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$9F]N M="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@8V%R&ET>2!O9B!T M:&4@87-S971S(&]R('1H90T*(&QI86)I;&ET>2P@8GD@=7-I;F<@;VYE(&]R M(&%L;"!O9B!T:&4@9F]L;&]W:6YG(&%P<')O86-H97,Z/"]P/@T*(#QP('-T M>6QE/3-$9F]N="US:7IE.C9P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T M=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1% M4BU#3TQ,05!313I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.R!F;VYT+7-I>F4Z,3!P="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS M1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D M('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=VED=&@],T0R)2!V86QI M9VX],T1T;W`@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=VED M=&@],T0Q)2!V86QI9VX],T1T;W`^)B-X03`[/"]T9#X-"B`\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1'1O<#Y-87)K970@87!P6QE/3-$9F]N="US:7IE.C9P M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#X-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!3 M13L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P M="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P M('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[ M/"]T9#X-"B`\=&0@=VED=&@],T0R)2!V86QI9VX],T1T;W`@86QI9VX],T1L M969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=VED=&@],T0Q)2!V86QI9VX],T1T M;W`^)B-X03`[/"]T9#X-"B`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O M<#Y#;W-T(&%P<')O86-H("8C>#(P,3,[(&)A6QE/3-$9F]N="US:7IE.C9P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM M8F]T=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN M9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@ M/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=VED=&@],T0R)2!V M86QI9VX],T1T;W`@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@ M=VED=&@],T0Q)2!V86QI9VX],T1T;W`^)B-X03`[/"]T9#X-"B`\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1'1O<#Y);F-O;64@87!P$$P.SPO=&0^ M#0H@/'1D('=I9'1H/3-$,B4@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#XF M(W@R,#(R.SPO=&0^#0H@/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$=&]P/B8C M>$$P.SPO=&0^#0H@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^475O M=&5D('!R:6-E$$P.SPO M=&0^#0H@/'1D('=I9'1H/3-$,B4@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F M=#XF(W@R,#(R.SPO=&0^#0H@/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$=&]P M/B8C>$$P.SPO=&0^#0H@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^ M475O=&5D('!R:6-E$$P.SPO=&0^#0H@/'1D('=I9'1H/3-$,B4@=F%L:6=N/3-$=&]P(&%L:6=N M/3-$;&5F=#XF(W@R,#(R.SPO=&0^#0H@/'1D('=I9'1H/3-$,24@=F%L:6=N M/3-$=&]P/B8C>$$P.SPO=&0^#0H@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1T;W`^56YO8G-E6QE/3-$)VUA3I4:6UE M'0M:6YD96YT.C0E.R!F;VYT M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4 M:&4@0V]M<&%N>2!R979I97=S(&ET6EN9R!A;6]U;G0@;V8@ M=&AE(&%S6QE M/3-$)VUA3I4:6UE"`H1U-4*3PO M:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA3I4:6UE'!E;G-EF5D(&YE="!O9B!T:&4@ M86UO=6YT(&]F#0H@87-S;V-I871E9"!'4U0L('5N;&5S&%T:6]N(&%U=&AO2!IF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B`\8CX\:3Y2979E;G5E(%)E8V]G;FET:6]N/"]I/CPO8CX\+W`^ M#0H@/'`@#(P,3D[$$P.S$P-"!A;F0@05-##0H@-C`U(%)E=F5N=64@4F5C;V=N M:71I;VXN/"]P/@T*(#QP('-T>6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@0V]M<&%N M>28C>#(P,3D[6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!2979E;G5E M(&9R;VT@2!I6QE/3-$ M9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP M<'0^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)VUA3I4:6UE2!E:71H97(@=F5N9&]R('-P M96-I9FEC(&]B:F5C=&EV92!E=FED96YC92!O<@T*('1H:7)D('!A28C>#(P,3D[6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B!5;F1E2!I;F-L=61E(&]N92!O3I4:6UE2!G96YE0T*(&AU MF5D M(&%S(')E=F5N=64@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@=&AE('-P96-I M9FEE9`T*(&UI;&5S=&]N92X@268@=&AE(&YO;BUR969U;F1A8FQE(&UI;&5S M=&]N92!P87EM96YT(&ES(&YO=`T*('-U8G-T86YT:79E(&]R('-T86YD+6%L M;VYE('9A;'5E+"!T:&4@/&9O;G0@0T*(&%R92!E>'!E8W1E M9"!T;R!B92!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@86-T:79I=&EE6UE;G1S(&EN M9&EC871I=F4@;V8@:71S(&-O2P@86YD M(&%S('-U8V@@:&%V92!A8V-O=6YT960-"B!F;W(@=&AI#(P,40[+CPO<#X-"B`\+V1I=CX\'0^)SQD:78^#0H@/'`@2!!9W)E96UE;G0@=V%S#0H@2`R,#`Y+B!4:&4@0V]M M<&%N>2!H87,-"B!C;VYC;'5D960@=&AE($UA0T*(&-L96%R86YC92!T;R!S96QL('1H92!B M;&]O9"!G;'5C;W-E('!R;V1U8W0@*&UI;&5S=&]N92!P87EM96YT*2P@,BD- M"B!C;VYT6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5. M5#H@-"4G/@T*($%L;"!C;VYS:61E2!A<'!R;W9A;"!W87,@6UE M;G1S(&9R;VT@4VEE;65N2!S=6)M:7-S M:6]N28C>#(P,3D[F5D(&%S('1H92!C;VYT:6YG96YC:65S(&%R92!M970@86YD('1H92!C;VYS M:61E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0[($U!4D=) M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1'1O<"!W:61T:#TS1#(E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^26X@2G5N92`R,#$R+"!T:&4@ M0V]M<&%N>2!D96QI=F5R960-"B!O;B!I=',@9FER6UE;G0@;V8@ M020Q+#4R,BPU,S0-"B`H97%U:79A;&5N="!T;R!54R0Q+C4@;6EL;&EO;BD@ M87,@8V]N$$P.SPO<#X-"B`\=&%B;&4@0T* M(&]F(&%N;W1H97(@;F5W('1E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H97)E('=E$$P.S,P+"`R,#$T(&%N9"!397!T96UB M97(F(WA!,#LS,"P@,C`Q,R!R96QA=&EN9PT*('1O('1H92!D96QI=F5R>2!O M9B!T:&4@;6EL97-T;VYE65AF5D(&%S(&ET(&%C8W)U97,L('1A M:VEN9R!I;G1O(&%C8V]U;G0-"B!T:&4@969F96-T:79E('EI96QD(&]N('1H M92!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+CPO<#X-"B`\+V1I=CX\'0^)SQD:78^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY M(&AA2X@5&AE(')E"!I;F-E;G1I=F4@:6YC;VUE(&ES(')E8V]R9&5D('5N9&5R M('1H92!C87!T:6]N#0H@)B-X,C`Q0SM/=&AE#(P,40[(&EN('1H92!C M;VYS;VQI9&%T960@"!I;F-E;G1I=F4@:6YC;VUE#0H@"!M M;VYT:',@96YD960@2G5N928C>$$P.S,P+"`R,#$S(&%S('1H90T*(&-R:71E M2!D971E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y&;W)E:6=N($-U2!E M8V]N;VUI8R!E;G9I#(P,4,[=&AE(&9U;F-T:6]N86P@8W5R6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@ M,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!C;VYS;VQI9&%T960@9FEN M86YC:6%L('-T871E;65N=',@87)E('!R97-E;G1E9"!U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1F]R96EG;B!C=7)R96YC M>2!T&-H86YG92!R871E6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T* M(%1H92!#;VUP86YY(&AA2!A;F0-"B`H020T-#0L.36QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D M('9A;&EG;CTS1'1O<"!W:61T:#TS1#,E(&%L:6=N/3-$;&5F=#XF(W@R,#(R M.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^87-S971S(&%N M9"!L:6%B:6QI=&EE6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[ M/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE&-H86YG92!R871E&EM871I;VX@;V8@=&AE M(&5F9F5C="!O9B!T:&4-"B!R871E$$P.SPO<#X-"B`\=&%B;&4@#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$ M,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F M=#YA;&P@6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*($]N(&-O;G-O;&ED871I;VXL(&5X8VAA;F=E(&1I9F9E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX- M"B`\8CX\:3Y#;VUM:71M96YT6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@3&EA8FEL:71I97,@ M9F]R(&QO$$P.S,P+"`R,#$T(&%R92!A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P M/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE2!U0T*(&EN6UE;G1S(&1U2!T:&4@;F]N+6=L M=6-O6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$%%.SPO M$%%.SPO2!A2!A9&1I=&EO;F%L(&%M;W5N=',@<&5R('-T#(P,4,[;6%N=69A8W1U6UE;G1S)B-X,C`Q1#LI+B!!="!T:&4@65A6UE M;G0N/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D M('9A;&EG;CTS1'1O<"!W:61T:#TS1#,E(&%L:6=N/3-$;&5F=#XF(W@R,#(R M.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^=V4@:&%V92!E M;F=A9V5D(%!L86YE="!);FYO=F%T:6]N(%!T>0T*($QT9"`H)B-X,C`Q0SM0 M;&%N970@26YN;W9A=&EO;B8C>#(P,40[*2!T;R!A6UE;G0@=7!O;B!T:&4@9F]R M;6%L#0H@86-C97!T86YC92!O9B!T:&4@86YA;'EZ97(@9F]R(&-O;6UE6UE;G0@8V%N;F]T(&)E(')E;&EA8FQY#0H@ M97-T:6UA=&5D+CPO=&0^#0H@/"]TF5D('!R;V1U8W1S(&%R92!C87!I=&%L:7IE9"!A;F0-"B!A;6]R M=&EZ960@;W9E'!E;G-E'0^)SQD:78^#0H@/'`@'0M:6YD96YT.C0E M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B!#;&EN:6-A;"!T6UE;G1S('1O('1H92!S97)V:6-E('!R;W9I9&5R3I4:6UE'!E;G-EF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\ M:3Y,96%S960@07-S971S/"]I/CPO8CX\+W`^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q.'!T)SX-"B`\8CX\:3Y3=&]C:RUB87-E9"!#;VUP96YS871I;VX\ M+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%=E(&UE M87-U65E($]P=&EO;G,-"B`H)B-X,C`Q0SM:15!/ M#(P,40[*2X@4E-528C>#(P,3D["!R871E(&EN('1H90T*(&IUF5D(&9O`T*(')E='5R;B!A&-E961S('1H92!D969E"!D961U8W1I;VX@:7,@;&5S2!A9&]P M=&5D(&%N(&5M<&QO>65E(&]P=&EO;B!P;&%N#0H@*"8C>#(P,4,[4&QA;B8C M>#(P,40[*2X@3W!T:6]N2!P97)S;VX@8V]N2!T:&4@8F]A M2!E>&5R8VES92!C;VYD:71I;VYS(&UU&5R8VES90T*(&]F(&%N M(&]P=&EO;BX@268@=&AE($-O;7!A;GD@8VAA;F=E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4 M15A4+4E.1$5.5#H@-"4G/@T*($EN(&%C8V]R9&%N8V4@=VET:"!!4T,@-S$X M+"!T:&4@9F%I6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q."!A M;&EG;CTS1&-E;G1E6QE M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($5X97)C:7-E(%!R:6-E("A!)"D\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C$W/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/DYI;#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XP+C0Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-S$\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8S/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XV,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M65A$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`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`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C0Y/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,C@\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PV,#8L,#DY/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N,#<\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($=R86YT960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ-3(L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C`N,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*($5X97)C:7-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@X+#,S,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$N,#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.S,P+"`R,#$T/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XY+#DQ-"PW-S(\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ+C`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4 M15A4+4E.1$5.5#H@-"4G/@T*(%1H92!N=6UB97(@;V8@;W!T:6]N&5R M8VES86)L92!A2X-"B!4:&4@=&]T86P@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%S(&]F(%-E<'1E M;6)E$$P.S,P+"`R,#$T+"!T:&5R92!W87,@020R,#$L,3@Y(&]F('5N M'!E;G-E(')E;&%T960@=&\@ M=6YV97-T960@'!E M;G-E(&ES#0H@97AP96-T960@=&\@8F4@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A M;&EG;CTS1&-E;G1E6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U+#@V.3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CDP-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(P,2PQ.#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.S,P M+"`R,#$S('=A2!T:&4@0F]A M65E(%-H87)E M(%!L86X@<&5R;6ET65E2!O;B!A#0H@65E(&-E87-E2!O9B!I=',@87-S;V-I871E9"!G6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G M/@T*(%1H92!T86)L92!B96QO=R!S971S(&9O2!T:&4@0V]M<&%N>2!S:6YC90T*($IA;G5A6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$$P.U9A;'5E)B-X03`[;V8\8G(@+SX-"B!2 M97-T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$T,BPX,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M.R!415A4+4E.1$5.5#H@-"4G/@T*(%)E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-C`L.#`Q M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-S(\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%)E;&5A$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH.2PP-S<\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-S<\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=R86YT960\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`T,#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XP+C0Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-S$\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A M;GD@8V]N=')I8G5T97,@=&\@65E28C M>$$P.S$L(#(P,3,@86YD(#DN-24@9G)O;0T*($IU;'DF(WA!,#LQ+"`R,#$T M(&]F(&5A8V@@#(P,3D[65R65E)B-X,C`Q.3MS(')E;75N97)A=&EO;@T*('1O M(&%N(&%P<')O=F5D('-U<&5R86YN=6%T:6]N(&9U;F0@=&AA="!T:&4@96UP M;&]Y964@:7,@='EP:6-A;&QY#0H@;F]T(&%B;&4@=&\@86-C97-S('5N=&EL M('1H97D@87)E(')E=&ER960N(%1H92!#;VUP86YY('!E6%B;&4N/"]P M/@T*(#PO9&EV/CQS<&%N/CPO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y.970@3&]S6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0F%S:6,@86YD(&1I;'5T960@;F5T M(&QO#(P,3,[($5A6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/CQI M/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]I/CPO8CX\+W`^ M#0H@/'`@2US<&5C:69I8PT*(&=U:61A;F-E+CPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/ M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@8V]R92!P0T*(')E8V]G;FEZ97,@$$P.SPO<#X-"B`\=&%B M;&4@$$P.SPO<#X-"B`\=&%B;&4@$$P.SPO<#X-"B`\=&%B;&4@$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$."4^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T/B8C M>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y296-O M9VYI>F4@#(P M,3D[2!T;R!T2!A8W1I=FET:65S("AE M+F2P@<&QA;G0L(&%N9`T* M(&5Q=6EP;65N=#L@*#(I)B-X03`[$$P M.VEN=&%N9VEB;&4@87-S971S*2X-"B!%>&ES=&EN9R!A8V-O=6YT:6YG(&=U M:61A;F-E(&%P<&QI8V%B;&4@=&\@=&AE2!E>'!A;F1E9"!D:7-C;&]S=7)E$$P.S$U+"`R,#$V+"!F;W(@<'5B;&EC(&5N=&ET:65S+B!% M87)L>2!A<'!L:6-A=&EO;B!I6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5. M5#H@-"4G/@T*($5N=&ET:65S(&AA=F4@=&AE(&]P=&EO;B!O9B!U$$P.SPO<#X-"B`\=&%B;&4@ M#(P,30[(%)E=')O6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X- M"B`\='(^#0H@/'1D('=I9'1H/3-$."4^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T/B8C>#(P,C([/"]T M9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y-;V1I9FEE9"!R971R M;W-P96-T:79E(&%P<&QI8V%T:6]N#0H@)B-X,C`Q-#L@56YD97(@=&AE(&UO M9&EF:65D(&%P<')O86-H+"!A;B!E;G1I='D@#(P M,4,[=&AE(&-U;75L871I=F4@969F96-T(&]F(&EN:71I86QL>2!A<'!L>6EN M9R!T:&4@05-5(&%S(&%N#0H@861J=7-T;65N="!T;R!T:&4@;W!E;FEN9R!B M86QA;F-E(&]F(')E=&%I;F5D(&5A2!A<'!L:65S('1H90T*(&=U:61A;F-E(&EN('1H92!! M4U4@=&\@97AI2!T:&4@28C>#(P,3D[7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS M<&%N/CPO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0V]S=',@;V8@ M<'5R8VAA2!A6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)' M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT+#$V.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C0L,C`W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T2!O9B!296-E:79A8FQE'0^)SQD:78^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#M-;VYT M:',F(WA!,#M%;F1E9#QB$$P.S,P+#PO8CX\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/"]T$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*($%L;&]W86YC92!F;W(@9&]U8G1F=6P@9&5B=',\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.S,P+"`R,#$T(&%N9"`R,#$S M(&%R92!A6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#M- M;VYT:',F(WA!,#M%;F1E9#QB$$P.S,P+#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SX-"B`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`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XS+#DP,2PX,C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T'0^)SQD:78^#0H@/'`@$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($]P96YI;F<@8F%L86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(L-30Y+#DR.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR+#,U,2PT-C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($%C8W)E=&EO;B!E>'!E;G-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$Y."PT-C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#$P,"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@ M/'1D('=I9'1H/3-$-S4E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C`N,3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-#D\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C$W/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C`N-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-SD\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%9O;&%T:6QI='D\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8S M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV-#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'!E8W1E9"!, M:69E("AY96%R$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)I$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($9A:7(@5F%L=64@;V8@3W!T:6]N("A!)"D\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C$P/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-#D\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W M:61T:#TS1#6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ,"PV,#8L,#DY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N M,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=R86YT960\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-3(L,#`P/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C`N,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X97)C:7-E9#PO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X+#,S,SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N,#(\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.S,P M+"`R,#$T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#DQ-"PW-S(\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ+C`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]TF5D($-O;7!E;G-A=&EO;B!%>'!E M;G-E(%)E;&%T960@=&\@56YV97-T960@4VAA'!E8W1E9"!T;R!B92!296-O9VYI>F5D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`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`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(U+#@V.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP-CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P,2PQ.#D\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.U-H87)E$$P M.RA!)"D\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($UA>2P@,C`Q,SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDQ-SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ-#(L.#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C8Y+#DW,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(L,#0P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\ M+V1I=CX\2!D=7)I;F<@=&AE(&-U$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/E=E:6=H=&5D)B-X03`[879E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XP+C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@870@4V5P=&5M M8F5R)B-X03`[,S`L(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U M,RPW-C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO6UE;G1S(&1E;&EV97)E9#PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO"!I;F-E;G1I=F4@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XS+#4V,2PR,#D\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!T'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!,:69E4V-A;B!T:&5R96%F=&5R/"]T9#X-"B`@("`@("`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`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S(T(&UO;G1H M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0\+W1D/@T*("`@("`@("`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`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,2PW,#,\'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO'0^)S,@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO65R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2P@3F5T("A$971A M:6PI("A!540I/&)R/CPO2P@3F5T+"!4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XU,"PP-S(\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G0@07=A'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'!E8W1E9"!,:69E("AY96%R'0^)S<@>65A'0^ M)S<@>65A3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-64S-V$T-U]C-C8U7S0T M-V9?8C5C95\W,F5A,3'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA65E(%-T;V-K($]P=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\V-64S-V$T-U]C-C8U7S0T-V9?8C5C95\W,F5A,3'0O:'1M;#L@8VAA2!O9B!3 M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("T@4F5S=')I8W1E9"!3 M:&%R97,@27-S=65D("A$971A:6PI("A!540I/&)R/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H1&5T86EL*2`H055$*3QB7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO2!R96QA=&5D('!A M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!W:&EC:"!H87,@;VYE(&]F(&]U2!W:&EC:"!H87,@;VYE M(&]F(&]U'0^)SQS<&%N/CPO M2!4'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!R96QA=&5D('!A'0^)SQS<&%N/CPO M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-64S-V$T M-U]C-C8U7S0T-V9?8C5C95\W,F5A,3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XR,RPP,CDL-SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO6EN9R!V86QU92P@;F]N+6-U M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO2!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO&5R8VES86)L92!P97)I;V0\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO&5R8VES92!I;B!M=6QT:7!L97,@;V8@'0^)SQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-64S-V$T-U]C M-C8U7S0T-V9?8C5C95\W,F5A,3&UL#0I#;VYT96YT+51R86YS9F5R M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E M>'0O:'1M;#L@8VAA&UL;G,Z;STS M1")U'1087)T7S8U93,W830W7V,V-C5?-#0W9E]B-6-E7S XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail)
Sep. 30, 2014
USD ($)
Sep. 30, 2014
AUD
Dec. 31, 2013
USD ($)
Dec. 31, 2013
AUD
Debt Disclosure [Abstract]        
2014 $ 1,083,125   $ 2,532,500  
2015 1,749,167   1,749,167  
2016 1,732,500   1,732,500  
2017 1,732,500   1,732,500  
2018 16,732,500   16,732,500  
Thereafter 0   0  
Total minimum payments 23,029,792   24,479,167  
Less amount representing interest and other fees (8,029,792)   (9,479,167)  
Gross balance of long term debt 15,000,000   15,000,000  
Less fair value of warrants recorded within loan (815,655)   (815,655)  
Plus amortization of warrants 127,376   5,363  
Total carrying value 14,311,721 16,352,515 14,189,708 15,857,966
Less current portion 0 0 0 0
Total carrying value, non-current portion $ 14,311,721 16,352,515 $ 14,189,708 15,857,966
XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transactions - Additional Information (Detail) (AUD)
1 Months Ended
Aug. 31, 2013
Sep. 30, 2011
Sep. 27, 2013
Maximum [Member]
     
Related Party Transaction [Line Items]      
Decrease in ownership shares held by related party in the company     1.00%
SpeeDx [Member]
     
Related Party Transaction [Line Items]      
Agreement of milestone payments   500,000  
Consulting fees 77,758    
Success fee 50,000    
Ownership shares held in Company which has one of our directors     33.00%
Ownership shares held in Company which has one of our directors     33.00%
SpeeDx [Member] | Minimum [Member]
     
Related Party Transaction [Line Items]      
Sales and licensing revenues payments   5.00%  
SpeeDx [Member] | Maximum [Member]
     
Related Party Transaction [Line Items]      
Sales and licensing revenues payments   15.00%  
PFM Cornerstone Limited [Member]
     
Related Party Transaction [Line Items]      
Decrease in ownership shares held by related party in the company     6.00%
XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Parenthetical) (Detail) (USD $)
Sep. 30, 2014
Dec. 31, 2013
Debt Disclosure [Abstract]    
Fair value included in long term debt carrying value $ 815,655 $ 815,655
XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Borrowings - Additional Information (Detail)
Share data in Millions, unless otherwise specified
0 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2014
USD ($)
Jan. 31, 2014
AUD
Dec. 31, 2013
USD ($)
Dec. 19, 2013
Feb. 28, 2013
AUD
Dec. 19, 2013
Athyrium Credit Agreement [Member]
USD ($)
Sep. 30, 2014
Athyrium Credit Agreement [Member]
USD ($)
Dec. 31, 2013
Athyrium Credit Agreement [Member]
USD ($)
Dec. 19, 2013
Athyrium Credit Agreement [Member]
Debt Instrument [Line Items]                  
Athyrium credit agreement, date               Dec. 19, 2013  
Secured term loan, amount           $ 25,000,000      
Secured term loan, drawn amount 15,000,000   15,000,000         15,000,000  
Secured term loan, undrawn amount               10,000,000  
Amount available to be drawn within 30 days             5,000,000    
Quarterly service fee revenues             1,800,000    
Amount available to be drawn within 30 days             5,000,000    
Verio QSF plus coagulation manufacturing revenues             2,500,000    
Term loan maturity date             Dec. 19, 2018    
Interest charged   2.88%     2.95%   10.50%    
Term loan period             5 years    
Default interest rate under credit agreement             13.00%    
Minimum voluntary repayments             2,500,000    
Percentage of prepayment to lenders on net cash proceeds received             100.00%    
Prepayment premium prior to second anniversary, percentage             20.00%    
Prepayment premium after second anniversary, percentage             15.00%    
Non-refundable fee paid           625,000      
Non-refundable fee as percentage of aggregate credit facility           2.50%      
Percentage of commitment fee paid           2.00%      
Percentage of milestone payments             30.00%    
Maximum milestone payments             600,000    
Minimum unrestricted cash required             2,000,000    
Number of common stock entitled by issuing warrants       4.5   4.5      
Exercise price                 1.00
Percentage of premium over closing price of common stock           117.00%      
Warrants exercisable period             7 years    
Total amount financed   568,677     767,471        
XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Interim Financial Statements
9 Months Ended
Sep. 30, 2014
Quarterly Financial Information Disclosure [Abstract]  
Interim Financial Statements

Interim Financial Statements

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the financial statements and footnotes thereto as of and for the year ended December 31, 2013, included in the Form 10-K of Universal Biosensors, Inc.

The year-end consolidated condensed balance sheets data as at December 31, 2013 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain prior year amounts in the consolidated condensed financial statements have been reclassified to conform to the current presentation.

XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Warrants - Additional Information (Detail)
9 Months Ended
Sep. 30, 2014
Dec. 19, 2013
Other Liabilities Disclosure [Abstract]    
Number of common stock entitled by issuing warrants   4,500,000
Warrants exercise expiration date Dec. 19, 2020  
Warrants exercise in multiples of shares, minimum 500,000  
XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Condensed Balance Sheets(AUD)
Sep. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents 19,830,109 23,742,422
Inventories, net 393,745 4,207
Accounts receivable 2,012,682 2,167,867
Prepayments 870,573 825,800
Other current assets 5,850,695 9,049,283
Total current assets 28,957,804 35,789,579
Non-current assets:    
Property, plant and equipment 34,470,592 33,816,691
Less accumulated depreciation (19,701,816) (17,906,571)
Property, plant and equipment - net 14,768,776 15,910,120
Other non-current assets 2,920,000 2,920,000
Total non-current assets 17,688,776 18,830,120
Total assets 46,646,580 54,619,699
Current liabilities:    
Accounts payable 957,140 974,754
Accrued expenses 2,615,730 2,329,440
Deferred revenue 979,368 957,916
Employee entitlements provision 1,412,121 1,160,177
Total current liabilities 5,964,359 5,422,287
Non-current liabilities:    
Asset retirement obligations 2,600,000 2,549,928
Employee entitlements provision 131,165 147,662
Long term secured loan 16,352,515 15,857,966
Deferred revenue 979,368 957,916
Total non-current liabilities 20,063,048 19,513,472
Total liabilities 26,027,407 24,935,759
Commitments and contingencies 0 0
Stockholders' equity:    
Preferred stock, US$0.01 par value. Authorized 1,000,000 shares; issued and outstanding nil in 2014 (2013: nil)      
Common stock, US$0.0001 par value. Authorized 300,000,000 shares; issued and outstanding 175,610,978 shares in 2014 (2013: 175,600,605) 17,561 17,560
Additional paid-in capital 94,736,989 94,955,051
Accumulated deficit (64,990,359) (53,356,552)
Current year loss (8,846,706) (11,633,807)
Accumulated other comprehensive income (298,312) (298,312)
Total stockholders' equity 20,619,173 29,683,940
Total liabilities and stockholders' equity 46,646,580 54,619,699
XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Condensed Statements of Cash Flows (AUD)
9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash flows from operating activities:    
Net loss (8,846,706) (8,366,769)
Adjustments to reconcile net loss to net cash provided by/(used in) operating activities:    
Depreciation and amortization 1,847,314 1,890,162
Share based payments expense (219,061) 469,125
Loss on fixed assets disposal 8,098 907
Net exchange difference 390,708 23,549
Financing costs - amortization of warrants 133,361 0
Change in assets and liabilities:    
Inventory (389,538) 1,218,518
Accounts receivable 155,185 577,192
Prepaid expenses and other assets 3,153,816 (4,361,105)
Deferred revenue 42,904 0
Employee entitlements 236,446 284,844
Accounts payable and accrued expenses 1,934,897 (1,915,731)
Net cash used in operating activities (1,552,576) (10,179,308)
Cash flows from investing activities:    
Purchases of property, plant and equipment (691,465) (135,252)
Net cash used in investing activities (691,465) (135,252)
Cash flows from financing activities:    
Proceeds from borrowings 552,772 767,471
Repayment of borrowings (552,772) (639,559)
Proceeds from stock options exercised 0 194,761
Financing costs (1,638,752) 0
Net cash provided by/(used in) financing activities (1,638,752) 322,673
Net decrease in cash and cash equivalents (3,882,793) (9,991,887)
Cash and cash equivalent at beginning of period 23,742,422 23,649,417
Effect of exchange rate fluctuations on the balances of cash held in foreign currencies (29,520) 1,013,372
Cash and cash equivalents at end of period 19,830,109 14,670,902
XML 26 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Asset Retirement Obligations (Detail) (AUD)
9 Months Ended 12 Months Ended
Sep. 30, 2014
Dec. 31, 2013
Accounting Policies [Abstract]    
Opening balance 2,549,928 2,351,464
Accretion expense 50,072 198,464
Ending balance 2,600,000 2,549,928
XML 27 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Stock Option Activity (Detail) (AUD)
9 Months Ended
Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Options, Outstanding Number of shares, Beginning Balance 10,606,099
Stock Options, Number of shares, Granted 152,000
Stock Options, Number of shares, Exercised (8,333)
Stock Options, Number of shares, Lapsed (834,994)
Stock Options, Outstanding Number of shares, Ending Balance 9,914,772
Stock Options, Weighted average exercise price, Beginning Balance 1.07
Stock Options, Weighted average exercise price, Granted 0.10
Stock Options, Weighted average exercise price, Exercised 0.00
Stock Options, Weighted average exercise price, Lapsed 1.02
Stock Options, Weighted average exercise price, Ending Balance 1.06
XML 28 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 29 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Organization of the Company
9 Months Ended
Sep. 30, 2014
Accounting Policies [Abstract]  
Organization of the Company

Organization of the Company

We are a specialist medical diagnostics company focused on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use.

We were incorporated in the State of Delaware on September 14, 2001 and our shares of common stock in the form of CHESS Depositary Interests (“CDIs”) have been quoted on the Australian Securities Exchange (“ASX”) since December 13, 2006. Our securities are not currently traded on any other public market. Our wholly owned subsidiary and primary operating vehicle, UBS, was incorporated as a proprietary limited company in Australia on September 21, 2001. UBS conducts our research, development and manufacturing activities in Melbourne, Australia.

We have rights to an extensive patent portfolio, with certain patents owned by UBS and a number licensed to UBS by LifeScan, Inc. (“LifeScan”) and other third party licensees. Unless otherwise noted, references to “LifeScan” in this document are references collectively or individually to LifeScan, Inc., and/or LifeScan Europe, a division of Cilag GmbH International, both affiliates of Johnson and Johnson.

We are using our electrochemical cell technology platform to develop tests for a number of different markets. Our current focus is as set out below:

 

    Coagulation testing market – we are working with Siemens Healthcare Diagnostics, Inc. (“Siemens”) to develop a range of products for the point-of-care coagulation market pursuant to a collaboration agreement with Siemens (“Collaboration Agreement”) and, subject to being approved for sale, plan to manufacture test strips for these products under a supply agreement with Siemens (“Supply Agreement”). We are also developing our own Prothrombin Time International Normalized Ratio (“PT-INR”) test targeted at the patient self-test market and intend to enter into distribution agreements with respect to that test.

 

    Blood glucose – we provide services to LifeScan as required from time to time, pursuant to a Master Services and Supply Agreement (“Master Services and Supply Agreement”) and a development and research agreement (“Development and Research Agreement”) with LifeScan.

 

    Other electrochemical-cell based tests – we are working on proving the broader applicability of our technology platform, including tests based on enzymatic, immunoassay and molecular diagnostic methods. We may seek to enter into collaborative arrangements, strategic alliances or distribution agreements with respect to any tests arising from this work.
XML 30 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Condensed Balance Sheets (Parenthetical) (USD $)
Sep. 30, 2014
Dec. 31, 2013
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued      
Preferred stock, shares outstanding      
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 175,610,978 175,600,605
Common stock, shares outstanding 175,610,978 175,600,605
XML 31 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation - Additional Information (Detail) (Minimum [Member])
9 Months Ended
Sep. 30, 2014
Minimum [Member]
 
Basis Of Presentation [Line Items]  
Sufficient cash and cash equivalents to fund our operations 12 months
XML 32 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
9 Months Ended
Sep. 30, 2014
Oct. 29, 2014
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2014  
Document Fiscal Year Focus 2014  
Document Fiscal Period Focus Q3  
Trading Symbol UBI  
Entity Registrant Name UNIVERSAL BIOSENSORS INC  
Entity Central Index Key 0001279695  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   175,610,978
XML 33 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Additional Information (Detail)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 9 Months Ended
Sep. 30, 2014
AUD
Strips
Milestone
Sep. 30, 2013
AUD
Jun. 30, 2013
AUD
Sep. 30, 2014
USD ($)
Sep. 30, 2014
AUD
Strips
Milestone
Sep. 30, 2013
AUD
Jun. 30, 2014
Jul. 31, 2012
Research and Development Arrangement [Member]
USD ($)
Jul. 31, 2012
Research and Development Arrangement [Member]
AUD
Jun. 30, 2012
Research and Development Arrangement [Member]
USD ($)
Jun. 30, 2012
Research and Development Arrangement [Member]
AUD
Sep. 30, 2014
Research and Development Arrangement [Member]
AUD
Sep. 30, 2014
Research and Development Arrangement [Member]
USD ($)
Payment
Sep. 30, 2014
Research and Development Arrangement [Member]
AUD
Dec. 31, 2012
Research and Development Arrangement [Member]
USD ($)
Dec. 31, 2012
Research and Development Arrangement [Member]
AUD
Sep. 09, 2011
Research and Development Arrangement [Member]
USD ($)
Sep. 09, 2011
Research and Development Arrangement [Member]
AUD
Sep. 30, 2014
Maximum [Member]
Sep. 30, 2014
Minimum [Member]
Sep. 30, 2014
Employee Stock Option [Member]
AUD
Sep. 30, 2014
Employee Stock Option [Member]
Maximum [Member]
Sep. 30, 2014
Employee Stock Option [Member]
Minimum [Member]
Sep. 30, 2014
Zero Priced Employee Options [Member]
USD ($)
Summary Of Significant Accounting Policies [Line Items]                                                
Minimum maturity period of highly liquid investments purchase       3 months 3 months                                      
Short-term investments maturity period, minimum 3 months                                              
Short-term investments maturity period, maximum 12 months                                              
Property plant and equipment useful life                                     10 years 3 years        
Non-refundable payment                                 $ 3,000,000 2,961,245            
Maximum number of payments entity may receive from Siemens                         6 6                    
Number of milestone payments delivered 2     2 2                                      
Received a payment               1,500,000 1,438,711 1,500,000 1,522,534                          
Revenue from services 1,949,297 1,117,229     4,815,229 3,495,585   2,142,857 2,055,301 2,142,857 2,175,048 0   0 4,285,714 4,230,349                
Revenue recognition, milestone method, revenue recognized                         3,000,000 2,961,245                    
Deferred revenue up-front payment recognized                         3,000,000                      
Research and development tax incentive income 3,561,209 4,250,864 0   7,281,358 4,250,864                                    
Foreign currency transaction (losses)/gains 399,417 15,926     444,973 724,989                                    
First obligation to reimburse patent fees paid by LifeScan 50.00%     50.00% 50.00%                                      
Obligation to reimburse patent fees paid by LifeScan thereafter 50.00%     50.00% 50.00%                                      
Minimum amount to be paid on first commercial sale of non-glucose product       1,600,000                                        
Maximum amount to be paid on first commercial sale of non-glucose product       1,800,000                                        
Lump sum payment period for patent fees       45 days 45 days                                      
Monthly installment period for patent fees       24 months 24 months                                      
Percentage of manufacturing initial payment 40.00%     40.00% 40.00%                                      
Duration of payment of marketing support payment on achieving target sales       2 years 2 years                                      
Target strips to be sold for payment of marketing support payment 1,000,000,000     1,000,000,000 1,000,000,000                                      
Total amount of expected marketing support payments       2,000,000                                        
Number of common stock given to each option holder       1 1                                      
Exercise price                                                 
Options granted under our share option plan                                           10 years 3 years  
Number of options exercisable 8,219,892 8,344,277   8,219,892 8,219,892 8,344,277                                    
Stock compensation expense recognized 61,703 175,623     (219,061) 469,125                                    
Unrecognized compensation expense related to unvested share-based compensation arrangements                                         201,189      
Aggregate intrinsic value for all options outstanding 0 0     0 0                                    
Restricted shares of common stock to employees 1,000       1,000                                      
Period of non traded years of existing shares of common stock       3 years 3 years                                      
Employers contribution to standard defined contribution superannuation funds on behalf of all employees 9.50%         9.00% 9.25%                                  
XML 34 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Condensed Statements of Comprehensive Income (AUD)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Revenue        
Revenue from products 137,294 1,396,357 137,294 8,597,428
Revenue from services 1,949,297 1,117,229 4,815,229 3,495,585
Total revenue 2,086,591 2,513,586 4,952,523 12,093,013
Cost of goods sold & services        
Cost of goods sold 218,298 1,756,957 218,298 8,677,388
Cost of services 127,084 236,334 150,006 868,347
Total cost of goods sold & services 345,382 1,993,291 368,304 9,545,735
Contribution from products & services 1,741,209 520,295 4,584,219 2,547,278
Other operating costs & expenses        
Research and development 4,715,444 3,901,823 13,900,999 11,807,954
General and administrative 1,522,175 1,684,703 4,588,686 4,480,101
Total operating costs & expenses 6,237,619 5,586,526 18,489,685 16,288,055
Loss from operations (4,496,410) (5,066,231) (13,905,466) (13,740,777)
Other income/(expense)        
Interest income 103,398 123,663 187,247 417,022
Interest expense (4,772) (7,547) (15,905) (18,867)
Financing costs (654,095) 0 (1,944,995) 0
Other 3,157,820 4,266,790 6,832,413 4,975,853
Total other income 2,602,351 4,382,906 5,058,760 5,374,008
Net loss before tax (1,894,059) (683,325) (8,846,706) (8,366,769)
Income tax benefit/(expense) 0 0 0 0
Net loss (1,894,059) (683,325) (8,846,706) (8,366,769)
Earnings per share        
Basic and diluted net loss per share (0.01) 0.00 (0.05) (0.05)
Other comprehensive loss, net of tax:        
Reclassification for gain/(loss) realized in net income 0 0 0 0
Other comprehensive gain/(loss) 0 0 0 0
Comprehensive loss (1,894,059) (683,325) (8,846,706) (8,366,769)
XML 35 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Borrowings
9 Months Ended
Sep. 30, 2014
Debt Disclosure [Abstract]  
Borrowings

Borrowings

Future maturities, interest and other payments under the Company’s long term secured loan pursuant to the credit agreement (described below) as of September 30, 2014 and December 31, 2013 are as follows:

 

     September 30, 2014      December 31, 2013  
     US$     A$      US$     A$  

2014

     1,083,125           2,532,500     

2015

     1,749,167           1,749,167     

2016

     1,732,500           1,732,500     

2017

     1,732,500           1,732,500     

2018

     16,732,500           16,732,500     

Thereafter

     0           0     
  

 

 

      

 

 

   

Total minimum payments

     23,029,792           24,479,167     

Less amount representing interest and other fees

     (8,029,792        (9,479,167  
  

 

 

      

 

 

   

Gross balance of long term debt

     15,000,000           15,000,000     

Less fair value of warrants recorded within loan (a)

     (815,655        (815,655  

Plus amortization of warrants

     127,376           5,363     
  

 

 

      

 

 

   

Total carrying value

     14,311,721        16,352,515         14,189,708        15,857,966   
  

 

 

   

 

 

    

 

 

   

 

 

 

Less current portion

     0        0         0        0   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total carrying value, non-current portion

     14,311,721        16,352,515         14,189,708        15,857,966   
  

 

 

   

 

 

    

 

 

   

 

 

 

 

(a) The warrants issued in December 2013 had a fair value of US$815,655 as of September 30, 2014 and December 31, 2013, and are included in long term debt carrying value.

Athyrium Credit Agreement

On December 19, 2013 (“Closing Date”), UBI and its wholly owned subsidiary, UBS (together UBI and UBS, the “Transaction Parties”) entered into a credit agreement with Athyrium Opportunities Fund (A) LP (“Athyrium A”), as administrative agent (the “Administrative Agent”) and as a lender, and Athyrium Opportunities Fund (B) LP (“Athyrium B”) as a lender (Athyrium A and Athyrium B together with any other lenders party thereto from time to time, the “Lenders”) for a secured term loan of up to US$25 million (“Credit Agreement”). Of this amount, US$15 million had been drawn at December 31, 2013, with a further US$10 million available to be drawn down as follows:

 

    US$5 million available within 30 days after the end of any quarter until January 30, 2015, conditional upon UBS satisfying certain conditions precedent including that in the immediately preceding quarter, UBS achieves quarterly service fee revenues from the sale of the OneTouch® Verio® blood glucose strips (“Verio QSFs”) plus coagulation manufacturing revenues of not less than US$1,800,000 in the aggregate; and

 

    US$5 million available within 30 days after the end of any quarter until January 30, 2015, conditional upon UBS satisfying certain conditions precedent including that in the immediately preceding quarter, UBS achieves Verio QSFs plus coagulation manufacturing revenues of not less than US$2,500,000 in the aggregate.

 

The term loan has a maturity date of December 19, 2018 (“Maturity Date”) and bears interest at 10.5% per annum payable in cash quarterly in arrears over the five year term, and as otherwise described in the Credit Agreement. A default interest rate of 13% per annum shall apply during the existence of a default under the Credit Agreement. Other than as summarized below, UBS is not required to make payments of principal for amounts outstanding under the term loan until maturity, December 19, 2018. The term loan under the Credit Agreement is secured by substantially all of UBI and UBS’ assets. UBI (together with any future subsidiaries) guarantees all of UBS’s obligations under the term loan.

Voluntary prepayments of the term loans are not permitted prior to the second anniversary of the Closing Date, except in the event of a change of control of a Transaction Party. After the second anniversary, UBS can make voluntary repayments in minimum principal amounts of US$2,500,000 together with interest, plus the premium described below. UBS must make mandatory prepayments in certain prescribed circumstances, including in the event of raising additional debt financing, a sale or transfer of assets other than in certain circumstances and in the event of other specified extraordinary receipts. Extraordinary receipts include cash received or paid other than in the ordinary course of business, such as tax refunds (other than GST and R&D tax rebates), LifeScan lump sum fee payments and Siemens termination fees. In such events, UBS must prepay to the Lenders 100% of the net cash proceeds received. In the event of a prepayment on or prior to the second anniversary of the Closing Date, UBS must also pay a prepayment premium of 20% of the loans due and payable on that date. If there is a prepayment after the second anniversary of the Closing Date, UBS must pay a prepayment premium commencing at 15% of the loans due and payable on the applicable date and reducing pro-rata on a monthly basis until the Maturity Date.

UBS paid a non-refundable fee of US$625,000 to the Lenders on the Closing Date (being 2.5% of the aggregate credit facility) and a 2% commitment fee based on any available unused borrowing commitment under the Credit Agreement until January 30, 2015. The Lenders will also be entitled to receive 30% of the net proceeds of milestone payments paid under the Collaboration Agreement by and among UBS, UBI and Siemens Healthcare Diagnostics, Inc., up to a maximum of US$600,000 in the aggregate. UBS has also agreed to pay certain taxes arising in connection with the Credit Agreement and other Loan Documents, including withholding taxes. UBS has also agreed to pay certain reasonable out-of-pocket expenses incurred by the Lenders in connection with the loan documents, or as may be incurred in connection with the enforcement or protection of their rights.

The Credit Agreement also contains certain covenants, including among other things, covenants: (i) relating to the delivery of financial and other information and certificates, notices of defaults, litigation and other material events; payment of taxes and other obligations; maintenance of insurance; (ii) which limit or restrict the incurrence of liens; the making of investments; the incurrence of certain indebtedness; mergers, dispositions, liquidations, or consolidations and significant asset sales; restricted payments; transactions with affiliates other than on normal and arms-length terms; burdensome agreements; prepayment of other indebtedness; ownership of subsidiaries; and (iii) which require UBS to maintain unrestricted cash of not less than US$2,000,000 in a specified bank account at any time.

As further described below, pursuant to the Credit Agreement, UBI issued to the lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at a price of A$1.00 per share (the “Exercise Price”), which represents a 117% premium over the closing price of UBI’s common stock on December 19, 2013. The warrants are immediately exercisable and have a term of seven years.

 

Other

In January 2014, UBS entered into an arrangement with Pacific Premium Funding to fund the Group’s insurance premium. The total amount financed was A$568,677 at inception. Interest is charged at a fixed rate of 2.88% per annum and the short-term borrowing has been fully repaid. The short-term borrowing was secured by the insurance premium refund. In February 2013, UBS entered into an arrangement with Lumley Finance Ltd to fund the Group’s insurance premium. The total amount financed was A$767,471 at inception. Interest was charged at a fixed rate of 2.95% per annum and the short-term borrowing was fully repaid by December 2013. The short-term borrowing was secured by the insurance premium refund.

XML 36 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transactions
9 Months Ended
Sep. 30, 2014
Related Party Transactions [Abstract]  
Related Party Transactions

Related Party Transactions

Details of related party transactions material to the operations of the Group other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, are set out below.

In September 2011, we entered into a non-exclusive license agreement with SpeeDx Pty Ltd (“SpeeDx”) pursuant to which SpeeDx granted us a license to use its proprietary MNAzyme technology in the field of molecular diagnostics. Under the agreement we make milestone payments totaling A$500,000 to SpeeDx if certain specified targets are achieved, and royalty payments ranging from 5% to 15% of that portion of our sales and licensing revenues arising from SpeeDx technology or products incorporating SpeeDx technology.

 

In August 2013, we entered into a consulting agreement with SpeeDx pursuant to which we provided certain services relating to the establishment and maintenance of a quality management system at SpeeDx. Consulting fees received under this agreement were A$77,758. In addition, a success fee of A$50,000 is payable by SpeeDx during the fourth quarter of 2014 as the criteria for successful completion of the engagement has been met.

Messrs Denver and Jane are directors of the Company and SpeeDx. Talu Ventures Pty Ltd, of which Mr. Jane is a director, is a fund manager for a fund which holds approximately 33% of the issued shares in SpeeDx. Until September 27, 2013, PFM Cornerstone Limited held approximately 6% of our shares (this holding has since decreased to less than 1.0% of our shares) and PFM Cornerstone Limited also holds approximately 33% of the issued shares in SpeeDx. Messrs Denver and Hanley are directors of the Company and PFM Cornerstone Limited.

XML 37 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Assumptions for Option Grants Issued (Detail) (AUD)
1 Months Ended
Aug. 31, 2014
Aug-14 [Member]
Dec. 31, 2013
Dec-13 [Member]
Dec. 31, 2013
Dec-13 [Member]
Aug. 31, 2013
Aug-13 [Member]
Mar. 31, 2013
Mar-13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Exercise price 0.17   0.49 0.71 0.79
Share Price at Grant Date 0.17 0.49 0.49 0.71 0.79
Volatility 71.00% 63.00% 63.00% 64.00% 65.00%
Expected Life (years) 7 years 7 years 7 years 7 years 7 years
Risk Free Interest Rate 3.13% 3.82% 3.82% 3.54% 3.37%
Fair Value of Option 0.10 0.49 0.28 0.41 0.45
XML 38 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Inventory, Net (Detail) (AUD)
Sep. 30, 2014
Dec. 31, 2013
Accounting Policies [Abstract]    
Raw materials 315,036 4,169
Work in progress 78,709 38
Finished goods 0 0
Inventory, Net, Total 393,745 4,207
XML 39 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2014
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, UBS. All intercompany balances and transactions have been eliminated on consolidation.

Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations and obligations related to employee benefits. Actual results could differ from those estimates.

Cash & Cash Equivalents

Cash & Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments.

Short-Term Investments (Held-to-maturity)

Short-Term Investments (Held-to-maturity)

Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.

Concentration of Credit Risk and Other Risks and Uncertainties

Concentration of Credit Risk and Other Risks and Uncertainties

Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated balance sheets. The Company’s cash and cash equivalents are invested with one of Australia’s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.

Derivative Instruments and Hedging Activities

Derivative Instruments and Hedging Activities

Derivative financial instruments

The Company uses derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.

Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.

 

Cash flow hedges

Exposure to foreign exchange risks arises in the normal course of the Company’s business and it is the Company’s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.

Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the non-financial asset or liability.

For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated statements of comprehensive income.

When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated statements of comprehensive income.

Derivative Instruments and Hedging Activities

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. At September 30, 2014 and year ended December 31, 2013, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2. The fair value methodologies described as Level 2 and 3 inputs are defined elsewhere in these notes to the financial statements.

Inventory

Inventory

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Raw materials

     315,036         4,169   

Work in progress

     78,709         38   

Finished goods

     0         0   
  

 

 

    

 

 

 
     393,745         4,207   
  

 

 

    

 

 

 
Receivables

Receivables

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Accounts receivable

     2,012,682         2,167,867   

Allowance for doubtful debts

     0         0   
  

 

 

    

 

 

 
     2,012,682         2,167,867   
  

 

 

    

 

 

 
Property, Plant, and Equipment

Property, Plant, and Equipment

Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.

Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.

The Company receives Victorian government grant monies under grant agreements to support our development activities, including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.

Research and Development

Research and Development

Research and development expenses consist of costs incurred to further the Group’s research and development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.

 

Research and development expenses for the three and nine months ended September 30, 2014 and 2013 are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

Research and development expenses

     4,715,444         3,901,823         13,900,999         11,807,954   
  

 

 

    

 

 

    

 

 

    

 

 

 
Income Taxes

Income Taxes

The Company applies ASC 740 - Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.

We are subject to income taxes in the United States and Australia. U.S. federal income tax returns up to and including the 2013 financial year has been filed. Internationally, consolidated income tax returns up to and including the 2013 financial year have been filed.

Asset Retirement Obligations

Asset Retirement Obligations

Asset retirement obligations (“ARO”) are legal obligations associated with the retirement and removal of long-lived assets. ASC 410 – Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.

The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.

Our overall ARO changed as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Opening balance

     2,549,928         2,351,464   

Accretion expense

     50,072         198,464   
  

 

 

    

 

 

 

Ending balance

     2,600,000         2,549,928   
  

 

 

    

 

 

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:

 

    Market approach – based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

 

    Cost approach – based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.

 

    Income approach – based on the present value of a future stream of net cash flows

These fair value methodologies depend on the following types of inputs:

 

    Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)

 

    Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs)

 

    Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company reviews its capital assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows.

Australian Goods and Services Tax (GST)

Australian Goods and Services Tax (GST)

Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheets.

Revenue Recognition

Revenue Recognition

We recognize revenue from all sources based on the provisions of the U.S. SEC’s Staff Accounting Bulletin No. 104 and ASC 605 Revenue Recognition.

The Company’s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.

Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.

 

Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company’s best estimate of selling price when fair value is not available for a given unit of accounting.

Under ASC 605-25, the delivered item(s) are separate units of accounting, provided (i) the delivered item(s) have value to a customer on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following: non-refundable, upfront payments; funding of research and/or development efforts; and milestone payments.

We typically generate milestone payments from our customers pursuant to the various agreements we have with them. Non-refundable milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the non-refundable milestone payment is not substantive or stand-alone value, the non-refundable milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.

Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company’s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as “revenues”.

Master Services and Supply Agreement

Master Services and Supply Agreement

In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a non-exclusive manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).

All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.

Collaboration Agreement

Collaboration Agreement

On September 9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. In addition to an up-front, non-refundable payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement contained a further six payments from Siemens upon the achievement of certain defined milestones. These six milestones relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the up-front payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company’s best estimate of selling price. The deliverables related to each milestone are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.

Of the six milestones, the Company has delivered on two as of September 30, 2014:

 

    In June 2012, the Company delivered on its first milestone by achieving proof of technical feasibility of a new test strip and received a payment of A$1,522,534 (equivalent to US$1.5 million) as consideration. A sum of A$2,175,048 (equivalent to US$2,142,857) has been recognized as revenue from services in June 2012 in this regards.

 

    In July 2012, the Company delivered on its second milestone by achieving proof of technical feasibility of another new test strip and received a payment of A$1,438,711 (equivalent to US$1.5 million) as consideration. A sum of A$2,055,301 (equivalent to US$2,142,857) has been recognized as revenue from services in July 2012 in this regards.

There were no revenues recognized for the three and nine months ended September 30, 2014 and September 30, 2013 relating to the delivery of the milestones pursuant to the Collaboration Agreement. Of the total amount of A$4,230,349 (equivalent to US$4,285,714) recognized as revenue for the 2012 financial year, A$2,961,245 (equivalent to US$3.0 million) relates to the achievement of the two milestones whilst the balance relates to a portion of the deferred US$3 million up-front payment allocated to these milestones based upon their relative estimate of selling price.

Interest income

Interest income

Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.

Research and development tax incentive income

Research and development tax incentive income

Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.

The Company has recorded research and development tax incentive income of A$3,561,209 and A$4,250,864 for the three month period ended September 30, 2014 and 2013, respectively and A$7,281,358 and A$4,250,864 for the nine month period ended September 30, 2014 and 2013, respectively. The research and development tax incentive income is recorded under the caption “Other” in the consolidated statements of comprehensive income. There was no research and development tax incentive income recognized for the six months ended June 30, 2013 as the criteria was not met. The Company determined that it qualified and became eligible for this incentive income during the third quarter of the 2013 financial year.

Foreign Currency

Foreign Currency

Functional and reporting currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of the Company and UBS is AUD or A$ for all years presented.

 

The consolidated financial statements are presented using a reporting currency of Australian dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of comprehensive income.

The Company has recorded foreign currency transaction (losses)/gains of (A$399,417) and A$15,926 for the three month period ended September 30, 2014 and 2013, respectively and (A$444,973) and A$724,989 for the nine month period ended September 30, 2014 and 2013, respectively.

The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:

 

  assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;

 

  income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and

 

  all resulting exchange differences are recognized as a separate component of equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.

Commitments and Contingencies

Commitments and Contingencies

Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Our contingent liabilities as at September 30, 2014 are as follows:

 

  we have a potential obligation to pay 50% of the patent fees paid by LifeScan in respect of the patents we license from LifeScan prior to the date of the first commercial sale of a non-glucose product that utilizes the technology licensed from LifeScan and 50% of the patent fees incurred by LifeScan in respect of such patents thereafter. In the event of the first commercial sale of a non-glucose product, the initial amount that could be paid by us to LifeScan is projected to be between US$1.6 million to US$1.8 million. We would have the right to make this payment either as a lump sum within 45 days of receipt of the supporting documentation from LifeScan or in equal monthly installment payments during the 24 months subsequent to the date of receipt of the supporting documentation. Currently the non-glucose products continue to be in the research and development phase.

 

  during 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch® Verio®, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by us in 2010 and 2011 up to a specified volume limit (“manufacturing initiation payments”). At the same time, we agreed to pay LifeScan a marketing support payment in each of the two years following the first year in which 1 billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The total amount of marketing support payments expected to be paid to LifeScan is approximately US$2 million. Based on the current volume of strips sold by LifeScan and that we have no visibility of future sales by LifeScan, it is uncertain whether we would be required to make this marketing support payment.

 

  we have engaged Planet Innovation Pty Ltd (“Planet Innovation”) to assist us with design and engineering for future analyzers. As part of the agreement, Planet Innovation will be paid a success payment upon the formal acceptance of the analyzer for commercial manufacture and a further success payment on launch sign-off for the first commercial sale of the analyzer. All of the analyzers Planet Innovation is currently working on are in the research and development phases, and therefore at this stage their commercial manufacture and sale and the amount of any future success payment cannot be reliably estimated.
Patent and License Costs

Patent and License Costs

Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in research and development expense. Legal and maintenance fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents.

Clinical Trial Expenses

Clinical Trial Expenses

Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.

These prepaid or accrued expenses are based on estimates of the work performed under service agreements.

Leased Assets

Leased Assets

All of the Company’s leases for the periods ending September 30, 2014 and December 31, 2013 are considered operating leases. The costs of operating leases are charged to the statement of comprehensive income on a straight-line basis over the lease term.

Stock-based Compensation

Stock-based Compensation

We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (“RSUs”) and Zero Priced Employee Options (“ZEPOs”). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company’s stock price. The exercise price of ZEPOs is nil.

We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to paid-in-capital are still available if the tax deduction is less than the deferred tax asset.

 

(a) Stock Option Plan

In 2004, the Company adopted an employee option plan (“Plan”). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.

An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.

In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:

 

     Grant Date  
     Aug-14     Dec-13     Dec-13     Aug-13     Mar-13  

Exercise Price (A$)

     0.17        Nil        0.49        0.71        0.79   

Share Price at Grant Date (A$)

     0.17        0.49        0.49        0.71        0.79   

Volatility

     71     63     63     64     65

Expected Life (years)

     7        7        7        7        7   

Risk Free Interest Rate

     3.13     3.82     3.82     3.54     3.37

Fair Value of Option (A$)

     0.10        0.49        0.28        0.41        0.45   

Stock option activity during the current period is as follows:

 

     Number of shares     Weighted average
exercise price
A$
 

Balance at December 31, 2013

     10,606,099        1.07   

Granted

     152,000        0.10   

Exercised

     (8,333     0.00   

Lapsed

     (834,994     1.02   
  

 

 

   

 

 

 

Balance at September 30, 2014

     9,914,772        1.06   
  

 

 

   

 

 

 

The number of options exercisable as at September 30, 2014 and September 30, 2013 was 8,219,892 and 8,344,277, respectively. The total stock compensation expense recognized in income statement was A$61,703 and A$175,623 for the three month period ended September 30, 2014 and 2013, respectively and (A$219,061) and A$469,125 for the nine month period ended September 30, 2014 and 2013, respectively.

As of September 30, 2014, there was A$201,189 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized as follows:

 

Fiscal Year    A$  

2014

     69,817   

2015

     104,597   

2016

     25,869   

2017

     906   
  

 

 

 
     201,189   
  

 

 

 

The aggregate intrinsic value for all options outstanding as at September 30, 2014 and September 30, 2013 was zero.

 

(b) Restricted Share Plan

Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to non-executive directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company currently proposes to continue to issue A$1,000 worth of RSUs to employees of the Company on a recurring basis, but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.

The table below sets forth the RSUs issued by the Company since January 1, 2013:

 

     Number of
Restricted Shares
Issued
     Market Value of
Restricted Shares
Issued (A$)
 

May, 2013

     917        1,000   

December, 2013

     142,800        69,972   

June, 2014

     2,040        1,000   

Restricted stock awards activity during the current period is as follows:

 

     Number of shares     Weighted average
issue price
A$
 

Balance at December 31, 2013

     260,801        0.72   

Release of restricted shares

     (9,077     0.77   

Granted

     2,040        0.49   
  

 

 

   

 

 

 

Balance at September 30, 2014

     253,764        0.71   
  

 

 

   

 

 

 
Employee Benefit Costs

Employee Benefit Costs

The Company contributes to standard defined contribution superannuation funds on behalf of all employees. This contribution amount, formerly equal to 9% of each employee’s salary, was increased by law to 9.25% from July 1, 2013 and 9.5% from July 1, 2014 of each such employee’s salary. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee’s remuneration to an approved superannuation fund that the employee is typically not able to access until they are retired. The Company permits employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.

Net Loss per Share and Anti-dilutive Securities

Net Loss per Share and Anti-dilutive Securities

Basic and diluted net loss per share is presented in conformity with ASC 260 – Earnings per Share. Basic and diluted net loss per share has been computed using the weighted-average number of common shares outstanding during the period. Other than in a profit making year, the potentially dilutive options issued under the Universal Biosensors Employee Option Plan were not considered in the computation of diluted net loss per share because they would be anti-dilutive given the Company’s loss making position.

Total Comprehensive Income

Total Comprehensive Income

The Company follows ASC 220 – Comprehensive Income. Comprehensive income is defined as the total change in shareholders’ equity during the period other than from transactions with shareholders, and for the Company, includes net income and cumulative translation adjustments.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

On May 28, 2014, the FASB issued ASU 2014-09 which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance.

The core principle of the revenue model is that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” In applying the revenue model to contracts within its scope, an entity will:

 

    Identify the contract(s) with a customer (step 1).

 

    Identify the performance obligations in the contract (step 2).

 

    Determine the transaction price (step 3).

 

    Allocate the transaction price to the performance obligations in the contract (step 4).

 

    Recognize revenue when (or as) the entity satisfies a performance obligation (step 5).

The ASU applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. Certain of the ASU’s provisions also apply to transfers of nonfinancial assets, including in-substance nonfinancial assets that are not an output of an entity’s ordinary activities (e.g., sales of (1) property, plant, and equipment; (2) real estate; or (3) intangible assets). Existing accounting guidance applicable to these transfers (e.g., ASC 360-20) has been amended or superseded.

Compared with current U.S. GAAP, the ASU also requires significantly expanded disclosures about revenue recognition.

The ASU is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, for public entities. Early application is not permitted (however, early adoption is optional for entities reporting under IFRSs).

Entities have the option of using either a full retrospective or a modified approach to adopt the guidance in the ASU:

 

    Full retrospective application — Retrospective application would take into account the requirements in ASC 250 (with certain practical expedients).

 

    Modified retrospective application — Under the modified approach, an entity recognizes “the cumulative effect of initially applying the ASU as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application” (revenue in periods presented in the financial statements before that date is reported under guidance in effect before the change). Using this approach, an entity applies the guidance in the ASU to existing contracts (those for which the entity has remaining performance obligations) as of, and new contracts after, the date of initial application. The ASU is not applied to contracts that were completed before the effective date (i.e., an entity has no remaining performance obligations to fulfill). Entities that elect the modified approach must disclose an explanation of the impact of adopting the ASU, including the financial statement line items and respective amounts directly affected by the standard’s application.

The Company is currently evaluating the method and impact the adoption of ASU 2014-09 will have on the Company’s condensed consolidated financial statements.

XML 40 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Warrants
9 Months Ended
Sep. 30, 2014
Text Block [Abstract]  
Warrants

Warrants

Pursuant to the Credit Agreement, UBS issued to the Lenders warrants entitling the holder to purchase up to an aggregate total of 4.5 million shares of UBI’s common stock in the form of CDIs at the Exercise Price.

The warrants may be exercised at any time until December 19, 2020, in whole or in part in minimum multiples of 500,000 shares of common stock. The holder of the warrants can pay the Exercise Price in cash or it has the right to pay all or a portion of the Exercise Price by making a cashless exercise, therefore reducing the number of shares of common stock the holder would otherwise be issued.

The warrant is subject to adjustments in the event of certain issuances by UBS, such as bonus issues, pro rata (rights) issues and reorganizations (e.g., consolidation, subdivision).

The Company assessed that the warrants are not liabilities within scope of ASC 480-10-25. The warrants are legally detachable from the loan and separately exercisable and as such meet the definition of a freestanding derivative instrument pursuant to ASC 815.

However, the scope exception in accordance with ASC 815-10-15-74 applies to warrants and it meets the requirements of ASC 815 that would be classified in stockholders’ equity. Therefore, the warrants were initially accounted for within stockholders’ equity, and subsequent changes in fair value will not be recorded. The fair value of the warrant was estimated using the Trinomial Lattice model.

The debt issuance costs were recorded as deferred issuance costs and are amortized as interest expense, using the effective interest method, over the term of the loan pursuant to ASC 835-30-35-2.

XML 41 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restricted Cash
9 Months Ended
Sep. 30, 2014
Cash and Cash Equivalents [Abstract]  
Restricted Cash

Restricted Cash

Restricted cash maintained by the Company in the form of term deposits is as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Financial covenant pursuant to the Credit Agreement

     2,600,000         2,600,000   

Letter of credit issued in favour of a supplier

     0         575,000   

Collateral for facilities

     320,000         320,000   
  

 

 

    

 

 

 
     2,920,000         3,495,000   
  

 

 

    

 

 

 

 

Universal Biosensors, Inc.

XML 42 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2014
Accounting Policies [Abstract]  
Inventory, Net

Costs of purchased inventory are determined after deducting rebates and discounts.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Raw materials

     315,036         4,169   

Work in progress

     78,709         38   

Finished goods

     0         0   
  

 

 

    

 

 

 
     393,745         4,207   
  

 

 

    

 

 

 
Summary of Receivables

Account balances are charged against the allowance when it is probable the receivable will not be recovered.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Accounts receivable

     2,012,682         2,167,867   

Allowance for doubtful debts

     0         0   
  

 

 

    

 

 

 
     2,012,682         2,167,867   
  

 

 

    

 

 

 
Research and Development Expenses

Research and development expenses for the three and nine months ended September 30, 2014 and 2013 are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

Research and development expenses

     4,715,444         3,901,823         13,900,999         11,807,954   
  

 

 

    

 

 

    

 

 

    

 

 

 
Asset Retirement Obligations

Our overall ARO changed as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Opening balance

     2,549,928         2,351,464   

Accretion expense

     50,072         198,464   
  

 

 

    

 

 

 

Ending balance

     2,600,000         2,549,928   
  

 

 

    

 

 

 
Assumptions for Option Grants Issued

The assumptions for these grants were:

 

     Grant Date  
     Aug-14     Dec-13     Dec-13     Aug-13     Mar-13  

Exercise Price (A$)

     0.17        Nil        0.49        0.71        0.79   

Share Price at Grant Date (A$)

     0.17        0.49        0.49        0.71        0.79   

Volatility

     71     63     63     64     65

Expected Life (years)

     7        7        7        7        7   

Risk Free Interest Rate

     3.13     3.82     3.82     3.54     3.37

Fair Value of Option (A$)

     0.10        0.49        0.28        0.41        0.45   
Stock Option Activity

Stock option activity during the current period is as follows:

 

     Number of shares     Weighted average
exercise price
A$
 

Balance at December 31, 2013

     10,606,099        1.07   

Granted

     152,000        0.10   

Exercised

     (8,333     0.00   

Lapsed

     (834,994     1.02   
  

 

 

   

 

 

 

Balance at September 30, 2014

     9,914,772        1.06   
  

 

 

   

 

 

 
Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized

This expense is expected to be recognized as follows:

 

Fiscal Year    A$  

2014

     69,817   

2015

     104,597   

2016

     25,869   

2017

     906   
  

 

 

 
     201,189   
  

 

 

 

The aggregate intrinsic value for all options outstanding as at September

Restricted Shares Issued

The table below sets forth the RSUs issued by the Company since January 1, 2013:

 

     Number of
Restricted Shares
Issued
     Market Value of
Restricted Shares
Issued (A$)
 

May, 2013

     917        1,000   

December, 2013

     142,800        69,972   

June, 2014

     2,040        1,000   
Restricted Stock Awards Activity

Restricted stock awards activity during the current period is as follows:

 

     Number of shares     Weighted average
issue price
A$
 

Balance at December 31, 2013

     260,801        0.72   

Release of restricted shares

     (9,077     0.77   

Granted

     2,040        0.49   
  

 

 

   

 

 

 

Balance at September 30, 2014

     253,764        0.71   
  

 

 

   

 

 

 
XML 43 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Research and Development Expenses (Detail) (AUD)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Accounting Policies [Abstract]        
Research and development expenses 4,715,444 3,901,823 13,900,999 11,807,954
XML 44 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Restricted Shares Issued (Detail) (AUD)
1 Months Ended
Jun. 30, 2014
Dec. 31, 2013
May 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]      
Number of Restricted Shares Issued 2,040 142,800 917
Market Value of Restricted Shares Issued 1,000 69,972 1,000
XML 45 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Condensed Statements of Changes in Stockholders' Equity and Comprehensive Income (AUD)
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income [Member]
Beginning Balance at Dec. 31, 2012 39,372,139 17,396 93,009,607 (53,356,552) (298,312)
Beginning Balance, Shares at Dec. 31, 2012   173,959,863      
Net loss (8,366,769) 0 0 (8,366,769) 0
Exercise of stock options issued to employees 194,761 82 194,679 0 0
Exercise of stock options issued to employees, Shares   824,663      
Shares issued to employees 1,000 1 999 0 0
Shares issued to employees, Shares   917      
Stock option expense 469,125 0 469,125 0 0
Ending Balance at Sep. 30, 2013 31,670,256 17,479 93,674,410 (61,723,321) (298,312)
Ending Balance, Shares at Sep. 30, 2013   174,785,443      
Beginning Balance at Dec. 31, 2013 29,683,940 17,560 94,955,051 (64,990,359) (298,312)
Beginning Balance, Shares at Dec. 31, 2013   175,600,605      
Net loss (8,846,706) 0 0 (8,846,706) 0
Exercise of stock options issued to employees 0 0 0 0 0
Exercise of stock options issued to employees, Shares 8,333 8,333      
Shares issued to employees 1 1 999 0 0
Shares issued to employees, Shares   2,040      
Stock option expense (219,061) 0 (219,061) 0 0
Ending Balance at Sep. 30, 2014 20,619,173 17,561 94,736,989 (73,837,065) (298,312)
Ending Balance, Shares at Sep. 30, 2014   175,610,978      
XML 46 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2014
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, UBS. All intercompany balances and transactions have been eliminated on consolidation.

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of property, plant and equipment, deferred income taxes, asset retirement obligations and obligations related to employee benefits. Actual results could differ from those estimates.

Cash & Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments.

Short-Term Investments (Held-to-maturity)

Short-term investments constitute all highly liquid investments with term to maturity from three months to twelve months. The carrying amount of short-term investments is equivalent to their fair value.

Concentration of Credit Risk and Other Risks and Uncertainties

Cash and cash equivalents and accounts receivable consist of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the consolidated balance sheets. The Company’s cash and cash equivalents are invested with one of Australia’s largest banks. The Company is exposed to credit risk in the event of default by the banks holding the cash or cash equivalents to the extent of the amount recorded on the consolidated balance sheets. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company has not identified any collectability issues with respect to receivables.

Derivative Instruments and Hedging Activities

Derivative financial instruments

The Company uses derivative financial instruments to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes. However, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.

Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on remeasurement to fair value is recognized immediately in the income statement. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.

 

Cash flow hedges

Exposure to foreign exchange risks arises in the normal course of the Company’s business and it is the Company’s policy to use forward exchange contracts to hedge anticipated sales and purchases in foreign currencies. The amount of forward cover taken is in accordance with approved policy and internal forecasts.

Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from equity and included in the initial cost or other carrying amount of the non-financial asset or liability.

For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from equity and recognized in the consolidated statements of comprehensive income in the same period or periods during which the hedged forecast transaction affects the consolidated statements of comprehensive income and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated statements of comprehensive income.

When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in equity is recognized immediately in the consolidated statements of comprehensive income.

Derivative Instruments and Hedging Activities

In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as consider our own and counterparty credit risk. At September 30, 2014 and year ended December 31, 2013, we did not have any assets or liabilities that utilize Level 3 inputs. The valuation of our foreign exchange derivatives are based on the market approach using observable market inputs, such as forward rates and incorporate non-performance risk (the credit standing of the counterparty when the derivative is in a net asset position, and the credit standing of the Company when the derivative is in a net liability position). Our derivative assets are categorized as Level 2. The fair value methodologies described as Level 2 and 3 inputs are defined elsewhere in these notes to the financial statements.

Inventory

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to dispose. Inventories are principally determined under the average cost method which approximates cost. Cost comprises direct materials, direct labour and an appropriate portion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost also includes the transfer from equity of any gains/losses on qualifying cash flow hedges relating to purchases of raw material. Costs of purchased inventory are determined after deducting rebates and discounts.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Raw materials

     315,036         4,169   

Work in progress

     78,709         38   

Finished goods

     0         0   
  

 

 

    

 

 

 
     393,745         4,207   
  

 

 

    

 

 

 

Receivables

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those accounts that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded within general and administrative expenses in the consolidated statements of comprehensive income. Account balances are charged against the allowance when it is probable the receivable will not be recovered.

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Accounts receivable

     2,012,682         2,167,867   

Allowance for doubtful debts

     0         0   
  

 

 

    

 

 

 
     2,012,682         2,167,867   
  

 

 

    

 

 

 

Property, Plant, and Equipment

Property, plant, and equipment are recorded at acquisition cost, less accumulated depreciation.

Depreciation on plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is 3 to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred, include normal services, and do not include items of a capital nature.

The Company receives Victorian government grant monies under grant agreements to support our development activities, including in connection with the purchase of plant and equipment. Plant and equipment is presented net of the government grant. The grant monies are recognized against the acquisition costs of the related plant and equipment as and when the related assets are purchased.

Research and Development

Research and development expenses consist of costs incurred to further the Group’s research and development activities and include salaries and related employee benefits, costs associated with clinical trial and preclinical development, regulatory activities, research-related overhead expenses, costs associated with the manufacture of clinical trial material, costs associated with developing a commercial manufacturing process, costs for consultants and related contract research, facility costs and depreciation. Research and development costs are expensed as incurred.

 

Research and development expenses for the three and nine months ended September 30, 2014 and 2013 are as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  
     A$      A$      A$      A$  

Research and development expenses

     4,715,444         3,901,823         13,900,999         11,807,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income Taxes

The Company applies ASC 740 - Income Taxes which establishes financial accounting and reporting standards for the effects of income taxes that result from a company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where it is more likely than not that some portion or all of the deferred tax assets will not be realized, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that is more likely than not to be realized.

We are subject to income taxes in the United States and Australia. U.S. federal income tax returns up to and including the 2013 financial year has been filed. Internationally, consolidated income tax returns up to and including the 2013 financial year have been filed.

Asset Retirement Obligations

Asset retirement obligations (“ARO”) are legal obligations associated with the retirement and removal of long-lived assets. ASC 410 – Asset Retirement and Environmental Obligations requires entities to record the fair value of a liability for an asset retirement obligation when it is incurred. When the liability is initially recorded, the Company capitalizes the cost by increasing the carrying amounts of the related property, plant and equipment. Over time, the liability increases for the change in its present value, while the capitalized cost depreciates over the useful life of the asset. The Company derecognizes ARO liabilities when the related obligations are settled.

The ARO is in relation to our premises where in accordance with the terms of the lease, the lessee has to restore part of the building upon vacating the premises.

Our overall ARO changed as follows:

 

     Nine Months Ended
September 30,
     Year Ended
December 31,
 
     2014      2013  
     A$      A$  

Opening balance

     2,549,928         2,351,464   

Accretion expense

     50,072         198,464   
  

 

 

    

 

 

 

Ending balance

     2,600,000         2,549,928   
  

 

 

    

 

 

 

 

Fair Value of Financial Instruments

The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined, depending on the nature and complexity of the assets or the liability, by using one or all of the following approaches:

 

    Market approach – based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

 

    Cost approach – based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.

 

    Income approach – based on the present value of a future stream of net cash flows

These fair value methodologies depend on the following types of inputs:

 

    Quoted prices for identical assets or liabilities in active markets (Level 1 inputs)

 

    Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs)

 

    Unobservable inputs that reflect estimates and assumptions (Level 3 inputs)

Impairment of Long-Lived Assets

The Company reviews its capital assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing the review, the Company estimates undiscounted cash flows from products under development that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value, based on discounted cash flows.

Australian Goods and Services Tax (GST)

Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheets.

Revenue Recognition

We recognize revenue from all sources based on the provisions of the U.S. SEC’s Staff Accounting Bulletin No. 104 and ASC 605 Revenue Recognition.

The Company’s revenue represents revenue from sales of products, provision of services and collaborative research and development agreements.

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, assuming all other revenue recognition criteria have been met. Generally, this is at the time products are shipped to the customer.

Revenue from services is recognized when a persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue recognition principles are assessed for each new contractual arrangement and the appropriate accounting is determined for each service.

 

Where our agreements contain multiple elements, or deliverables, such as the manufacture and sale of products, provision of services or research and development activities, they are assessed to determine whether separate delivery of the individual elements of such arrangements comprises more than one unit of accounting. Where an arrangement can be divided into separate units of accounting (each unit constituting a separate earnings process), the arrangement consideration is allocated amongst those varying units based on the relative selling price of the separate units of accounting and the applicable revenue recognition criteria applied to the separate units. Selling prices are determined using fair value as determined by either vendor specific objective evidence or third party evidence of the selling price, when available, or the Company’s best estimate of selling price when fair value is not available for a given unit of accounting.

Under ASC 605-25, the delivered item(s) are separate units of accounting, provided (i) the delivered item(s) have value to a customer on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Where the arrangement cannot be divided into separate units, the individual deliverables are combined as a single unit of accounting and the total arrangement consideration is recognized across other deliverables in the arrangement or over the estimated collaboration period. Payments under these arrangements typically include one or more of the following: non-refundable, upfront payments; funding of research and/or development efforts; and milestone payments.

We typically generate milestone payments from our customers pursuant to the various agreements we have with them. Non-refundable milestone payments which represent the achievement of a significant technical/regulatory hurdle in the research and development process pursuant to collaborative agreements, and are deemed to be substantive, are recognized as revenue upon the achievement of the specified milestone. If the non-refundable milestone payment is not substantive or stand-alone value, the non-refundable milestone payment is deferred and recognized as revenue either over the estimated performance period stipulated in the agreement or across other deliverables in the arrangement.

Management has concluded that the core operations of the Company are expected to be research and development activities, commercial manufacture of approved medical or testing devices and the provision of services. The Company’s ultimate goal is to utilize the underlying technology and skill base for the development of marketable products that the Company will manufacture. The Company considers revenue from the sales of products, revenue from services and the income received from milestone payments indicative of its core operating activities or revenue producing goals of the Company, and as such have accounted for this income as “revenues”.

Master Services and Supply Agreement

In October 2007, the Company and LifeScan entered into a Master Services and Supply Agreement, under which the Company would provide certain services to LifeScan in the field of blood glucose monitoring and act as a non-exclusive manufacturer of blood glucose test strips. The Master Services and Supply Agreement was subsequently amended and restated in May 2009. The Company has concluded the Master Services and Supply Agreement should be accounted for as three separate units of accounting: 1) research and development to assist LifeScan in receiving regulatory clearance to sell the blood glucose product (milestone payment), 2) contract manufacturing of the blood glucose test strips (contract manufacturing) which ceased in December 2013, and 3) ongoing services and efforts to enhance the product (product enhancement).

All consideration within the Master Services and Supply Agreement is contingent. The Company concluded the undelivered items were not priced at a significant incremental discount to the delivered items and revenue for each deliverable will be recognized as each contingency is met and the consideration becomes fixed and determinable. The milestone payment was considered to be a substantive payment and the entire amount has been recognized as revenue when the regulatory approval was received. Revenues for contract manufacturing and ongoing efforts to enhance the product are recognized as revenue from products or revenue from services, respectively, when the four basic criteria for revenue recognition are met.

 

Collaboration Agreement

On September 9, 2011 the Company entered into a Collaboration Agreement with Siemens to develop coagulation related products for hospital point-of-care and ambulatory care coagulation markets. In addition to an up-front, non-refundable payment of A$2,961,245 (equivalent to US$3 million), the Collaboration Agreement contained a further six payments from Siemens upon the achievement of certain defined milestones. These six milestones relate to feasibility, regulatory submissions and the launch of the products to be developed. The Company has concluded that the up-front payment is not a separate unit of accounting and recorded the amount as deferred revenue to be recognized as revenue across other deliverables in the arrangement with Siemens based upon the Company’s best estimate of selling price. The deliverables related to each milestone are considered substantive and are not priced at a significant incremental discount to the other deliverables. As the achievement of the milestones is contingent upon a future event, the revenue for each deliverable will be recognized as the contingencies are met and the consideration becomes fixed and determinable.

Of the six milestones, the Company has delivered on two as of September 30, 2014:

 

    In June 2012, the Company delivered on its first milestone by achieving proof of technical feasibility of a new test strip and received a payment of A$1,522,534 (equivalent to US$1.5 million) as consideration. A sum of A$2,175,048 (equivalent to US$2,142,857) has been recognized as revenue from services in June 2012 in this regards.

 

    In July 2012, the Company delivered on its second milestone by achieving proof of technical feasibility of another new test strip and received a payment of A$1,438,711 (equivalent to US$1.5 million) as consideration. A sum of A$2,055,301 (equivalent to US$2,142,857) has been recognized as revenue from services in July 2012 in this regards.

There were no revenues recognized for the three and nine months ended September 30, 2014 and September 30, 2013 relating to the delivery of the milestones pursuant to the Collaboration Agreement. Of the total amount of A$4,230,349 (equivalent to US$4,285,714) recognized as revenue for the 2012 financial year, A$2,961,245 (equivalent to US$3.0 million) relates to the achievement of the two milestones whilst the balance relates to a portion of the deferred US$3 million up-front payment allocated to these milestones based upon their relative estimate of selling price.

Interest income

Interest income is recognized as it accrues, taking into account the effective yield on the cash and cash equivalents.

Research and development tax incentive income

Research and development tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.

The Company has recorded research and development tax incentive income of A$3,561,209 and A$4,250,864 for the three month period ended September 30, 2014 and 2013, respectively and A$7,281,358 and A$4,250,864 for the nine month period ended September 30, 2014 and 2013, respectively. The research and development tax incentive income is recorded under the caption “Other” in the consolidated statements of comprehensive income. There was no research and development tax incentive income recognized for the six months ended June 30, 2013 as the criteria was not met. The Company determined that it qualified and became eligible for this incentive income during the third quarter of the 2013 financial year.

Foreign Currency

Functional and reporting currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The functional currency of the Company and UBS is AUD or A$ for all years presented.

 

The consolidated financial statements are presented using a reporting currency of Australian dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of comprehensive income.

The Company has recorded foreign currency transaction (losses)/gains of (A$399,417) and A$15,926 for the three month period ended September 30, 2014 and 2013, respectively and (A$444,973) and A$724,989 for the nine month period ended September 30, 2014 and 2013, respectively.

The results and financial position of all the Group entities that have a functional currency different from the reporting currency are translated into the reporting currency as follows:

 

  assets and liabilities for each balance sheet item reported are translated at the closing rate at the date of that balance sheet;

 

  income and expenses for each income statement item reported are translated at average exchange rates (unless this is not a reasonable approximation of the effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and

 

  all resulting exchange differences are recognized as a separate component of equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are taken to the Accumulated Other Comprehensive Income.

Commitments and Contingencies

Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Our contingent liabilities as at September 30, 2014 are as follows:

 

  we have a potential obligation to pay 50% of the patent fees paid by LifeScan in respect of the patents we license from LifeScan prior to the date of the first commercial sale of a non-glucose product that utilizes the technology licensed from LifeScan and 50% of the patent fees incurred by LifeScan in respect of such patents thereafter. In the event of the first commercial sale of a non-glucose product, the initial amount that could be paid by us to LifeScan is projected to be between US$1.6 million to US$1.8 million. We would have the right to make this payment either as a lump sum within 45 days of receipt of the supporting documentation from LifeScan or in equal monthly installment payments during the 24 months subsequent to the date of receipt of the supporting documentation. Currently the non-glucose products continue to be in the research and development phase.

 

  during 2009, LifeScan chose not to proceed with the registration of the then current product but to proceed with an enhanced product, called OneTouch® Verio®, and acknowledged that there would be a delay as a result. As a result of this change, LifeScan agreed to pay additional amounts per strip manufactured by us in 2010 and 2011 up to a specified volume limit (“manufacturing initiation payments”). At the same time, we agreed to pay LifeScan a marketing support payment in each of the two years following the first year in which 1 billion strips are sold by LifeScan equal to 40% of the total manufacturing initiation payments made. The total amount of marketing support payments expected to be paid to LifeScan is approximately US$2 million. Based on the current volume of strips sold by LifeScan and that we have no visibility of future sales by LifeScan, it is uncertain whether we would be required to make this marketing support payment.

 

  we have engaged Planet Innovation Pty Ltd (“Planet Innovation”) to assist us with design and engineering for future analyzers. As part of the agreement, Planet Innovation will be paid a success payment upon the formal acceptance of the analyzer for commercial manufacture and a further success payment on launch sign-off for the first commercial sale of the analyzer. All of the analyzers Planet Innovation is currently working on are in the research and development phases, and therefore at this stage their commercial manufacture and sale and the amount of any future success payment cannot be reliably estimated.

 

Patent and License Costs

Legal and maintenance fees incurred for patent application costs have been charged to expense and reported in research and development expense. Legal and maintenance fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents.

Clinical Trial Expenses

Clinical trial costs are a component of research and development expenses. These expenses include fees paid to participating hospitals and other service providers, which conduct certain testing activities on behalf of the Company. Depending on the timing of payments to the service providers and the level of service provided, the Company records prepaid or accrued expenses relating to these costs.

These prepaid or accrued expenses are based on estimates of the work performed under service agreements.

Leased Assets

All of the Company’s leases for the periods ending September 30, 2014 and December 31, 2013 are considered operating leases. The costs of operating leases are charged to the statement of comprehensive income on a straight-line basis over the lease term.

Stock-based Compensation

We measure stock-based compensation at grant date, based on the estimated fair value of the award, and recognize the cost as an expense on a straight-line basis over the vesting period of the award. We estimate the fair value of stock options using the Trinomial Lattice model. We also grant our employees Restricted Stock Units (“RSUs”) and Zero Priced Employee Options (“ZEPOs”). RSUs are stock awards granted to employees that entitle the holder to shares of common stock as the award vests. ZEPOs are stock options granted to employees that entitle the holder to shares of common stock as the award vests. The value of RSUs are determined and fixed on the grant date based on the Company’s stock price. The exercise price of ZEPOs is nil.

We record deferred tax assets for awards that will result in deductions on our income tax returns, based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported in our income tax return are recorded in expense or in capital in excess of par value if the tax deduction exceeds the deferred tax assets or to the extent that previously recognized credits to paid-in-capital are still available if the tax deduction is less than the deferred tax asset.

 

(a) Stock Option Plan

In 2004, the Company adopted an employee option plan (“Plan”). Options may be granted pursuant to the Plan to any person considered by the board to be employed by the Group on a permanent basis (whether full time, part time or on a long term casual basis). Each option gives the holder the right to subscribe for one share of common stock. The total number of options that may be issued under the Plan is such maximum amount permitted by law and the Listing Rules of the ASX. The exercise price and any exercise conditions are determined by the board at the time of grant of the options. Any exercise conditions must be satisfied before the options vest and become capable of exercise. The options lapse on such date determined by the board at the time of grant or earlier in accordance with the Plan. Options granted to date have had a term up to 10 years and generally vest in equal tranches over three years.

An option holder is not permitted to participate in a bonus issue or new issue of securities in respect of an option held prior to the issue of shares to the option holder pursuant to the exercise of an option. If the Company changes the number of issued shares through, or as a result of, any consolidation, subdivision, or similar reconstruction of the issued capital of the Company, the total number of options and the exercise price of the options (as applicable) will likewise be adjusted.

In accordance with ASC 718, the fair value of the option grants was estimated on the date of each grant using the Trinomial Lattice model. The assumptions for these grants were:

 

     Grant Date  
     Aug-14     Dec-13     Dec-13     Aug-13     Mar-13  

Exercise Price (A$)

     0.17        Nil        0.49        0.71        0.79   

Share Price at Grant Date (A$)

     0.17        0.49        0.49        0.71        0.79   

Volatility

     71     63     63     64     65

Expected Life (years)

     7        7        7        7        7   

Risk Free Interest Rate

     3.13     3.82     3.82     3.54     3.37

Fair Value of Option (A$)

     0.10        0.49        0.28        0.41        0.45   

Stock option activity during the current period is as follows:

 

     Number of shares     Weighted average
exercise price
A$
 

Balance at December 31, 2013

     10,606,099        1.07   

Granted

     152,000        0.10   

Exercised

     (8,333     0.00   

Lapsed

     (834,994     1.02   
  

 

 

   

 

 

 

Balance at September 30, 2014

     9,914,772        1.06   
  

 

 

   

 

 

 

The number of options exercisable as at September 30, 2014 and September 30, 2013 was 8,219,892 and 8,344,277, respectively. The total stock compensation expense recognized in income statement was A$61,703 and A$175,623 for the three month period ended September 30, 2014 and 2013, respectively and (A$219,061) and A$469,125 for the nine month period ended September 30, 2014 and 2013, respectively.

As of September 30, 2014, there was A$201,189 of unrecognized compensation expense related to unvested share-based compensation arrangements under the Employee Option Plan. This expense is expected to be recognized as follows:

 

Fiscal Year    A$  

2014

     69,817   

2015

     104,597   

2016

     25,869   

2017

     906   
  

 

 

 
     201,189   
  

 

 

 

The aggregate intrinsic value for all options outstanding as at September 30, 2014 and September 30, 2013 was zero.

 

(b) Restricted Share Plan

Our Employee Share Plan was adopted by the Board of Directors in 2009. The Employee Share Plan permits our Board to grant shares of our common stock to our employees and directors (although our Board has determined not to issue equity to non-executive directors). The number of shares able to be granted is limited to the amount permitted to be granted at law, the ASX Listing Rules and by the limits on our authorized share capital in our certificate of incorporation. All our employees are eligible for shares under the Employee Share Plan. The Company currently proposes to continue to issue A$1,000 worth of RSUs to employees of the Company on a recurring basis, but no more frequently than annually. The restricted shares have the same terms of issue as our existing shares of common stock but are not able to be traded until the earlier of three years from the date on which the shares are issued or the date the relevant employee ceases to be an employee of the Company or any of its associated group of companies.

The table below sets forth the RSUs issued by the Company since January 1, 2013:

 

     Number of
Restricted Shares
Issued
     Market Value of
Restricted Shares
Issued (A$)
 

May, 2013

     917        1,000   

December, 2013

     142,800        69,972   

June, 2014

     2,040        1,000   

Restricted stock awards activity during the current period is as follows:

 

     Number of shares     Weighted average
issue price
A$
 

Balance at December 31, 2013

     260,801        0.72   

Release of restricted shares

     (9,077     0.77   

Granted

     2,040        0.49   
  

 

 

   

 

 

 

Balance at September 30, 2014

     253,764        0.71   
  

 

 

   

 

 

 

Employee Benefit Costs

The Company contributes to standard defined contribution superannuation funds on behalf of all employees. This contribution amount, formerly equal to 9% of each employee’s salary, was increased by law to 9.25% from July 1, 2013 and 9.5% from July 1, 2014 of each such employee’s salary. Superannuation is a compulsory savings program whereby employers are required to pay a portion of an employee’s remuneration to an approved superannuation fund that the employee is typically not able to access until they are retired. The Company permits employees to choose an approved and registered superannuation fund into which the contributions are paid. Contributions are charged to the consolidated condensed statements of comprehensive income as they become payable.

Net Loss per Share and Anti-dilutive Securities

Basic and diluted net loss per share is presented in conformity with ASC 260 – Earnings per Share. Basic and diluted net loss per share has been computed using the weighted-average number of common shares outstanding during the period. Other than in a profit making year, the potentially dilutive options issued under the Universal Biosensors Employee Option Plan were not considered in the computation of diluted net loss per share because they would be anti-dilutive given the Company’s loss making position.

Total Comprehensive Income

The Company follows ASC 220 – Comprehensive Income. Comprehensive income is defined as the total change in shareholders’ equity during the period other than from transactions with shareholders, and for the Company, includes net income and cumulative translation adjustments.

 

Recent Accounting Pronouncements

On May 28, 2014, the FASB issued ASU 2014-09 which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance.

The core principle of the revenue model is that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” In applying the revenue model to contracts within its scope, an entity will:

 

    Identify the contract(s) with a customer (step 1).

 

    Identify the performance obligations in the contract (step 2).

 

    Determine the transaction price (step 3).

 

    Allocate the transaction price to the performance obligations in the contract (step 4).

 

    Recognize revenue when (or as) the entity satisfies a performance obligation (step 5).

The ASU applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. Certain of the ASU’s provisions also apply to transfers of nonfinancial assets, including in-substance nonfinancial assets that are not an output of an entity’s ordinary activities (e.g., sales of (1) property, plant, and equipment; (2) real estate; or (3) intangible assets). Existing accounting guidance applicable to these transfers (e.g., ASC 360-20) has been amended or superseded.

Compared with current U.S. GAAP, the ASU also requires significantly expanded disclosures about revenue recognition.

The ASU is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, for public entities. Early application is not permitted (however, early adoption is optional for entities reporting under IFRSs).

Entities have the option of using either a full retrospective or a modified approach to adopt the guidance in the ASU:

 

    Full retrospective application — Retrospective application would take into account the requirements in ASC 250 (with certain practical expedients).

 

    Modified retrospective application — Under the modified approach, an entity recognizes “the cumulative effect of initially applying the ASU as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application” (revenue in periods presented in the financial statements before that date is reported under guidance in effect before the change). Using this approach, an entity applies the guidance in the ASU to existing contracts (those for which the entity has remaining performance obligations) as of, and new contracts after, the date of initial application. The ASU is not applied to contracts that were completed before the effective date (i.e., an entity has no remaining performance obligations to fulfill). Entities that elect the modified approach must disclose an explanation of the impact of adopting the ASU, including the financial statement line items and respective amounts directly affected by the standard’s application.

The Company is currently evaluating the method and impact the adoption of ASU 2014-09 will have on the Company’s condensed consolidated financial statements.

XML 47 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Restricted Stock Awards Activity (Detail) (AUD)
9 Months Ended
Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Number of shares, Beginning Balance 260,801
Number of shares, Release of restricted shares (9,077)
Number of shares, Granted 2,040
Number of shares, Ending Balance 253,764
Weighted average issue price, Beginning Balance 0.72
Weighted average issue price, Release of restricted shares 0.77
Weighted average issue price, Granted 0.49
Weighted average issue price, Ending Balance 0.71
XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 83 261 1 false 20 0 false 10 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.universalbiosensors.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Consolidated Condensed Balance Sheets Sheet http://www.universalbiosensors.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Condensed Balance Sheets false false R3.htm 104 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) Sheet http://www.universalbiosensors.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Condensed Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Consolidated Condensed Statements of Comprehensive Income Sheet http://www.universalbiosensors.com/taxonomy/role/StatementOfIncome Consolidated Condensed Statements of Comprehensive Income false false R5.htm 106 - Statement - Consolidated Condensed Statements of Changes in Stockholders' Equity and Comprehensive Income Sheet http://www.universalbiosensors.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Condensed Statements of Changes in Stockholders' Equity and Comprehensive Income false false R6.htm 107 - Statement - Consolidated Condensed Statements of Cash Flows Sheet http://www.universalbiosensors.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Condensed Statements of Cash Flows false false R7.htm 108 - Disclosure - Organization of the Company Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Organization of the Company false false R8.htm 109 - Disclosure - Interim Financial Statements Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock Interim Financial Statements false false R9.htm 110 - Disclosure - Basis of Presentation Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation false false R10.htm 111 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies false false R11.htm 112 - Disclosure - Related Party Transactions Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions false false R12.htm 113 - Disclosure - Borrowings Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Borrowings false false R13.htm 114 - Disclosure - Warrants Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsWarrantsDisclosureTextBlock Warrants false false R14.htm 115 - Disclosure - Restricted Cash Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock Restricted Cash false false R15.htm 116 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) false false R16.htm 117 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.universalbiosensors.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) false false R17.htm 118 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation Basis of Presentation - Additional Information (Detail) false false R18.htm 119 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) false false R19.htm 120 - Disclosure - Summary of Significant Accounting Policies - Inventory, Net (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryNet Summary of Significant Accounting Policies - Inventory, Net (Detail) false false R20.htm 121 - Disclosure - Summary of Significant Accounting Policies - Summary of Receivables (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReceivables Summary of Significant Accounting Policies - Summary of Receivables (Detail) false false R21.htm 122 - Disclosure - Summary of Significant Accounting Policies - Research and Development Expenses (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses Summary of Significant Accounting Policies - Research and Development Expenses (Detail) false false R22.htm 123 - Disclosure - Summary of Significant Accounting Policies - Asset Retirement Obligations (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssetRetirementObligations Summary of Significant Accounting Policies - Asset Retirement Obligations (Detail) false false R23.htm 124 - Disclosure - Summary of Significant Accounting Policies - Assumptions for Option Grants Issued (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAssumptionsForOptionGrantsIssued Summary of Significant Accounting Policies - Assumptions for Option Grants Issued (Detail) false false R24.htm 125 - Disclosure - Summary of Significant Accounting Policies - Stock Option Activity (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesStockOptionActivity Summary of Significant Accounting Policies - Stock Option Activity (Detail) false false R25.htm 126 - Disclosure - Summary of Significant Accounting Policies - Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesUnrecognizedCompensationExpenseRelatedToUnvestedShareBasedCompensationArrangementsExpectedToBeRecognized Summary of Significant Accounting Policies - Unrecognized Compensation Expense Related to Unvested Share-Based Compensation Arrangements Expected to be Recognized (Detail) false false R26.htm 127 - Disclosure - Summary of Significant Accounting Policies - Restricted Shares Issued (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedSharesIssued Summary of Significant Accounting Policies - Restricted Shares Issued (Detail) false false R27.htm 128 - Disclosure - Summary of Significant Accounting Policies - Restricted Stock Awards Activity (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedStockAwardsActivity Summary of Significant Accounting Policies - Restricted Stock Awards Activity (Detail) false false R28.htm 129 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) false false R29.htm 130 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureBorrowingsFutureMaturitiesInterestAndOtherPaymentsUnderCompanysLongTermSecuredLoanPursuantToCreditAgreement Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Detail) false false R30.htm 131 - Disclosure - Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Parenthetical) (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureBorrowingsFutureMaturitiesInterestAndOtherPaymentsUnderCompanysLongTermSecuredLoanPursuantToCreditAgreementParenthetical Borrowings - Future Maturities, Interest and Other Payments under Company's Long Term Secured Loan Pursuant to Credit Agreement (Parenthetical) (Detail) false false R31.htm 132 - Disclosure - Borrowings - Additional Information (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureBorrowingsAdditionalInformation Borrowings - Additional Information (Detail) false false R32.htm 133 - Disclosure - Warrants - Additional Information (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureWarrantsAdditionalInformation Warrants - Additional Information (Detail) false false R33.htm 134 - Disclosure - Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Detail) Sheet http://www.universalbiosensors.com/taxonomy/role/DisclosureRestrictedCashRestrictedCashMaintainedByTheCompanyInTheFormOfTermDeposits Restricted Cash - Restricted Cash Maintained by the Company in the Form of Term Deposits (Detail) false false All Reports Book All Reports Element us-gaap_LineOfCreditFacilityAmountOutstanding had a mix of decimals attribute values: -6 0. 'Shares' elements on report '133 - Disclosure - Warrants - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Consolidated Condensed Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2014 USD ($)' Process Flow-Through: Removing column 'Dec. 31, 2013 USD ($)' Process Flow-Through: Removing column 'Sep. 30, 2013 AUD' Process Flow-Through: Removing column 'Dec. 31, 2012 AUD' Process Flow-Through: 104 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Consolidated Condensed Statements of Comprehensive Income Process Flow-Through: 107 - Statement - Consolidated Condensed Statements of Cash Flows ubi-20140930.xml ubi-20140930.xsd ubi-20140930_cal.xml ubi-20140930_def.xml ubi-20140930_lab.xml ubi-20140930_pre.xml true true XML 49 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Summary of Receivables (Detail) (AUD)
Sep. 30, 2014
Dec. 31, 2013
Accounting Policies [Abstract]    
Accounts receivable 2,012,682 2,167,867
Allowance for doubtful debts 0 0
Accounts Receivable, Net, Current, Total 2,012,682 2,167,867